AMERICAN PSYCHIATRIC ASSOCIATION
2004 ANNUAL MEETING

Dissolving the Mind-Brain Barrier

Psychotherapy and Psychopharmacology:

New York, NY  □  May 1-6, 2004

May 1, 2004

Dear Colleagues and Guests:

Welcome to the 157th Annual Meeting of the American Psychiatric Association. The coming week will highlight the best in our profession in the largest psychiatric meeting in the world. Our meeting has become an outstanding international forum to discuss the latest scientific advances and traditional humane values in psychiatry and how we will continue to integrate these bodies of knowledge to provide excellent patient care.

This year’s Annual Meeting theme is “Psychotherapy and Psychopharmacology: Dissolving the Mind-Brain Barrier.” Many sessions throughout the week will highlight important aspects of the theme. In addition, please make a special effort to attend the Presidential Symposia, from 2:00-5:00 p.m., on Monday, Tuesday, and Wednesday. On Tuesday evening, a special Presidential Forum will be presenting with the showing of the extraordinary film, “I Am Sam.” An entire track of sessions, presented in collaboration with the National Institute on Drug Abuse have been scheduled throughout the meeting.

I join our colleagues from North America in greeting the thousands of colleagues from other parts of the world who have joined us in New York. At the Opening Session, from 5:00 p.m.-6:30 p.m., on Sunday, we will officially welcome the leaders from psychiatric societies in the U.S. and around the world. I will present my Presidential Address, and I look forward to seeing you there.

Please also make sure to attend the Convocation of Distinguished Fellows on Monday night at 5:30 p.m., where we will honor all those being inducted as fellows and distinguished fellows and many receiving awards from APA. The William C. Menninger Memorial lecture will be presented by the distinguished writer, Tom Wolfe.

Organizing a meeting like ours represents the best in collaboration between our members and our staff. Special congratulations go to Dr. Geetha Jayaram and the members of the Scientific Program Committee and to the APA staff who work on the Annual Meeting.

Welcome to New York.

Sincerely,

Marcia Kraft Goin, M.D.
APA President

2004 SCIENTIFIC PROGRAM COMMITTEE
Dear APA Members and Guests:

Welcome to New York, NY, and the 157th Annual Meeting of the American Psychiatric Association. This historic city, with its vibrancy, cultural diversity, and excitement, provides a perfect setting for the scientific presentations we have planned. As you read through the Program Book, you will notice a number of sessions related to the theme “Psychotherapy and Psychopharmacology: Dissolving the Mind-Brain Barrier,” chosen by our President, Dr. Marcia Kraft Goin. Let me draw your attention to just a few of the many exciting sessions presented this week. One Presidential Symposium will be presented each day on Monday-Wednesday from 2:00 p.m.-5:00 p.m. A Presidential Forum will be held on Tuesday evening where the film, “I Am Sam,” will be shown and discussed.

The Business Meeting will be held on Sunday, from 12:30 p.m. to 1:30 p.m.; all voting members are encouraged to attend. The Opening Session will be held on Sunday, from 5:00 p.m. to 6:00 p.m. Exhibits will be open 10:00 a.m. to 4:30 p.m. on Sunday, 10:00 a.m. to 5:30 p.m. on Monday, 10:00 a.m.-6:00 p.m. on Tuesday, and from 10:00 a.m. to 3:00 p.m. on Wednesday. Please note that the Convocation of Distinguished Fellows will begin at 5:30 p.m., on Monday, May 3. Award-winning author, Tom Wolfe, will present the William C. Menninger Memorial Lecture during the Convocation.

The Advances in Research session will be held on Monday at 10:30 a.m. This session highlights the latest research findings in psychiatry and summarizes their relevance to clinical practice. This session has become an excellent way to start off the Annual Meeting’s research programs, in conjunction with the Young Investigators’ Poster and Oral/Slide Sessions also on Monday. You will find an expanded number of small group sessions, including Discussion Groups; Research Consultations with selected experts in the field; and Master Educator Clinical Consultations, a series of clinically-based seminars with outstanding clinician educators, offered to APA members only. A special series of sessions will be presented in collaboration with the National Institute on Drug Abuse. Please consult the brochure in your registration packet for further information.

You will note in the Program Book that we are continuing with an expanded series of noon Forums. This format allows us to schedule sessions that may not fit in the usual formats or that focus on late-breaking topics of importance to the field.

It is extremely important that you fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in your opinion regarding the quality of the content of the Annual Meeting. The information we obtain will be used to plan next year’s Annual Meeting.

Once again, welcome to New York. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

Geetha Jayaram, M.D., M.B.A.
Chairperson
Scientific Program Committee
American Psychiatric Association Exhibit
Located in Halls 1A-C, Level 1, Javits Center, along with the Publishers' Bookfair. Hours of operation will be: Saturday, 10:00 a.m.-5:00 p.m.; Sunday, 8:00 a.m.-4:30 p.m.; Monday, 10:00 a.m.-3:00 p.m.; Tuesday, 10:00 a.m.-6:00 p.m.; and Wednesday, 10:00 a.m.-3:00 p.m. A few of the many APA activities exhibited include: membership, APAs Internet-based programs, continuing medical education, quality improvement, psychopharmacologic services, clinical resources, advocacy tools, career development, and APA Periodicals.

APA Job Bank
Located in the APA Resource Center and open during the center's hours of operation. Visit the APA on-site Job Bank at APA 2004! The online APA Job Bank will provide the popular on-site Job Bank providing improved tools for both employers and candidates at the APA's Annual Meeting. Candidates and employers are encouraged to activate their resumes and job postings in advance of the meeting for best results. For more information on the Job Bank, visit www.psych.org/jobbank.

APA Communications Office/Press Office
Located in Rooms 1C02/3/4, Level 1, Javits Center. Hours of operation: Saturday, 12 noon-5:00 p.m.; Sunday-Wednesday, 8:00 a.m.-6:00 p.m.; and Thursday, 8:00 a.m.-11:00 a.m.
The Press Office is for the use of registered press only.

Daily Bulletin
The Daily Bulletin accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. The issue for Saturday/Sunday's is printed in advance. For the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off in Rooms 1C02/3/4, Level 1, by 12 noon prior to the date of publication.

Residents' Resource Center
Located in the Versailles Terrace, Second Floor, Sheraton New York. The Residents' Resource Center will be open from 7:00 a.m. to 6:00 p.m., Sunday, May 2, through Wednesday, May 5. Daily activities are scheduled for residents (such as the Residents Only Discussion Groups and Resident Summits) and for medical students as well. Meet and network with leaders in psychiatry and your colleagues. Resources specifically for residents and medical students available are available here.

Women's Resource Center
The Center will be open from 7:00 a.m. to 5:00 p.m., Sunday, May 2, and Monday, May 3. The Center is located in Javits Center. On Sunday, in Room 1D06, Level 1, and on Monday in Room Room 2D16, Level 2. This is an informal networking Center with some workshops on topics such as “passing the boards.”

Center for International Guests
Due to a lack of funding, we regret we are unable to provide an International Visitor Center this year.

Business Centers
Javits Center Location: Mail Boxes, Etc., Crystal Palace (202-244-3744)
Times of operation: Open during show hours
Marriott: Location: 8th Floor (to the far left of the hotel check-in counters)
Times of operation: Saturday: 8:15 a.m.-6:00 p.m.; Sunday: 9:15 a.m.-7:00 p.m.; Monday-Friday: 6:30 a.m.-10:30 p.m.
Hilton: Location: 2nd Floor (behind the elevators)
Times of operation: Saturday-Sunday: 7:00 a.m.-7:00 p.m.; Monday-Friday: 7:00 a.m.-9:00 p.m.;
ADMISSION TO ALL SESSIONS BY REGISTRATION BADGE
Located in the North Pavilion, Level 1, Javits Center. Hours of operation:
Saturday, 10:00 a.m.-5:00 p.m.; Sunday, 7:30 a.m.-5:00 p.m.; Monday, 7:30
a.m.-3:30 p.m.; Tuesday, 7:30 a.m.-6:00 p.m.; Wednesday, 7:30 a.m.-5:00 p.m.;
and Thursday, 7:30 a.m.-2:00 p.m.

On-Site Registration Fee Schedule:

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>APA MEMBERS</td>
<td></td>
</tr>
<tr>
<td>Full-Time Registration</td>
<td>$275.00</td>
</tr>
<tr>
<td>International Members</td>
<td>$425.00</td>
</tr>
<tr>
<td>Members-in-Training (Member Class MT)</td>
<td>$75.00</td>
</tr>
<tr>
<td>Daily Registration (North American)</td>
<td>$140.00</td>
</tr>
<tr>
<td>Daily Registration (International)</td>
<td>$215.00</td>
</tr>
<tr>
<td>Medical Students</td>
<td>no charge</td>
</tr>
</tbody>
</table>

| NONMEMBERS                              |             |
| Full-Time Registration                   | $790.00     |
| Nonmember Residents, Students, Advocacy |             |
| Group Members, or Mental Health Chaplains| $95.00      |
| Daily Registration (Nonmember)          | $400.00     |
| Medical Students                        | no charge   |

| GUEST REGISTRATION                      |             |
| One only per full-time registrant       | $100.00     |
| Only one guest is allowed to register   |             |
| with each full-time meeting registrant  |             |
| The guest must reside in the same       |             |
| household and be able to receive mail   |             |
| at the same address. APA members         |             |
| cannot register as a "guest"; they      |             |
| must register as an APA member.         |             |

| One-Day Exhibit Hall Only Pass (18 and older) | $10.00       |
| (Only paid registrant can purchase an exhibit hall pass) | |

On-site fees can be paid by cash, check, money order, American Express, VISA or MasterCard. Registration fees are waived only for CME Course Faculty, APA Honorary Fellows, APA Distinguished Fellows, APA Life Fellows, medical students (with proper identification), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the day) they present.

NONMEMBER PSYCHIATRIC RESIDENTS AND OTHER FULL-TIME STUDENTS must present documentation to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 hours per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

NAME BADGES
Badges are required for all sessions including the Opening Session and exhibit area. Only an APA member badge will admit you to the Business Meeting.

Badges are required for all sessions including the Opening Session and exhibit area. Only an APA member badge will admit you to the Business Meeting.

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>APA MEMBERS</td>
<td></td>
</tr>
<tr>
<td>Full-Time Registration</td>
<td>$275.00</td>
</tr>
<tr>
<td>International Members</td>
<td>$425.00</td>
</tr>
<tr>
<td>Members-in-Training (Member Class MT)</td>
<td>$75.00</td>
</tr>
<tr>
<td>Daily Registration (North American)</td>
<td>$140.00</td>
</tr>
<tr>
<td>Daily Registration (International)</td>
<td>$215.00</td>
</tr>
<tr>
<td>Medical Students</td>
<td>no charge</td>
</tr>
</tbody>
</table>

| NONMEMBERS                              |             |
| Full-Time Registration                   | $790.00     |
| Nonmember Residents, Students, Advocacy |             |
| Group Members, or Mental Health Chaplains| $95.00      |
| Daily Registration (Nonmember)          | $400.00     |
| Medical Students                        | no charge   |

| GUEST REGISTRATION                      |             |
| One only per full-time registrant       | $100.00     |
| Only one guest is allowed to register   |             |
| with each full-time meeting registrant  |             |
| The guest must reside in the same       |             |
| household and be able to receive mail   |             |
| at the same address. APA members         |             |
| cannot register as a "guest"; they      |             |
| must register as an APA member.         |             |

| One-Day Exhibit Hall Only Pass (18 and older) | $10.00       |
| (Only paid registrant can purchase an exhibit hall pass) | |

On-site fees can be paid by cash, check, money order, American Express, VISA or MasterCard. Registration fees are waived only for CME Course Faculty, APA Honorary Fellows, APA Distinguished Fellows, APA Life Fellows, medical students (with proper identification), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the day) they present.

NONMEMBER PSYCHIATRIC RESIDENTS AND OTHER FULL-TIME STUDENTS must present documentation to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 hours per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

Note: There are no exemptions or reduced fees available for CME courses. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the Program Book, APA Exhibits Guide, and New Research Program and Abstract Books, and for most categories, a copy of the Syllabus.

CME COURSE ENROLLMENT
TICKET PURCHASE REQUIRED FOR CME COURSES
Located in the North Pavilion, Level 1, Javits Center. Hours of operation are the same as registration. Tickets for CME Courses not sold by April 3 will be on sale to all registrants beginning at 10:00 a.m. on Saturday, May 1. You must show your registration badge before you can enroll in courses.

APA ART ASSOCIATION
Located in the Registration Area and staffed during the Resource Center's hours. The exhibit includes paintings, photography, ceramics, and crafts done by APA members and/or their significant others. Please stop by the exhibit for information on joining the APA Art Association.

APA AUXILIARY BOOTH
Located on the North Concourse, Level 2, Javits Center. Hours of operation: Saturday, May 1, through Wednesday, May 5, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Auxiliary's program schedule and information on membership.

APA PERIODICALS
Complimentary copies of the latest issues of The American Journal of Psychiatry, Psychiatric Services, Academic Psychiatry, The American Journal of Geriatric Psychiatry, The Journal of Neurosurgery, and Clinical Neurosurgery, Psychosurgery, and APA's new CME journal, Focus, may be obtained at the APA/APP Sponsored Exhibit in the Apples Bookstore. Complimentary copies of Psychiatric News will be available at stands located throughout Javits Center. Staff will sell discounted subscriptions to all APA/APP journals, demonstrate online access for subscribers, answer questions regarding submissions, and show authors and reviewers how to use Manuscript Central, the new Web-based manuscript submission and review system. Persons who wish to contact editors or reporters of Psychiatric News are asked to leave a message on the message board in the Annual Meetings Office. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper's consideration may be left with staff at the Periodicals Exhibit.

AUDIOTAPES
Audiotapes of most sessions are available shortly after each session concludes and may be purchased at the Multi-tape Booth located on the North Concourse, in Javits Center.

CONTINUING MEDICAL EDUCATION
Educational Objectives: At the conclusion of this meeting, participants will be able to:
- Better understand new research findings in the fields of psychiatry and neuroscience;
- Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;
- Identify and remove barriers to the transfer of new knowledge for their practice, including provision of culturally competent care for diverse populations;
- Assess a variety of treatment choices, including psychotherapeutic and pharmacological options; and
- Better understand mental health service delivery issues, including barriers to care.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 66 category 1 CME credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions on the official Annual Meeting program, with some exceptions, meet the criteria for category 1 CME credit. Sessions in the following program
formats are designated as category 1: Advances in Psychopharmacology, Advances in Research, Clinical Case and Continuous Clinical Case Conferences, CME Courses, Focus Live, Forums, Industry-Supported Symposia, Lectures, Medical Updates, New Research Oral/Slide Sessions, Research Advances in Medicine, Presidential Symposia, Review of Psychiatry, Scientific and Clinical Reports, Symposia, and Workshops. Other program activities may be reported as category 2: Debate, Discussion Groups, Master Educator Clinical Consultations, New Research Poster Sessions, and Research Consultations. Scientific sessions are open to all Annual Meeting registrants, except for the Clinical Case and Continuous Clinical Case Conferences and the Master Educator Clinical Consultations, which are open to APA members only.

PLEASE NOTE: APA MEMBERS ARE REQUIRED TO MAINTAIN THEIR OWN RECORDS OF CME HOURS. REPORTING OF CME CREDIT IS ON AN HONOR BASIS.

To document CME credit earned at the Annual Meeting, participants should record the sessions they attended on the Certificate of Attendance log sheet found in the front of the 2004 Annual Meeting CME Syllabus & Proceeding Summary Book. Credit is earned on an hour-for-hour basis. A parchment Certificate of Attendance is also available.

The Certificate of Attendance (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires members to participate in a total of 150 hours of CME activities within a three-year reporting period. At least 60 hours must be in category 1 activities.

CME report forms may be obtained from the Department of CME at the APA or online at www.psych.org. Staff will be available in the APA Resource Center to answer any of your questions about CME.

ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year’s Annual Meeting. A participant evaluation form is enclosed with your registration packet and includes instructions for completing the form. BEFORE YOU LEAVE THE MEETING, PLEASE COMPLETE YOUR FORM AND DROP IT IN ONE OF THE EVALUATION BOXES LOCATED THROUGHOUT THE MEETING SITES. You can receive a parchment Certificate of Attendance at the Annual Meeting by returning your completed form (to the Annual Meetings Office, Information/Locator Center, or APA Exhibit, all located in Javits Center) or by completing the computerized general evaluation on the Concourse, Level 1, in Javits Center.

SESSION CAPACITY

So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

- Please find seating as far forward as possible.
- Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
- Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
- If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use and by members of the media. Registrants are welcome to use their own small, portable audiotape recorders to record any session except the Master Educator Clinical Consultations, Clinical Case Conferences, and the Continuous Clinical Case Conference, or unless prohibited by the presenters. Larger professional tape recorders, however, are not permitted other than those utilized by members of the media and personnel representing the professional taping firm authorized by APA to audiotape sessions. The badges of personnel representing this firm and members of the media will clearly identify them. Non-media registrants are not permitted to videotape any session because the intrusive nature of the recording may disrupt the session. More detailed guidelines for media representatives may be obtained in the Press Office.

SMOKING POLICY

There will be NO SMOKING in scientific sessions or in the exhibit hall. Smoking will only be permitted in designated areas.

GUIDE TO THE PROGRAM BOOK

On page V, you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day’s sessions is listed by start time with the formats listed alphabetically under those times. NOTE: To make it easier for you to plan your day, we have prepared a separate "Days-at-a-Glance," which is included in your registration packet.

If you have any questions about this book or the scientific sessions, please feel free to stop by the Annual Meetings Office in Javits Center, and we will be glad to help you. Also, all central office APA staff members will be wearing green badges. Please feel free to direct your questions to them.

FUTURE APA MEETINGS

APA ANNUAL MEETINGS

2005 May 21-26
2006 May 20-25
Atlanta, GA
Toronto, Ont., Canada

INSTITUTES ON PSYCHIATRIC SERVICES

2004 October 6-10
2005 October 5-9
2006 October 6-10
Atlanta, GA
San Diego, CA
New York, NY

Tentative program schedules and hotel information for the 2004 Institute on Psychiatric Services are available at the Information/Locator Center, located on the North Concourse, Javits Center.
TABLE OF CONTENTS

Floor Plans for Javits Center, New York Hilton, and Marriott Marquis .............................................................. VI-XV
City Map .................................................................................................................................................. XVI
Local Information ........................................................................................................................................ XVII
Special Acknowledgments .......................................................................................................................... XVIII-XX
Audiotape Sales Information ...................................................................................................................... XXI
Format Descriptions .................................................................................................................................. XXII-XXIII
Disclosure Information ............................................................................................................................. XXIV-XXXIX
Saturday Sessions ...................................................................................................................................... 1-4
Sunday Sessions .......................................................................................................................................... 5-12
Monday Sessions .......................................................................................................................................... 13-40
Tuesday Sessions ......................................................................................................................................... 41-67
Call for 2005 Annual Meeting Papers ........................................................................................................ 68
Wednesday Sessions .................................................................................................................................... 69-92
Thursday Sessions ........................................................................................................................................ 93-106
Topic Index .................................................................................................................................................. 107-121
Participant Index .......................................................................................................................................... 122-134
Call for 2005 Annual Meeting Papers ......................................................................................................... 135
Audiotape Sales Information ....................................................................................................................... 136
2004 Institute on Psychiatric Service ............................................................................................................. 137
American Psychiatric Publishing Inc. ........................................................................................................... 138-139
Industry-Supported Symposia ...................................................................................................................... 140-166
APA Exhibit ................................................................................................................................................ Back Cover

Refer to the APA Exhibits Guide for information on: Exhibits, Publishers' Bookfair, and Dining Facilities in Javits Center.

The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.

© American Psychiatric Association.
Getting Around the Javits Center
LOCAL INFORMATION

New York City is the Capital of the World. It's a magnet for meetings, because there's something for everyone: for high-rollers and the budget-conscious, art aficionados and sports fans, lovers of show tunes and lovers of Wagner. It's a city of architectural treasures and gorgeous parks, and it's easy to get to. New York is a city of over nine million people covering 301 square miles. New York City is made up of five distinct boroughs: Manhattan (where the vast majority of sights are located), the Bronx, Queens, Brooklyn, and Staten Island. Many of New York's oldest and newest buildings rub shoulders in Lower Manhattan. It is from here, too, that you can take the Staten Island ferry for breathtaking views of the famous skyline and the Statue of Liberty. The Theater District and Midtown offer Fifth Avenue's glittering shops as well as museums, entertainment, and such landmark skyscrapers as the glorious Chrysler Building. Museum Mile on the Upper East Side is a cultural paradise, and since it runs alongside Central Park, you can rest en-route and watch New Yorkers at play.

ACCESSIBILITY

Buses and trains have individual travel passes there is no joint travel pass. Avoid buses, taxis, and the subway during rush hour; walk instead.

Taxi stands are scarce. Hotels, Penn Station, and Grand Central Terminal are the best places to find one, or hail one in the street. All licensed taxi cabs are yellow, available when roof numbers are lit up.

The subway is open 24 hours a day, full service between 6:00 a.m. and midnight.

AIRPORT TRANSPORTATION

From JFK, Queens, NY
Distance to midtown = 25 miles
Means of transportation:
Private car service = $25 - $130
Public bus (MTA) = $2.00
Subway (MTA) = $2.00
Shuttle services = $10 - $15

From LaGuardia, Queens, NY
Distance to midtown = 8 miles
Means of transportation:
Private car service = $25 - $150
Public bus (MTA) = $2.00
Subway (MTA) = $2.00
Shuttle services = $13 - $19

TAXI COMPANIES

New York City Taxi & Limousine Commission regulates the city's famous yellow fleet of 12,187 licensed medallion taxis. Within the city, taxis cruise the streets looking for passengers. Taxi stands are at many hotels and transportation terminals. Yellow medallion taxis are the only vehicles authorized to pick up street hails. One fare covers all passengers: cabs need not be shared. Fare begins at $2.00, and then increases 30¢ for each fifth of a mile (or 90 seconds of waiting time). Nightly 50¢ surcharge 8:00 p.m.-6:00 a.m.

TOURS/VISITOR INFORMATION

APA has contracted with a company to provide a limited number of local tours. Detailed information may be viewed and you may sign up for tours by going to the APA website (www.psych.org) and clicking on the direct link to the tour company.

FOREIGN CURRENCY EXCHANGE

American Express at Bloomingdale's, 59th Street and Lexington Avenue (10:00 a.m.-6:00 p.m.).
Chequepoint USA, 1568 Broadway, 8:00 a.m.-11:30 p.m.
Harold Reuter & Co.; Grand Central Station, 7:00 a.m.-7:00 p.m., Monday-Friday; 8:00 a.m.-3:00 p.m., Saturday and Sunday.
Kara International, 1225 Broadway, Suite 813, 9:00 a.m.-6:00 p.m., Monday-Friday; 9:00 a.m.-3:30 p.m., Saturday.
Thomas Cook, 1590 Broadway, 9:00 a.m.-7:00 p.m., Monday-Saturday.

MEDICAL EMERGENCIES

NY Hotel Urgent Medical Services/Travelers Medical Center
952 Fifth Avenue (76th - 77 Streets), #1D, NYC 10021. Telephone: (212) 737-1212. Contact Sheila Martinez. Medical/dental services 24 hours for house calls or at urgent care center, provided by caring, board-certified doctors.

APA GOLF TOURNAMENT

The Golfers of the APA (GAPA) invite you to participate in their 2004 golf tournament to benefit the American Psychiatric Foundation. The tournament is scheduled for Monday, May 3, 2004, at Cherry Creek Golf Links. This is a scenic links-style course with rolling fairways and elevated tees and greens situated in Riverhead on the eastern end of Long Island. The course, designed by Charles Jurgens can stretch to 7,187 yards with a par of 73 and the fairways are generous and long with water coming into play on four of the holes. If you are interested in registering for this event, please contact W. Stanley Jennings, Jr., M.D., at 804-320-7881, by email at wsjennings@tuckerpsychiatric.com or mbears@comcast.net or by mail, W.S. Jennings, Jr., M.D., 7149 Jahnke Road, Richmond, VA 23225.

TOP TEN NY RESTAURANTS (212-)

Café des Artistes, 1 W. 67th St., 877-3500
Florent, 69 Gansevoort St., 989-5779
The Four Seasons, 99 E. 52nd St., 754-9494
Golden Unicorn, 18 E. Broadway, 941-0911
Hatsumura, 17 E. 48th St., 355-3345
Lespinasse, St. Regis Hotel, 2 E. 55th St., 339-6719
Oyster Bar, Grand Central Terminal, Grand Central Station, Lower Level, 496-6650
The Rainbow Room, 65th Floor, GE Building, 30 Rockefeller Plaza, 632-5000
Union Square Café, 21 E. 16th St., 243-4020
Zen Palate, 663 9th Ave., 582-1669

BROADWAY THEATERS (212-)

Ambassador, 215 W. 49th St., 239-6200
Barrymore, 243 W. 47th St., 239-6200
Belasco, 111 W. 44th St., 239-6200
Booth, 222 W. 45th St., 239-6200
Broadhurst, 235 W. 44th St., 239-6200
Broadway, 1681 Broadway, 239-6200
Brooks Atkinson, 256 W. 47th St., 307-4100
Cort, 138 W. 48th St., 239-6200
Eugene O'Neill, 230 W. 49th St., 239-6200
Gershwin, 222 W. 51st St., 307-4100
John Golden, 252 W. 45th St., 239-6200
Helen Hayes, 240 W. 44th St., 307-4100
Imperial, 249 W. 45th St., 239-6200
Longacre, 120 W. 48th St., 239-6200
Lunt-Fontanne, 205 W. 46th St., 307-4100
Lyceum, 149 W. 45th St., 239-6200
Majestic, 245 W. 44th St., 239-6200
Marquis, 211 W. 45th St., 307-4100
Martin Beck, 302 W. 45th St., 239-6200
Minskoff, 200 W. 45th St., 307-4100
Music Box, 239 W. 45th St., 239-6200
Nederlander, 208 W. 41st St., 307-4100
Neil Simon, 250 W. 52nd St., 307-4100
Palace, 1564 Broadway, 307-4100
Plymouth, 236 W. 45th St., 239-6200
Richard Rodgers, 225 W. 46th St., 307-4100
Roundabout, 1530 Broadway, 869-8400
Royale, 242 W. 45th St., 239-6200
St. James, 246 W. 44th St., 239-6200
Shubert, 225 W. 44th St., 239-6200
SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

**Abbott Laboratories**: support of the Industry-Supported Symposia, “Combination Therapy: New Strategies in the Management of Severe Mental Disorders,” Sunday, May 2, 1:30 p.m.; and “Challenges in Treating Bipolar Illness and Comorbid Disorders,” Tuesday, May 4, 7:00 p.m.

**American Academy of Psychiatry and the Law**: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 2, 2:30 p.m.

**American Association of Psychiatric Administrators**: co-support of the Administrative Psychiatry Award Lecture, Wednesday, May 5, 11:00 a.m.

**American Psychiatric Foundation**: support of the Disaster Psychiatry Fellowship; and the APIRE Practice Research Network (PRN).

**Association of Mental Health Clergy**: co-support of the Oskar Pfister Award Lecture, Tuesday, May 4, 11:00 a.m.

**Association of Women Psychiatrists**: support of the joint AWP/APA Women’s Career reception and meeting.

**AstraZeneca Pharmaceuticals**: support of the Industry-Supported Symposia, “The Role of Dopamine in Health and Illness: Science to Practice,” Saturday, May 1, 6:00 p.m.; “Broadening the Horizon of Atypical Antipsychotic Applications,” Sunday, May 2, 8:00 a.m.; and “Choosing the Right Dose of Atypical Antipsychotics: Art or Science?,” Sunday, May 2, 7:00 p.m.; the Industry-Supported Breakfast Symposium, “Transcending Efficacy: Effective Treatment of Psychosis Across Disorders” Monday, May 3, and Tuesday, May 4, 7:00 a.m.; the APA/AstraZeneca Minority Fellowship and reception, Monday, May 3, 8:00 p.m.; the American Psychiatric Foundation “Conversations” event, Tuesday, May 4, 5:30 p.m.; the APIRE/AstraZeneca Young Minds in Psychiatry Award; and the AstraZeneca Young Minds and Minority Fellows Poster Session, Monday, May 3, 7:00 p.m.

**Aventis**: support of the Travel Fellowship for Women Resident Leaders in Psychiatry and Leadership Luncheon, Sunday, May 2, 12 noon.

**Bristol-Myers Squibb Company**: support of the Industry-Supported Symposia, “Effective Long-Term Management of Schizophrenia: Real-World Considerations,” Sunday, May 2, 7:00 p.m.; “BPD: Regulation of Affect and Impulse Control,” Monday, May 3, 7:00 p.m.; and “Optimizing Antipsychotic Treatment in Patients With Schizophrenia and Bipolar Disorder,” Wednesday, May 5, 7:00 p.m.; the Industry-Supported Breakfast Symposium, “New Advances in the Treatment of Psychosis,” Monday, May 3, and Tuesday, May 4, 7:00 a.m.; the APA’s Solomon Carter Fuller Award Lecture, Monday, May 3, 2:00 p.m.; and the Reception for the Solomon Carter Fuller Award Recipient.

**Eisai, Inc., Pfizer Inc.**: support of the Industry-Supported Symposium, “Adult ADHD: Clinical Utility and Validity,” Saturday, May 1, 12:30 p.m.; “Bipolar Disorder: Improving Outcomes When Theory, Science, and Clinical Practice Converge,” Saturday, May 1, 6:00 p.m.; and “Recovering From Schizophrenia: How Treatment Can Improve Outcomes and Prevent Chronicity,” Sunday, May 2, 7:00 p.m.; the Industry-Supported Breakfast Symposium, “Recognizing the Many Faces of Bipolar Disorder,” Monday, May 3, and Tuesday, May 4, 7:00 a.m.; partial support of the Simon Bolivar Award Lecture, Wednesday, May 5, 9:00 a.m.; and support of the APA/Lilly Resident Research Awards.

**Eli Lilly and Company**: support of the Industry-Supported Symposia, “Conversations” event, Tuesday, May 4, 5:30 p.m.; the APIRE/AstraZeneca Young Minds in Psychiatry Award; and the AstraZeneca Young Minds and Minority Fellows Poster Session, Monday, May 3, 7:00 p.m.

**Forest Laboratories, Inc.**: support of the Industry-Supported Symposia, “From Pathology to Practice: Evolving Therapeutic Strategies for Alzheimer’s Disease,” Sunday, May 2, 8:00 a.m.; “Moderators and Mediators of Antidepressant Response,” Sunday, May 2, 7:00 p.m.; and “Panic Anxiety: Understanding Its Nature and Nurturing Recovery,” Tuesday, May 4, 7:00 p.m.; the Industry-Supported Breakfast Symposium, “Current Alzheimer’s Disease Treatments and Beyond: Advances Impacting Clinical Practice,”

**Cyberonics, Inc.**: support of the American Psychiatric Foundation “A Toast to New York” benefit event, Monday, May 3, 7:00 p.m.

**Eli Lilly and Company**: support of the Industry-Supported Symposia, “Novel Intervention Strategies Across the Spectrum of Dementia: Real Patients and Real Outcomes,” Sunday, May 2, 7:00 p.m.

**Cyberonics, Inc.**: support of the American Psychiatric Foundation “A Toast to New York” benefit event, Monday, May 3, 7:00 p.m.

**Eisai, Inc., Pfizer Inc.**: support of the Industry-Supported Symposium, “Novel Intervention Strategies Across the Spectrum of Dementia: Real Patients and Real Outcomes,” Sunday, May 2, 7:00 p.m.

**Forest Laboratories, Inc.**: support of the Industry-Supported Symposia, “From Pathology to Practice: Evolving Therapeutic Strategies for Alzheimer’s Disease,” Sunday, May 2, 8:00 a.m.; “Moderators and Mediators of Antidepressant Response,” Sunday, May 2, 7:00 p.m.; and “Panic Anxiety: Understanding Its Nature and Nurturing Recovery,” Tuesday, May 4, 7:00 p.m.; the Industry-Supported Breakfast Symposium, “Current Alzheimer’s Disease Treatments and Beyond: Advances Impacting Clinical Practice,”

**Cyberonics, Inc.**: support of the American Psychiatric Foundation “A Toast to New York” benefit event, Monday, May 3, 7:00 p.m.

**Eisai, Inc., Pfizer Inc.**: support of the Industry-Supported Symposium, “Novel Intervention Strategies Across the Spectrum of Dementia: Real Patients and Real Outcomes,” Sunday, May 2, 7:00 p.m.

**Forest Laboratories, Inc.**: support of the Industry-Supported Symposia, “From Pathology to Practice: Evolving Therapeutic Strategies for Alzheimer’s Disease,” Sunday, May 2, 8:00 a.m.; “Moderators and Mediators of Antidepressant Response,” Sunday, May 2, 7:00 p.m.; and “Panic Anxiety: Understanding Its Nature and Nurturing Recovery,” Tuesday, May 4, 7:00 p.m.; the Industry-Supported Breakfast Symposium, “Current Alzheimer’s Disease Treatments and Beyond: Advances Impacting Clinical Practice,”

**Cyberonics, Inc.**: support of the American Psychiatric Foundation “A Toast to New York” benefit event, Monday, May 3, 7:00 p.m.

**Eisai, Inc., Pfizer Inc.**: support of the Industry-Supported Symposium, “Novel Intervention Strategies Across the Spectrum of Dementia: Real Patients and Real Outcomes,” Sunday, May 2, 7:00 p.m.

**Forest Laboratories, Inc.**: support of the Industry-Supported Symposia, “From Pathology to Practice: Evolving Therapeutic Strategies for Alzheimer’s Disease,” Sunday, May 2, 8:00 a.m.; “Moderators and Mediators of Antidepressant Response,” Sunday, May 2, 7:00 p.m.; and “Panic Anxiety: Understanding Its Nature and Nurturing Recovery,” Tuesday, May 4, 7:00 p.m.; the Industry-Supported Breakfast Symposium, “Current Alzheimer’s Disease Treatments and Beyond: Advances Impacting Clinical Practice,”

**Cyberonics, Inc.**: support of the American Psychiatric Foundation “A Toast to New York” benefit event, Monday, May 3, 7:00 p.m.

**Eisai, Inc., Pfizer Inc.**: support of the Industry-Supported Symposium, “Novel Intervention Strategies Across the Spectrum of Dementia: Real Patients and Real Outcomes,” Sunday, May 2, 7:00 p.m.

**Forest Laboratories, Inc.**: support of the Industry-Supported Symposia, “From Pathology to Practice: Evolving Therapeutic Strategies for Alzheimer’s Disease,” Sunday, May 2, 8:00 a.m.; “Moderators and Mediators of Antidepressant Response,” Sunday, May 2, 7:00 p.m.; and “Panic Anxiety: Understanding Its Nature and Nurturing Recovery,” Tuesday, May 4, 7:00 p.m.; the Industry-Supported Breakfast Symposium, “Current Alzheimer’s Disease Treatments and Beyond: Advances Impacting Clinical Practice,”

**Cyberonics, Inc.**: support of the American Psychiatric Foundation “A Toast to New York” benefit event, Monday, May 3, 7:00 p.m.

**Eisai, Inc., Pfizer Inc.**: support of the Industry-Supported Symposium, “Novel Intervention Strategies Across the Spectrum of Dementia: Real Patients and Real Outcomes,” Sunday, May 2, 7:00 p.m.

**Forest Laboratories, Inc.**: support of the Industry-Supported Symposia, “From Pathology to Practice: Evolving Therapeutic Strategies for Alzheimer’s Disease,” Sunday, May 2, 8:00 a.m.; “Moderators and Mediators of Antidepressant Response,” Sunday, May 2, 7:00 p.m.; and “Panic Anxiety: Understanding Its Nature and Nurturing Recovery,” Tuesday, May 4, 7:00 p.m.; the Industry-Supported Breakfast Symposium, “Current Alzheimer’s Disease Treatments and Beyond: Advances Impacting Clinical Practice,”
Monday, May 3, and Tuesday, May 4, 7:00 a.m.; the American Psychiatric Foundation "A Toast to New York" benefit event, Monday, May 3, 7:00 p.m.; and the registration portfolios.

GlaxoSmithKline: support of the Industry-Supported Symposia, “Preventive Psychiatry in Mood Disorders: A New Frontier,” Saturday, May 1, 12:30 p.m.; “Sex, Sexuality, and 5HT,” Saturday, May 1, 6:00 p.m.; “The Hidden Faces of Anxiety,” Sunday, May 2, 8:00 a.m.; “Psychopharmacology and Reproductive Transitions: Impact of Psychotropic Medications and Sex Hormones on Brain Functioning, Weight, and Reproductive Safety,” Sunday, May 2, 7:00 p.m.; and “Does the Pharmacology of Antidepressant Drugs Matter?” Tuesday, May 4, 7:00 p.m.; the Industry-Supported Breakfast Symposium, “Bipolar Disorder in Women: Reproductive Implications of Treatment,” Wednesday, May 5, 7:00 a.m.; the APA/GlaxoSmithKline Fellowship Program and reception; the annual contribution to the APA Presidential Fund; the APA/GlaxoSmithKline Young Faculty Award for Research Development in Biological Psychiatry; the APIRE/GlaxoSmithKline Severe Mental Illness Fellowship; and the American Psychiatric Foundation “A Toast to New York” benefit event, Monday, May 3.

Gnalick Foundation: support of the Alexander Gralnick, M.D., Award for Research in Schizophrenia.

Harding Foundation: co-support of the Oskar Pfister Award Lecture, Tuesday, May 4, 11:00 a.m.

Ittleson Foundation: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

Janssen Pharmaceutica and Research Foundation: support of the Industry-Supported Symposia, “Treatment Resistance: Concepts and Management in Mood and Anxiety Disorders,” Saturday, May 1, 12:30 p.m.; and “Unmasking Bipolar Disorder: Overcoming the Barriers to Treatment Success,” Sunday, May 2, 1:30 p.m.; the Committee of Asian-American Psychiatrists recruitment reception; and the American Psychiatric Institute for Research and Education/Janssen Research Scholars on Severe Mental Ill Program.

Johnon & Johnson: support of an unrestricted educational grant to support international activities.

Lilly Research Laboratories, a Division of Eli Lilly & Company: support of the APA/Lilly Psychiatric Research Fellowship.


National Institute of Mental Health: co-support of the APA/NIMH Vestermark Psychiatry Educator Award Lecture, Wednesday, May 5, 2:00 p.m.; support of the American Psychiatric Institute for Research in Education (APIRE) Annual Meeting activities for research trainees; the Program for Minority Research Training in Psychiatry (PMRTP); and the Research Colloquium for Junior Investigators.

National Institute on Drug Abuse: support of the special Annual Meeting series, “Integrating the Science of Addiction into Psychiatric Practice”; the American Psychiatric Institute for Research and Education/Research Training activities; and the Drug Abuse Research Scholars in Psychiatry Program (DARSP).

Neurocrine Biosciences Inc.: support of the Industry-Supported Symposium, “Exploring the True Morbidity of Insomnia,” Tuesday, May 4, 7:00 p.m.

Novartis Pharmaceuticals Corporation: support of the Industry-Supported Symposium, “Reaching Beyond Alzheimer’s Disease With Cholinergic Therapy,” Monday, May 3, 7:00 p.m.

Organon Inc.: support of the Industry-Supported Symposium, “Antidepressant Treatments You May Not Know About, But Should...,” Sunday, May 2, 8:00 a.m.

Ortho-McNeil Pharmaceuticals: support of the Industry-Supported Symposia, “Bipolar Disorder and Alcoholism: Diagnostic Challenges and Therapeutic Interventions,” Saturday, May 1, 12:30 p.m.; “Impulsivity: Emerging Clinical Perspectives,” Saturday, May 1, 6:00 p.m.; and “Binge-Eating Disorder: Genes, Treatments, and Consequences,” Tuesday, May 4, 7:00 p.m.

Otsuka America Pharmaceutical, Inc.: support of the International Medical Graduates (IMG) Caucus Reception; the Minority Mental Health Awards; and the American Psychiatric Foundation “A Toast to New York” benefit event, Monday, May 3, 7:00 p.m.

Pfizer Inc.: support of the Industry-Supported Symposia, “GAD: Evidence-Based Considerations From Pathophysiology to Long-Term Management,” Saturday, May 1, 6:00 p.m.; “The Many Faces of Anxiety: Origins, Pathogenesis, and Management,” Sunday, May 2, 8:00 a.m.; and “Are All Atypical Antipsychotics Equal for Treatment of Cognitive and Affective Symptoms in Schizophrenia?” Sunday, May 2, 1:30 p.m.; partial support of the Simon Bolivar Award Lecture, Wednesday, May 5, 9:00 a.m.; support of the Residents’ Session, “Meet the Experts: Sunny-Side Up,” Monday, May 3, 7:00 a.m.; the “Abstracts-On-Disk” Program; and the APA Daily Bulletin newspaper.

Professional Risk Management Services, Inc.: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 2, 2:30 p.m. and the American Psychiatric Foundation “A Toast to New York” benefit event, Monday, May 3, 7:00 p.m.

Reckitt Benckiser Pharmaceuticals: support of the Industry-Supported Symposium, “Pharmacotherapy of Addictions: From Clinics Into Office Practice,” Monday, May 3, 7:00 p.m.
SPECIAL ACKNOWLEDGMENTS

Roche Laboratories: support of the Industry-Supported Symposium, "Interferon-Induced Depression: Consequences of Treating Chronic Hepatitis C," Monday, May 3, 7:00 p.m.; and the Benjamin Rush Award Lecture, Monday, May 3, 9:00 a.m.

Sanofi-Synthelabo, Inc.: support of the Residents, Medical Students, and Training Directors Luncheon, Sunday, May 2, 12 noon and the American Psychiatric Foundation "A Toast to New York" benefit event, Monday, May 3, 7:00 p.m.

Sepracor, Inc.: support of the Industry-Supported Symposium, "Beyond Sleep Onset: New Perspectives on the Treatment of Insomnia," Sunday, May 2, 7:00 p.m.; and shuttle bus system.

Shire US, Inc.: support of the Industry-Supported Symposia, "Conceptualizing and Treating ADHD Adults," Monday, May 3, 7:00 p.m.; and "Adult ADHD Diagnosis and Treatment," Tuesday, May 4, 7:00 p.m.; and the nine APA/Shire Child and Adolescent Psychiatry Fellowships.

Substance Abuse and Mental Health Services Administration (CMHS, CSAP, CSAT): sponsorship of the APA/SAMHSA Minority Fellowship Program.

The Psychiatrist's Program, The APA-Endorsed Professional Liability Insurance Program: support of the ECP luncheon, Tuesday, May 4, 12 noon.

UCB Pharma, Inc.: support of the Industry-Supported Symposium, "Broadening Horizons: Advances in Understanding the Etiology, Effects, and Treatment of Anxiety Disorders," Sunday, May 2, 8:00 a.m.

University of California-Davis, Department of Psychiatry: support of the Residents, Fellows, and Medical Student's Reception, Monday, May 3, 5:00 p.m.

Wyeth Pharmaceuticals: support of the Industry-Supported Symposia. "Interface Between Depression and Medical Illness," Saturday, May 1, 6:00 p.m.; "The Treacherous Triad for Depression," Sunday, May 2, 1:30 p.m.; "Hormones, Mood, and Cognition: Treatment Considerations in Older Women," Monday, May 3, 7:00 p.m.; "Emotion Regulation and Plasticity of Underlying Circuitry: Implications for Depression, Anxiety, and Long-Term Brain Function," Tuesday, May 4, 7:00 p.m.; and "Core Symptom Domains in the Anxiety Disorders," Wednesday, May 5, 7:00 p.m.; the Industry-Supported Breakfast Symposium, "Evidence-Based Medicine: The Next Generation," Monday, May 3, and Tuesday, May 4, 7:00 a.m. and the APA/Wyeth Pharmaceuticals M.D., Ph.D., Research Fellowship; support of the Jeanne Spurlock, M.D. Congressional Fellowship; and the daily in-house TV program, "APA News Network."
American Psychiatric Association
Audiotapes
Recorded Live!

High Quality Continues for the 2004 Annual Meeting ...

Live recordings will be available for most of the following:

• Lectures • Advances in Research
• Advances in Psychopharmacology
• Presidential Symposia • Medical Updates
• Scientific and Clinical Reports • Symposia
• Debate • Roundtable Discussion
• Research Advances in Medicine

Tapes may be purchased on site at Mobiltape's booth at the Javits Convention Center.

Mobiltape Company, Incorporated
24730 Avenue Tibbitts, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504 • (800) 369-5718
Fax: (661) 295-8474
Website: www.mobiltape.com
ADVANCES IN PSYCHOPHARMACOLOGY
This three-and-one-half hour session will summarize important new clinical and research findings in the treatment of selected psychiatric disorders, with an emphasis on psychopharmacologic interventions. The session will be based in part, on material contained in *The American Psychiatric Publishing Textbook of Psychopharmacology, Third Edition*, edited by Drs. Alan F. Schatzberg and Charles B. Nemeroff. Authors of selected chapters from the textbook will present material from their chapters. The topics were selected by the editor to represent disorders of particular current interest to psychiatrists and to focus on aspects of psychopharmacology that may be of greatest importance to APA members.

ADVANCES IN RESEARCH
During this two-hour session, a brief overview of major advances in research in psychiatry and a preview of selected research presentations scheduled at the Annual Meeting, leading clinical researchers present the latest developments in four different, clinically-relevant areas of research.

CLINICAL CASE CONFERENCES
During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCES
The presenters will review the progress of psychotherapy in two successive three-hour sessions on consecutive days (Monday-Tuesday and Wednesday-Thursday, beginning at 9:00 a.m.). Audience participation is encouraged throughout. Participants are requested to attend both sessions in their entirety. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES
Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day), six-hour (full-day), and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Participants must purchase tickets to attend.

DEBATE
Experts in the field, including psychiatrists and nonpsychiatrists, will debate a controversial topic in psychiatry. The debate format allows for members to hear both pro and con views about important, interesting and timely concerns for our members. Someone who has expertise in the topic area moderates the debate. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

DISCUSSION GROUPS
This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the expert. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

FOCUS LIVE
These 90-minute sessions allow participants to test their knowledge using an interactive Audience Response System (ARS), offering a new and entertaining way to learn. ARS sessions can make a group of 300 feel like they are having a small group consultation with an expert clinician. Experts, who served as guest editors of *FOCUS*, will lead lively multiple choice question-based discussions, and the audience will enter their answers with hand-held devices. Results are instantly tallied and projected on the screen.

FORUMS
These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

LECTURES
Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturer.

MASTER EDUCATOR CLINICAL CONSULTATIONS
These 90 minute, clinically-based seminars are presented by outstanding educators. Formats and subject matter will vary, but all will utilize clinical material offered by participants. These sessions are limited to 25 participants on a first-come, first-served basis. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDICAL UPDATES
These 90-minute sessions are designed to provide psychiatrists with the latest clinical developments in other areas of medicine. Topics may range from subspecialty areas of adult or pediatric medicine (infectious disease, cardiology, gastroenterology, etc.) to new techniques or procedures in surgery or radiology. The interface between psychiatry and these areas is not necessarily emphasized. The intent is to give participants an update from a physician in a particular specialty.

NEW RESEARCH
This format allows for presentation of the very recent findings. The three types of presentations include: Posters, which are visual, self-explanatory presentations; Young Investigators’ Posters, with presentations from young investigators, residents, medical students, and research or clinical fellows; and Young Investigators’ Oral/Slide which are fifteen-minute presentations with three minutes for discussion.

RESEARCH ADVANCES IN MEDICINE
This two-hour format presents an overview of cutting-edge research in various aspects of medicine. In contrast to the Medical Update series, which is more clinically-focused, this session will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine. Several speakers, authorities in their fields, will present on their topics.

RESEARCH CONSULTATIONS WITH
This 90-minute format provides an opportunity, in a small group setting, for participants to obtain consultations around problems in research from outstanding senior researchers. Participants should come prepared to present a specific problem in research, whether it’s one of research design, methodology, subject selection or data analysis, etc., which could be presented briefly to the consultant. These sessions are limited to 25 participants on a first-come, first-served basis.

REVIEW OF PSYCHIATRY
There will be four, three-and-one-half hour sessions presented, based on the annual American Psychiatric Publishing Review of Psychiatry Series. Each session includes an abridged presentation by the senior author from each of the chapters in each volume. The topics were selected by the overall editors of the series to represent current areas of new research, new developments in clinical care, and special issues of importance to APA members.
FORMAT DESCRIPTIONS

SCIENTIFIC AND CLINICAL REPORT SESSIONS
Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussant.

SYMPOSIA
Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as “Industry-Supported Symposia” in this Program Book.

WORKSHOPS
Workshops are 90-minute sessions (either Issue or Component), which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive.

Media Workshops are three-hour sessions held Monday-Thursday, in which a feature-length film is shown and discussed.
The American Psychiatric Association requires disclosure by presenters at CME activities of any significant financial or other affiliation with commercial goods/organization(s) regulated by the Food and Drug Administration, which may have a direct or indirect interest in the subject matter of the scientific program. A “financial interest” may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include, holding a position on an advisory committee or some other role or benefit to a supporting organization. The existence of such relationships does not necessarily constitute a conflict of interest, but the prospective audience must be informed of the presenter’s affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if AV equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The following presenters have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial services(s). The presenter's name and the company's name are listed below, along with the page # the presenter appears on this Program Book. The nature of the presenter's relationship with the disclosed company is indicated by the following code: consultant or advisory board¹, full-time employment², research/grant support³, speakers' bureau⁴, stock or other financial options⁵, other financial or business relationships⁶. If a number has not been assigned, the presenter has not disclosed the relationship to the company.

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Susan E. Abbey, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company⁴; Lundbeck⁵; GlaxoSmithKline⁶; U.S. Pharmaceuticals, Pfizer Inc.; Organon Pharmaceuticals Inc.⁴</td>
<td>87</td>
</tr>
<tr>
<td>Anissa Abi-Dargham, M.D.</td>
<td>Bristol-Myers Squibb⁶</td>
<td>11</td>
</tr>
<tr>
<td>Lenard A. Adler, M.D.</td>
<td>Novartis Pharmaceuticals Corporation⁷; U.S. Pharmaceuticals, Pfizer Inc.⁵</td>
<td>2, 67</td>
</tr>
<tr>
<td>George S. Alexopoulos, M.D.</td>
<td>Eli Lilly and Company⁴; Shire Ridgwood Pharmaceuticals⁶; McNeil Pharmaceuticals⁶; Johnson and Johnson PRD⁶</td>
<td>7</td>
</tr>
<tr>
<td>Nassima Ait-Daoud, M.D.</td>
<td>Johnson and Johnson PRD¹</td>
<td>64</td>
</tr>
<tr>
<td>Hagop S. Akiskal, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company⁴; GlaxoSmithKline⁶; Bristol-Myers Squibb⁶; Janssen Pharmaceutica Inc.⁴</td>
<td>65</td>
</tr>
<tr>
<td>Andrew F. Angelino, M.D.</td>
<td>Forest Laboratories, Inc.; Cephalon Inc.⁴; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica Inc.⁴; Bristol-Myers Squibb⁶</td>
<td>47, 56, 70</td>
</tr>
<tr>
<td>Raymond F. Anton, Jr., M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company⁴; Boehringer Ingelheim⁶; Schering Corporation⁴; Wyeth Ayerst Laboratories⁴</td>
<td>64</td>
</tr>
<tr>
<td>Michael R. Arambula, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.⁴</td>
<td>46</td>
</tr>
<tr>
<td>David B. Arciniegas, M.D.</td>
<td>Novartis Pharmaceuticals Corporation⁷; U.S. Pharmaceuticals, Pfizer Inc.⁴; Janssen Pharmaceutica Inc.⁴</td>
<td>87, 93</td>
</tr>
<tr>
<td>Scott C. Armstrong, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.⁴; Novartis Pharmaceuticals Corporation⁴; Eli Lilly and Company⁴</td>
<td>71</td>
</tr>
<tr>
<td>Bruce A. Arrow, Ph.D.</td>
<td>Saropharmaceuticals, Inc.; Regeneron; Amgen; TAP Pharmaceuticals; Bristol-Myers Squibb; Abbott Laboratories, Inc.⁶; Ortho McNeil Pharmaceuticals⁶; Roche Laboratories, a member of the Roche Group⁴</td>
<td>39</td>
</tr>
<tr>
<td>Louis J. Aronne, M.D.</td>
<td>Eli Lilly and Company⁴</td>
<td>67</td>
</tr>
<tr>
<td>Gregory M. Asnis, M.D.</td>
<td>Roche Laboratories, a member of the Roche Group⁶</td>
<td>38</td>
</tr>
<tr>
<td>Claudia F. Baldassano, M.D.</td>
<td>AstraZeneca Pharmaceuticals⁶</td>
<td>12</td>
</tr>
<tr>
<td>Russell A. Barkley, Ph.D.</td>
<td>Eli Lilly and Company⁴; Shire Ridgwood Pharmaceuticals⁶; Novartis Pharmaceuticals Corporation⁷</td>
<td>39</td>
</tr>
<tr>
<td>Ernest S. Barratt, M.D.</td>
<td>Ortho McNeil Pharmaceuticals⁴</td>
<td>3</td>
</tr>
<tr>
<td>Barbara D. Bartlik, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.⁴; GlaxoSmithKline⁶; Sensaquest, Inc.⁴</td>
<td>60</td>
</tr>
<tr>
<td>Andrius Baslaks, M.D.</td>
<td>AstraZeneca Pharmaceuticals⁷; Novartis Pharmaceuticals Corporation⁷; Janssen Pharmaceutica Inc.⁴</td>
<td>13</td>
</tr>
<tr>
<td>Elizabeth A. Baxter, M.D.</td>
<td>Eli Lilly and Company⁴</td>
<td>80</td>
</tr>
<tr>
<td>Joseph H. Beitchman, M.D.</td>
<td>Eli Lilly and Company⁴</td>
<td>100</td>
</tr>
</tbody>
</table>

XXIV
<table>
<thead>
<tr>
<th>Disclosure Index</th>
<th>45, 58, 82</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Biederman, M.D.</td>
<td>GlaxoSmithKline®</td>
</tr>
<tr>
<td>Ayseal Belger, Ph.D.</td>
<td>Eli Lilly and Company®</td>
</tr>
<tr>
<td>Ruth M. Benca, M.D.</td>
<td>Neurocrine®; US. Pharmaceuticals, Pfizer Inc.; Taakeda Pharmaceuticals®; Sepracor Inc.; Wyeth-Ayerst Laboratories®; Merck &amp; Co., Inc.; Sanofi-Synthelabo Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Joseph Biederman, M.D.</td>
<td>Shire Ridgewood Pharmaceuticals®; Eli Lilly and Company®; Cephalon Inc.; NICHDD; Wyeth-Ayerst Laboratories®; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline®; Stanley Foundation®; Alza/McNeil Pharmaceuticals®; National Institute on Drug Abuse®; Noven Pharmaceutical®</td>
</tr>
<tr>
<td>Jed E. Black, M.D.</td>
<td>Sepracor Inc®</td>
</tr>
<tr>
<td>Mary Blehar, Ph.D.</td>
<td>GlaxoSmithKline®</td>
</tr>
<tr>
<td>Kathleen T. Brady, M.D.</td>
<td>Abbott Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; SmithKline Beecham Pharmaceuticals®</td>
</tr>
<tr>
<td>William Breitbart, M.D.</td>
<td>Cephalon Inc.; Janssen Pharmaceutica Inc.; Purdue Pharma®; Eli Lilly and Company; Bristol-Myers Squibb®</td>
</tr>
<tr>
<td>Ronald Brenner, M.D.</td>
<td>Janssen Pharmaceutica Inc.; Wyeth-Ayerst Laboratories; GlaxoSmithKline®; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
</tr>
<tr>
<td>E. Sherwood Brown, M.D.</td>
<td>AstraZeneca Pharmaceuticals®; Eli Lilly and Company; Bristol-Myers Squibb®</td>
</tr>
<tr>
<td>Richard Brown, M.D.</td>
<td>Janssen Pharmaceutica Inc.; Purdue Pharma®</td>
</tr>
<tr>
<td>Richard A. Brown, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.®</td>
</tr>
<tr>
<td>Thomas E. Brown, Ph.D.</td>
<td>Cephalon Inc.; Eli Lilly and Company®; GlaxoSmithKline Beecham Healthcare®; McNeil Consumer Healthcare®; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Shire Ridgewood Pharmaceuticals®</td>
</tr>
<tr>
<td>Robert S. Brown, Jr., M.D.</td>
<td>Schering Corporation®; Roche Laboratories, a member of the Roche Group®; Ortho Biotech®; Glead; Amgen®</td>
</tr>
<tr>
<td>Peter F. Buckley, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals®; Bristol-Myers Squibb®; Janssen Pharmaceutica Inc.; Novartis Pharmaceuticals Corporation; Eli Lilly and Company®</td>
</tr>
<tr>
<td>Cathy L. Budman, M.D.</td>
<td>Eli Lilly and Company®; Novartis Pharmaceuticals Corporation; Eli Lilly and Company®</td>
</tr>
<tr>
<td>Alan J. Budney, Ph.D.</td>
<td>Sanofi-Synthelabo Pharmaceuticals, Inc.®</td>
</tr>
<tr>
<td>John W. Burruss, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company®; Wyeth-Ayerst Laboratories®; AstraZeneca Pharmaceuticals®; Bristol-Myers Squibb®</td>
</tr>
<tr>
<td>Vivien K. Burt, M.D.</td>
<td>Eli Lilly and Company®; Wyeth-Ayerst Laboratories®; Lilly Research Laboratories, a division of Eli Lilly and Company®</td>
</tr>
<tr>
<td>Marian I. Butterfield, M.D.</td>
<td>Bristol-Myers Squibb®; Lilly Research Laboratories, a division of Eli Lilly and Company®</td>
</tr>
<tr>
<td>Daniel J. Buyse, M.D.</td>
<td>Sanofi-Synthelabo Pharmaceuticals, Inc.; Cephalon Inc.; Sepracor Inc.; Neurocrine®; Wyeth-Ayerst Laboratories®; Lilly Research Laboratories, a division of Eli Lilly and Company®; Merck &amp; Co., Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.®</td>
</tr>
<tr>
<td>Joseph R. Calabrese, M.D.</td>
<td>National Institute of Mental Health®; Abbott Laboratories, Inc.; GlaxoSmithKline®; Giba Geigy Corporation, Pharmaceutical Division; Merck &amp; Co., Inc.; Teva Pharmaceuticals®; Janssen Pharmaceutica Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company®; MacArthur Foundation®; National Alliance for Research in Schizophrenia and Affective Disorders®; Parke-Davis, Division of Warner-Lambert Company®; Robert Wood Johnson Pharmaceutical Research Institute®; Sandoz Pharmaceuticals Corporation; SmithKline Beecham Pharmaceuticals®; Stanley Foundation®; Tap Holdings, Inc.; UCB Pharma, Inc.; Wyeth-Ayerst Laboratories®; AstraZeneca Pharmaceuticals®; Bristol-Myers Squibb®; Eli Lilly and Company®; Janssen Clar®; Novartis Pharmaceuticals Corporation; Shire Ridgewood Pharmaceuticals®</td>
</tr>
<tr>
<td>Lucile Capuron, Ph.D.</td>
<td>Roche Laboratories, a member of the Roche Group®</td>
</tr>
<tr>
<td>Gabrielle Carlson, M.D.</td>
<td>Janssen Pharmaceutica Inc.; Eli Lilly and Company®; Abbott Laboratories, Inc.®</td>
</tr>
<tr>
<td>Linda L. Carpenter, M.D.</td>
<td>Novartis Pharmaceuticals Corporation®; Johnson and Johnson PRD®; Bristol-Myers Squibb®</td>
</tr>
<tr>
<td>David A. Casey, M.D.</td>
<td>Corcept Therapeutics, Inc.; Abbott Laboratories, Inc.; Somerseet Pharmaceuticals®; Wyeth-Ayerst Laboratories®; U.S. Pharmaceuticals, Pfizer Inc.®; Medtronics®</td>
</tr>
<tr>
<td>Giovanni B. Cassano, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.®</td>
</tr>
<tr>
<td>F. Xavier Castellanos, M.D.</td>
<td>McNeil Pharmaceuticals®; Johnson and Johnson PRD®; Shire Ridgewood Pharmaceuticals®; GlaxoSmithKline® R&amp;D®</td>
</tr>
<tr>
<td>Ruby C. Castilla-Puentes, M.D.</td>
<td>GlaxoSmithKline®</td>
</tr>
<tr>
<td>Wilma I. Castilla-Puentes, M.D.</td>
<td>GlaxoSmithKline®</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Kiki D. Chang, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Abbott Laboratories, Inc.; Shire Ridgewood Pharmaceuticals; Janssen Pharmaceutica Inc.; Ortho McNeil Pharmaceuticals; AstraZeneca Pharmaceuticals</td>
</tr>
<tr>
<td>Dennis S. Charney, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Aventis Pharmaceuticals; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Somerene Pharmaceuticals; Vela Pharmaceuticals; Wyeth-Ayerst Laboratories; Organon Pharmaceuticals, Inc.; Otsuka Pharmaceuticals</td>
</tr>
<tr>
<td>K.N. Roy Chengappa, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica Inc.; Ortho McNeil Pharmaceuticals; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation; Abbott Laboratories, Inc.</td>
</tr>
<tr>
<td>Joseph A. Cheong, M.D.</td>
<td>Janssen Pharmaceutica Inc.; GlaxoSmithKline; Ortho McNeil Pharmaceuticals; AstraZeneca Pharmaceuticals; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
</tr>
<tr>
<td>John A. Chiles, M.D.</td>
<td>Janssen Pharmaceutica Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals</td>
</tr>
<tr>
<td>James C.Y. Chou, M.D.</td>
<td>Abbott Laboratories, Inc.</td>
</tr>
<tr>
<td>Daniel D. Christensen, M.D.</td>
<td>Bayer Corporation, Pharmaceutical Division; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Pharmaceutica Inc.; Designer Genes Inc.; Eli Lilly and Company; Eisai America Inc.; NPS Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals; Wyeth-Ayerst Laboratories; Abbott Laboratories, Inc.; Novartis Pharmaceuticals Corporation; Upjohn, Inc.; Ecolis Institute of Human Genetics; Myriad Genetics, Inc.; Oragnon USA; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Berlex Laboratories</td>
</tr>
<tr>
<td>Leslie L. Citrome, M.D.</td>
<td>Eli Lilly and Company; Abbott Laboratories, Inc.; SmithKline Beecham Pharmaceuticals; Forest Laboratories, Inc.</td>
</tr>
<tr>
<td>Bruce M. Cohen, M.D.</td>
<td>Eli Lilly and Company; Merc &amp; Co., Inc.; Variagenes; Forest Laboratories, Inc.; Janssen Pharmaceutica Inc.; Wyeth-Ayerst Laboratories; GlaxoSmithKline; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Berlex Laboratories</td>
</tr>
<tr>
<td>Lee S. Cohen, M.D.</td>
<td>Forest Laboratories, Inc.; Janssen Pharmaceutica Inc.; Wyeth-Ayerst Laboratories; GlaxoSmithKline; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Berlex Laboratories</td>
</tr>
<tr>
<td>Michael Cohen</td>
<td>EEG Spectrum International; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Aventis; Pharmaceuticals; Organon Pharmaceuticals; Eli Lilly and Company; Bristol-Myers Squibb; Zenith-Goldkline</td>
</tr>
<tr>
<td>Kathryn M. Connor, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; Ortho McNeil Pharmaceuticals; Cephalon Inc.; Wyeth-Ayerst Pharmaceutical Company; Solvay Pharmaceuticals, Inc.; Ancile Pharmaceuticals; Nutrition 21</td>
</tr>
<tr>
<td>Jeremy D. Coplan, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Eli Lilly and Company</td>
</tr>
<tr>
<td>Sara A. Corey, M.D.</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Daniel J. Cox, Ph.D.</td>
<td>McNeil Pharmaceuticals</td>
</tr>
<tr>
<td>Joseph T. Coyle, Jr., M.D.</td>
<td>Abbott Laboratories, Inc.; Merc &amp; Co., Inc.; Proctor &amp; Gamble; Applied Biosystems; Aventis; Johnson and Johnson PRD; Pharmaceuticals; Cephalon Inc.; Avera Pharm; Prestwick Pharm</td>
</tr>
<tr>
<td>Kelly L. Cozza, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
</tr>
<tr>
<td>Catherine C. Crone, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Eisai America Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
</tr>
<tr>
<td>Jeffrey L. Cummings, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica Inc.; Bristol-Myers Squibb; Shire Ridgewood Pharmaceuticals; Organon Pharmaceuticals, Inc.; Ono Pharmaceuticals; SynXPharma; Bristol-Myers Squibb; Cephalon Inc.; Abbott Laboratories, Inc; Solvay Pharmaceuticals, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.; Eli Lilly and Company; Lilly Research Laboratories, a division of Eli Lilly and Company; Pure World Botanicals, Inc.; Ancile Pharmaceuticals; Roche Laboratories, a member of the Roche Group; UCB Pharma, Inc.; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals, Inc.; Nutrition 21; Boehringer-Ingelheim Pharmaceuticals; Johnson and Johnson PRD; Allegra; Schubert; Pharmacia &amp; Upjohn Company, Inc.; Boots Pharmaceuticals; Guilford Publications; Bristol-Myers Squibb; MultiHealth Systems Inc.; Penguin Putnam</td>
</tr>
<tr>
<td>Jonathan R.T. Davidson, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica Inc.; Bristol-Myers Squibb; Shire Ridgewood Pharmaceuticals; Organon Pharmaceuticals, Inc.; Ono Pharmaceuticals; SynXPharma; Bristol-Myers Squibb; Cephalon Inc.; Abbott Laboratories, Inc; Solvay Pharmaceuticals, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.; Eli Lilly and Company; Lilly Research Laboratories, a division of Eli Lilly and Company; Pure World Botanicals, Inc.; Ancile Pharmaceuticals; Roche Laboratories, a member of the Roche Group; UCB Pharma, Inc.; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals, Inc.; Nutrition 21; Boehringer-Ingelheim Pharmaceuticals; Johnson and Johnson PRD; Allegra; Schubert; Pharmacia &amp; Upjohn Company, Inc.; Boots Pharmaceuticals; Guilford Publications; Bristol-Myers Squibb; MultiHealth Systems Inc.; Penguin Putnam</td>
</tr>
<tr>
<td>Name</td>
<td>Disclosures</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Lori L. Davis, M.D.         | Abbott Laboratories, Inc.³;
Bristol-Myers Squibb³;
GlaxoSmithKline³;
Forest Laboratories, Inc.³;
Neurocrine Biosciences Inc.³;
Lilly Research Laboratories, a division of Eli Lilly and Company³;
Janssen Pharmaceuticals Inc.³;
Ortho McNeil Pharmaceuticals³⁴; 66, 104 |
| Mary H. Davis, M.D.         | Abbott Laboratories, Inc.³;
Bristol-Myers Squibb³;
GlaxoSmithKline³;
Forest Laboratories, Inc.³;
Wyeth-Ayerst Laboratories³; 18 |
| Charles DeBattista, M.D.    | Abbott Laboratories, Inc.³;
Bristol-Myers Squibb³;
GlaxoSmithKline³;
Forest Laboratories, Inc.³;
Janssen Pharmaceuticals Inc.³;
NARSAD³; National Institute of Mental Health³; 52, 92 |
| Melissa P. DelBello, M.D.   | Abbott Laboratories, Inc.³;
AstraZeneca Pharmaceuticals³; 1-3; Eli Lilly and Company³; 18, 42, 64 |
| Pedro L. Delgado, M.D.      | Abbott Laboratories, Inc.³;
Bristol-Myers Squibb³;
GlaxoSmithKline³;
Forest Laboratories, Inc.³;
Janssen Pharmaceuticals Inc.³;
Organon Pharmaceuticals Inc.³; 39, 43 |
<p>| Abhilash K. Desai, M.D.     | Eli Lilly and Company³; 47, 100 |
| Michael J. Detke, M.D.      | Eli Lilly and Company³; 47, 100 |
| Daniel A. Deutschman, M.D.  | Eli Lilly and Company³; 47, 100 |
| Mantosh J. Dewan, M.D.      | Eli Lilly and Company³; 47, 100 |
| Karl Doghramji, M.D.        | Eli Lilly and Company³; 47, 100 |
| P. Murali Doraiswamy, M.D.  | Eli Lilly and Company³; 47, 100 |
| Martin Dossenbach, M.D.     | Eli Lilly and Company³; 47, 100 |
| Robert E. Drake, M.D.       | Eli Lilly and Company³; 47, 100 |
| Roxanne C. Dryden-Edwards, M.D. | Eli Lilly and Company³; 47, 100 |
| Eduardo Dunayevich, M.D.    | Eli Lilly and Company³; 47, 100 |
| Boadie W. Dunlop, M.D.      | Eli Lilly and Company³; 47, 100 |
| James M. Ellison, M.D.      | Eli Lilly and Company³; 47, 100 |
| Abdelouahed Elmouchtari, M.D.| Eli Lilly and Company³; 47, 100 |
| Milton K. Erman, M.D.       | Eli Lilly and Company³; 47, 100 |
| Javier I. Escobar, M.D.     | Eli Lilly and Company³; 47, 100 |
| Dwight L. Evans, M.D.       | Eli Lilly and Company³; 47, 100 |
| Wanchal E. Faison, M.D.     | Eli Lilly and Company³; 47, 100 |
| Stephen V. Farame, Ph.D.    | Eli Lilly and Company³; 47, 100 |
| Martin K. Farlow, M.D.      | Eli Lilly and Company³; 47, 100 |
| Maurizio Fava, M.D.         | Eli Lilly and Company³; 47, 100 |</p>
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert L. Findling, M.D.</td>
<td>Bristol-Myers Squibb(^1,3,4); Janssen Pharmaceutica Inc.(^1,3,4); AstraZeneca Pharmaceuticals(^1,3,4); Lilly Research Laboratories, a division of Eli Lilly and Company(^1,3)</td>
<td>13, 26</td>
</tr>
<tr>
<td>Helen E. Fisher, Ph.D.</td>
<td>GlaxoSmithKline(^4)</td>
<td>4, 82</td>
</tr>
<tr>
<td>Alastair J. Flint, M.B.</td>
<td>Janssen Pharmaceutica Inc.(^4); Pfizer Canada(^4); Lundbeck Canada(^4); Forest Laboratories, Inc.(^4)</td>
<td>85</td>
</tr>
<tr>
<td>Edna B. Foa, Ph.D.</td>
<td>Ceptalon Inc.(^8)</td>
<td>1, 64, 93</td>
</tr>
<tr>
<td>Ellen Frank, Ph.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.(^1); Pfizer Italia; Eli Lilly and Company(^1); Forest Laboratories, Inc.(^3); Merck &amp; Co., Inc.(^3); Janssen Pharmaceutica Inc.(^3)</td>
<td>1, 59, 102</td>
</tr>
<tr>
<td>Jean A. Frazier, M.D.</td>
<td>AstraZeneca Pharmaceuticals(^4); Bristol-Myers Squibb(^1,3,4); Janssen Pharmaceutica Inc.(^4)</td>
<td>61</td>
</tr>
<tr>
<td>Nick Freemantle, Ph.D.</td>
<td>Wyeth-Ayerst Laboratories(^5); U.S. Pharmaceuticals, Pfizer Inc.(^3)</td>
<td>13</td>
</tr>
<tr>
<td>Edward S. Friedman, M.D.</td>
<td>Wyeth-Ayerst Laboratories(^3,4,5); Cyberonics Inc.(^3); Bristol-Myers Squibb(^3,4,6); Eli Lilly and Company(^3,4); US. Pharmaceuticals, Pfizer Inc.(^3); Organon Pharmaceuticals, Inc.(^3); Forest Laboratories, Inc.(^3); Merck &amp; Co., Inc.(^3); Pfizer Inc.(^3); Pfizer Inc.(^3); Cephalon Inc.(^1); GlaxoSmithKline(^1); Abbott Laboratories, Inc.(^3); Upjohn (Kalamazoo, MI)(^3)</td>
<td>26</td>
</tr>
<tr>
<td>Matthew J. Friedman, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.(^1); GlaxoSmithKline(^1); Johnson and Johnson PRD(^1)</td>
<td>18, 25, 60</td>
</tr>
<tr>
<td>Mark A. Frye, M.D.</td>
<td>Abbott Laboratories, Inc.(^1,3,4); AstraZeneca Pharmaceuticals(^1); Bristol-Myers Squibb(^1,3,4); Cephalon Inc.(^1); Eli Lilly and Company(^1); GlaxoSmithKline(^1,3,4); Janssen-Cilag Pharmaceuticals Inc.(^1); Johnson and Johnson PRD(^1); Novartis Pharmaceuticals Corporation(^4); Ortho McNeil Pharmaceuticals Inc.(^3); Osuka Pharmaceuticals Inc.(^3); UCB Pharma, Inc.(^3); King Pharmaceuticals Inc.(^3); National Institute of Mental Health; Solvay Pharmaceuticals, Inc.(^3); Stanley Medical Research Institute(^3)</td>
<td>22, 29, 38, 45</td>
</tr>
<tr>
<td>Glen O. Gabbard, M.D.</td>
<td>Bristol-Myers Squibb(^6)</td>
<td>67</td>
</tr>
<tr>
<td>Joel Gallant, M.D.</td>
<td>Abbott Laboratories Inc.(^1,4); Boehringer Ingelheim(^1,3); Bristol-Myers Squibb(^1,3,4); GlaxoSmithKline(^1,4); Roche Laboratories, a member of the Roche Group(^3,4); Gilead Sciences(^1,3,4); Vertex(^1); Tanso(^3); Tistoce-Virclo(^1,3,5); ViroLogic(^3); Ortho Biotech, Inc.(^1,3,4)</td>
<td>45</td>
</tr>
<tr>
<td>David R. Gastfriend, M.D.</td>
<td>Alkermes(^1,3,4); Eli Lilly and Company(^1); Bristol-Myers Squibb(^4); CMHC Systems(^1); TeleSage(^1); Drug Abuse Sciences(^1); Purdue Pharma(^4)</td>
<td>100</td>
</tr>
<tr>
<td>F. Moises Gaviria, M.D.</td>
<td>GlaxoSmithKline(^4); Novartis Pharmaceuticals Corporation(^4); Janssen Pharmaceutica Inc.(^3)</td>
<td>74</td>
</tr>
<tr>
<td>David Geldmacher, M.D.</td>
<td>Pfizer Inc.(^1,3,4); Eisai America Inc.(^1,3,4); Janssen Pharmaceutica Inc.(^3); Takeda Pharmaceuticals(^3); Forest Laboratories, Inc.(^3)</td>
<td>11</td>
</tr>
<tr>
<td>Joel Gelernter, M.D.</td>
<td>Janssen Pharmaceutica Inc.(^3); Lilly Research Laboratories, a division of Eli Lilly and Company(^3); 7, 30</td>
<td></td>
</tr>
<tr>
<td>Mark S. George, M.D.</td>
<td>GlaxoSmithKline(^3); Parke-Davis, Division of Warner-Lambert Company(^3); Medronic(^3); Amnham(^4); Cyberonics Inc.(^1,3,4); Philips(^4); Dupont(^3); Dupont Pharma(^3); Solvay Pharmaceuticals, Inc.(^3); Medipher(^3,4); Janssen Pharmaceutica Inc.(^1,3,4); AstraZeneca Pharmaceuticals(^3,4); GlaxoSmithKline(^1,3); Abbott Laboratories, Inc.(^3); Eli Lilly and Company(^3); U.S. Pharmaceuticals, Pfizer Inc.(^3)</td>
<td>9, 1, 46, 66</td>
</tr>
<tr>
<td>Walter Ginter</td>
<td>Reckitt-Benckiser Pharmaceuticals(^6)</td>
<td>39</td>
</tr>
<tr>
<td>Leslie H. Gise, M.D.</td>
<td>Medco Health(^1)</td>
<td>87, 100</td>
</tr>
<tr>
<td>Michael J. Gitlin, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company(^4); Wyeth-Ayerst Laboratories(^4); 88</td>
<td></td>
</tr>
<tr>
<td>Marcia Kraft Goin, M.D.</td>
<td>GlaxoSmithKline(^4); Bristol-Myers Squibb(^4); AstraZeneca Pharmaceuticals(^4); Lilly Research Laboratories, a division of Eli Lilly and Company(^3,4); U.S. Pharmaceuticals, Pfizer Inc.(^3)</td>
<td>24, 50, 63, 99</td>
</tr>
<tr>
<td>Robert M. Goisman, M.D.</td>
<td>AstraZeneca Pharmaceuticals(^4); Bristol-Myers Squibb(^1)</td>
<td>7, 10, 14, 22, 29, 37, 55, 67, 83, 102</td>
</tr>
<tr>
<td>Joseph F. Goldberg, M.D.</td>
<td>Abbott Laboratories, Inc.(^1,3,4); AstraZeneca Pharmaceuticals(^3,4); Bristol-Myers Squibb(^1,3,4); Eli Lilly and Company(^1,3,4); Forest Laboratories, Inc.(^3); GlaxoSmithKline(^1,3,4); UCB Pharma, Inc.(^3,3); Novartis Pharmaceuticals Corporation(^1,3); Ortho McNeil Pharmaceuticals Inc.(^3,3); Pfizer Inc.(^3,3)</td>
<td>71</td>
</tr>
<tr>
<td>Pablo Goldberg, M.D.</td>
<td>Bristol-Myers Squibb(^5)</td>
<td>38</td>
</tr>
<tr>
<td>Robert N. Golden, M.D.</td>
<td>Bristol-Myers Squibb(^1,3,4); AstraZeneca Pharmaceuticals(^4); Forest Laboratories, Inc.(^3); GlaxoSmithKline(^1,3); Novartis Pharmaceuticals Corporation(^1,3); Ortho McNeil Pharmaceuticals Inc.(^3); Pfizer Inc.(^3,3)</td>
<td>4</td>
</tr>
<tr>
<td>Stephen M. Goldfinger, M.D.</td>
<td>Bristol-Myers Squibb(^1,3,4); Janssen Pharmaceutica Inc.(^1,3,4); AstraZeneca Pharmaceuticals(^3,4); Us. Pharmaceuticals, Pfizer Inc.(^3); Mallinckrodt Pharmaceuticals(^1,4); IVAX(^1,4)</td>
<td>27, 54, 77, 99</td>
</tr>
<tr>
<td>Marion Z. Goldstein, M.D.</td>
<td>Eli Lilly and Company(^1)</td>
<td>86</td>
</tr>
<tr>
<td>Gerardo Gonzalez, M.D.</td>
<td>Reckitt-Benckiser Pharmaceuticals(^6)</td>
<td>39</td>
</tr>
<tr>
<td>Name</td>
<td>Company and Medically Related Entities</td>
<td>Disclosures</td>
</tr>
<tr>
<td>----------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Jack M. Gorman, M.D.</td>
<td>National Institute of Mental Health; NARSAD; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>9, 19, 50, 77, 92</td>
</tr>
<tr>
<td>Elizabeth Gould, Ph.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>66</td>
</tr>
<tr>
<td>Barbara L. Gracios, M.D.</td>
<td>GlaxoSmithKline</td>
<td>12</td>
</tr>
<tr>
<td>Tana A. Grady-Weliky, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>8, 18, 19, 50</td>
</tr>
<tr>
<td>John F. Greden, M.D.</td>
<td>Janssen Research Laboratories, a division of Eli Lilly and Company</td>
<td>18, 20, 47, 51</td>
</tr>
<tr>
<td>Benjamin D. Greenberg, M.D.</td>
<td>McNeil Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>106</td>
</tr>
<tr>
<td>Laurence L. Greenhill, M.D.</td>
<td>Shire Ridgwood Pharmaceuticals</td>
<td>83</td>
</tr>
<tr>
<td>John H. Greist, M.D.</td>
<td>Abbott Laboratories, Inc.; Forest Laboratories, Inc.; Organon Pharmaceuticals, Inc.</td>
<td>4</td>
</tr>
<tr>
<td>Faiz Hameed, M.D.</td>
<td>Janssen Research Laboratories, a division of Eli Lilly and Company; Sanofi-Synthelabo Pharmaceuticals</td>
<td>4</td>
</tr>
<tr>
<td>Mark B. Hamner, M.D.</td>
<td>Eli Lilly and Company; Bristol-Myers Squibb; Janssen Pharmaceutica Inc.</td>
<td>53</td>
</tr>
<tr>
<td>Silvia Hafliger, M.D.</td>
<td>Roche Laboratories, a member of the Roche Group</td>
<td>37, 50</td>
</tr>
<tr>
<td>Robert E. Hales, M.D.</td>
<td>Bristol-Myers Squibb; GlaxoSmithKline; Forest Laboratories, Inc.</td>
<td>13, 41</td>
</tr>
<tr>
<td>Philip D. Harvey, Ph.D.</td>
<td>Janssen Pharmaceutica Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>25</td>
</tr>
<tr>
<td>Stephan H. Heckers, M.D.</td>
<td>Eli Lilly and Company</td>
<td>13, 41, 61</td>
</tr>
<tr>
<td>David C. Henderson, M.D.</td>
<td>Janssen Pharmaceutica Inc.; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals</td>
<td>88</td>
</tr>
<tr>
<td>Michael E. Henry</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>61</td>
</tr>
<tr>
<td>J. Paul Hieble, Ph.D.</td>
<td>GlaxoSmithKline; Eli Lilly and Company; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>95</td>
</tr>
<tr>
<td>Alan R. Hirsch, M.D.</td>
<td>Ciba Geigy Corporation, Pharmaceutical Division; Johnson and Johnson PRD</td>
<td>9</td>
</tr>
<tr>
<td>Robert M.A. Hirschfeld, M.D.</td>
<td>Abbott Laboratories, Inc.; Bristol-Myers Squibb; GlaxoSmithKline</td>
<td>9</td>
</tr>
<tr>
<td>Eric Hollander, M.D.</td>
<td>Ortho McNeil Pharmaceuticals; Solvay Pharmaceuticals, Inc.; UCB Pharma, Inc.</td>
<td>3, 63, 75, 92, 103</td>
</tr>
<tr>
<td>Rona Hu, M.D.</td>
<td>Cephalon Inc.</td>
<td>7</td>
</tr>
<tr>
<td>James I. Hudson, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Ortho McNeil Pharmaceuticals</td>
<td>67</td>
</tr>
<tr>
<td>John R. Hughes, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; Sanofi-Synthelabo Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>61</td>
</tr>
<tr>
<td>Michael Y. Hwang, M.D.</td>
<td>Janssen Pharmaceutica Inc.; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>53</td>
</tr>
<tr>
<td>Dan V. Iosifescu, M.D.</td>
<td>GlaxoSmithKline; Organon Pharmaceuticals, Inc.; Eli Lilly and Company; NARSAD; Janssen Pharmaceutica Inc.; National Institute of Mental Health; Aspect Medical Systems, Inc.</td>
<td>50, 66</td>
</tr>
<tr>
<td>Waguih W. Ishak, M.D.</td>
<td>Eli Lilly and Company; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Bayer Corporation, Pharmaceutical Division; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td>1, 95</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Jeanne Jackson-Siegel, M.D.</td>
<td>US. Pharmaceuticals, Pfizer Inc. 1, 4; Abbott Laboratories, Inc. 4; Eli Lilly and Company 6, 5; Organon Pharmaceuticals, Inc. 4; AstraZeneca Pharmaceuticals 1, 4; Forest Laboratories, Inc. 1, 4</td>
<td>41</td>
</tr>
<tr>
<td>Philip G. Janicak, M.D.</td>
<td>Abbott Laboratories, Inc. 3; Janssen Pharmaceuticals Inc. 1, 3; Bristol-Myers Squibb 1, 4; Pfizer Inc. 1, 4; Lilly Research Laboratories, a division of Eli Lilly and Company 8; AstraZeneca Pharmaceuticals 4</td>
<td>14</td>
</tr>
<tr>
<td>Geetha Jayaram, M.D.</td>
<td>GlaxoSmithKline 4</td>
<td>6, 10, 20, 45, 71, 80, 94, 99</td>
</tr>
<tr>
<td>Richard T. Jernyn, D.O.</td>
<td>Merck &amp; Co., Inc. 4; Cephalon Inc. 4; Parke-Davis, Division of Warner-Lambert Company 4; Ortho McNeil Pharmaceuticals 4</td>
<td>95</td>
</tr>
<tr>
<td>Dilip V. Jeste, M.D.</td>
<td>AstraZeneca Pharmaceuticals 1, 3; Bristol-Myers Squibb 1, 3; Eli Lilly and Company 6, 4; Janssen Pharmaceuticals Inc. 1, 3; U.S. Pharmaceuticals, Pfizer Inc. 1, 3</td>
<td>13, 74</td>
</tr>
<tr>
<td>Michael D. Jibson, M.D.</td>
<td>AstraZeneca Pharmaceuticals 4; U.S. Pharmaceuticals, Pfizer Inc. 4; Janssen Pharmaceuticals Inc. 4</td>
<td>73</td>
</tr>
<tr>
<td>Hadine Joffe, M.D.</td>
<td>Eli Lilly and Company 8; GlaxoSmithKline 4; U.S. Pharmaceuticals, Pfizer Inc. 4, 4</td>
<td>39, 40, 93</td>
</tr>
<tr>
<td>Bankole A. Johnson, M.D.</td>
<td>Johnson and Johnson PRD 1; Ortho McNeil Pharmaceuticals 4</td>
<td>2, 64, 77</td>
</tr>
<tr>
<td>Lewis L. Judd, M.D.</td>
<td>Roche Biosciences 1, 3</td>
<td>21, 65</td>
</tr>
<tr>
<td>Rajinder A. Judge, M.D.</td>
<td>Novartis Pharmaceuticals Corporation 2; Organon Pharmaceuticals, Inc. 3; Merck &amp; Co., Inc. 5; U.S. Pharmaceuticals, Pfizer Inc. 4; Lilly Research Laboratories, a division of Eli Lilly and Company 4</td>
<td>5</td>
</tr>
<tr>
<td>Ned H. Kalin, M.D.</td>
<td>National Institutes of Health 2; Dana Foundation 2; Janssen Pharmaceuticals Inc. 3, 4; GlaxoSmithKline 4</td>
<td>66</td>
</tr>
<tr>
<td>Peter W. Kalivas, Ph.D.</td>
<td>Janssen Pharmaceuticals Inc. 3</td>
<td>90</td>
</tr>
<tr>
<td>John M. Kane, M.D.</td>
<td>Abbott Laboratories, Inc. 4; AstraZeneca Pharmaceuticals 1, 3; Bristol-Myers Squibb 1, 4; Novartis Pharmaceuticals Corporation 2, 4; Aventis Pharmaceuticals 4; Organon Pharmaceuticals, Inc. 1, 4; U.S. Pharmaceuticals, Pfizer Inc. 1, 4; Lilly Research Laboratories, a division of Eli Lilly and Company 4; Janssen Pharmaceuticals Inc. 1, 4</td>
<td>11</td>
</tr>
<tr>
<td>Sandra J. Kaplan, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc. 3</td>
<td>54</td>
</tr>
<tr>
<td>Shitij Kapur, M.D.</td>
<td>Eli Lilly and Company 1, 3, 4; Janssen Pharmaceuticals Inc. 1, 3, 4; U.S. Pharmaceuticals, Pfizer Inc. 1, 3, 4; Wyeth-Ayerst Laboratories 1, 3, 4; AstraZeneca Pharmaceuticals 1, 3, 4; Bristol-Myers Squibb 1, 3; Solvay Kingswood 1; Neuromolecular, Inc. 1, 4; GlaxoSmithKline 4</td>
<td>3, 12</td>
</tr>
<tr>
<td>Wayne J. Katon, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company 4, 5; U.S. Pharmaceuticals, Pfizer Inc. 4; SmithKline Beecham Pharmaceuticals 1, 4; Wyeth-Ayerst Laboratories 1, 4; Venlafaxine 1; Paxil 1; Duloxetine 1; forest Laboratories, Inc. 4; Pharmacia &amp; Upjohn Company, Inc. 5</td>
<td>32</td>
</tr>
<tr>
<td>Walter H. Kaye, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company 4, 5; AstraZeneca Pharmaceuticals 3; Abbott Laboratories, Inc. 1, 3; AstraZeneca Pharmaceuticals 1, 3; Bristol-Myers Squibb 1, 3; Corcept Therapeutics 1; GlaxoSmithKline 3; Janssen Pharmaceuticals Inc. 4, 5; Eli Lilly and Company 4, 5; Novartis Pharmaceuticals Corporation 1, 3; UCB Pharma, Inc. 1, 3; Ortho McNeil Pharmaceuticals 3, 4; U.S. Pharmaceuticals, Pfizer Inc. 1, 3; Wyeth-Ayerst Laboratories 1; Shire Ridgewood Pharmaceuticals 1; Eli Lilly and Company 1; Merck &amp; Co., Inc. 3; National Institute of Mental Health 1; National Institute on Drug Abuse 1; Organon Pharmaceuticals, Inc. 1; the Stanley Medical Research Institute 1; Richard S.E. Keefe, Ph.D.</td>
<td>10</td>
</tr>
<tr>
<td>Richard S.E. Keefe, Ph.D.</td>
<td>AstraZeneca Pharmaceuticals 1, 3; Janssen Pharmaceuticals Inc. 1, 3; Aventis Pharmaceuticals 1; U.S. Pharmaceuticals, Pfizer Inc. 1; Abbott Laboratories, Inc. 1; GlaxoSmithKline 1; Pharmacia &amp; Upjohn Company, Inc. 1; Organon Pharmaceuticals, Inc. 1; Lilly Research Laboratories, a division of Eli Lilly and Company 1, 3</td>
<td>10</td>
</tr>
<tr>
<td>Martin B. Keller, M.D.</td>
<td>Bristol-Myers Squibb 1, 3; Cyberonics Inc. 1, 4; Eli Lilly and Company 4, 5; Forest Laboratories, Inc. 1, 3, 4; Janssen Pharmaceuticals Inc. 1, 4; Merck &amp; Co., Inc. 1, 3, 4; Organon Pharmaceuticals, Inc. 1, 3, 4; Pharmastar 4; U.S. Pharmaceuticals, Pfizer Inc. 1, 3, 4; Pharmacia &amp; Upjohn Company, Inc. 1, 4; Sepracor Inc. 1, 4; Vela Pharmaceuticals 1, 4; Mitsubishi Pharma Corporation 1; Schex; Cypress Biosciences 1, 4; Colgaur 4; Wyeth-Ayerst Laboratories 1, 3, 4; Cephalon Inc. 1; GlaxoSmithKline 1; Novartis Pharmaceuticals Corporation 1; Sanofi-Synthelabo Pharmaceuticals, Inc. 1; Somerset Pharmaceuticals 1; Osuna Pharmaceuticals 1, 4</td>
<td>6, 84</td>
</tr>
<tr>
<td>Sidney H. Kennedy, M.D.</td>
<td>AstraZeneca Pharmaceuticals 4; Boehringer Ingelheim 3, 4; Eli Lilly and Company 3, 4; GlaxoSmithKline 4</td>
<td>88</td>
</tr>
<tr>
<td>Justine M. Kent, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc. 1; Cephalon Inc. 1</td>
<td>34, 92</td>
</tr>
<tr>
<td>Ronald C. Kessler, Ph.D.</td>
<td>GlaxoSmithKline 1; U.S. Pharmaceuticals, Pfizer Inc. 1; Eli Lilly and Company 4</td>
<td>2, 4</td>
</tr>
</tbody>
</table>

XXX
<table>
<thead>
<tr>
<th>Name</th>
<th>Companies</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terence A. Ketter, M.D.</td>
<td>Abbott Laboratories, Inc. 1,3,4; AstraZeneca Pharmaceuticals 1,3,4; Bristol-Myers Squibb 1,3,4; Eli Lilly and Company 1,3,4; Forest Laboratories, Inc. 3; Janssen Pharmaceutica Inc. 1,3,4; GlaxoSmithKline 1,3,4; Cephalon Inc.; Novartis Pharmaceuticals Corporation 1,4; Shire Ridgewood Pharmaceuticals 1,3</td>
<td>51</td>
</tr>
<tr>
<td>Paul A. Kettl, M.D.</td>
<td>Abbott Laboratories, Inc. 1,3,4; Novartis Pharmaceuticals Corporation 1,4; Janssen Pharmaceutica Inc. 1,3,4; Wyeth-Ayerst Laboratories 1,3,4; Novartis Pharmaceuticals Corporation 1,4</td>
<td>81</td>
</tr>
<tr>
<td>Ali Khadivi, Ph.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company 1,4</td>
<td>46</td>
</tr>
<tr>
<td>Arifulla Khan, M.D.</td>
<td>Wyeth-Ayerst Laboratories 1,4</td>
<td>13</td>
</tr>
<tr>
<td>Edward Kim, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company 1,4; Janssen Pharmaceutica Inc. 1,4; Wyeth-Ayerst Laboratories 1,3,4; Novartis Pharmaceuticals Corporation 1,4</td>
<td>53, 75</td>
</tr>
<tr>
<td>Bryan H. King, M.D.</td>
<td>Janssen Pharmaceutica Inc. 4</td>
<td>18, 100</td>
</tr>
<tr>
<td>David G. Kingdon, M.D.</td>
<td>Eli Lilly and Company 1,3,4; Janssen Pharmaceutica Inc. 1,3,4; Bristol-Myers Squibb 1,3,4; Pfizer Inc. 1,3,4</td>
<td>8, 46</td>
</tr>
<tr>
<td>Herbert D. Kleber, M.D.</td>
<td>Reckitt Benckiser Pharmaceuticals 1,4</td>
<td>48, 81, 84, 97</td>
</tr>
<tr>
<td>James H. Kocsis, M.D.</td>
<td>Wyeth-Ayerst Laboratories 1,3,4; Forest Laboratories, Inc. 3; Novartis Pharmaceuticals Corporation 1,4</td>
<td>60</td>
</tr>
<tr>
<td>Lili Kopala, M.D.</td>
<td>AstraZeneca Pharmaceuticals 1,3; Eli Lilly and Company 1,3; Janssen Pharmaceutica Inc. 1,3; Novartis Pharmaceuticals Corporation 1,3</td>
<td>9</td>
</tr>
<tr>
<td>Amos Korczyn, M.D.</td>
<td>Novartis Pharmaceuticals Corporation 4</td>
<td>40</td>
</tr>
<tr>
<td>Susan G. Kornstein, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc. 1,3; Bristol-Myers Squibb 1,3; Pfizer Inc. 1,3</td>
<td>11</td>
</tr>
<tr>
<td>Thomas R. Kosten, M.D.</td>
<td>Reckitt Benckiser Pharmaceuticals 1,4</td>
<td>19, 39, 70</td>
</tr>
<tr>
<td>Renu Kotswal, M.D.</td>
<td>Ortho McNeil Pharmaceuticals 1,4</td>
<td>3</td>
</tr>
<tr>
<td>K. Ranga R. Krishnan, M.D.</td>
<td>Novartis Pharmaceuticals Corporation 1,4; U.S. Pharmaceuticals, Pfizer Inc. 1,4; UCB Pharma Inc. 1,4; Somerset Pharmaceuticals 1,4; Lilly Research Laboratories, a division of Eli Lilly and Company 1,4; Syntec 1,4</td>
<td>9, 13</td>
</tr>
<tr>
<td>Kurt Kroenke, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc. 1,4; Wyeth-Ayerst Laboratories 1,3,4; Eli Lilly and Company 1,4</td>
<td>8</td>
</tr>
<tr>
<td>Andrew D. Krystal, M.D.</td>
<td>Sepracor Inc. 1,3,4; Wyeth-Ayerst Laboratories 1,3,4; Sanofi-Synthelabo Pharmaceuticals, Inc. 1,3</td>
<td>11</td>
</tr>
<tr>
<td>David J. Kupfer, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc. 1,4; Eli Lilly and Company 1,3,4; Forest Laboratories, Inc. 3</td>
<td>11</td>
</tr>
<tr>
<td>Sandra L. Kwater, M.D.</td>
<td>GlaxoSmithKline 1,4</td>
<td>12</td>
</tr>
<tr>
<td>Justine K. Lalonde, M.D.</td>
<td>Eli Lilly and Company 1,4; U.S. Pharmaceuticals, Pfizer Inc. 2,3; Ortho McNeil Pharmaceuticals 3</td>
<td>67</td>
</tr>
<tr>
<td>Raymond W. Lam, M.D.</td>
<td>Cyberonics Inc. 1,4; Eli Lilly Canada 1,3,4; GlaxoSmithKline Canada 1,3,4; Lundbeck Canada 1,4; Pfizer Canada 1,4; Wyeth-Ayerst Laboratories 1,3,4; Merck &amp; Co., Canada 1,3; Lifebox Company, Inc. 1,4; Roche Canada, a member of the Roche Group 1,3; Organon Canada 1,4; Servier Canada 1,3</td>
<td>88, 99</td>
</tr>
<tr>
<td>John Lauriello, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc. 1,4; AstraZeneca Pharmaceuticals 1,4; Eli Lilly and Company 1,4</td>
<td>28</td>
</tr>
<tr>
<td>Philip Lavoni, Ph.D.</td>
<td>Cyberonics Inc. 1,4; Forest Laboratories, Inc. 5; Neuronetics Inc. 1,4</td>
<td>11</td>
</tr>
<tr>
<td>Helen Lavretskey, M.D.</td>
<td>Eisai America Inc. 5</td>
<td>11</td>
</tr>
<tr>
<td>Barry Levin</td>
<td>Merck &amp; Co., Inc. 1,3,4; Proctor &amp; Gamble 1,4; U.S. Pharmaceuticals, Pfizer Inc. 1,3</td>
<td>35</td>
</tr>
<tr>
<td>Frances R. Levin, M.D.</td>
<td>Eli Lilly and Company 1,4; PharmaNet, Inc. 3</td>
<td>47, 51, 84</td>
</tr>
<tr>
<td>Jeffrey M. Levine, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc. 1,4; Wyeth-Ayerst Laboratories 1,4; GlaxoSmithKline 1,4</td>
<td>99</td>
</tr>
<tr>
<td>Lydia J. Lewis, B.A.</td>
<td>Wyeth-Ayerst Laboratories 1,4</td>
<td>4</td>
</tr>
<tr>
<td>Roberto Lewis-Fernandez, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc. 1,4</td>
<td>5, 91</td>
</tr>
<tr>
<td>Jeffrey A. Lieberman, M.D.</td>
<td>Eli Lilly and Company 1,4</td>
<td>10, 28, 38</td>
</tr>
<tr>
<td>Michael R. Liebowitz, M.D.</td>
<td>Wyeth-Ayerst Laboratories 1,4; U.S. Pharmaceuticals, Pfizer Inc. 1,4; GlaxoSmithKline 1,4</td>
<td>92</td>
</tr>
<tr>
<td>Russell F. Lim, M.D.</td>
<td>Bristol-Myers Squibb 1,4; Eli Lilly and Company 1,4</td>
<td>5</td>
</tr>
<tr>
<td>Jean-Pierre Lindenmayer, M.D.</td>
<td>Novartis Pharmaceuticals Corporation 1,4; Lilly Research Laboratories, a division of Eli Lilly and Company 1,4; Janssen Pharmaceutica Inc. 1,3; Eli Lilly and Company 1,3; Abbott Laboratories, Inc. 3</td>
<td>73</td>
</tr>
<tr>
<td>Marsha M. Linehan, Ph.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company 1,4</td>
<td>19, 27, 58</td>
</tr>
<tr>
<td>Walter Ling, M.D.</td>
<td>Reckitt Benckiser Pharmaceuticals 1,4</td>
<td>30, 39, 70</td>
</tr>
<tr>
<td>Sarah H. Lisanby, M.D.</td>
<td>Neuronetics Inc. 1,4</td>
<td>30, 83, 93</td>
</tr>
<tr>
<td>James F. List, M.D.</td>
<td>Ortho McNeil Pharmaceuticals 1,4</td>
<td>67</td>
</tr>
<tr>
<td>Donna L. Londino, M.D.</td>
<td>Janssen Pharmaceutica Inc. 1,3; Eli Lilly and Company 1,3; Abbott Laboratories, Inc. 3</td>
<td>80</td>
</tr>
<tr>
<td>Susan Lukac, M.D.</td>
<td>Solvay Pharmaceuticals, Inc. 1,4; GlaxoSmithKline 1,4; Novartis Pharmaceuticals Corporation 1,4</td>
<td>22</td>
</tr>
<tr>
<td>Edward Kim, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company 1,4</td>
<td>19, 27, 58</td>
</tr>
<tr>
<td>Michael R. Liebowitz, M.D.</td>
<td>Wyeth-Ayerst Laboratories 1,4; U.S. Pharmaceuticals, Pfizer Inc. 1,4; GlaxoSmithKline 1,4</td>
<td>92</td>
</tr>
<tr>
<td>Russell F. Lim, M.D.</td>
<td>Bristol-Myers Squibb 1,4; Eli Lilly and Company 1,4</td>
<td>5</td>
</tr>
<tr>
<td>Jean-Pierre Lindenmayer, M.D.</td>
<td>Novartis Pharmaceuticals Corporation 1,4; Lilly Research Laboratories, a division of Eli Lilly and Company 1,4; Janssen Pharmaceutica Inc. 1,3; Eli Lilly and Company 1,3; Abbott Laboratories, Inc. 3</td>
<td>73</td>
</tr>
<tr>
<td>Marsha M. Linehan, Ph.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company 1,4</td>
<td>19, 27, 58</td>
</tr>
<tr>
<td>Walter Ling, M.D.</td>
<td>Reckitt Benckiser Pharmaceuticals 1,4</td>
<td>30, 39, 70</td>
</tr>
<tr>
<td>Sarah H. Lisanby, M.D.</td>
<td>Neuronetics Inc. 1,4</td>
<td>30, 83, 93</td>
</tr>
<tr>
<td>James F. List, M.D.</td>
<td>Ortho McNeil Pharmaceuticals 1,4</td>
<td>67</td>
</tr>
<tr>
<td>Donna L. Londino, M.D.</td>
<td>Janssen Pharmaceutica Inc. 1,3; Eli Lilly and Company 1,3; Abbott Laboratories, Inc. 3</td>
<td>80</td>
</tr>
<tr>
<td>Susan Lukac, M.D.</td>
<td>Solvay Pharmaceuticals, Inc. 1,4; GlaxoSmithKline 1,4; Novartis Pharmaceuticals Corporation 1,4</td>
<td>22</td>
</tr>
<tr>
<td>Edward Kim, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company 1,4</td>
<td>19, 27, 58</td>
</tr>
<tr>
<td>Michael R. Liebowitz, M.D.</td>
<td>Wyeth-Ayerst Laboratories 1,4; U.S. Pharmaceuticals, Pfizer Inc. 1,4; GlaxoSmithKline 1,4</td>
<td>92</td>
</tr>
<tr>
<td>Russell F. Lim, M.D.</td>
<td>Bristol-Myers Squibb 1,4; Eli Lilly and Company 1,4</td>
<td>5</td>
</tr>
<tr>
<td>Jean-Pierre Lindenmayer, M.D.</td>
<td>Novartis Pharmaceuticals Corporation 1,4; Lilly Research Laboratories, a division of Eli Lilly and Company 1,4; Janssen Pharmaceutica Inc. 1,3; Eli Lilly and Company 1,3; Abbott Laboratories, Inc. 3</td>
<td>73</td>
</tr>
<tr>
<td>Marsha M. Linehan, Ph.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company 1,4</td>
<td>19, 27, 58</td>
</tr>
<tr>
<td>Walter Ling, M.D.</td>
<td>Reckitt Benckiser Pharmaceuticals 1,4</td>
<td>30, 39, 70</td>
</tr>
<tr>
<td>Sarah H. Lisanby, M.D.</td>
<td>Neuronetics Inc. 1,4</td>
<td>30, 83, 93</td>
</tr>
<tr>
<td>James F. List, M.D.</td>
<td>Ortho McNeil Pharmaceuticals 1,4</td>
<td>67</td>
</tr>
<tr>
<td>Donna L. Londino, M.D.</td>
<td>Janssen Pharmaceutica Inc. 1,3; Eli Lilly and Company 1,3; Abbott Laboratories, Inc. 3</td>
<td>80</td>
</tr>
<tr>
<td>Susan Lukac, M.D.</td>
<td>Solvay Pharmaceuticals, Inc. 1,4; GlaxoSmithKline 1,4; Novartis Pharmaceuticals Corporation 1,4</td>
<td>22</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Constantine Lyetsos, M.D.</td>
<td>Forest Laboratories, Inc.(^1,3,4), Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica Inc.(^1,3,4), U.S. Pharmaceuticals, Pfizer Inc.(^1,3,4), Neuro Logic Inc.(^1,3,4), DuPont(^1,4), Astra Zeneca Pharmaceuticals(^1,3,4), Organon Pharmaceuticals, Inc.(^1,3,4), Parke-Davis, Division of Warner-Lambert Company(^1,3,4), Bayer Corporation, Pharmaceutical Division(^1,3,4); Eisai America Inc.(^1,3,4), Novartis Pharmaceuticals Corporation(^1,3,4), Lundbeck(^1,3,4), Bristol-Myers Squibb(^1,3,4)</td>
<td>20, 65</td>
</tr>
<tr>
<td>Thomas Lynch, M.D.</td>
<td>Wyeth-Ayerst Laboratories(^4)</td>
<td>41</td>
</tr>
<tr>
<td>Robert J. Malcolm, Jr., M.D.</td>
<td>Johnson and Johnson PRD(^1)</td>
<td>64</td>
</tr>
<tr>
<td>Jose R. Maldonado, M.D.</td>
<td>Abbott Laboratories, Inc.(^3,4), U.S. Pharmaceuticals, Pfizer Inc.(^3,4), Forest Laboratories, Inc.(^4)</td>
<td>7, 15, 43, 98</td>
</tr>
<tr>
<td>Anil K. Malhora, M.D.</td>
<td>Pfizer Inc.(^3,4), Eli Lilly and Company(^3,4), Janssen Pharmaceutica Inc.(^3,4), Abbott Laboratories, Inc.(^3,4)</td>
<td>63</td>
</tr>
<tr>
<td>Theo C. Manschreck, M.D.</td>
<td>Bristol-Myers Squibb(^1,3,4), Eli Lilly and Company(^1,3,4), Pfizer Inc.(^1,3,4), Abbott Laboratories, Inc.(^1,3,4)</td>
<td>62</td>
</tr>
<tr>
<td>Lauren B. Marangell, M.D.</td>
<td>Cyberonics Inc.(^1,3,4), Stanley Foundation; National Institutes of Health; Eli Lilly and Company(^1,3,4)</td>
<td>30, 70, 93</td>
</tr>
<tr>
<td>Sheila Marcus, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.(^1), Wyeth-Ayerst Laboratories(^1)</td>
<td></td>
</tr>
<tr>
<td>Stephen R. Marder, M.D.</td>
<td>Janssen Pharmaceutica Inc.(^1,3,4), Lilly Research Laboratories, a division of Eli Lilly and Company(^1,3,4)</td>
<td>11, 14</td>
</tr>
<tr>
<td>John C. Markowiz, M.D.</td>
<td>National Institute of Mental Health; Forest Laboratories, Inc.(^3); NARSD(^3)</td>
<td>5, 59, 101</td>
</tr>
<tr>
<td>Randall D. Marshall, M.D.</td>
<td>Pfizer Inc.(^3,4), GlaxoSmithKline(^3,4), Bristol-Myers Squibb(^1,3,4), UCB Pharma, Inc.(^3,4), Cephalon Inc.(^3,4)</td>
<td>37, 51, 69</td>
</tr>
<tr>
<td>Humberto Martinez, M.D.</td>
<td>Eli Lilly and Company(^3,4), Janssen Pharmaceutica Inc.(^3,4), Bristol-Myers Squibb(^3,4)</td>
<td>36</td>
</tr>
<tr>
<td>Prakash S. Masand, M.D.</td>
<td>Astra Zeneca Pharmaceuticals(^1,3,4), Janssen Pharmaceuticals Inc.(^1,3,4), Glaxo SmithKline(^1,3,4)</td>
<td>6, 9</td>
</tr>
<tr>
<td>Helen S. Mayberg, M.D.</td>
<td>Mallinckrodt Pharmaceuticals(^4), Wyeth-Ayerst Laboratories(^4), Bristol-Myers Squibb(^4)</td>
<td>27, 44, 50, 81, 84, 94, 99</td>
</tr>
<tr>
<td>W. Vaughan McCall, M.D.</td>
<td>GlaxoSmithKline(^6)</td>
<td>2</td>
</tr>
<tr>
<td>Robin G. McCreadie, D.Sc.</td>
<td>Sepacor Inc.(^1,3); Wyeth-Ayerst Laboratories(^1,3); Sanofi-Synthelabo Pharmaceuticals, Inc.(^1,3)</td>
<td>14, 89</td>
</tr>
<tr>
<td>Stephen P. McDermott, M.D.</td>
<td>Eli Lilly and Company(^3), U.S. Pharmaceuticals, Pfizer Inc.(^3)</td>
<td>103</td>
</tr>
<tr>
<td>William A. McDonald, M.D.</td>
<td>Shire Ridgewood Pharmaceuticals(^8)</td>
<td>67</td>
</tr>
<tr>
<td>David M. McDowell, M.D.</td>
<td>Wyeth-Ayerst Laboratories(^8)</td>
<td>4</td>
</tr>
<tr>
<td>Susan L. McElroy, M.D.</td>
<td>Mallinckrodt Pharmaceuticals(^4), Wyeth-Ayerst Laboratories(^4), Bristol-Myers Squibb(^4)</td>
<td>84, 94, 99</td>
</tr>
<tr>
<td>A. Thomas McAllan, Ph.D.</td>
<td>Abbott Laboratories, Inc.; Bristol-Myers Squibb; Eli Lilly and Company; Janssen Pharmaceutical Corporation; Ortho McNeil Pharmaceuticals; Wyeth-Ayerst Laboratories; Sanofi-Synthelabo Pharmaceuticals, Inc; Forest Laboratories, Inc.; Merck &amp; Co., Inc.; U.S. Pharmaceuticals, Pfizer Inc.; UCB Pharma, Inc.; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>2, 9</td>
</tr>
<tr>
<td>Bruce S. McEwen, Ph.D.</td>
<td>Wyeth-Ayerst Laboratories(^8)</td>
<td>8</td>
</tr>
<tr>
<td>Roger S. McIntyre, M.D.</td>
<td>Wyeth-Ayerst Laboratories(^8), Lundbeck(^1,3,4), Janssen Pharmaceuticals Inc.(^1,3,4), GlaxoSmithKline(^1,3,4)</td>
<td>9</td>
</tr>
<tr>
<td>Ian G. McKeith, M.D.</td>
<td>Astra Zeneca Pharmaceuticals(^1,3,4), Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td></td>
</tr>
<tr>
<td>A. Thomas McAllan, Ph.D.</td>
<td>Organon Pharmaceuticals, Inc.(^1,4), Oryx(^1,4)</td>
<td></td>
</tr>
<tr>
<td>Kris A. McLoughlin, M.S.N.</td>
<td>Perdue Pharmaceuticals(^1)</td>
<td>57</td>
</tr>
<tr>
<td>Laura F. McNicholas, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.(^5)</td>
<td>18</td>
</tr>
<tr>
<td>Herbert Y. Meltzer, M.D.</td>
<td>Reckitt Benckiser Pharmaceuticals(^8)</td>
<td>39, 70</td>
</tr>
<tr>
<td>Alan J. Mendelowiz, M.D.</td>
<td>Bristol-Myers Squibb(^1,3,4), Astra Zeneca Pharmaceuticals(^1,3,4), Janssen Pharmaceutical Corporation(^1,3,4), Lilly Research Laboratories, a division of Eli Lilly and Company(^1,3,4), U.S. Pharmaceuticals, Pfizer Inc.(^1,3,4), Sanofi-Synthelabo Pharmaceuticals, Inc.(^1,3,4), Solvay Pharmaceuticals, Inc.(^1,3,4)</td>
<td>9</td>
</tr>
<tr>
<td>Julien Mendelowiz, M.D.</td>
<td>Astra Zeneca Pharmaceuticals(^1,3,4), Pfizer Inc.(^1,3,4), Wyeth-Ayerst Laboratories(^8)</td>
<td>92</td>
</tr>
<tr>
<td>Matthew A. Menza, M.D.</td>
<td>Lundbeck(^1); Wyeth-Ayerst Laboratories(^8)</td>
<td>21, 65</td>
</tr>
<tr>
<td>Jonathan M. Meyer, M.D.</td>
<td>Cephalon Inc.(^1,3,4), U.S. Pharmaceuticals, Pfizer Inc.(^1,3,4), Bayer Corporation, Pharmaceutical Division; GlaxoSmithKline(^1), Merck &amp; Co., Inc.(^1), Forest Laboratories, Inc.(^3)</td>
<td>65, 86</td>
</tr>
<tr>
<td>Barnett S. Meyers, M.D.</td>
<td>Abbott Laboratories, Inc.; Astra Zeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Janssen Pharmaceutical Corporation; U.S. Pharmaceuticals, Pfizer Inc.(^3)</td>
<td>9, 15</td>
</tr>
<tr>
<td>David Miklowitz, Ph.D.</td>
<td>Eli Lilly and Company(^3); Glaxo SmithKline Canada(^1,3,4), Lundbeck Canada(^1,3,4); Janssen Pharmaceutical Inc. Canada(^1,3,4); AstraZeneca Pharmaceuticals Canada</td>
<td>88</td>
</tr>
<tr>
<td>Roumen V. Milev, M.D.</td>
<td>Eli Lilly and Company(^3); Glaxo SmithKline Canada(^1,3,4), Lundbeck Canada(^1,3,4); Janssen Pharmaceutical Inc. Canada(^1,3,4); AstraZeneca Pharmaceuticals Canada</td>
<td>88</td>
</tr>
<tr>
<td>Alexander L. Miller, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutical Inc.(^1,3,4); U.S. Pharmaceuticals, Pfizer Inc.(^3)</td>
<td>12</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>H. George Nurnberg, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc. 1,3,4; Eli Lilly and Company 4,; Bristol-Myers Squibb 1,3,4; SmithKline Beecham Pharmaceuticals 1,3,4; Abbott Laboratories, Inc. 3,4; Glaxo-Wellcome 1,4; Wyeth-Ayerst Laboratories 1,4; Parke-Davis, Division of Warner-Lambert Company; Robert Wood Johnson Pharmaceutical Research Institute; LIPHA Pharmaceuticals 3</td>
<td>86</td>
</tr>
<tr>
<td>David J. Nutt, M.D.</td>
<td>Cephalon Inc. 6</td>
<td>69</td>
</tr>
<tr>
<td>Charles P. O'Brien, M.D.</td>
<td>Allergens; Drug Abuse Sciences; Schering-Plough, France 1</td>
<td>48, 49</td>
</tr>
<tr>
<td>Maurice M. Ohayon, M.D.</td>
<td>Eli Lilly and Company 6</td>
<td>39</td>
</tr>
<tr>
<td>John M. Oldham, M.D.</td>
<td>Bristol-Myers Squibb 6</td>
<td>23, 38, 59, 91</td>
</tr>
<tr>
<td>Mary B. O'Malley, M.D.</td>
<td>Cephalon Inc. 4; Neurocrine Biosciences Inc. 4</td>
<td>67</td>
</tr>
<tr>
<td>Maria A. Oquendo, M.D.</td>
<td>Bristol-Myers Squibb 6</td>
<td>47, 63, 94</td>
</tr>
<tr>
<td>Patricia I. Ordonez, M.D.</td>
<td>Eli Lilly and Company 4; Bristol-Myers Squibb 1; U.S. Pharmaceuticals, Pfizer Inc. 1</td>
<td>18, 26, 44, 46, 73, 81</td>
</tr>
<tr>
<td>Michael J. Ostacher, M.D.</td>
<td>AstraZeneca Pharmaceuticals 4</td>
<td>78</td>
</tr>
<tr>
<td>Michael W. Otto, Ph.D.</td>
<td>GlaxoSmithKline 3; U.S. Pharmaceuticals, Pfizer Inc. 1,3,4; Janssen Pharmaceutica Inc. 1; UCB Pharma, Inc. 5</td>
<td>6, 9</td>
</tr>
<tr>
<td>Michele T. Pato, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company 6; Wyeth-Ayerst Laboratories 1</td>
<td>42, 73</td>
</tr>
<tr>
<td>Diana O. Perkins, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company 4; AstraZeneca Pharmaceuticals 3; Osula Pharmaceuticals 4; Bristol-Myers Squibb 3</td>
<td>92</td>
</tr>
<tr>
<td>Roy H. Perlis, M.D.</td>
<td>Eli Lilly and Company 4; GlaxoSmithKline 4; Bristol-Myers Squibb 4; Eli Lilly and Company 4</td>
<td>4</td>
</tr>
<tr>
<td>Ethel S. Person, M.D.</td>
<td>GlaxoSmithKline 6</td>
<td>4</td>
</tr>
<tr>
<td>Eric D. Peselow, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc. 4; GlaxoSmithKline 4</td>
<td>47, 50</td>
</tr>
<tr>
<td>Timothy J. Petersen, Ph.D.</td>
<td>Organon Pharmaceuticals, Inc. 9</td>
<td>5</td>
</tr>
<tr>
<td>Debra A. Pinals, M.D.</td>
<td>Pfizer Inc. 4; Eli Lilly and Company 4; AstraZeneca Pharmaceuticals 4; Janssen Pharmaceutica Inc. 4</td>
<td>81</td>
</tr>
<tr>
<td>Mark H. Pollack, M.D.</td>
<td>Bristol-Myers Squibb 1; Cephalon Inc. 1,3,4; Novartis Pharmaceuticals Corporation 1; Lilly Research Laboratories, Janssen Pharmaceutica Inc. 1,3,4; Roche Laboratories, a member of the Roche Group 1; Forest Laboratories, Inc. 4; Solvay Pharmaceuticals, Inc. 4; Organon Pharmaceuticals, Inc. 4</td>
<td>6, 92</td>
</tr>
<tr>
<td>Teodor T. Postolache, M.D.</td>
<td>AstraZeneca Pharmaceuticals 4; Cephalon Inc. 1,4; Sanofi-Synthelabo Pharmaceuticals, Inc. 4</td>
<td>78</td>
</tr>
<tr>
<td>Marc N. Potenza, M.D.</td>
<td>GlaxoSmithKline 4; Forest Laboratories, Inc. 3</td>
<td>54</td>
</tr>
<tr>
<td>Steven G. Potkin, M.D.</td>
<td>Novartis Pharmaceuticals Corporation 1,3,4</td>
<td>40</td>
</tr>
<tr>
<td>Konasale M.R. Prasad, M.D.</td>
<td>GlaxoSmithKline 4; Janssen Pharmaceutica Inc. 4</td>
<td>52</td>
</tr>
<tr>
<td>Jefferson B. Prince, M.D.</td>
<td>Forest Laboratories, Inc. 4</td>
<td>1, 5, 14, 39</td>
</tr>
<tr>
<td>Maria A. Pugliese, M.D.</td>
<td>GlaxoSmithKline 6</td>
<td>42</td>
</tr>
<tr>
<td>Andres J. Pumariega, M.D.</td>
<td>Forest Laboratories, Inc. 3,4</td>
<td>71, 79</td>
</tr>
<tr>
<td>David C. Purselle, M.D.</td>
<td>Forest Laboratories, Inc. 6</td>
<td>67</td>
</tr>
<tr>
<td>Cameron D. Quanbeck, M.D.</td>
<td>Ortho McNeil Pharmaceuticals 6</td>
<td>2</td>
</tr>
<tr>
<td>Charles Raison, M.D.</td>
<td>Schering Corporation; Roche Laboratories, a member of the Roche Group 4; Wyeth-Ayerst Laboratories 4</td>
<td>39</td>
</tr>
<tr>
<td>Luis F. Ramirez, M.D.</td>
<td>Bristol-Myers Squibb 1; Novartis Pharmaceuticals Corporation 1,4; Organon Pharmaceuticals, Inc. 4; Cephalon Inc. 6, 8</td>
<td>8, 27</td>
</tr>
<tr>
<td>Mark H. Rapaport, M.D.</td>
<td>Eli Lilly and Company 1,3,4; U.S. Pharmaceuticals, Pfizer Inc. 3,4; Eli Lilly and Company 3,4; Novartis Pharmaceuticals Corporation 1,4; Forest Laboratories, Inc. 1,4,3,4; GlaxoSmithKline 4,4; AstraZeneca Pharmaceuticals 4; Bristol-Myers Squibb 4,4; Wyeth-Ayerst Laboratories 4; Janssen Pharmaceutica Inc. 1,4; SmithKline Beecham Pharmaceuticals 4</td>
<td>1, 16, 21, 28</td>
</tr>
<tr>
<td>Natalie L. Rasgon, M.D.</td>
<td>Forest Laboratories, Inc. 1,4; Abbott Laboratories, Inc. 1,4; Eli Lilly and Company 1,4; U.S. Pharmaceuticals, Pfizer Inc. 1,4; GlaxoSmithKline 4,4; Wyeth-Ayerst Laboratories 1,4</td>
<td>66, 70</td>
</tr>
<tr>
<td>John F. Reimus, M.D.</td>
<td>Roche Laboratories, a member of the Roche Group 4; Eli Lilly and Company 4</td>
<td>38</td>
</tr>
<tr>
<td>John A. Renner, Jr., M.D.</td>
<td>Eli Lilly and Company 4</td>
<td>80</td>
</tr>
<tr>
<td>Perry F. Renschaw, M.D.</td>
<td>GlaxoSmithKline 4; Eli Lilly and Company 4</td>
<td>61</td>
</tr>
<tr>
<td>Roy O. Resnikoff, M.D.</td>
<td>AstraZeneca Pharmaceuticals 4; Forest Laboratories, Inc. 4; GlaxoSmithKline 4; Bristol-Myers Squibb 4; Lilly Research Laboratories, a division of Eli Lilly and Company 4; Pfizer Inc. 4; Wyeth-Ayerst Laboratories 4</td>
<td>5</td>
</tr>
<tr>
<td>Kerry J. Ressler, M.D.</td>
<td>Cephalon Inc. 4</td>
<td>2</td>
</tr>
<tr>
<td>Charles F. Reynolds III, M.D.</td>
<td>Forest Laboratories, Inc. 3,4; GlaxoSmithKline 3,4</td>
<td>91</td>
</tr>
<tr>
<td>XXXIV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Disclosures</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Richard K. Ries, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; Janssen Pharmaceutica Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.</td>
<td></td>
</tr>
<tr>
<td>Gerald R. Magri, M.D.</td>
<td>Ortho Biotech, Inc.</td>
<td></td>
</tr>
<tr>
<td>Steven P. R. rose, M.D.</td>
<td>Forest Laboratories, Inc.; Organon Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Eli Lilly and Company</td>
<td></td>
</tr>
<tr>
<td>Jerrold F. Rosenbaum, M.D.</td>
<td>Bristol-Myers Squibb; Cyberonics Inc.; Eli Lilly and Company; Forest Laboratories, Inc.</td>
<td></td>
</tr>
<tr>
<td>Richard N. Rosenthal, M.D.</td>
<td>Alkermes (Cambridge, MA)</td>
<td></td>
</tr>
<tr>
<td>Erik J. Roske, M.D.</td>
<td>Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td></td>
</tr>
<tr>
<td>Thomas Roth, Ph.D.</td>
<td>Taiho Pharmaceuticals; Sanofi-Synthelabo Pharmaceuticals, Inc.; Cephalon Inc.; Novartis Pharmaceuticals Corporation; Aventis Pharmaceuticals; Neurocrine Biosciences, Inc.</td>
<td></td>
</tr>
<tr>
<td>Eugenio M. Rothe, M.D.</td>
<td>Shire Ridgewood Pharmaceuticals; McNeil Pharmaceuticals; AstraZeneca Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Anthony J. Rothschild, M.D.</td>
<td>Bristol-Myers Squibb; Lilly Research Laboratories, a division of Eli Lilly and Company; Merck &amp; Co., Inc.; Wyeth-Ayerst Laboratories; Abbott Laboratories, Inc.</td>
<td></td>
</tr>
<tr>
<td>Peter P. Roy-Byrne, M.D.</td>
<td>GlaxoSmithKline; Cephalon Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutica Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals; Mitsubishi Pharma Corporation; Eli Lilly and Company</td>
<td></td>
</tr>
<tr>
<td>Michael N. Rubenstein, M.D.</td>
<td>Janssen Pharmaceutica Inc.</td>
<td></td>
</tr>
<tr>
<td>A. John Rush, M.D.</td>
<td>Robert Wood Johnson Pharmaceutical Research Institute; National Institute of Mental Health; Stanley Foundation; Eli Lilly and Company; Forest Laboratories, Inc.; Cyberonics Inc.; GlaxoSmithKline; Merck &amp; Co., Inc.; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb</td>
<td></td>
</tr>
<tr>
<td>J. Michael Ryan, M.D.</td>
<td>National Institute of Mental Health; Janssen Research Foundation; Eisai Inc.; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals; Mitsubishi Pharma Corporation; Eli Lilly and Company</td>
<td></td>
</tr>
<tr>
<td>Gary S. Sachs, M.D.</td>
<td>Abbott Laboratories, Inc.; Janssen Pharmaceutica Inc.; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Sigma-Tau; Eli Lilly and Company; Shire Ridgewood Pharmaceuticals; Solvay Pharmaceuticals, Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td></td>
</tr>
<tr>
<td>Harold A. Sackheim, Ph.D.</td>
<td>Cyberonics Inc.; Neurontics, Inc.; Forest Laboratories, Inc.</td>
<td></td>
</tr>
<tr>
<td>Martha Sajatovic, M.D.</td>
<td>Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals; Abbott Laboratories, Inc.; Janssen Pharmaceutica Inc.; U.S. Pharmaceuticals, Pfizer Inc.</td>
<td></td>
</tr>
<tr>
<td>Kenneth M. Salameh, M.D.</td>
<td>Bristol-Myers Squibb; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td></td>
</tr>
<tr>
<td>Stephen P. Salloway, M.D.</td>
<td>Pfizer Inc.; Eisai Inc.; Johnson and Johnson PRD; Novartis Pharmaceuticals Corporation; Abbott Laboratories, Inc.; Janssen Pharmaceutica Inc.</td>
<td></td>
</tr>
<tr>
<td>Carl Salzman, M.D.</td>
<td>Otsuka Pharmaceuticals; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb</td>
<td></td>
</tr>
<tr>
<td>Mary Sano, Ph.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Neurocrine Biosciences, Inc.</td>
<td></td>
</tr>
<tr>
<td>Seddon R. Savage, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica Inc.; Forest Laboratories, Inc.</td>
<td></td>
</tr>
<tr>
<td>Mary Ann Schaepper, M.D.</td>
<td>AstraZeneca Pharmaceuticals; Bristol-Myers Squibb</td>
<td></td>
</tr>
<tr>
<td>Martin B. Scharf, Ph.D.</td>
<td>Sepracor Inc.; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; Eli Lilly and Company; Aventis Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Alan F. Schatzberg, M.D.</td>
<td>Abbott Laboratories, Inc.; Aventis Pharmaceuticals; Bristol-Myers Squibb; OrganoPharmaceuticals, Inc.; Concept Therapeutics; Eli Lilly and Company</td>
<td></td>
</tr>
<tr>
<td>S. Charles Schatzberg, M.D.</td>
<td>Abbott Laboratories, Inc.; Janssen Pharmaceutica Inc.; AstraZeneca Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Larry J. Seidman, Ph.D.</td>
<td>Shire Ridgewood Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Stuart N. Seidman, M.D.</td>
<td>Bayer Corporation, Pharmaceutical Division; GlaxoSmithKline; ICOS; Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td></td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>David V. Sheehan, M.D.</td>
<td>Abbott Laboratories, Inc.²,³,⁴; AstraZeneca Pharmaceuticals²,³; Boos Pharmaceuticals⁴;</td>
<td>6, 22</td>
</tr>
<tr>
<td></td>
<td>Boehringer Ingelheim Pharmaceuticals; Bristol-Myers Squibb³; GlaxoSmithKline³,⁴;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Burroughs-Wellcome Pharmaceutical Company³,⁴; Eli Lilly and Company³; Cephalon Inc.¹;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ciba Geigy Corporation, Pharmaceutical Division¹; Distal Products Company¹; Quintiles¹;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Excerpta Medica Asia; Glaxo Pharmaceuticals³; Humana¹; McNeil Pharmaceuticals¹;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kali-Duphar Laboratories, Inc.³; Glaxo-Wellcome¹; Merck Sharp &amp; Dohme¹; Organon Inc.;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Parke-Davis, Division of Warner-Lambert Company¹; U.S. Pharmaceuticals, Pfizer Inc.³,⁴;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Parma &amp; Upjohn Company, Inc.¹,²; Rhone-Poulenc-Rorer Pharmaceuticals²; Roerig¹;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Roche Laboratories, a member of the Roche Group¹; Sandoz Pharmaceuticals¹; Faymed, Inc²;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Schering Corporation; SmithKline Beecham Pharmaceuticals¹; Solvay Pharmaceuticals, Inc.;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tap Holdings, Inc.¹; The Upjohn Company; Wyeth-Ayerst Laboratories¹; Eisai America, Inc.;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>National Institutes of Health; Forest Laboratories, Inc.; International Clinical Research;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Janssen Pharmaceutical Inc.; Novartis Pharmaceuticals Corporation; Marion-Merrell Dow;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sanofi-Synthelabo Research; Cortex Pharmaceutical¹;</td>
<td></td>
</tr>
<tr>
<td>Yvette I. Sheline, M.D.</td>
<td>Wyeth-Ayerst Laboratories¹;</td>
<td>20</td>
</tr>
<tr>
<td>Hong Shen, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.⁵</td>
<td>72</td>
</tr>
<tr>
<td>Kenneth I. Shulman, M.D.</td>
<td>Eli Lilly and Company⁶</td>
<td>13</td>
</tr>
<tr>
<td>Sally A. Shumaker, Ph.D.</td>
<td>Eli Lilly and Company⁶; Wyeth-Ayerst Laboratories⁶; GlaxoSmithKline⁶</td>
<td>12, 40</td>
</tr>
<tr>
<td>Larry J. Siever, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company⁶</td>
<td>85</td>
</tr>
<tr>
<td>Jonathan M. Silver, M.D.</td>
<td>Novartis Pharmaceuticals Corporation¹;³</td>
<td>87, 88, 93</td>
</tr>
<tr>
<td>Naomi M. Simon, M.D.</td>
<td>Cephalon Inc.¹; Forest Laboratories, Inc.³,⁴; GlaxoSmithKline³,⁴; UCB Pharma, Inc.³,⁴;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company³; Janssen Pharmaceuticals Inc.³;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novartis Pharmaceuticals Corporation¹,³; U.S. Pharmaceuticals, Pfizer Inc.³,⁴;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wyeth-Ayerst Laboratories³; Pharmacia &amp; Upjohn Company, Inc.³</td>
<td></td>
</tr>
<tr>
<td>Samuel G. Siris, M.D.</td>
<td>Bristol-Myers Squibb¹; U.S. Pharmaceuticals, Pfizer Inc.¹; Abbott Laboratories, Inc.¹;</td>
<td>53</td>
</tr>
<tr>
<td>Elizabeth Sirota, M.D.</td>
<td>Janssen Pharmaceutical Inc.³</td>
<td>80</td>
</tr>
<tr>
<td>Andrew E. Skodol II, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.⁵; Bristol-Myers Squibb⁶</td>
<td>38, 101</td>
</tr>
<tr>
<td>Christine E. Skotzko, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.⁵; AstraZeneca Pharmaceuticals⁴</td>
<td>42</td>
</tr>
<tr>
<td>Gary W. Small, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.⁵; Forest Laboratories, Inc.¹,²,³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>U.S. Pharmaceuticals, Pfizer Inc.⁵; Eisai Inc.¹, ²; AstraZeneca Pharmaceuticals⁴;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Janssen Pharmaceuticals Inc.¹,²; AstraZeneca Pharmaceuticals⁴,³,⁴; Abbott Laboratories, Inc.³,⁴;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Forest Laboratories, Inc.¹,²; Novartis Pharmaceuticals Corporation¹,³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company¹;</td>
<td>5</td>
</tr>
<tr>
<td>Michael W. Smith, M.D.</td>
<td>Janssen Pharmaceutical Inc.³,⁴; Lilly Research Laboratories, a division of Eli Lilly and Company²; AstraZeneca Pharmaceuticals²,³; Pfizer Inc.²; Bristol-Myers Squibb²; Stanley Foundation³</td>
<td></td>
</tr>
<tr>
<td>Claudio N. Soares, M.D.</td>
<td>Wyeth-Ayerst Laboratories¹,²,³; Forest Laboratories, Inc.¹,²,³; GlaxoSmithKline¹,²</td>
<td>12, 39, 88</td>
</tr>
<tr>
<td>Thomas J. Spencer, M.D.</td>
<td>Share Pharmaceuticals Development, Inc.¹,²; Abbott Laboratories, Inc.²; Bristol-Myers Squibb²;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cephalon Inc.¯; Eli Lilly and Company³,⁴; GlaxoSmithKline³,⁴; McNeil Pharmaceuticals³,⁴;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Janssen Pharmaceutical Inc.³,⁴; Celltech Pharmaceuticals, Ltd.³; Wyeth-Ayerst Laboratories³,⁴;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novartis Pharmaceuticals Corporation¹,³,⁴; U.S. Pharmaceuticals, Pfizer Inc.¹,³; Share US Inc.¹,³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wyeth-Ayerst Laboratories⁶</td>
<td>4, 7, 15, 51,</td>
</tr>
<tr>
<td>David Spiegel, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Margaret G. Spinelli, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline⁴</td>
<td>10, 70, 100</td>
</tr>
<tr>
<td>Stephen M. Stahl, M.D.</td>
<td>AstraZeneca Pharmaceuticals²,³; Bayer Corporation, Pharmaceutical Division³, ⁴ Asahi³⁰;Boehringer Ingelheim³,⁴; Bristol-Myers Squibb³,⁴; Cephalon Inc.³,⁴; Oyppress Biosciences³⁰;</td>
<td>7, 9</td>
</tr>
<tr>
<td></td>
<td>Forest Laboratories, Inc.³,⁴, GlaxoSmithKline³,⁴; Janssen Pharmaceutical Inc.³,⁴;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eli Lilly and Company³,⁴; Lundbeck³,⁴; Organon Pharmaceuticals, Inc.³,⁴, Watson³,⁴;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Parke-Davis, Division of Warner-Lambert Company³,⁴; Solvay Pharmaceuticals, Inc.³,⁴;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>U.S. Pharmaceuticals, Pfizer Inc.³,⁴; Pharmacia &amp; Upjohn Company, Inc.³,⁴, Yamamoto³,⁴;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sanofi-Synthelabo Pharmaceuticals, Inc.³,², Wyeth-Ayerst Laboratories³,⁴, Abbott Laboratories, Inc.¹; Aventis Pharmaceuticals¹; Lorex¹; Neurocrine Biosciences, Inc.¹; Novartis Pharmaceuticals Corporation;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Roche Laboratories, a member of the Roche Group¹; Searle¹; Sumitomo¹; Thales Abbott Pharmaceuticals¹</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AstraZeneca Pharmaceuticals³, Eli Lilly and Company³, GlaxoSmithKline³, Lundbeck³, Otsuka³, U.S. Pharmaceuticals, Pfizer Inc.³,²; Pharmacia &amp; Upjohn Company, Inc.³; Server²;</td>
<td>3, 63</td>
</tr>
<tr>
<td></td>
<td>Solvay Pharmaceuticals, Inc.³; Roche Laboratories, a member of the Roche Group²; Wyeth-Ayerst Laboratories³; Sumitomo³; Ortho McNeil Pharmaceuticals³</td>
<td></td>
</tr>
</tbody>
</table>

XXXVI
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael A. Van Ameringen, M.D.</td>
<td>AstraZeneca Pharmaceuticals³; Bristol-Myers Squibb²; Cephalon Inc.¹; GlaxoSmithKline¹, ², ³, ⁴</td>
<td>23</td>
</tr>
<tr>
<td>Eve Van Cauter, M.D.</td>
<td>Eli Lilly and Company²; Janssen-Ortho Pharmaceutical Inc.²; Lundbeck³; Novartis Pharmaceuticals Corporation¹; U.S. Pharmaceuticals, Pfizer Inc.¹, ², ³, ⁴; Wyeth-Ayerst Laboratories¹, ²; Solvay Pharmaceuticals, Inc.¹</td>
<td></td>
</tr>
<tr>
<td>George J. Viamontes, M.D.</td>
<td>Neurocine Biosciences, Inc.⁶</td>
<td>67</td>
</tr>
<tr>
<td>Adele C. Viguera, M.D.</td>
<td>Johnson and Johnson PRD²; Wyeth-Ayerst Laboratories³; GlaxoSmithKline³; Pfizer Inc.³</td>
<td>45, 58</td>
</tr>
<tr>
<td>Nora D. Volkow, M.D.</td>
<td>Eli Lilly and Company⁶; GlaxoSmithKline⁶</td>
<td>4, 69, 93</td>
</tr>
<tr>
<td>Serena Y. Volpp, M.D.</td>
<td>AstraZeneca Pharmaceuticals⁶</td>
<td>3, 20, 35, 44</td>
</tr>
<tr>
<td>Elizabeth Vreeland, M.S.N.</td>
<td>GlaxoSmithKline⁶</td>
<td>4</td>
</tr>
<tr>
<td>Karen D. Wagner, M.D.</td>
<td>Eli Lilly and Company¹, ², ³, ⁴; Johnson and Johnson PRD⁶</td>
<td>75</td>
</tr>
<tr>
<td>B. Timothy Walsh, M.D.</td>
<td>Abbott Laboratories, Inc.¹, ², ³; Bristol-Myers Squibb¹, ², ³; Wyeth-Ayerst Laboratories¹, ²; Cyberonics Inc.¹</td>
<td>9</td>
</tr>
<tr>
<td>James G. Waxmonsky, M.D.</td>
<td>Forest Laboratories, Inc.¹, ², ³; GlaxoSmithKline¹, ², ³; Janssen Pharmaceutical Inc.¹, ²; UCB Pharma, Inc.¹; Novartis Pharmaceuticals Corporation¹; U.S. Pharmaceuticals, Pfizer Inc.¹, ², ³, ⁴; Organon Inc.; National Institute of Mental Health¹</td>
<td></td>
</tr>
<tr>
<td>Allison M. Wehr, M.D.</td>
<td>U.S. Pharmaceuticals, Pfizer Inc.³</td>
<td>6</td>
</tr>
<tr>
<td>Peter J. Weiden, M.D.</td>
<td>Eli Lilly and Company⁴; Novartis Pharmaceuticals Corporation¹; Purdue Pharma¹;</td>
<td>2</td>
</tr>
<tr>
<td>Risa B. Weissberg, Ph.D.</td>
<td>Janssen Pharmaceutical Inc.¹, ², ³; U.S. Pharmaceuticals, Pfizer Inc.¹, ², ³</td>
<td>6</td>
</tr>
<tr>
<td>Jeffrey Weiss, Ph.D.</td>
<td>Bristol-Myers Squibb⁶</td>
<td>19</td>
</tr>
<tr>
<td>Margaret D. Weiss, M.D.</td>
<td>Eli Lilly and Company²; Novartis Pharmaceuticals Corporation¹; Purdue Pharma¹;</td>
<td></td>
</tr>
<tr>
<td>Gary L. Wenk, Ph.D.</td>
<td>AstraZeneca Pharmaceuticals¹, ², ³, ⁴; Bristol-Myers Squibb¹, ², ³</td>
<td></td>
</tr>
<tr>
<td>Paul Whalen, Ph.D.</td>
<td>Janssen Pharmaceutical Inc.¹, ², ³; GlaxoSmithKline¹, ², ³; National Institute of Mental Health¹; National Institute on Drug Abuse¹, ², ³, ⁴; Novartis Pharmaceuticals Corporation¹; U.S. Pharmaceuticals, Pfizer Inc.¹, ², ³; SmithKline Beecham Pharmaceuticals¹, ², ³, ⁴; Shire Ridgwood Pharmaceuticals¹, ³, ⁴; United States Pharmacopeial Convention; Wyeth-Ayerst Laboratories¹, ², ³, ⁴; Eli Lilly and Company¹, ², ³; Wyeth-Ayerst Laboratories¹, ², ³, ⁴; Eli Lilly and Company²</td>
<td>55, 67, 92</td>
</tr>
<tr>
<td>Timothy E. Wilens, M.D.</td>
<td>Forest Laboratories, Inc.⁸</td>
<td>6</td>
</tr>
<tr>
<td>John W. Winkelman, M.D.</td>
<td>Wyeth-Ayerst Laboratories⁶</td>
<td>66</td>
</tr>
<tr>
<td>Daniel K. Winstead, M.D.</td>
<td>Abbott Laboratories, Inc.¹, ², ³; Celltech Medica¹, ², ³; McNeil Pharmaceuticals¹, ², ³, ⁴; Lilly Research Laboratories, a division of Eli Lilly and Company¹, ², ³; GlaxoSmithKline¹, ², ³, ⁴; National Institute of Mental Health¹, ², ³, ⁴; National Institute on Drug Abuse¹, ², ³, ⁴; Novartis Pharmaceuticals Corporation¹, ², ³, ⁴; U.S. Pharmaceuticals, Pfizer Inc.¹, ², ³; SmithKline Beecham Pharmaceuticals¹, ², ³, ⁴; Shire Ridgwood Pharmaceuticals¹, ³, ⁴; United States Pharmacopeial Convention; Wyeth-Ayerst Laboratories¹, ², ³, ⁴; Eli Lilly and Company¹, ², ³; Wyeth-Ayerst Laboratories¹, ², ³, ⁴; Eli Lilly and Company²; Wyeth-Ayerst Laboratories¹, ², ³, ⁴</td>
<td>70, 100</td>
</tr>
<tr>
<td>Katherine L. Wisner, M.D.</td>
<td>Pfizer Inc.¹, ², ³; GlaxoSmithKline¹; Lilly Research Laboratories, a division of Eli Lilly and Company², ³</td>
<td>70, 100</td>
</tr>
<tr>
<td>Tom Wolfe</td>
<td>Wyeth-Ayerst Laboratories⁶</td>
<td>38</td>
</tr>
<tr>
<td>Janet Wozniak, M.D.</td>
<td>Eli Lilly and Company²; Janssen Pharmaceutical Inc.⁴; GlaxoSmithKline⁶</td>
<td>69, 85</td>
</tr>
<tr>
<td>Joel Yager, M.D.</td>
<td>Ortho McNeil Pharmaceuticals¹</td>
<td>7, 15, 47, 60, 93</td>
</tr>
<tr>
<td>Rachel Yehuda, Ph.D.</td>
<td>Johnson and Johnson PRD¹, ², ³; U.S. Pharmaceuticals, Pfizer Inc.¹, ², ³, ⁴; GlaxoSmithKline¹, ², ³, ⁴; Wyeth-Ayerst Laboratories¹, ², ³, ⁴; Novartis Pharmaceuticals Corporation¹</td>
<td>75, 92, 105</td>
</tr>
<tr>
<td>Kimberly A. Yonkers, M.D.</td>
<td>Berlex Laboratories¹; GlaxoSmithKline¹; Beecham Pharmaceuticals¹, ², ³; Eli Lilly and Company⁴; U.S. Pharmaceuticals, Pfizer Inc.⁴; Wyeth-Ayerst Laboratories¹</td>
<td>6, 61, 100</td>
</tr>
<tr>
<td>Stuart C. Yudofsky, M.D.</td>
<td>Bristol-Myers Squibb²</td>
<td>13, 41, 45, 70, 93</td>
</tr>
<tr>
<td>Deborah A. Yurgelus-Todd, Ph.D.</td>
<td>Eli Lilly and Company⁴</td>
<td>4, 41, 61</td>
</tr>
<tr>
<td>Mary C. Zanarini, Ed.D.</td>
<td>Eli Lilly and Company¹</td>
<td>23, 38, 64, 102</td>
</tr>
<tr>
<td>Wei Zhang, M.D.</td>
<td>Cephalon Inc.⁸; U.S. Pharmaceuticals, Pfizer Inc.⁸</td>
<td>4, 93</td>
</tr>
<tr>
<td>Douglas M. Zedonis, M.D.</td>
<td>Janssen Pharmaceutical Inc.¹, ², ³; AstraZeneca Pharmaceuticals¹, ², ³; Bristol-Myers Squibb¹, ²</td>
<td>48, 62, 84, 100</td>
</tr>
<tr>
<td>Joseph Zohar, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company², ³</td>
<td></td>
</tr>
<tr>
<td>Jon-Kar Zubieta, M.D.</td>
<td>Novartis Pharmaceuticals Corporation¹; Wyeth-Ayerst Laboratories¹, ², ³; Solvay Pharmaceuticals, Inc.¹, ², ³; Lundbeck¹, ²; Pfizer Inc.¹, ²; Lilly Research Laboratories, a division of Eli Lilly and Company⁴</td>
<td>92</td>
</tr>
<tr>
<td>XXXVIII</td>
<td>Wyeth-Ayerst Laboratories³</td>
<td>8, 30</td>
</tr>
</tbody>
</table>
Voting members of the Board of Trustees, Assembly officers, and members of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participation in Industry-Supported Symposia. In accordance with this policy, the following members are participating in an Industry-Supported Symposium and will not receive any compensation:

**Presenter**

Glen O. Gabbard, M.D.

Geetha Jayaram, M.D.

Philip R. Muskin, M.D.

**Program Page #**

38

6

4

The following presenters on this year's scientific program had not, at the time of this book's printing, returned the APA Disclosure Form. In accordance with APA policy, these presenters are required to submit a Disclosure Form and also provide oral or visual disclosure to participants at the session.

<table>
<thead>
<tr>
<th>Name</th>
<th>Program Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Margo S. Adams</td>
<td>53</td>
</tr>
<tr>
<td>Cristiano Adiutori</td>
<td>46</td>
</tr>
<tr>
<td>Jeffrey S. Akman, M.D.</td>
<td>15, 43</td>
</tr>
<tr>
<td>Jack D. Barchas, M.D.</td>
<td>44</td>
</tr>
<tr>
<td>Gregory Brown, Ph.D.</td>
<td>19</td>
</tr>
<tr>
<td>Bill Burmester, M.A.</td>
<td>82</td>
</tr>
<tr>
<td>B.J. Casey, Ph.D.</td>
<td>72</td>
</tr>
<tr>
<td>Lisa Colosimo</td>
<td>46</td>
</tr>
<tr>
<td>David W. Garland, Esq.</td>
<td>73</td>
</tr>
<tr>
<td>Harvey R. Greenberg, M.D.</td>
<td>90</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Program Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roy M. Gulick, M.D.</td>
<td>63</td>
</tr>
<tr>
<td>Erik W. Gunderson, M.D.</td>
<td>81</td>
</tr>
<tr>
<td>Charles J. Hynes, J.D.</td>
<td>27</td>
</tr>
<tr>
<td>Samuel C. Klagsbrun, M.D.</td>
<td>27</td>
</tr>
<tr>
<td>Norwood Knight-Richardson, M.D.</td>
<td>83</td>
</tr>
<tr>
<td>Lynn Lavendar, Esq.</td>
<td>99</td>
</tr>
<tr>
<td>Kenneth Linn, Esq.</td>
<td>27</td>
</tr>
<tr>
<td>David B. Mallott, M.D.</td>
<td>99</td>
</tr>
<tr>
<td>Michael L. Melamed, M.D.</td>
<td>74</td>
</tr>
<tr>
<td>Melodie Morgan-Minott, M.D.</td>
<td>72</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Program Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alessandro Nicolo</td>
<td>46</td>
</tr>
<tr>
<td>Stefania Papirio</td>
<td>46</td>
</tr>
<tr>
<td>Trevor R. P. Price, M.D.</td>
<td>99</td>
</tr>
<tr>
<td>Ricardo Secin, M.D.</td>
<td>58</td>
</tr>
<tr>
<td>Anne J. Swern, J.D.</td>
<td>27</td>
</tr>
<tr>
<td>Rozalia Vernikov, M.D.</td>
<td>74</td>
</tr>
<tr>
<td>Gabriel Weimann, Ph.D.</td>
<td>31</td>
</tr>
<tr>
<td>Francine Weiss, Esq.</td>
<td>73</td>
</tr>
<tr>
<td>Robert A. Wise, M.D.</td>
<td>45</td>
</tr>
</tbody>
</table>
This page intentionally left blank
SCHEDULED FOR SATURDAY, MAY 1, 2004

8:00 a.m. Sessions

COURSES 1-3

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 1 8:00 a.m.-12 noon
Room 1E06, Level 1, Javits Center

ASSESSMENT AND TREATMENT OF DRUG-INDUCED MOVEMENT DISORDERS

Director: Herman M. Van Praag, M.D.
Faculty: Anton J.M. Loonen, M.D.

COURSE 2 8:00 a.m.-12 noon
Room 1E09, Level 1, Javits Center

ADD IN CHILDREN AND ADOLESCENTS

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 3 8:00 a.m.-12 noon
Room 2D02/3, Level 2, Javits Center

USING NEUROFEEDBACK IN YOUR PRACTICE: INTRODUCTION WITH HANDS-ON EXPERIENCE

Co-Directors: Thomas M. Broad, M.D., Michael Cohen
Faculty: Laurence Hirshberg, Ph.D., Henry B. Mann, M.D.

9:00 a.m. Sessions

COURSES 4-6

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 4 9:00 a.m.-4:00 p.m.
Room 1E17, Level 1, Javits Center

INTERPERSONAL PSYCHOTHERAPY

Director: Scott P. Stuart, M.D.
Faculty: Paula Ravitz, M.D.

COURSE 5 9:00 a.m.-4:00 p.m.
Rooms 2D10/11, Level 2, Javits Center

THE BIOPSYCHOSOCIAL FORMULATION: AN APPROACH TO ORAL BOARD PRESENTATIONS

Co-Directors: William H. Campbell, M.D., Robert M. Rohrbaugh, M.D.
Faculty: Catherine Chiles, M.D., Paul D. Kirwin, M.D.

COURSE 6 9:00 a.m.-4:00 p.m.
Rooms 2D14/15, Level 2, Javits Center

THE CONCEPTUAL BASIS OF PSYCHIATRY

Co-Directors: S. Nassir Ghaemi, M.D., David H. Brendel, M.D.

12:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIUM 1-5

INDUSTRY-SUPPORTED SYMPOSIUM 1
12:30 p.m.-3:30 p.m.
Special Events Hall 1D, Level 1, Javits Center

TREATMENT RESISTANCE: CONCEPTS AND MANAGEMENT IN MOOD AND ANXIETY DISORDERS
Supported by Janssen Pharmaceuticals and Research Foundation

Chp.: Mark H. Rapaport, M.D.

A Treatment Resistance in Mood and Anxiety Disorders: Evidence From Clinical Trials
Ellen Frank, Ph.D.

B Psychotherapeutic Approaches for Patients With Treatment-Resistant Mood and Anxiety Disorders
Edna B. Foa, Ph.D.

C Clinical Pathways for Mood and Anxiety Disorders
Waguih W. Ishak, M.D.

D Emerging Treatment Options in Treatment-Resistant Mood and Anxiety Disorders
Mark H. Rapaport, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 2
12:30 p.m.-3:30 p.m.
Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

PREVENTIVE PSYCHIATRY IN MOOD DISORDERS:
A NEW FRONTIER
Supported by GlaxoSmithKline

Chp.: Charles B. Nemeroff, M.D.

(Continued on next page)
A Identification of Risk Factors for Development of Depression: Focus on Early-Life Trauma
Charles B. Nemeroff, M.D.

B Achieving the Optimal Balance Between Treatment of Maternal Depression and Infant Medication Exposure
Zachary N. Stowe, M.D.

C Functional Brain Imaging: Subtyping Depression
Helen S. Mayberg, M.D.

D Genetic Research in Psychiatry: Diagnostic and Therapeutic Implications
Stephan Claes, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 3
12:30 p.m.-3:30 p.m.
Grand Ballroom East, Third Floor, Hilton New York

BIPOLAR DISORDER AND ALCOHOLISM: DIAGNOSTIC CHALLENGES AND THERAPEUTIC INTERVENTIONS
Supported by Ortho-McNeil Pharmaceuticals

Chp.: Mark A. Frye, M.D.

A Neurobiology of Alcohol Withdrawal
Hugh Myrick, M.D.

B Pharmacotherapy for Alcoholism
Bankole A. Johnson, M.D.

C The Impact of Alcoholism on the Presentation and Course of Bipolar Disorder
Susan L. McElroy, M.D.

D The Role of Mood Stabilizers in Bipolar Disorder With Comorbid Alcohol Dependence
Joseph F. Goldberg, M.D.

E Bipolar Illness, Substance Abuse Comorbidity, and the Legal System
Cameron D. Quanbeck, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 4
12:30 p.m.-3:30 p.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

ADULT ADHD: CLINICAL UTILITY AND VALIDITY
Supported by Eli Lilly and Company

Chp.: T. Bedirhan Üstün, M.D.

A Prevalence of Adult ADHD in the United States: Results From the National Comorbidity Survey Replication (NCS-R)
Ronald C. Kessler, Ph.D.

B Adult ADHD Diagnostic and Self-Report Symptom Scales: Development and Validation in the National Comorbidity Survey Replication (NCS-R) Cohort
Lenard A. Adler, M.D.

C Current Concepts in the Neurobiology of ADHD
Joseph Biederman, M.D.

D Treatment Options and Response Patterns in Adult ADHD
Margaret D. Weiss, M.D.

E Our New Understanding of the Prevalence, Impairments, Comorbidity, and Treatment of Adults With ADHD
Thomas J. Spencer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 5
12:30 p.m.-3:30 p.m.
Imperial Ballroom A, Second Floor, Sheraton New York

TOWARDS DSM-V: PHENOMENOLOGY, NEUROBIOLOGY, AND TREATMENT RESPONSE IN DEPRESSION
Supported by Cephalon, Inc.

Chp.: Philip T. Ninan, M.D.

A Pathophysiology of Major Depression: Monoamines, Peptides, and Neurotrophins
Kerry J. Ressler, M.D.

B Homology Between Pathophysiology and Symptoms in Major Depression
Boadie W. Dunlop, M.D.

C Enhancing Emergence of Antidepressant Benefit
Charles DeBattista, M.D.

D Pharmacological Approaches to Management of Residual Symptoms in Depression
Maurizio Fava, M.D.

E MIND: Lessons From the Brain
Philip T. Ninan, M.D.

1:00 p.m. Sessions

COURSES 7-12
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.
SATURDAY

COURSE 7  1:00 p.m.-5:00 p.m.
Room 1E01/2, Level 1, Javits Center

MANAGEMENT OF PSYCHIATRIC DISORDERS IN PREGNANT AND POSTPARTUM MOTHERS: OVERVIEW

Co-Directors: Shaila Misri, M.D., Diana Carter, M.B.
Faculty: Maria R. Corral, M.D., Deirdre M. Ryan, M.B.

COURSE 8  1:00 p.m.-5:00 p.m.
Room 1E06, Level 1, Javits Center

BEHAVIORAL NEUROANATOMY: AN INTRODUCTION

Director: Nashaat N. Boutros, M.D.
Faculty: David L. Clark, Ph.D., Edward C. Lauterbach, M.D.

COURSE 9  1:00 p.m.-5:00 p.m.
Room 1E09, Level 1, Javits Center

PSYCHIATRIC GENOMICS: APPLICATIONS FOR CLINICAL PRACTICE

Director: David A. Mrazek, M.D.
Faculty: John L. Black, M.D., Brett A. Koplin, M.D.

COURSE 10  1:00 p.m.-5:00 p.m.
Rooms 2D02/3, Level 2, Javits Center

COGNITIVE THERAPY FOR SEVERE MENTAL DISORDERS

Director: Jesse H. Wright, M.D.
Faculty: Michael E. Thase, M.D., Monica A. Basco, Ph.D.

COURSE 11  1:00 p.m.-5:00 p.m.
Rooms 2D04/5, Level 2, Javits Center

ASSESSING THE RISK OF VIOLENCE IN BOTH FORENSIC AND SEX OFFENDER SETTINGS

Director: Bradley R. Johnson, M.D.
Faculty: Judith V. Becker, Ph.D.

COURSE 12  1:00 p.m.-5:00 p.m.
Rooms 2D06/7, Level 2, Javits Center

SYSTEMIC THERAPIES FOR SUBSTANCE ABUSE DISORDERS

Co-Directors: Peter J. Steinglass, M.D., Marc Galanter, M.D.

6:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 6-11

INDUSTRY-SUPPORTED SYMPOSIUM 6
6:00 p.m.-9:00 p.m.
Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

THE ROLE OF DOPAMINE IN HEALTH AND ILLNESS: SCIENCE TO PRACTICE
Supported by AstraZeneca Pharmaceuticals

Chp.: Peter J. Weiden, M.D.

A The Role of Dopamine as a Mediator of Normal Human Reward
   Nora D. Volkow, M.D.

B From Dopamine to Salience to Psychosis: Why Antipsychotics Are Antipsychotic
   Shitij Kapur, M.D.

C Dopamine and Neuroleptic Dysphoria in Practice
   Peter J. Weiden, M.D.

D The Role of Dopaminergic/Cholinergic Interaction in Cognition and Psychosis
   Rajiv Tandon, M.D.

E The Role of Dopamine in the Neurobiology of Sexual Dysfunction
   Abdelouahed Elmouchtari, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 7
6:00 p.m.-9:00 p.m.
Grand Ballroom East, Third Floor, Hilton New York

IMPULSIVITY: EMERGING CLINICAL PERSPECTIVES
Supported by Ortho-McNeil Pharmaceuticals

Chp.: Eric Hollander, M.D.

A Neurobiology of Impulsive Behavior
   Alan C. Swann, M.D.

B When Does Impulsive Behavior Become Pathologic?
   Ernest S. Barratt, M.D.

C Clinical Issues of Impulsivity in Psychiatry
   Dan J. Stein, M.D.

D Addressing Impulsive Behavior in Eating Disorders
   Renu Kotwal, M.D.

E Identifying the Spectrum of Impulse-Control Disorders
   Eric Hollander, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 8
6:00 p.m.-9:00 p.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

BIPOLAR DISORDER: IMPROVING OUTCOMES
WHEN THEORY, SCIENCE, AND CLINICAL
PRACTICE CONVERGE
Supported by Eli Lilly and Company

Chp.: Joseph F. Goldberg, M.D.

A The Convergence of Pharmacotherapy and
Psychotherapy in Maintenance Treatment of Bipolar
Disorder
Paul E. Keck, Jr., M.D.

B Considerations in the Female Patient During
Childbearing Years
Adele C. Viguera, M.D.

C Choosing Treatments in Bipolar Depression: What,
When, and Why?
Roy H. Perlis, M.D.

D Cognitive Functioning Outcomes: From First Episode
to Functional Recovery
Deborah A. Yurgelun-Todd, Ph.D.

E Translating Research Into Clinical Practice: From the
Bench to the Trenches
Joseph F. Goldberg, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 9
6:00 p.m.-9:00 p.m.
Grand Ballroom, Mezzanine Level, Roosevelt

GAD: EVIDENCE-BASED CONSIDERATIONS FROM
PATHOPHYSIOLOGY TO LONG-TERM
MANAGEMENT
Supported by Pfizer Inc.

Chp.: John H. Greist, M.D.

A Prevalence of GAD in the U.S.: Results From the
National Comorbidity Survey Replication
Ronald C. Kessler, Ph.D.

B Distinguishing GAD: Unique Characteristics
Wei Zhang, M.D.

C The Molecular and Cellular Pathophysiology of GAD
Carl Salzman, M.D.

D Cognitive-Behavior Therapy for the Treatment of GAD
Michelle G. Newman, Ph.D.

E Pharmacotherapies for GAD: From Rough Empiricism
to Elegant Evidence
John H. Greist, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 10
6:00 p.m.-9:00 p.m.
Imperial Ballroom A, Second Floor, Sheraton New York

SEX, SEXUALITY, AND 5HT
Supported by GlaxoSmithKline

Chp.: Philip R. Muskin, M.D.

A Do Sexual Side Effects of Most Antidepressants
Jeopardize Romantic Love and Marriage?
Helen E. Fisher, Ph.D.

B Love and Sex
Ethel S. Person, M.D.

C Talking to Gay Patients About Sex: What Do You Need
to Know?
Serena Y. Volpp, M.D.

D Effects of Psychiatric Illness and Medication on Sexual
Function
Anita L.H. Clayton, M.D.

E Talking About Sexual Dysfunction to Enhance
Adherence With Medication
Philip R. Muskin, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 11
6:00 p.m.-9:00 p.m.
Imperial Ballroom B, Second Floor, Sheraton New York

INTERFACE BETWEEN DEPRESSION AND
MEDICAL ILLNESS
Supported by Wyeth Pharmaceuticals

Chp.: Dwight L. Evans, M.D.
Co-Chp.: Dennis S. Charney, M.D.

A Heartache and Heartbreak: Depression and
Cardiovascular Disease
Charles B. Nemeroff, M.D.

B The Relationship of Depression to Cancer and HIV
Infection
David Spiegel, M.D.

C Comorbidity of Depression in Neurological Disorders
William M. McDonald, M.D.

D Mood Disorders and Medical Illness: Diabetes,
Osteoporosis, Obesity, and Pain
Robert N. Golden, M.D., Dominique L. Musselman, M.D.,
Philip W. Gold, M.D., Albert J. Stunkard, M.D., Frank Keefe

E Mood Disorders in the Medically Ill: The Patient's
Perspective
Lydia J. Lewis, B.A.
8:00 a.m. Sessions

COURSES 13-19
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 13 8:00 a.m.-12 noon
Rooms 1E01/2, Level 1, Javits Center
RISK ASSESSMENT FOR VIOLENCE
Director: Phillip J. Resnick, M.D.

COURSE 14 8:00 a.m.-12 noon
Rooms 1E03/4/5, Level 1, Javits Center
ADD IN ADULTS
Director: Thomas E. Brown, Ph.D.
Faculty: Jeffrey B. Prince, M.D.

COURSE 15 8:00 a.m.-12 noon
Room 1E06, Level 1, Javits Center
ENGAGING RESISTANT AND HOSTILE PATIENTS INTO PARTICIPATORY TREATMENT
Director: David Mee-Lee, M.D.

COURSE 16 8:00 a.m.-12 noon
Rooms 2D06/7, Level 2, Javits Center
DSM-IV-TR CULTURAL FORMULATIONS: DIAGNOSIS AND THERAPY
Director: Russell F. Lim, M.D.
Faculty: Candace M. Fleming, Ph.D., Roberto Lewis-Fernandez, M.D., Francis G. Lu, M.D., J. Charles Ndlela, M.D., Michael W. Smith, M.D.

COURSE 17 8:00 a.m.-12 noon
Rooms 2D10/11, Level 2, Javits Center
INTERPERSONAL PSYCHOTHERAPY
Director: John C. Markowicz, M.D.

COURSE 18 8:00 a.m.-12 noon
Rooms 2D12/13, Level 2, Javits Center
TEACHING PSYCHIATRY? LET HOLLYWOOD HELP!
Director: Steven E. Hyler, M.D.
Faculty: Carol A. Bernstein, M.D., Michael B. First, M.D.

COURSE 19 8:00 a.m.-12 noon
Rooms 2D14/15, Level 2, Javits Center
PERSONALITY DISORDERS: COMBINING RELATIONAL THERAPY AND PSYCHOPHARMACOLOGY
Director: Roy O. Resnikoff, M.D.

INDUSTRY-SUPPORTED SYMPOSIA 12-13

INDUSTRY-SUPPORTED SYMPOSIUM 12
8:00 a.m.-11:00 a.m.
Special Events Hall ID, Level 1, Javits Center
ANTIDEPRESSANT TREATMENTS YOU MAY NOT KNOW ABOUT, BUT SHOULD . . .
Supported by Organon Inc.
Chp.: Jerrold F. Rosenbaum, M.D.
A The Next Generation of Antidepressants: What Is in the Pipeline?
Rajinder A. Judge, M.D.
B Alternative Medications for Depression
Andrew A. Nierenberg, M.D.
C Evidence-Based Psychotherapy for Depression: Principles and Practice
Timothy J. Petersen, Ph.D.
D Device-Based Treatments for Depression
A. John Rush, M.D.
E The Future of Treatment-Matching in Depression
Steven P. Roose, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 13
8:00 a.m.-11:00 a.m.
Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt
BROADENING THE HORIZON OF ATYPICAL ANTIPSYCHOTIC APPLICATIONS
Supported by AstraZeneca Pharmaceuticals
Chp.: S. Charles Schulz, M.D.
A Atypical Antipsychotics in Anxiety and PTSD
Mark B. Hamner, M.D.
B Atypical Antipsychotics Treatment of Substance Abuse
E. Sherwood Brown, M.D.
C Role of Atypicals in the Treatment of Pediatric Psychotic Disorders and Common Comorbidities
Melissa P. DelBello, M.D.
(Continued on next page)
SUNDAY

D Atypicals in the Treatment of Anorexia Nervosa
   Walter H. Kaye, M.D.

E Atypicals in BPD
   S. Charles Schulz, M.D., A. Adityanjee, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 14
8:00 a.m.-11:00 a.m.
Grand Ballroom East, Third Floor, Hilton New York

THE MANY FACES OF ANXIETY: ORIGINS, PATHOGENESIS, AND MANAGEMENT
Supported by Pfizer Inc.

Chp.: Martin B. Keller, M.D.

A Generalized Anxiety, Social Anxiety, and Panic Disorder: New Views on Validity and Nosology
   Risa B. Weisberg, Ph.D.

B Origins and Pathogenesis of Anxiety Symptoms and Syndromes
   Dennis S. Charney, M.D.

C Pharmacologic Approaches for Panic Disorder
   David V. Sheehan, M.D.

D GAD: Current Opinions and Future Options
   Linda L. Carpenter, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 15
8:00 a.m.-11:00 a.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

FROM PATHOLOGY TO PRACTICE: EVOLVING THERAPEUTIC STRATEGIES FOR ALZHEIMER'S DISEASE
Supported by Forest Laboratories, Inc.

Chp.: Jacobo E. Mintzer, M.D.

A Synaptic Dysfunction and Neurodegeneration in Alzheimer's Disease
   Gary L. Wenk, Ph.D.

B Alzheimer's Disease Update: New Targets, New Options
   Jacobo E. Mintzer, M.D.

C Alzheimer's Disease and Vascular Dementia: Where Is the Overlap?
   John C. Morris, M.D.

D Multicultural Issues in Addressing Barriers to Diagnosis and Treatment
   Warachal E. Faison, M.D.

E A Rational Approach to Combination Treatment
   Mary Sano, Ph.D.
COURSE 20  9:00 a.m.-4:00 p.m.
Room IE15, Level 1, Javits Center

ADVANCES IN NEUROPSYCHIATRY
American Neuropsychiatric Association

Director: C. Edward Coffey, M.D.
Faculty: Jeffrey L. Cummings, M.D., Mark S. George, M.D.,
Michael R. Trimble, M.D.

COURSE 21  9:00 a.m.-4:00 p.m.
Room IE17, Level 1, Javits Center

EVIDENCE-BASED MEDICINE: AN INTRODUCTION FOR PSYCHIATRISTS

Director: Gregory E. Gray, M.D.
Faculty: Gabrielle F. Beaubrun, M.D., Letitia A. Pinson, M.D.

12:30 p.m. Session

BUSINESS MEETING
(Voting Members Only)
12:30 p.m.-1:30 p.m.
Westside Ballroom, 5th Floor, Marriott Marquis

CALL TO ORDER
Marcia Kraft Goin, M.D., President

MEMORIAL TO DECEASED MEMBERS

ANNOUNCEMENT OF ELECTION RESULTS
Liza H. Gold, M.D., Chairperson, Committee of Tellers

REPORTS TO THE MEMBERSHIP
Secretary: Nada L. Stotland, M.D.
Treasurer: Carol A. Bernstein, M.D.
Speaker, Assembly: Prakash N. Desai, M.D.
Speaker, Elect, Assembly: James E. Nininger, M.D.
Chairperson, By-Laws Committee: Derek Puddester, M.D.
Chairperson, Elections Committee: Yvonne B. Ferguson, M.D.
Chairperson, Membership Committee: Mary K. Marrocco, M.D.
Medical Director: James H. Scully, Jr., M.D.

ANNUAL FORUM

ADJOURNMENT

*Members-in-Training, General Members, Distinguished Fellows, Fellows, Life Fellows, Distinguished Life Fellows, and Life Members. Badge or APA membership card necessary for admission. No cameras or tape recorders will be permitted.
1:00 p.m. Sessions

COURSES 24-31
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 24 1:00 p.m.-5:00 p.m.
Rooms 1E01/2, Level 1, Javits Center
MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP, AND OTHER BODY CLOCK DISORDERS
Director: Alfred J. Lewy, M.D.
Faculty: Michael Terman, Ph.D.

COURSE 25 1:00 p.m.-5:00 p.m.
Rooms 1E03/4/5, Level 1, Javits Center
COGNITIVE THERAPY FOR SCHIZOPHRENIA
Director: Jesse H. Wright, M.D.
Faculty: Douglas Turkington, M.B., David G. Kingdon, M.D.

COURSE 26 1:00 p.m.-5:00 p.m.
Room 1E06, Level 1, Javits Center
DETERMINING MEDICAL FITNESS TO DRIVE: RELEVANT ISSUES FOR PSYCHIATRISTS
Director: Ian A. Gillespie, M.D.

COURSE 27 - CANCELLED

COURSE 28 1:00 p.m.-5:00 p.m.
Room 1E12, Level 1, Javits Center
CURRENT CONCEPTS IN CHILD AND ADOLESCENT EATING DISORDERS
Director: Mae S. Sokol, M.D.
Faculty: Kristina Hoffman-Rieken, R.D.

COURSE 29 1:00 p.m.-5:00 p.m.
Rooms 2D6/7, Level 2, Javits Center
USING BOUNDARY CROSSINGS AS CREATIVE THERAPY INSTEAD OF SLIPPERY SLOPES
Director: Gail E. Robinson, M.D.
Faculty: Gary R. Schoener, Psy.D., Howard E. Book, M.D., Linda M. Jorgenson, J.D.

1:30 p.m. Sessions

COURSE 30 1:00 p.m.-5:00 p.m.
Rooms 2D10/11, Level 2, Javits Center
PSYCHIATRIC INTERVENTIONS IN DISASTERS: LESSONS FROM EXPERIENCE
Co-Directors: Carol S. North, M.D., Betty Pfefferbaum, M.D.
Faculty: Anthony T. Ng, M.D., Phebe M. Tucker, M.D.

COURSE 31 1:00 p.m.-5:00 p.m.
Rooms 2D14/15, Level 2, Javits Center
IMPROVING YOUR PRESENTATION SKILLS: A COACHING APPROACH
Director: Luis F. Ramirez, M.D.

1:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 19-23

INDUSTRY-SUPPORTED SYMPOSIUM 19
1:30 p.m.-4:30 p.m.
Special Events Hall 1D, Level 1, Javits Center
THE TREACHEROUS TRIAD FOR DEPRESSION
Supported by Wyeth Pharmaceuticals
Chp.: John F. Greden, M.D.

A Underdetection and Inadequate Treatment of Physical Symptoms of Depression: The Real Barriers to Remission
Kurt Kroenke, M.D.

B Neurochemical Systems Interfacing Physical and Emotional Stressors
Jon-Kar Zubieta, M.D.

C Stress Effects on the Hippocampus: Relevance to Depression
Bruce S. McEwen, Ph.D.

D Gender Considerations in the Treatment of Physical Symptoms of Depression
Vivien K. Burt, M.D.

E Best Practices for Achieving Remission in Depression With Physical Symptoms: Current and Future Trends
John F. Greden, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 20
1:30 p.m.-4:30 p.m.
Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

BEYOND 5HT: NEW TREATMENTS FOR DEPRESSION
Supported by Merck & Co., Inc.

Chp.: Jack M. Gorman, M.D.
A Combining Treatment to Enhance SSRI Response
Jack M. Gorman, M.D.
B What to Do for SSRI Nonresponders?
Michael E. Thase, M.D.
C The Relationship Between Substance P, 5HT, and Other Neurotransmitter Systems
Linda L. Carpenter, M.D.
D Substance P Antagonists: Mechanism of Action and Clinical Implications
K. Ranga R. Krishnan, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 21
1:30 p.m.-4:30 p.m.
Grand Ballroom East, Third Floor, Hilton New York

ARE ALL ATYPICAL ANTIPIPSYCHOTICS EQUAL FOR TREATMENT OF COGNITIVE AND AFFECTIVE SYMPTOMS IN SCHIZOPHRENIA?
Supported by Pfizer Inc.

Chp.: Stephen M. Stahl, M.D.
A Schizophrenia: From Circuits to Symptoms
Stephen M. Stahl, M.D.
B Effect of Atypical Antipsychotic Drugs on Cognition and Negative Symptoms
Herbert Y. Meltzer, M.D.
C Optimal Health Outcomes in Schizophrenia
Jonathan M. Meyer, M.D.
D Maximizing Function in Patients With Schizophrenia
Lili Kopala, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 22
1:30 p.m.-4:30 p.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

COMBINATION THERAPY: NEW STRATEGIES IN THE MANAGEMENT OF SEVERE MENTAL DISORDERS
Supported by Abbott Laboratories

Chp.: Susan L. McElroy, M.D.
A Rational Combination Therapy Versus Irrational Polypharmacy
Susan L. McElroy, M.D.
B Combination Treatment for Acute Mania
Gary S. Sachs, M.D.
C Management of Bipolar Depression: Combination Therapy Versus Monotherapy
Robert M.A. Hirschfeld, M.D.
D Managing Bipolar Disorder in Children and Adolescents
Karen D. Wagner, M.D.
E Evidence for the Mechanisms and Efficacy of Anticonvulsants in the Treatment of Schizophrenia
Henry A. Nasrallah, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 23
1:30 p.m.-4:30 p.m.
Imperial Ballroom A, Second Floor, Sheraton New York

UNMASKING BIPOLAR DISORDER: OVERCOMING THE BARRIERS TO TREATMENT SUCCESS
Supported by Janssen Pharmaceutica and Research Foundation

Chp.: S. Nassir Ghaemi, M.D.
A Bipolar Disorder: A National Health Concern
Roger S. McIntyre, M.D.
B Redefining Mood Stabilizing Agents: Improved Treatment Options for Bipolar Disorder
S. Nassir Ghaemi, M.D.
C Safety Considerations in Treating the Bipolar Disorder Patient
Prakash S. Masand, M.D.
D The Essential Role of Psychotherapy in Managing Bipolar Disorder
Michael W. Otto, Ph.D.
2:30 p.m. Session

LECTURE 1

2:30 p.m.-4:00 p.m.
Rooms 1E07/8, Level 1, Javits Center

AAPL/APA'S MANFRED S. GUTTMACHER
AWARD LECTURE

Margaret G. Spinelli, M.D.

Infanticide: The Hope of Prevention
and the Promise of Saved Lives

Chp.: Michael A. Norko, M.D.

Margaret G. Spinelli, M.D., is Assistant Professor of
Clinical Psychiatry, Columbia University College of
Physicians and Surgeons; and Director of the Maternal
Mental Health Program, New York State Psychiatric
Institute. Dr. Spinelli came to the field of perinatal
psychiatry after a 15-year career as a nurse in Obstetrics
and Gynecology. She graduated from Cornell
University Medical College in New York, and
completed her residency training in psychiatry at the
Payne Whitney Clinic/Cornell University/The New
York Hospital. A clinical clerkship on the Mother-
Infant Postpartum Unit of the Royal Maudsley and
Bethlem Hospital in London inspired her clinical
philosophy. A career in academic and research
psychiatry followed a Postdoctoral Research Fellowship
at Columbia University College of Physicians and
Surgeons and The New York State Psychiatric
Institute. Her area of NIMH Clinical Research
includes Interpersonal Psychotherapy for Antepartum
Depression. Her field of publications includes
Pregnancy and Postpartum Psychiatric disorders,
Postpartum Psychosis, Infanticide, Neonaticide,
Neurohormones and Mood. Dr. Spinelli’s clinical work
focuses on the treatment of women with psychiatric
disorders during pregnancy and postpartum periods.
She has testified in criminal cases of mentally ill
mothers who have killed their infants and works with
Project Liberty 9/11 and the New York Police
Department.

THIS SESSION WILL BE AUDIOTAPED.

5:00 p.m. Session

OFFICIAL OPENING SESSION

5:00 p.m.-6:30 p.m.
Hall 3E, Level 3, Javits Center

CALL TO ORDER
Marcia Kraft Goin, M.D., President

INTRODUCTION OF STAGE GUESTS

INTRODUCTION OF CHAIRPERSON OF
THE SCIENTIFIC PROGRAM COMMITTEE

Geetha Jayaram, M.D.
Chairperson, Annual Meeting Scientific Program Committee

INTRODUCTION OF VISITING
DIGNITARIES

PRESIDENTIAL ADDRESS
Marcia Kraft Goin, M.D.
To be introduced by George M. Simpson, M.D.

RESPONSE OF THE PRESIDENT-ELECT
Michelle B. Riba, M.D.
To be introduced by Allan Tasman, M.D.

ADJOURNMENT

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 24-30

INDUSTRY-SUPPORTED SYMPOSIUM 24
7:00 p.m.-10:00 p.m.
Special Events Hall 1D, Level 1, Javits Center

RECOVERING FROM SCHIZOPHRENIA: HOW
TREATMENT CAN IMPROVE OUTCOMES AND
PREVENT CHRONICITY
Supported by Eli Lilly and Company

Chp.: Jeffrey A. Lieberman, M.D.

A Laboratory and Imaging Aids to Diagnosis and
Assessment of Schizophrenia
Ayseil Belger, Ph.D.

B Treating First-Episode Schizophrenia: Differential
Effects of Atypical and Typical Antipsychotics on Brain
Pathomorphology
Jeffrey A. Lieberman, M.D.

C Approaches to Improved Maintenance Treatment and
Relapse Prevention
T. Scott Stroup, M.D.

D Psychiatric Rehabilitation
Robert E. Drake, M.D.

E Cognitive Improvement and Therapeutic Alliance
Richard S. Keefe, Ph.D.
INDUSTRY-SUPPORTED SYMPOSIUM 25
7:00 p.m.-10:00 p.m.
Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

NOVEL INTERVENTION STRATEGIES ACROSS THE SPECTRUM OF DEMENTIA: REAL PATIENTS AND REAL OUTCOMES
Supported by Eisai, Inc.

Chp.: Gary W. Small, M.D.

A Identifying Early Dementia: Mild Cognitive Impairment and Early-Stage Alzheimer's Disease
P. Murali Doraiswamy, M.D.

B Identifying and Treating Early Dementia: Case Studies
Daniel D. Christensen, M.D.

C Exploring Vascular Dementia: Diagnosis, Treatment, and Behavior
Helen Lavretsky, M.D.

D Exploring Differences Between Vascular Dementia and Alzheimer’s Disease: Case Studies
Stephen P. Salloway, M.D.

E Defining and Achieving Positive Outcomes in Dementia Pharmacotherapy
David Geldmacher, M.D.

F Alzheimer’s Disease Prevention: Strategies for Improving Brain and Memory Fitness
Gary W. Small, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 26
7:00 p.m.-10:00 p.m.
Grand Ballroom East, Third Floor, Hilton New York

EFFECTIVE LONG-TERM MANAGEMENT OF SCHIZOPHRENIA: REAL-WORLD CONSIDERATIONS
Supported by Bristol-Myers Squibb Company

Chp.: John M. Kane, M.D.

A The Evolution of Antipsychotic Agents: A Mechanism-Based Review
Anissa Abi-Dargham, M.D.

B Optimizing the Long-Term Effectiveness of Antipsychotic Therapy
Stephen R. Marder, M.D.

C Managing Patients With Treatment-Resistant Schizophrenia
John M. Kane, M.D.

D What Is Effectiveness With Medications?
Peter J. Weiden, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 27
7:00 p.m.-10:00 p.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

MODERATORS AND MEDIATORS OF ANTIDEPRESSANT RESPONSE
Supported by Forest Laboratories, Inc.

Chp.: Steven P. Roose, M.D.

A Modifiers and Mediators of Treatment Effects in Antidepressant Trials
Philip Lavori, Ph.D.

B Gender as a Moderator of Antidepressant Response
Susan G. Kornstein, M.D.

C Moving the Goalposts: Is Response a Mediator of Remission?
David J. Kupfer, M.D.

D Antidepressant Treatment Duration: The Decision to Continue or Switch Treatment
Harold A. Sackeim, Ph.D.

E Placebo, Comparator, or Open Treatment? Design Counts
Steven P. Roose, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 28
7:00 p.m.-10:00 p.m.
Grand Ballroom, Mezzanine Level, Roosevelt

BEYOND SLEEP ONSET: NEW PERSPECTIVES ON THE TREATMENT OF INSOMNIA
Supported by Sepracor, Inc.

Chp.: Andrew D. Krystal, M.D.

A Prevalence and Impact of Insomnia: Treating the Entire Insomnia Syndrome
Mugdha E. Thakur, M.D.

B Differential Diagnosis of Insomnia and Comorbid Conditions: Importance of Sleep History
Jed E. Black, M.D.

C Measures of Treatment Efficacy
Thomas Roth, Ph.D.

D Overview of Insomnia Treatment
Andrew D. Krystal, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 29
7:00 p.m.-10:00 p.m.
Imperial Ballroom A, Second Floor, Sheraton New York

PSYCHOPHARMACOLOGY AND REPRODUCTIVE TRANSITIONS: IMPACT OF PSYCHOTROPIC MEDICATIONS AND SEX HORMONES ON BRAIN FUNCTIONING, WEIGHT, AND REPRODUCTIVE SAFETY
Supported by GlaxoSmithKline

Chp.: Claudio N. Scares, M.D.
Co-Chp.: Mary Blehar, Ph.D.

A Labeling Products for Use in Pregnancy: Moving Forward
Sandra L. Kweder, M.D.

B Weight Gain, Psychotropic Medications, and Gender: Potential Pharmacologic Strategies
Barbara L. Gracious, M.D.

C Testosterone Decline in the Aging Male: Does Andropause Exist?
Stuart N. Seidman, M.D.

D Perimenopause-Related Mood Disturbance: An Update on Risk Factors and Novel Treatment Strategies Available
Claudio N. Soares, M.D.

E Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women’s Health Initiative Memory Study Updates
Sally A. Shumaker, Ph.D., Claudine Legault, Ph.D., Stephen K. Rapp, Ph.D.

Discussant: William Harlan, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 30
7:00 p.m.-10:00 p.m.
Imperial Ballroom B, Second Floor, Sheraton New York

CHOOSING THE RIGHT DOSE OF ATYPICAL ANTIPSYCHOTICS: ART OR SCIENCE?
Supported by AstraZeneca Pharmaceuticals

Chp.: Peter F. Buckley, M.D.

A Dosing With Atypicals: Receptor Occupancy as a Guide to Titration and Maintenance
Shitij Kapur, M.D.

B Acute Stabilization of Psychosis: Options and Approaches
K.N. Roy Chengappa, M.D.
MONDAY, MAY 3, 2004

157TH ANNUAL MEETING

7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 31-35

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART 1
7:00 a.m.-8:30 a.m.
Grand Ballroom East, Third Floor, Hilton New York

NEW ADVANCES IN THE TREATMENT OF PSYCHOSIS
Supported by Bristol-Myers Squibb Company

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A Psychosis Associated With Dementia: Efficacy of the Newer Antipsychotics
Dilip V. Jeste, M.D.

B Antipsychotic Therapies in Pediatric Patients: The Importance of Safety and Tolerability
Robert L. Findling, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART 1
7:00 a.m.-8:30 a.m.
Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

CURRENT ALZHEIMER’S DISEASE TREATMENTS AND BEYOND: ADVANCES IMPACTING CLINICAL PRACTICE
Supported by Forest Laboratories, Inc.

Chp.: Trey Sunderland, M.D.

A The Molecular Genetics of Alzheimer’s Disease
Rudolph Tanzi, Ph.D.

B Diversity of Neuropsychiatric Impairment: Cognitive and Behavioral Implications
Jeffrey L. Cummings, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 33, PART 1
7:00 a.m.-8:30 a.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

RECOGNIZING THE MANY FACES OF BIPOLAR DISORDER
Supported by Eli Lilly and Company

Chp.: Bruce M. Cohen, M.D.

A Differential Diagnosis of Bipolar Disorder: Clinical Findings
Stephan H. Heckers, M.D.

B Recognizing Bipolar Disorder in Children and Adolescents
Gabrielle Carlson, M.D.

C Bipolarity in Old Age: Diagnostic and Management Issues
Kenneth I. Shulman, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 34, PART 1
7:00 a.m.-8:30 a.m.
Imperial Ballroom A, Second Floor, Sheraton New York

EVIDENCE-BASED MEDICINE: THE NEXT GENERATION
Supported by Wyeth Pharmaceuticals

Chp.: K. Ranga R. Krishnan, M.D.

A How to Make Judgments Under Uncertainty
K. Ranga R. Krishnan, M.D.

B Improving Outcomes in Anxiety Disorders
Nick Freemantle, Ph.D.

C Study Designs and Outcome in Antidepressant Clinical Trials
Arifulla Khan, M.D., Shirin R.F. Khan, B.S., Russel Korts, Ph.D., Michael E. Thase, M.D., Walter A. Brown, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 35, PART 1
7:00 a.m.-8:30 a.m.
Imperial Ballroom B, Second Floor, Sheraton New York

TRANSCENDING EFFICACY: EFFECTIVE TREATMENT OF PSYCHOSIS ACROSS DISORDERS
Supported by AstraZeneca Pharmaceuticals

Chp.: Pierre N. Tariot, M.D.
Co-Chp.: John W. Newcomer, M.D.

A Managing Psychosis and Agitation in Dementia
J. Michael Ryan, M.D.

B Movement Disorders in the Elderly: How Safe Are the Atypical Neuroleptics?
Richard N. Trosch, M.D.

C Lewy Body Dementia: What the Psychiatrist Needs to Know
Andrius Baskys, M.D.
RESIDENT’S SESSION
7:00 a.m.-8:30 a.m.
Versailles Ballroom, Second Floor, Sheraton New York

MEET THE EXPERTS: SUNNY-SIDE UP

Chp.: Marcia Kraft Goin, M.D.
Co-Chp.: Michelle B. Riba, M.D.

At this breakfast, nationally recognized “experts” will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include: Addiction/Substance Abuse, AIDS/HIV, Child and Adolescent Psychiatry, Consultation-Liaison, Cultural Competence, Forensic, Law and Ethics in Psychiatry, Geriatric, Medical Student Issues, Public and Community Mental Health, Professional and Leadership Development, Psychodynamic Psychotherapy, and Research in Psychiatry.

8:00 a.m. Sessions:

COURSES 32-40
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 35 8:00 a.m.-12 noon
Gramercy A, Second Floor, Hilton New York
THE PSYCHIATRIST AS EXPERT WITNESS
Director: Phillip J. Resnick, M.D.

COURSE 36 8:00 a.m.-12 noon
Gramercy B, Second Floor, Hilton New York
CURRENT CPT CODING AND DOCUMENTATION REQUIREMENTS
Co-Directors: Chester W. Schmidt, Jr., M.D., Tracy R. Gordy, M.D.

COURSE 37 8:00 a.m.-12 noon
Nassau Suite A, Second Floor, Hilton New York
FAMILIES COPING WITH MEDICAL ILLNESS: AN INTEGRATIVE TREATMENT APPROACH
Director: John S. Rolland, M.D.

COURSE 38 8:00 a.m.-12 noon
Rhineland Gallery North/Center, Second Floor, Hilton New York
ADVANCED ASSESSMENT AND TREATMENT OF ADD
Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 39 8:00 a.m.-12 noon
Sutton North, Second Floor, Hilton New York
ECT PRACTICE UPDATE
Director: Charles H. Kellner, M.D.
Faculty: Richard L. Jaffe, M.D., W. Vaughn McCall, M.D., Richard D. Weiner, M.D.

COURSE 40 8:00 a.m.-12 noon
Sutton Center, Second Floor, Hilton New York
COGNITIVE-BEHAVIOR THERAPY FOR ADULT AND PEDIATRIC OCD: THE BASICS
Co-Directors: Jonathan Abramowitz, Ph.D., Stephen Whiteside, Ph.D.
MONDAY

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 1
9:00 a.m.-10:30 a.m.
Rooms 3D06/7, Level 3, Javits Center

BOUNDARY ISSUES AND THE CHALLENGE OF THE SOMATIZING PATIENT

Moderator: James L. Levenson, M.D.
Presenter: Catherine C. Crone, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 1:
PART 1
9:00 a.m.-12 noon
Rooms 3D01/12, Level 3, Javits Center

HELPING PATIENTS COUNTER DEMORALIZATION WHILE LIVING WITH A CHRONIC OR RECURRENT PSYCHIATRIC ILLNESS

Moderator: James L. Griffith, M.D.
Presenters: Lynne M. Gaby, M.D., Julia B. Frank, M.D., Robert W. Keisling, M.D., Jeffrey S. Akman, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 41-44
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 41 9:00 a.m.-4:00 p.m.
Clinton Suite, Second Floor, Hilton New York
MONEY MATTERS I: USING THEORY IN CLINICAL PRACTICE
Director: Cecilia M. Mikalac, M.D.

COURSE 42 9:00 a.m.-4:00 p.m.
Murray Hill A, Second Floor, Hilton New York
TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC ASSESSMENT
Director: Robert P. Granacher, Jr., M.D.

COURSE 43 9:00 a.m.-4:00 p.m.
Murray Hill B, Second Floor, Hilton New York

DAVANLOO'S INTENSIVE SHORT-TERM DYNAMIC PSYCHOTHERAPY IN CLINICAL PRACTICE

Director: James Q. Schubmehler, M.D.
Faculty: Alan R. Beeber, M.D., Tewfik Said, M.D.

COURSE 44 9:00 a.m.-4:00 p.m.
Nassau Suite B, Second Floor, Hilton New York

ADVANCED HYPNOSIS: APPLICATIONS IN PSYCHIATRY

Director: Jose R. Maldonado, M.D.
Faculty: David Spiegel, M.D., Matthew May, M.D., Herbert Spiegel, M.D., Marcia Greenleaf, Ph.D.

DEBATE
9:00 a.m.-10:30 a.m.
Room 1E10, Level 1, Javits Center

RESOLVED: THE RRC SHOULD CONTINUE TO REQUIRE THAT PSYCHIATRIC RESIDENCY PROGRAMS MUST DEMONSTRATE THAT THE RESIDENTS HAVE ACHIEVED COMPETENCY IN PSYCHODYNAMIC PSYCHOTHERAPY

Moderator: Sheila Judge, M.D.
Affirmative: Allan Tasman, M.D., Lisa A. Mellman, M.D.
Negative: Joel Yager, M.D., Eugene H. Rubin, M.D.
THIS SESSION WILL BE AUDIOTAPE.

DISCUSSION GROUPS 1-4
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

1 Jonathan M. Meyer, M.D., on the Medical Care for the Chronically Mentally Ill: The Role of the Psychiatrist
(Meet the Authors)
Rooms 2D02/3, Level 2, Javits Center

2 Robert Michels, M.D., on Who Should Be Psychoanalyzed?
Rooms 2D04/5, Level 2, Javits Center

3 Robert R. Conley, M.D., on What Is the Best Medication for People Suffering From Schizophrenia?
Rooms 2D06/7, Level 2, Javits Center

4 Larry E. Tune, M.D., on Dementia and Delirium
Room 2D08, Level 2, Javits Center
MONDAY

FOCUS LIVE SESSION 1
9:00 a.m.-10:30 a.m.
Room 1E14, Level 1, Javits Center

Moderator: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.
Presenters: Laura W. Roberts, M.D., Paul S. Appelbaum, M.D., on Forensic and Ethical Issues in Psychiatry

Expert clinicians, who served as the guest editors of the first two issues of Foes, will lead lively multiple-choice, question-based discussions. This session covers Forensic and Ethical Issues in Psychiatry, the second session at 11:00 a.m. covers PTSD and Anxiety Disorders, and the third session at 2:00 p.m. covers Schizophrenia and Other Psychotic Disorders. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 2-4

LECTURE 2
9:00 a.m.-10:30 a.m.
Rooms 1E07/8, Level 1, Javits Center
Paul Greengard, Ph.D.
Signal Integration in the Brain
Collaborative Session With the National Institute on Drug Abuse

Chp.: Satish C. Varma, M.D.
Co-Chp.: Marianne T. Guschwan, M.D.

Paul Greengard, Ph.D., is the Vincent Astor Professor and Head of the Laboratory of Molecular and Cellular Neuroscience at the Rockefeller University in New York City. In 2000, Dr. Greengard received the Nobel Prize in Physiology or Medicine for his discovery of how dopamine and other neurotransmitters exert their action in the nervous system. A member of the U.S. National Academy of Sciences and the Institute of Medicine, Dr. Greengard is the recipient of numerous other honors, including the Metropolitan Life Foundation Award for Medical Research, the Charles A. Dana Award for Pioneering Achievements in Health, the Lieber Prize for Outstanding Achievement in Schizophrenia Research, and the National Academy of Sciences Award in the Neurosciences. Dr. Greengard is the Founder and Series Editor of Advances in Biochemical Psychopharmacology and Advances in Cyclic Nucleotide and Protein Phosphorylation Research. He is a member of the Scientific Council of the National Alliance for Research on Schizophrenia and Depression and a member of the Board of Directors of the Research Foundation for Mental Hygiene, Inc. Dr. Greengard received his doctorate in biophysics at Johns Hopkins University in Baltimore and received advanced training in brain biochemistry at the University of London and at the National Institute of Medical Research in London.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 3
9:00 a.m.-10:30 a.m.
Room 1E15, Level 1, Javits Center

APA'S BENJAMIN RUSH AWARD LECTURE

David Mechanic, Ph.D.
The Changing Face of Mental Health Services

Chp.: Avram H. Mack, M.D.

David Mechanic, Ph.D., examines changing patterns of mental health services, with a focus on the contribution of managed behavioral health care to the shaping of professional practice and delivery of services, particularly for persons with serious mental illness and those receiving behavioral health care through Medicaid. Dr. Mechanic is René Dubos University Professor of Behavioral Sciences and Founder and Director of the Institute for Health, Health Care Policy, and Aging Research at Rutgers University in New Brunswick, New Jersey. He is the author of more than 400 research articles and book chapters and the author or editor of 24 books, including Irresistible Decisions: The Imperatives of Health Reform and Mental Health and Social Policy: The Emergence of Managed Care. A member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the Institute of Medicine, Dr. Mechanic has received numerous awards, including the Distinguished Career Award, the Lifetime Contributions Award in Mental Health from the American Sociological Association, the Rema Lapouse Award, the first Carl Taube Award for Distinguished Contributions to Mental Health Services Research from the American Public Health Association, and the Baxter Health Services Research Prize. Dr. Mechanic received his doctorate in sociology from Stanford University in Stanford, California.

THIS SESSION WILL BE AUDIOTAPED.
LECTURE 4
9:00 a.m.-12:30 a.m.
Hall 3E, Level 3, Javits Center

Sri Sri Ravi Shankar
Psychiatry and Spirituality: A Holistic Perspective
Chp.: Richard P. Brown, M.D.
Co-Chp.: Geetha Jayaram, M.D.

Sri Sri Ravi Shankar, a humanitarian teacher, philosopher, and spiritual leader, was born in 1956 in Papanasum, a village in south India. He completed advanced degrees in modern science and Vedic studies by age 17 years. In 1982 he began to teach Sudarshan Kriya, a yogic breath technique that reduces stress, anxiety, and depression and promotes health. Sudarshan Kriya is now taught in more than 100 countries as part of the Art of Living Course. In the late 1990s, the Sudarshan Kriya technique gained increased recognition when additional medical studies confirming its benefits were published. Sri Sri Ravi Shankar created the Art of Living Foundation, which offers programs around the world to eliminate stress, restore human values, and encourage people from all backgrounds to join in service to humanity. He is also a founding member of the International Association for Human Values. Sri Sri Ravi Shankar has addressed large audiences at universities and institutions around the world, including the World Economic Forum, the International Conference on Human Values and Spiritual Regeneration, and the United Nations Millennium World Peace Summit of Religious and Spiritual Leaders. He is the author of several books, including Wisdom for the New Millennium.

MASTER EDUCATOR CLINICAL CONSULTATIONS 1-2
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

1 John C. Racy, M.D., on Treating One’s Students and Colleagues: The Eternal Challenge of Boundaries
Room ID04, Level 1, Javits Center

2 Eugene V. Beresin, M.D., on Evaluation and Treatment of Eating Disorders
Room ID05, Level 1, Javits Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

NEW RESEARCH YOUNG INVESTIGATORS’ POSTER SESSION 1
9:00 a.m.-10:30 a.m.
Galleria, Level 4, Javits Center

For further information on New Research Sessions, please refer to the New Research Program Book included in your registration packet.

WORKSHOPS

COMPONENTS 1-11:

COMPONENT WORKSHOP 1 9:00 a.m.-10:30 a.m.
Room ID06, Level 1, Javits Center

HOW TO TEACH AND LEARN CULTURAL COMPETENCE IN GERIATRIC PSYCHIATRY
APA Committee on Ethnic Minority Elderly
Chp.: Iqbal Ahmed, M.D.
Participants: Warachal E. Faison, M.D., Walter P. Bland, M.D., Kenneth M. Sakauye, M.D., Angela L. Guerrero, M.D.

COMPONENT WORKSHOP 2 9:00 a.m.-10:30 a.m.
Rooms 1E01/2, Level 1, Javits Center

CAN’T WORK, SHOULDN’T WORK, MUSTN’T WORK: ASSESSING FUNCTION AND MENTAL IMPAIRMENT IN PSYCHIATRIC ILLNESS
APA Corresponding Committee on Psychiatry in the Workplace
Chp.: Marcia A. Scott, M.D.
Participants: Andrea G. Stolar, M.D., Steven E. Pflanz, M.D.

COMPONENT WORKSHOP 3 9:00 a.m.-10:30 a.m.
Rooms 1E03/4/5, Level 1, Javits Center

PUBLIC HEALTH AND MENTAL HEALTH PARTNERSHIP IN TERRORISM AND DISASTERS
APA Committee on Psychiatric Dimensions of Disaster
Chp.: Robert J. Ursano, M.D.
Participants: Carol S. North, M.D., Dori B. Reissman, M.D.

COMPONENT WORKSHOP 4 9:00 a.m.-10:30 a.m.
Room 1E09, Level 1, Javits Center

CHILD SOLDIERS: CHILD VICTIMS OF WAR AND TERRORISM: PSYCHOSOCIAL AND SPIRITUAL NEEDS
APA Alliance
Co-Chps.: Mohammad Shafii, M.D., Rosalind Hayes, B.A.
Participants: Chet Lowe, M.A., Jon A. Shaw, M.D., Peter Moszynski, M.A.
COMPONENT WORKSHOP 5  9:00 a.m.-10:30 a.m.
Rooms 2D10/11, Level 2, Javits Center

CAREER CHOICES IN PSYCHIATRY: EXPLORING FELLOWSHIP TRAINING
APA Assembly Committee of Area Member-in-Training Representatives

Chp.: Thor J. Cornelius, M.D.
Participants: David M. Geller, M.D., Richard A. Montgomery, M.D., Charles V. Panadero, M.D., Shana P. Reinblatt, M.D.

COMPONENT WORKSHOP 6  9:00 a.m.-10:30 a.m.
Rooms 2D12/13, Level 2, Javits Center

FACILITATING RESEARCH ON MINORITY POPULATIONS BY MINORITY RESEARCHERS
APA Assembly Committee of Representatives of Minority Underrepresented Groups

Chp.: Jagannathan Srinivasaraghavan, M.D.
Participants: Renato D. Alarcon, M.D., Mantosh J. Dewan, M.D., Roger D. Walker, M.D., Tana A. Grady-Weliky, M.D.

COMPONENT WORKSHOP 7  9:00 a.m.-10:30 a.m.
Odets Room, Fourth Floor, Marriott Marquis

STATE HOSPITAL PSYCHIATRY: BEEN DOWN SO LONG IT LOOKS LIKE UP TO ME
APA Caucus of State Hospital Psychiatrists and American Association of Psychiatric Administrators

Co-Chps.: Yad M. Jabbarpour, M.D., Beatrice M. Kovasznay, M.D.
Participants: Jeffrey L. Geller, M.D., Michael F. Hogan, Ph.D., Kris A. McLoughlin, M.S.N.

COMPONENT WORKSHOP 8  9:00 a.m.-10:30 a.m.
O'Neill Room, Fourth Floor, Marriott Marquis

LEADERSHIP SKILLS FOR PUBLIC ADVOCACY
APA Committee on Public Affairs

Chp.: Mary H. Davis, M.D.
Participants: Nicholas Myers, B.S.C., Ericka L. Goodwin, M.D.

COMPONENT WORKSHOP 9  9:00 a.m.-10:30 a.m.
Ziegfeld Room, Fourth Floor, Marriott Marquis

MISSION POSSIBLE: THE SCIENCE OF PSYCHIATRY AND THE ART OF ADVOCACY
APA Committee on Developmental Disabilities

Chp.: Donald J. Mordecai, M.D.
Participants: Jeremy Veenstra-VanderWeele, M.D., Bryan H. King, M.D., Lee Combrinck-Graham, M.D., Mark Combrinck-Hertz

COMPONENT WORKSHOP 10  9:00 a.m.-10:30 a.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

BRIDGING ACROSS CULTURE AND GENERATIONS: AN ASIAN-AMERICAN PERSPECTIVE
APA Committee of Asian American Psychiatrists

Chp.: Eric C. Li, M.D.
Participants: Yujuan Choy, M.D., John S. Luo, M.D., Salman Akhtar, M.D., Surinder S. Nand, M.D.

COMPONENT WORKSHOP 11  9:00 a.m.-10:30 a.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

MENTAL HEALTH’S RESPONSE TO TERRORISM
APA Caucus of VA Psychiatrists

Co-Chps.: Albert C. Gaw, M.D., Patricia L. Ordorica, M.D.
Participants: Laurent S. Lehmann, M.D., Matthew J. Friedman, M.D., Harold S. Kudler, M.D., Mara Kushner, CSW.

ISSUES 1-18

ISSUE WORKSHOP 1  9:00 a.m.-10:30 a.m.
Room 1E11, Level 1, Javits Center

DISRUPTIVE EMPLOYEES: FEEDBACK-ASSISTED COUNSELING AND TREATMENT

Co-Chps.: Eva C. Ritvo, M.D., Gonzalo F. Quesada, M.D.
Participant: Larry Harmon, Ph.D.

ISSUE WORKSHOP 2  9:00 a.m.-10:30 a.m.
Room 1E12, Level 1, Javits Center

THE OFFICE OF THE FUTURE: TECHNOLOGY IN PSYCHIATRY
American Association for Technology in Psychiatry

Co-Chps.: Robert C. Hsiung, M.D., Ronnie S. Stangler, M.D.
Participants: Seth M. Powsner, M.D., Daniel A. Deutschman, M.D., Michael Bauer, M.D.

ISSUE WORKSHOP 3  9:00 a.m.-10:30 a.m.
Room 1E13, Level 1, Javits Center

E, K, AND GHB: THE NEW ABCS OF SUBSTANCE ABUSE
Collaborative Session With the National Institute on Drug Abuse

Chp.: Richard N. Rosenthal, M.D.
Participants: Ramon Solikhah, M.D., Petros Levounis, M.D.
<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 4</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room IE 16, Level 1, Javits Center</td>
<td></td>
</tr>
<tr>
<td>FUNCTIONAL IMAGING IN COURT: USES AND CONTROVERSIES</td>
<td></td>
</tr>
<tr>
<td>Chp.: Daniel G. Amen, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Joseph C. Wu, M.D., Steven E. Rudolph, D.O., Harold J. Bursztajm, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 5</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rooms 2D14/15, Level 2, Javits Center</td>
<td></td>
</tr>
<tr>
<td>REINVENTING CAREERS: TRANSITIONS AND LATER-LIFE STRATEGIES FOR PSYCHIATRISTS</td>
<td></td>
</tr>
<tr>
<td>Chp.: Carolyn B. Robinowitz, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Carol C. Nadelson, M.D., Edward Hanin, M.D., Mary V. Seeman, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 6</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 3D02/11, Level 3, Javits Center</td>
<td></td>
</tr>
<tr>
<td>DRUG ABUSE AND SUICIDAL BEHAVIOR: Collaborative Session With the National Institute on Drug Abuse</td>
<td></td>
</tr>
<tr>
<td>Chp.: Eric D. Caine, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Richard K. Ries, M.D., David B. Goldston, Ph.D., Marsha M. Linehan, Ph.D., Gregory Brown, Ph.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 7</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 3D03/10, Level 3, Javits Center</td>
<td></td>
</tr>
<tr>
<td>THE BENZODIAZEPINE CONTROVERSY REVISITED</td>
<td></td>
</tr>
<tr>
<td>Chp.: Christopher K. Chung, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Dean M. De Crisce, M.D., John W. Tsuang, M.D., Richardo Medoza, M.D., Karl S. Burgoyne, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 8</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rooms 3D04/9, Level 3, Javits Center</td>
<td></td>
</tr>
<tr>
<td>ARE THERE LIMITS TO BOUNDARY LIMITS?</td>
<td></td>
</tr>
<tr>
<td>Chp.: Malkah T. Notman, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Elissa P. Benedek, M.D., Linda M. Jorgenson, J.D., Carl P. Malmquist, M.D., Lawrence B. Inderbitzin, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 9</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rooms 3D05/8, Level 3, Javits Center</td>
<td></td>
</tr>
<tr>
<td>BROOKLYN MENTAL HEALTH COURT: FELONY OFFENDERS WITH MENTAL ILLNESS</td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Nancy J. Needell, M.D., Carol Fisler, J.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Matthew D'Emic, J.D., Lucille Jackson, M.S.W., Kelly O'Keefe, M.P.H., David Kelly, J.D., Mary Beth Anderson, J.D., Lisa Schreibersdorf, J.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 10</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wilder Room, Fourth Floor, Marriott Marquis</td>
<td></td>
</tr>
<tr>
<td>CAN EARLY INTERVENTION PREVENT PSYCHOSIS? MANAGEMENT OF THE PRODROMAL PHASE</td>
<td></td>
</tr>
<tr>
<td>Chp.: Clarice J. Kestenbaum, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Eric R. Marcus, M.D., Ian E. Alger, M.D., Lewis A. Opel, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 11</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis</td>
<td></td>
</tr>
<tr>
<td>DETOXIFICATION OF THE OPIOID-DEPENDENT CHRONIC-PAIN PATIENT</td>
<td></td>
</tr>
<tr>
<td>Chp.: Jon M. Streltzer, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Carl R. Sullivan, M.D., Thomas R. Kosten, M.D., Brian Johnson, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 12</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Booth/Edison Rooms, Fifth Floor, Marriott Marquis</td>
<td></td>
</tr>
<tr>
<td>DEATH BY SUICIDE: THE WORDS OF THOSE LEFT BEHIND</td>
<td></td>
</tr>
<tr>
<td>Chp.: Michael F. Myers, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: James E. Barrett, Carla Fine, M.S., Michelle M. Barwell, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 13</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis</td>
<td></td>
</tr>
<tr>
<td>THE AFTER-DEATH TELEPHONE CALL TO FAMILY MEMBERS: CLINICAL PERSPECTIVES</td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Sheila M. Loboprabhu, M.D., James W. Lomax II, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participant: Jennifer E. Pate, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 14</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis</td>
<td></td>
</tr>
<tr>
<td>EARLY TRAUMA, PTSD, AND HIV: ASSOCIATION WITH TRANSMISSION AND NONADHERENCE</td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Mary Ann Cohen, M.D., Jack M. Gorman, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Rosalind G. Hoffman, M.D., Heidi E. Hutson, Ph.D., Glenn J. Treisman, M.D., Jeffrey Weiss, Ph.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 15</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis</td>
<td></td>
</tr>
<tr>
<td>RESPONDING TO THE IMPACT OF SUICIDE ON CLINICIANS</td>
<td></td>
</tr>
<tr>
<td>Chp.: Eric M. Plakun, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Jane G. Tillman, Ph.D., Edward R. Shapiro, M.D.</td>
<td></td>
</tr>
</tbody>
</table>
COCAINE AND TOBACCO USE DURING PREGNANCY: ADVERSE OUTCOMES IN OFFSPRING

Collaborative Session With the National Institute on Drug Abuse

Chp.: Vincent L. Smeriglio, Ph.D.
Participants: Linda C. Mayes, M.D., Barry M. Lester, Ph.D., Lauren S. Wakschlag, Ph.D., Daniel Pine, M.D.

CONTROVERSIES AT THE INTERFACE BETWEEN RELIGION AND PSYCHIATRIC PRACTICE

Co-Chps.: Allan M. Josephson, M.D., John R. Peteet, M.D.
Participants: Yousef Abou-Allaban, M.D., Irving S. Wiesner, M.D., Nalini V. Juthani, M.D.

PSYCHIATRIC RESEARCH PERSPECTIVES IN LATIN AMERICA

Co-Chps.: Rodrigo A. Munoz, M.D., Pedro Ruiz, M.D.
Participants: Javier I. Escobar, M.D., Nora D. Volkow, M.D., Rodolfo D. Fahrer, M.D., Gerardo Heinze, M.D., Jose M. Caldas de Almeida, M.D.

Drummer Boy

Chp.: David L. Dawson, M.D.

The Movie Traffic Hollywood, Teen Substance Abuse, and U.S. Drug Policy

Co-Chps.: Steven E. Hyler, M.D., Isabel Burk, M.S.
FOCUS LIVE SESSION 2

11:00 a.m.-12:30 p.m.
Room 1E14, Level 1, Javits Center

Moderators: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.
Presenter: Jonathan R.T. Davidson, M.D., on PTSD and Anxiety Disorders: Test Your Knowledge

Expert clinicians, who served as the guest editors of the first two issues of Focus, will lead lively multiple-choice, question-based discussions. This session covers PTSD and Anxiety Disorders, the first session at 9:00 a.m. covers Forensic and Ethical Issues in Psychiatry, and the third session at 2:00 p.m. covers Schizophrenia and Other Psychotic Disorders. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 5-7

LECTURE 5

11:00 a.m.-12:30 p.m.
Rooms 1E07/8, Level 1, Javits Center

Robert Lipsyte
Surviving Jock Culture

Chp.: Ronald L. Kamm, M.D.
Co-Chp.: David A. Baron, D.O.

Robert Lipsyte, a longtime city and sports columnist for The New York Times, is the author of 16 books, including In the Country of Illness: Comfort and A duke for the Journey, and such best-selling young adult novels as The Contender, One Fat Summer, and Warrior Angel. A former network correspondent at CBS and NBC, Mr. Lipsyte won an Emmy Award in 1990 for on-camera achievement as host of the WNET nightly public affairs broadcast, “The Eleventh Hour.” He was also host of “The Health Show,” a weekly, live half-hour program of medical and health-related reportage. He contributes to the USA Today Op-Ed page and ESPN.com. In 1966 and in 1996, he won Columbia University’s Meyer Berger Award for distinguished reporting. In 2001, he won the American Library Association’s Margaret A. Edwards Award for lifetime achievement in young adult literature.

LECTURE 6

11:00 a.m.-12:30 p.m.
Room 1E15, Level 1, Javits Center

Julien Mendlewicz, M.D.
The Search for Genes of Bipolar Disorder: From Classical Genetics to Novel Molecular Targets

Chp.: Lewis L. Judd, M.D.
Co-Chp.: K. Roy MacKenzie, M.D.

Julien Mendlewicz, M.D., is Professor of Psychiatry on the Faculties of Medicine, Psychology, and Law at the University of Brussels in Brussels, Belgium; Chairman of the Department of Psychiatry at Erasme Hospital in Brussels; and Director of the Laboratory of Psychiatric Research of the Faculty of Medicine at the Free University of Brussels. Professor Mendlewicz’s research interests include molecular neurobiology and behavioral genetics, particularly of affective disorders; chronobiology and sleep; and neuropharmacology. The author of more than 600 scientific articles, Professor Mendlewicz is the Founding and Principal Editor of Neuropsychobiology and former Editor of the international series Advances in Biological Psychiatry. An active member of many international scientific societies, Professor Mendlewicz is President-Elect of the European College of Neuropsychopharmacology. The numerous honors he has received include the A.E. Bennett Research Award from the Society of Biological Psychiatry, the Anna Monika International Foundation Prize for Research in Depression, the Lieber Prize from the National Alliance for Research on Schizophrenia and Depression, the Emil Kraepelin Award from the Max-Planck-Institut für Psychiatrie, the APA Special Presidential Commendation 2003, and the International Forum Award on Mood and Anxiety Disorders 2003. Professor Mendlewicz received his medical and psychiatric degree from the Free University of Brussels and his doctorate in human genetics and development from Columbia University in New York City. International Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPELED.
LECTURE 7
11:00 a.m.-12:30 p.m.
Hall 3E, Level 3, Javits Center

APA'S ADOLF MEYER AWARD LECTURE
Glen O. Gabbard, M.D.

Mind, Brain, and Personality Disorders

Chp.: Marcia Kraft Goin, M.D.

Glen O. Gabbard, M.D., is Brown Foundation Chair of Psychoanalysis and Professor in the Department of Psychiatry at Baylor College of Medicine in Houston. He is also Training and Supervising Analyst in the Houston-Galveston Psychoanalytic Institute, Joint Editor-in-Chief of the International Journal of Psychoanalysis, and Associate Editor of the American Journal of Psychiatry. He is the author of more than 240 scientific papers and book chapters and the author or editor of 17 books, including Psychodynamic Psychiatry in Clinical Practice, Psychiatry and the Cinema, and Long-Term Psychodynamic Psychotherapy: A Basic Text. A Distinguished Fellow of APA, Dr. Gabbard has received numerous awards and honors, including the APA Distinguished Service Award, the Edward A. Strecker, M.D. Award from the Institute of Pennsylvania Hospital, and the Mary S. Sigourney Award for Outstanding Contributions to Psychoanalysis. Dr. Gabbard graduated from Rush Medical College in Chicago, completed his residency in psychiatry at the Karl Menninger School of Psychiatry in Topeka, Kansas, and received his psychoanalytic training at the Topeka Institute for Psychoanalysis.

THIS SESSION WILL BE AUDIOTAPEED.

MASTER EDUCATOR CLINICAL CONSULTATION 3-4
11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

3 Robert G. Robinson, M.D., on Neuropsychiatry of Stroke: Recent Advances
   Room 1D04, Level 1, Javits Center

4 Elizabeth Auchincloss, M.D., on Finding the Hidden Self: Engaging Difficult Patients in Exploratory Psychotherapy
   Room 1D05, Level 1, Javits Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.
MONDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 2
11:00 a.m.-12:30 p.m.
Room IE 11, Level 1, Javits Center

ANXIETY DISORDERS

Chp.: Gregory B. Sullivan, M.D.
Co-Chp.: Jeffrey A. Naser, M.D.

11:00 a.m.
5 Carbon Dioxide Test in Respiratory Panic Disorder: A Clonazepam Trial
   Antonio E. Nardi, M.D., Alexandre M. Valenca, M.D.,
   Fabiana L. Lopes, M.D., Walter A. Zin, M.D., Isabella
   Nascimento, M.D., Marco A. Mazzasalma, M.D.

11:30 a.m.
6 Child Abuse and the Development of PTSD in a Canadian Epidemiological Sample
   Michael A. Van Ameringen, M.D., Catherine L.
   Mancini, M.D., Beth Pipe, B.S.C, Jonathan Oakman, Ph.D.,
   Michael Boyle, Ph.D.

12 noon
7 Tiagabine Treatment of Social Anxiety Disorder
   Laszlo A. Papp, M.D., Philip T. Ninan, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 3
11:00 a.m.-12:30 p.m.
Room IE 12, Level 1, Javits Center

SPECTRUM OF PERSONALITY DISORDERS

Chp.: John M. Oldham, M.D.
Co-Chp.: Robert Kelly, M.D.

11:00 a.m.
8 Childhood Prevalence of BPD
   Mary C. Zanarini, Ed.D., Dieter Wolke, Ph.D., Jeremy
   Horwood, M.S.C, Andrea Waylen, Ph.D.

11:30 a.m.
9 Apparent Versus Reported Sadness: Correlation With Personality Traits
   Anand Pandya, M.D., Eric D. Peselow, M.D.

12 noon
10 High-Lethality Suicide Attempts in BPD
   Paul H. Solor, M.D., Anthony Fabio, Ph.D., Thomas M.
   Kelly, Ph.D., Kevin M. Malone, M.D., John J. Mann, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 4
11:00 a.m.-12:30 p.m.
Room 3D03/10, Level 3, Javits Center

RECOVERY ISSUES WITH SCHIZOPHRENIA

Chp.: Francine Cournos, M.D.
Co-Chp.: Viral N. Shah, M.D.

11:00 a.m.
11 Do Patients With Schizophrenia Show Periods of Complete Recovery? A 20-Year Follow-Up
   Martin Harrow, Ph.D., Linda S. Grossman, Ph.D., Thomas
   H. Jobe, M.D., Joseph F. Goldberg, M.D., Robert Faull, B.S.

11:30 a.m.
12 Twenty-Year Outcome in Schizophrenia: What's Sex Got to Do With It?
   Linda S. Grossman, Ph.D., Martin Harrow, Ph.D., Cherise
   Rosen, M.A., Ellen S. Herbener, Ph.D., Christopher G.
   Fichtner, M.D.

12 noon
13 Recovery From Schizophrenic Psychoses Until Age 35
   Erika Lauronen, Johanna Koskinen, Juha M. Veijola, Ph.D.,
   Jouko Miettunen, M.S.C, Peter B. Jones, M.D., Wayne S.
   Fenton, M.D., Matti K. Isohanni, Ph.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 5
11:00 a.m.-12:30 p.m.
Room 3D04/9, Level 3, Javits Center

COMPLICATIONS WITH ATYPICAL ANTIPSYCHOTICS

Chp.: Evaristo O. Akerele, M.D.
Co-Chp.: Anton C. Trinidad, M.D.

11:00 a.m.
14 A Program for Treating Weight Gain Induced by Atypical Antipsychotics
   Yael Nehama, M.D., Faina Tsodikov, M.S.C, Yaacov
   Ashkenazy, M.D., Henry Szor, M.D.

11:30 a.m.
15 Increased Lipid Levels and Antipsychotic Medication
   Flannu J. Koponen, M.D., Kaisa Saari, M.D., Sari
   Lindeman, M.D., Markku J. Savolainen, M.D., Matti K.
   Isohanni, Ph.D.

12 noon
16 QTc Prolongation Associated With Ziprasidone
   John W. Goethe, M.D., Bonnie L. Szarek, R.N., Charles F.
   Caley, Pharm.D., Deborah A. Piez, M.S.

THIS SESSION WILL BE AUDIOTAPE.
SCIENTIFIC AND CLINICAL REPORT SESSION 6
11:00 a.m.-12:30 p.m.
3D05/8, Level 3, Javits Center

PSYCHOTHERAPY AND PSYCHOPHARMACOLOGY: DISSOLVING THE MIND-BRAIN BARRIER

Chp.: David A. Casey, M.D.
Co-Chp.: Andrew O. Skinner, M.D.

11:00 a.m.
17 Interpersonal Psychotherapy for Depressed Elders With Cognitive Dysfunction
Mark D. Miller, M.D.

11:30 a.m.
18 Integrating Psychotherapy With Medication to Improve Outcome
Ira D. Glick, M.D.

12 noon
19 Review of Psychotherapy Research Involving a Pill-Placebo Control
Arthur Rifkin, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 7
11:00 a.m.-12:30 p.m.
Room 3D06/7, Level 3, Javits Center

TREATMENT OF DEPRESSION

Chp.: Thomas L. Schwartz, M.D.
Co-Chp.: Marketa M. Wills, M.D.

11:00 a.m.
20 Duloxetine Versus Placebo in the Prevention of Relapse of MDD
Michael J. Detke, M.D., Inmaculada Gilaberte, M.D., David G. Peralta, M.D., Faijun Wang, Ph.D., Thomas C. Lee, M.S., Pierre V. Tran, M.D.

11:30 a.m.
21 Response to Antidepressants Is Independent of Gender
Tamar D. Wohlfarth, Ph.D., Jitschak G. Storosum, M.D., Andre J. A. Elferink, M.D., Barbara J. van Zwieten, Ph.D., Annemarie Fouuwels, M.D., Wim Van Den Brink, M.D.

12 noon
22 Depression and BPD During the Immediate Prepartum Period
Gisele Apt-Danon, M.D., Rozenn Graignic-Phillippe, Marina Gianoli-Valente, Emmanuel Devouche, Ph.D., Annick Le Nestsour, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 8
11:00 a.m.-12:30 p.m.
Wilder Room, Fourth Floor, Marriott Marquis

HEALTH SERVICES

Chp.: Mary Jane England, M.D.
Co-Chp.: Steven A. Epstein, M.D.

11:00 a.m.
23 Treatment Effectiveness and Functional Recovery in Schizophrenia
Henry A. Nasrallah, M.D.

11:30 a.m.
24 Ethnic-Matched, Culturally-Competent, Model-Based ACT Team: Early Outcome Report
Samuel F. Law, M.D., Jian Yang, M.D., Rosalie Steinberg, M.S.C., Wendy Chow, M.S.W., Joel Sadavoy, M.D.

12 noon
25 Work Disability and Treatment Access in Psychiatry
Farifteh F. Duffy, Ph.D., Joyce C. West, Ph.D., Ilze Ruditis, M.S.W., William E. Narrow, M.D., Darrel A. Regier, M.D.

THIS SESSION WILL BE AUDIOTAPE.

WORKSHOPS

COMPONENTS 12-20

COMPONENT WORKSHOP 12 11:00 a.m.-12:30 p.m.
Rooms 1E03/4/5, Level 1, Javits Center

WHITHER OUR OWN HISTORY? DEBATING THE VALUE OF THE STUDY OF PSYCHIATRY'S PAST
APA Corresponding Committee on History and Library

Chp.: Avram H. Mack, M.D.

COMPONENT WORKSHOP 13 11:00 a.m.-12:30 p.m.
Room 1E09, Level 1, Javits Center

WHAT'S NEW IN PSYCHIATRY AND THE LAW AT APA?
APA Council on Psychiatry and Law and APA Committee on Judicial Action

Chp.: Renee L. Binder, M.D.
Participants: Jeffrey L. Metzner, M.D., Alan A. Stone, M.D., Richard G. Taranto, J.D., Howard V. Zonana, M.D.
MONDAY

COMPONENT WORKSHOP 14 11:00 a.m.-12:30 p.m.
Rooms 2D10/11, Level 2, Javits Center

NOVEL CAREERS IN PSYCHIATRY: WOMEN WHO HAVE MADE THEIR OWN WAY
APA Committee on Women

Co-Chps.: Melva I. Green, M.D., Madelaine M. Wohlreich, M.D.

COMPONENT WORKSHOP 15 11:00 a.m.-12:30 p.m.
Rooms 2D12/13, Level 2, Javits Center

UPDATE ON PRACTICE GUIDELINES: PTSD AND ACUTE STRESS DISORDER
APA Steering Committee on Practice Guidelines

Chp.: John S. McIntyre, M.D.
Participants: Robert J. Ursano, M.D., Matthew J. Friedman, M.D., Douglas F. Zatzick, M.D., David M. Benedek, M.D.

COMPONENT WORKSHOP 16 11:00 a.m.-12:30 p.m.
Rooms 2D14/15, Level 2, Javits Center

PUBLIC PSYCHIATRY: LEADING THE WAY IN TRANSFORMING SERVICE DELIVERY IN THE 21ST CENTURY
APA Council on Social Issues and Public Psychiatry

Co-Chps.: Altha J. Stewart, M.D., Jeffrey L. Geller, M.D.
Participants: Stephen M. Thielke, M.D., Kenneth S. Thompson, M.D., Joy D. McQuery, M.D.

COMPONENT WORKSHOP 17 11:00 a.m.-12:30 p.m.
Odets Room, Fourth Floor, Marriott Marquis

FITNESS TO PRACTICE MEDICINE: THE ROLES OF THE EVALUATING PSYCHIATRIST
APA Corresponding Committee on Physician Health, Illness, and Impairment

Chp.: John A. Fromson, M.D.
Participants: Richard F. Limoges, M.D., Stuart A. Anfang, M.D., Linda Logsdon, M.D., Michael H. Gendel, M.D., Suzanne E. Vogel-Scibilia, M.D.

COMPONENT WORKSHOP 18 11:00 a.m.-12:30 p.m.
Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

TERROR AT HOME: ADDRESSING DOMESTIC VIOLENCE IN YOUR PRACTICE
APA Committee on Family Violence and Abuse

Chp.: Carole L. Warshaw, M.D.
Participants: Graeme Hanson, M.D., Sandra L. Bloom, M.D.

COMPONENT WORKSHOP 19 11:00 a.m.-12:30 p.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

APPROACHES TO ASSESSMENT AND DIAGNOSIS OF INFANTS AND SMALL CHILDREN
APA Council on Children, Adolescents, and Their Families

Chp.: William C. Wood, M.D.
Participants: Joan L. Luby, M.D., Jean M. Thomas, M.D., Brian K. Wise, M.D., Harry H. Wright, M.D.

COMPONENT WORKSHOP 20 11:00 a.m.-12:30 p.m.
Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

HELPING OLDER PERSONS WITH SCHIZOPHRENIA: TREATMENT, RESEARCH, AND POLICY
APA Council on Aging

Chp.: Carl I. Cohen, M.D.
Participants: Susan K. Schultz, M.D., Harriet P. Lefley, Ph.D., Philip D. Harvey, Ph.D., Stephen J. Bartels, M.D.

ISSUES 19-32

ISSUE WORKSHOP 19 11:00 a.m.-12:30 p.m.
Room 1D06, Level 1, Javits Center

PSYCHIATRY IN THE PRIMARY CARE SETTING: MAKING IT WORK FOR THE PSYCHIATRIST

Chp.: John C. Urbaitis, M.D.
Participants: Ian M. Pullen, Joseph M. Schwartz, M.D., Shauna P. Reinblatt, M.D.

ISSUE WORKSHOP 20 11:00 a.m.-12:30 p.m.
Room 3D02/11, Level 3, Javits Center

NO-SUICIDE DECISIONS, CONTRACTS, AND ASSESSMENT OF RISK: VALUES AND CAUTIONS

Chp.: Robert C. Drye, M.D.
Participants: Cynthia R. Pfeffer, M.D., Robert I. Simon, M.D.

ISSUE WORKSHOP 21 11:00 a.m.-12:30 p.m.
O'Neill Room, Fourth Floor, Marriott Marquis

CHRONIC FATIGUE SYNDROME: DISEASE OR ABNORMAL ILLNESS BEHAVIOR?

Chp.: Peter Manu, M.D.
CAREER DEVELOPMENT FOR MINORITY WOMEN PSYCHIATRISTS

Chp.: Surinder S. Nand, M.D.
Participants: Nalini V. Juthani, M.D., Tanya R. Anderson, M.D., Patricia I. Ordorica, M.D., Kathleen M. Kim, M.D., Nutan A. Vaidya, M.D.

WHAT PSYCHIATRY RESIDENTS CAN EXPECT FROM NIMH-SPONSORED RESEARCH TRAINING

Co-Chps.: Joseph R. Calabrese, M.D., Della M. Hann, Ph.D.
Participants: Robert L. Findling, M.D., Omar Elhaj, M.D.

TREATING PHYSICIANS: ISSUES IN DIVERSITY

Chp.: Michael F. Myers, M.D.
Participants: Daniel P. Chapman, Ph.D., Donna M. Norris, M.D., David W. Hodo, M.D.

DRUG ABUSE AND MENTAL HEALTH TREATMENT IN LIEU OF IMPRISONMENT

Chp.: Rodrigo A. Munoz, M.D.
Participants: David Deitch, Ph.D., Gretchen Burns, Igor Koutsemok, M.D.

OBTAINING RESEARCH FUNDING FROM NIH: KEYS TO SUCCESSFUL GRANT WRITING

Chp.: Lucinda L. Miner, Ph.D.
Participant: Marina Volkov, Ph.D.

TO SMOKE OR NOT TO SMOKE: THE DILEMMAS OF TOBACCO-FREE ADDICTION TREATMENTS

Co-Chps.: Petros Levounis, M.D., Edward V. Nunes, M.D.
Participants: Paul J. Rinaki, Ph.D., Ronald B. Lonesome, M.D., Lisa Koen, M.A.
**12 noon Sessions**

**FORUMS 1-5**

**FORUM 1**
Room 1E 10, Level 1, Javits Center

**EVIDENCE-BASED PSYCHOTHERAPY**

Chp.: Darrel A. Regier, M.D.
Co-Chp.: John S. McIntyre, M.D.
Participants: A. John Rush, M.D., David Barlow, Ph.D.,
           Joshua E. Wilk, Ph.D., Lisa A. Mellman, M.D., Marsha M.
           Linehan, Ph.D., Anthony F. Lehman, M.D.
Discussants: Myrna M. Weissman, Ph.D., Robert
            Michels, M.D.

**FORUM 2**
Room 1E 16, Level 1, Javits Center

**ETHICAL DILEMMAS IN PRACTICE AND RESEARCH**

Chp.: David M. McDowell, M.D.
Participants: David J. Hellerstein, M.D., David A.
Lowenthal, M.D., Samuel C. Klugsbrun, M.D.

**FORUM 3**
Petit Trianon, Third Floor, Hilton New York

**ABPN UPDATE: REQUIREMENTS FOR ABPN EXAMINATION**

Chp.: Stephen C. Scheiber, M.D.
Participants: Michael H. Ebert, M.D., Larry R. Faulkner, M.D.,
           David A. Mrazek, M.D., Burton V. Reifler, M.D., Victor I.
           Reus, M.D., James H. Scully, Jr., M.D., Elizabeth B.
           Weller, M.D., Daniel K. Winstead, M.D.

**FORUM 4**
Rendezvous Trianon, Third Floor, Hilton New York

**JAILS OR TREATMENT? ALTERNATIVES TO INCARCERATION**

Chp.: Stephen M. Goldfinger, M.D.
Participants: Charles J. Hynes, J.D., Anne J. Swern, J.D.,
           Matthew D’Emic, J.D., Lisa Schreibersdorf, J.D.,
           Kenneth Linn, Esq.

**FORUM 5**
Astor Ballroom, Seventh Floor, Marriott Marquis

**MUSIC AND THE MIND: BEETHOVEN**

Chp.: Richard Kogan, M.D.

**1:00 p.m. Sessions**

**COURSES 45-52**

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

**COURSE 45**
Concourse A, Concourse Level, Hilton New York

**DEPRESSION IN LATER LIFE: AN INTERDISCIPLINARY APPROACH**

Co-Directors: James M. Ellison, M.D., Yusuf Sivrioglu, M.D.
Faculty: Francesca Cannavo Antognini, Ph.D., Donald A.
Davidoff, Ph.D.

**COURSE 46**
Concourse B, Concourse Level, Hilton New York

**DREAM TRANSLATION: ONE EMPIRICALLY-BASED APPROACH**

Director: Milton Kramer, M.D.

**COURSE 47**
Concourse E, Concourse Level, Hilton New York

**DIMENSIONS OF PSYCHOTHERAPY SUPERVISION: A CASE-BASED APPROACH**

Director: Paul Rodenhauser, M.D.
Faculty: Ramona Dvorak, M.D., Albert F. Painter, Psy.D.,
        John R. Rudisill, Ph.D.

**COURSE 48**
Concourse G, Concourse Level, Hilton New York

**GAY MEN AND THE PROBLEM OF ROMANTIC LOVE**

Director: Richard A. Isay, M.D.

**COURSE 49**
Gibson Suite, Second Floor, Hilton New York

**THE ADVANCED PRACTICE OF PSYCHOTHERAPY**

Director: T. Byram Karasu, M.D.

**COURSE 50**
Gramercy B, Second Floor, Hilton New York

**RATING SCALES: A BASIC OVERVIEW**

Co-Directors: Luis F. Ramirez, M.D., Martha Sajatovic, M.D.
COURSE 51
1:00 p.m.-5:00 p.m.
Madison Suite, Second Floor, Hilton New York

TEMPORAL LOBE AND LIMBIC SYSTEM ANATOMY AND THE RELATION TO PSYCHIATRIC ILLNESS

Co-Directors: Andrew L. Lautin, M.D., Jack Davis, M.S.
Faculty: Adam Wolkin, M.D., Ronald A. Jones, M.D., Hamada Hamid, M.D.

COURSE 52
1:00 p.m.-5:00 p.m.
Nassau Suite A, Second Floor, Hilton New York

CHILD MURDER BY PARENTS

Director: Phillip J. Resnick, M.D.

NEW RESEARCH YOUNG INVESTIGATORS' ORAL/SLIDE SESSIONS 2-4
1:00 p.m.-2:30 p.m.

2 Evidence-Based Medicine
Rooms 3D01/12, Level 3, Javits Center

3 Genetics and Brain Imaging: Recent Findings
Rooms 3D03/10, Level 3, Javits Center

4 Addictions, Alcoholism, and College Students
Rooms 3D06/7, Level 3, Javits Center

For further information on New Research Sessions, please refer to the New Research Program Book included in your registration packet.

2:00 p.m. Sessions

ADVANCES IN PSYCHOPHARMACOLOGY
2:00 p.m.-5:30 p.m.
Special Events Hall 1D, Level 1, Javits Center

AN UPDATE FOR CLINICIANS

Chp.: Alan F. Schatzberg, M.D.
Co-Chp.: Jeffrey A. Lieberman, M.D.

1 Introduction to Neurotransmitters, Receptors, Signal Transduction, and Second Messengers
Husseini K. Manji, M.D.

2 Immune System Pathology in Psychiatric Disease
Andrew H. Miller, M.D.

3 Second Generation Antipsychotics
Jeffrey A. Lieberman, M.D.

4 MAOIs
K. Ranga R. Krishnan, M.D.

5 Principles of Pharmacokinetics
C. Lindsay DeVane, Pharm.D.

FOCUS LIVE SESSION 3
2:00 p.m.-3:30 p.m.
Room IE 14, Level 1, Javits Center

Moderator: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.
Presenters: John Lauriello, M.D., on Schizophrenia and Other Psychotic Disorders

Expert clinicians, who served as the guest editors of the first two issues of Focus, will lead lively multiple-choice, question-based discussions. This session covers Schizophrenia and Other Psychotic Disorders, the first session at 9:00 a.m. covers Forensic and Ethical Issues in Psychiatry, and the second session at 11:00 a.m. covers PTSD and Anxiety Disorders. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 8-10

LECTURE 8
2:00 p.m.-3:30 p.m.
Rooms IE07/8, Level 1, Javits Center

Thomas R. Insel, M.D.
Social Neuroscience: A New Basic Science for Psychiatry

Chp.: Josepha A. Cheong, M.D.
Co-Chp.: Barton J. Blinder, M.D.

Thomas R. Insel, M.D., is Director of the National Institute of Mental Health in Bethesda, Maryland. He formerly was W.E. Timme Professor of Psychiatry and Behavioral Sciences and Director of the Center for Behavioral Neuroscience at Emory University. In his research, Dr. Insel has used molecular, cellular, and pharmacological approaches to explore the neurobiology of complex social behaviors, including maternal behavior, pairbond formation, and aggression. Dr. Insel has served on over 10 editorial boards for both neuroscience and psychiatric journals. A Fellow of the American College of Neuropsychopharmacology, Dr. Insel has received the Distinguished Investigator Award from the National Alliance for Research on Schizophrenia and Depression, the A.E. Bennett Award from the Society of Biological Psychia-
try, and the Outstanding Service Award from the U.S. Public Health Service. He is the author of more than 200 scientific articles and book chapters and the author or editor of four books, including *The Psychobiology of Obsessive-Compulsive Disorder* and *The Neurobiology of Parental Behavior*. Dr. Insel received his medical degree from Boston University Medical School and completed his residency in psychiatry at Langley Porter Neuropsychiatric Institute–University of California, San Francisco.

**Frontiers of Science Lecture Series**

**THIS SESSION WILL BE AUDIOTAPE**

---

**LECTURE 9**

2:00 p.m.–3:30 p.m.
Room IE 15, Level 1, Javits Center

**APA'S SOLOMON CARTER FULLER AWARD LECTURE**

**Phyllis Harrison-Ross, M.D.**

*I Am a Fact, Not a Fiction*

Chp.: Michelle O. Clark, M.D.

Phyllis Harrison-Ross, M.D., is Emeritus Professor of Psychiatry and Behavioral Health Services at the NY Medical College and Emeritus Attending Psychiatrist and Chief of Psychiatry at Metropolitan Hospital Center in New York City. She is also in the private practice of child and adult psychiatry. Since 2000 she has served as the Founder and Managing Partner of the Black Psychiatrists of Greater NY and Associates. Dr. Harrison-Ross currently is a member of the Medical Review Board of the NY State Commission of Corrections, a Board member of the Medical Health and Research Association of NY City, the Board of Directors of Northside Center for Child Development, and the Editorial Board of the NY Amsterdam News. In the 1970s she was a member of the President’s Advisory Council on Drug Abuse Prevention and helped form the New York City Federation of Mental Health, Mental Retardation, and Alcoholism Services. Her books include *The Black Child and Getting It Together*. She has written articles and book chapters on prison health issues. A Distinguished Life Fellow of the APA, Dr. Harrison-Ross is Past President of Black Psychiatrists of America. She received her medical degree from Wayne State University College of Medicine in Detroit, completed her residency in pediatrics at Cornell Medical College–NY Hospital in New York City, and completed her residency in adult psychiatry and a fellowship in child psychiatry at Albert Einstein College of Medicine and Bronx Municipal Hospital in the Bronx, NY. Recently, the use of Telepsychiatry to reach underserved populations has captured her interest.

---

**LECTURE 10**

2:00 p.m.–3:30 p.m.
Trianon Ballroom, Third Floor, Hilton New York

**Timothy J. Crow, M.B.**

Language, Psychosis, and the Speciation Event

Chp.: Ananda K. Pandurangi, M.D.
Co-Chp.: Michael D. Garrett, M.D.

Timothy J. Crow, M.B., is Professor of Psychiatry at the University of Oxford in Oxford, England, a member of the United Kingdom Medical Research Council (MRC) External Staff, Fellow of the Academy of Medical Sciences, and Honorary Director of the Prince of Wales Centre for SANE Research on Schizophrenia and Depression in Oxford. Previously he was Deputy Director and Head of the Division of Psychiatry at the MRC Clinical Sciences Centre and a member of the Scientific Staff of the Division of Neurophysiology and Neuropharmacology at the National Institute for Medical Research in London. Dr. Crow has received numerous awards in recognition of his work on brain structure and function in patients with schizophrenia, including the Alexander Gralnick Award for Research in Schizophrenia from the American Psychiatric Association, the Research Prize of the World Federation of Societies of Biological Psychiatry, and the Lieber Prize for Schizophrenia Research from the National Alliance for Research on Schizophrenia and Depression. Dr. Crow is a Fellow of the Royal College of Psychiatrists. He received his medical degree from London Hospital Medical College and completed his doctoral work in physiology at the University of Aberdeen, Aberdeen, Scotland.

**Distinguished Psychiatrist Lecture Series**

**THIS SESSION WILL BE AUDIOTAPE.**

---

**PRESIDENTIAL SYMPOSIUM 1**

2:00 p.m.–5:00 p.m.
Room IE 10, Level 1, Javits Center

THE BIOPSYCHOSOCIAL MODEL: MYTH OR REALITY?

Chp.: J. Pierre Loebel, M.D.
Co-Chp.: Marcia Kraft Goin, M.D.

A Biopsychosocial Model: History
John D. Wynn, M.D.

B Biopsychosocial Integration in Residency Training
Deborah S. Cowley, M.T.

C The Biopsychosocial Model: Contribution of Research
Charles B. Nemeroff, M.D.

D Biopsychosocial Psychiatry in Clinical Practice
Glen O. Gabbard, M.D.

**THIS SESSION WILL BE AUDIOTAPE.**
MONDAY

SYMPOSIA 1-26

SYMPOSIUM 1  2:00 p.m.-5:00 p.m.
Rooms 1E01/2, Level 1, Javits Center

BRAIN STIMULATION: NEW TREATMENTS FOR MOOD DISORDERS

Chp.: A. John Rush, M.D.
Co-Chp.: Harold A. Sackeim, Ph.D.

A ECT: Role in Brain Stimulation
Harold A Sackeim, PhD.

B Magnetic Seizure Therapy: Development of a Novel Convulsive Treatment
Sarah H. Lisanby, MD.

C Repeated Prefrontal Repetitive Transcranial Magnetic Stimulation as an Antidepressant: An Update
Mark S. George, M.D., Ziad H. Nahas, M.D., Andrew F. Kozel, M.D., Alexander Mashory, M.D., Xingbao Li, M.D., Berry Anderson, R.N.

D The Use of Vagus Nerve Stimulation (VNS) in the Long-Term Treatment of Mood Disorders
Lauren B. Marangell, M.D.

Discussant: Jerrold F. Rosenbaum, M.D.
THIS SESSION WILL BE AUDIOTAPE-D.

SYMPOSIUM 2  2:00 p.m.-5:00 p.m.
Rooms 1E03/4/5, Level 1, Javits Center

TREATMENT OF MALADAPTIVE PERSONALITY TRAITS

Chp.: James H. Reich, M.D.

A Drug Treatment of Maladaptive Personality Traits
James H. Reich, M.D.

B Neurobiology, Comorbidity, and Drug Treatment of Childhood Abused BPD Patients
Thomas Kinne, M.D., Wim Van Den Brink, M.D., Jaap G. Goekeoph, M.D., Roel H. Ryn, Ph.D., Ronald de Kloet, Ph.D.

C Development and Treatment of Family Pathology Around Cluster-B Traits
David M. Allen, M.D.

D Cognitive Therapy for Maladaptive Personality Traits
David P. Bernstein, Ph.D.

E Affective Deficits in Recurrent Suicidal Behavior
Paul S. Linke, M.D., Yvonne Bergmans, M.S.W., A. Barr, Ph.D.

F Narcissistic Traits in Substance Abusers: Any Treatment Implications?
Per Vaglum, M.D.

Discussant: John Livesley, M.D.
THIS SESSION WILL BE AUDIOTAPE-D.

SYMPOSIUM 3  2:00 p.m.-5:00 p.m.
Room 1E09, Level 1, Javits Center

FUNCTIONAL BRAIN IMAGING OF ADDICTION
Collaborative Session With the National Institute on Drug Abuse

Chp.: Elliot A. Stein, Ph.D.

A Neuropsychiatric Implications of Mapping Reward/Aversion Circuitry
Hans C. Breiter, M.D., Gregory P. Gasic, Ph.D.

B Endogenous Opioid Neurotransmissions: Interfacing Reward and Stress Regulation
Jon-Kar Zubieta, M.D.

C Chronic Effects of Drug Use and HIV
Linda Chang, M.D.

D Neurobiological Substrates of Stimulant Action and Reward
Elliot A. Stein, Ph.D.

E Affective Deficits in Recurrent Suicidal Behavior
Per Vaglum, M.D.

THIS SESSION WILL BE AUDIOTAPE-D.

SYMPOSIUM 4  2:00 p.m.-5:00 p.m.
Room 1E11, Level 1, Javits Center

TREATMENT OF CHRONIC PAIN IN RECOVERING ADDICTS
Collaborative Session With the National Institute on Drug Abuse

Chp.: Jag Khalsa, Ph.D.

A Pain Assessment and Issues in Screening
Russ Portenoy, M.D.

B Assessing Aberrant Drug-Taking Behaviors in Medically Ill Patients With Pain
Steve Passik, Ph.D.

C The Development and Treatment of Opioid-Induced Hyperalgesia
Walter Ling, M.D.

D Prescribing Pain Medications for Recovering Addicts With Chronic Pain
Richard Brown, M.D.

E Principles of Pain Treatment in Addictive Disorders
Seddon R. Savage, M.D.
THIS SESSION WILL BE AUDIOTAPE-D.
SYMPOSIUM 5  2:00 p.m.-5:00 p.m.
Room IE 12, Level 1, Javits Center

CHILD SOLDIERS, CHILD AND ADOLESCENT VICTIMS OF WAR AND TERRORISM:
BIOPSYCHOSOCIAL TREATMENT FOR REINTEGRATION INTO FAMILY AND SOCIETY
APA Alliance

Chp.: Frank G. Njenga, M.D.
Co-Chp.: Rosalind Hayes, B.A.

Frank G. Njenga, M.D.

B  The Voices of Girl-Child Soldiers
Yvonne Keairns, Ph.D.

C  Terror and Terrorism: Community Responses and Needs
Robert J. Ursano, M.D., Carol Fullerton, Ph.D.

D  Child Soldiers Reintegration: A Holistic Community-Based Approach
Michael Wessells, Ph.D.

E  Survey of Youth, Violence, and Public Health in Bogota, Colombia
Luis Duque, M.D., L.F. Klevins, M.D., C. Ramirez

Discussants: Robert J. Ursano, M.D., Yvonne Keairns, Ph.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 6  2:00 p.m.-5:00 p.m.
Room IE 13, Level 1, Javits Center

NEW DIRECTIONS IN TERRORISM AND POLITICAL VIOLENCE: CAUSES AND RESPONSES
International Society for Political Psychology and APA Council on Global Psychiatry

Chp.: Jerrold M. Post, M.D.

A  Path to Collective Madness
Dipak Gupta, Ph.D.

B  When Hatred Is Bred in the Bone
Jerrold M. Post, M.D.

C  Terror on the Internet: The New Arena, The New Challenges
Gabriel Weimann, Ph.D.

D  Cultural Approaches Linking Terrorism and Traumas
Stevan M. Weine, M.D.

E  Resource Loss and Impact on Civilian Populations:
Individuals and System Outcomes
Stevan Hobfoll, Ph.D.

Discussant: David Rothstein, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 7  2:00 p.m.-5:00 p.m.
Room IE 16, Level 1, Javits Center

I REST MY CASE
American Association of Practicing Psychiatrists

Chp.: Janis G. Chester, M.D.

A  The HIPAA Suit
Robert L. Pyles, M.D.

B  Shrager Versus Magellan
Daniel Shrager, M.D.

C  The RICO Suit
Janis G. Chester, M.D.

D  Eist Versus Maryland BPQA
Harold I. Eist, M.D.

Discussants: Deborah C. Peel, M.D., Roger Peele, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 8  2:00 p.m.-5:00 p.m.
Room 3D02/11, Level 3, Javits Center

FROM RESPONSE TO RECOVERY: THE CONSUMER AND CLINICIAN COLLABORATION IN DEPRESSION AND PSYCHOSIS

Chp.: Shervert H. Frazier, M.D.
Co-Chp.: Evelyn Barkin

A  Sarah's Struggle: Adolescence, Abandonment, and Bipolar Disorder
Sarah Duckworth

B  To Be or Not To Be? The Hidden Crisis of Adult and Adolescent Male Depression and Suicide
William S. Pollack, Ph.D.

C  From Illness to Wellness: New Strategies for Recovery
Anne Whitman, Ph.D.

D  Bipolar and MDD in Mid-Life
Paul E. Keck, Jr., M.D.

E  Geriatric Depression, Alcohol Abuse, and Suicidality
Everet Page

(Continued on next page)
MONDAY

F Late-Life Depression: Is Getting Well Enough?
Sumer Verma, M.D.

Discussant: Christopher M. Palmer, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 9 2:00 p.m.-5:00 p.m.
Rooms 3D04/9, Level 3, Javits Center

RECENT ADVANCES IN THE TREATMENT OF PSYCHIATRIC DISORDERS IN PRIMARY CARE: A U.S./U.K. PERSPECTIVE

Chp.: Wayne J. Katon, M.D.
Co-Chp.: Lawrence Myrnors-Wallis, D.M.

A The Pathways Study: A Randomized Trial of Collaborative Care in Patients With Diabetes and Depression
Wayne J. Katon, M.D., Michael Von Korff, Sc.D., Elizabeth Lin, M.D., Gregory Simon, M.D., Paul Ghechanowski, M.D., Evette Ludman, Ph.D., Edward A. Walker, M.D.

B Cognitive-Behavior Therapy and Medication for Primary Care Panic Disorder: Sustained Superiority to Usual Care
Peter P. Roy-Byrne, M.D., Michelle G. Craske, Ph.D., Murray B. Stein, M.D., J. Greer Sullivan, M.D., Alexander Bystritsky, M.D., Wayne J. Katon, M.D., Cathy D. Sherbourne, Ph.D.

C Problem-Solving Treatment by Nurses for Psychological Disorders in Primary Care

D Cost-Effectiveness of Antidepressants in Primary Care
Robert C. Peveler, M.D., Anthony Kendrick, M.D., Christopher Thompson, M.D., Martin Buxton
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 10 2:00 p.m.-5:00 p.m.
Rooms 3D05/8, Level 3, Javits Center

MENTAL HEALTH TEAM: HEALTH PROMOTION AND PRESERVATION IN WAR AND PEACE

Chp.: James J. Staudenmeier, Jr., M.D.
Co-Chp.: William F. Haning III, M.D.

A Mental Health Teams: Background and Recent History
James J. Staudenmeier, Jr., M.D., Bryan Bacon, D.O.,
William F. Haning III, M.D., Thomas A. Hicklin, M.D.

B Psychology of War
Jason L. Engeriser, M.D.

C Recent Mental Health Team Efforts in the Combat Support Hospital
Robert D. Forsten, M.D.

D Mental Health Intervention in Mortuary Affairs Workers During Combat
Panakkal David, M.D.

E Health-Promotion and Preventive-Medicine Efforts in the Most Recent Gulf Wars
Robert T. Ruiz, M.D.

F Jealous in Honor, Sudden in Quarrel: Psychiatric Practice in Iraqi Freedom
William F. Haning III, M.D.

G Emotional Cycle of Deployment: Family and Military Member Perspective
Simon H. Pincus, M.D.

Discussants: Robert D. Forsten, M.D., Panakkal David, M.D.,
Robert T. Ruiz, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 11 2:00 p.m.-5:00 p.m.
Odets Room, Fourth Floor, Marriott Marquis

PTSD IN PERSONS WITH SERIOUS MENTAL ILLNESS

Chp.: Kristina H. Muenzenmaier, M.D.
Co-Chp.: Lewis A. Opler, M.D.

A Prevalence and Patterns of PTSD Among Persons With Severe Mental Illness
David B. Albert, Ph.D., Linda A. Teplin, Ph.D.,
Karen M. Abram, Ph.D., Gary M. McClelland, Ph.D.

B An Exploration of PTSD and MDD Comorbidity
Patricia Resnick, Ph.D.

C Assessment and Treatment of Trauma in Persons With Serious Mental Illness
Kristina H. Muenzenmaier, M.D., Lewis A. Opler, M.D.,
Anne-Marie Shelley, Ph.D., Mary-Jane Alexander, Ph.D.,
Michelle Fox, B.A.

D Cognitive-Behavioral Treatment of PTSD in Clients With Severe Mental Illness
Kim T. Mueser, Ph.D., Stanley Rosenberg, Ph.D., Kay Jankowski, Ph.D., Jessica Hamblen, Ph.D., Patricia Carty, M.S.

Discussant: Judith Herman, M.D.
THIS SESSION WILL BE AUDIOTAPE.
SYMPOSIUM 12
O'Neill Room, Fourth Floor, Marriott Marquis

BEHAVIORAL DIMENSIONS OF PSYCHIATRIC DISORDERS

Chp.: Stephen B. Shanfield, M.D.

A Impulsivity in Psychiatric Disorders
Alan C. Swann, M.D.

B Aggression in Personality Disorders
Emil F. Coccaro, M.D.

C Mood Reactivity Dimension in Diagnosis
Conrad M. Swartz, M.D.

D The Dimensional Construct in Psychiatric Disorders
Stephen B. Shanfield, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 13
Wilder Room, Fourth Floor, Marriott Marquis

NEURODEVELOPMENT AND SCHIZOPHRENIA: CLINICAL AND BASIC SCIENCE PERSPECTIVES

Chp.: Alan S. Brown, M.D.

A In-Utero Exposure to Infection and Schizophrenia in Adult Offspring
Alan S. Brown, M.D., Melissa D. Begg, Sc.D., Catherine A. Schaefer, Ph.D., Stefan Gravenstein, M.D., Richard J. Wyatt, M.D., Michaeline Bresnahan, Ph.D., Ezra S. Susser, M.D.

B Prenatal Viral Infection, Brain Development, and Schizophrenia
S. Hossein Fatemi, M.D., M. Araghiniknam, Ph.D., Jessica Laurence, B.S., Robert Sidwell, Ph.D., Susanne Lee, Ph.D., Joel Stary, B.S.

C Advanced Paternal Age and Risk for Schizophrenia
Dolores Malaspina, M.D., Alan S. Brown, M.D., Ezra S. Susser, M.D., Susan Harlap, M.D., Raymond Goetz, Ph.D.

D Early Gestational Irradiation in the Primate as a Model of Schizophrenia
Lynn D. Selomen, Ph.D., John G. Csernansky, M.D., Lei Wang, Ph.D., Patricia S. Goldman-Rakic, Ph.D., Pasko Rakic, M.D.

Discussant: Ezra S. Susser, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 14
Ziegfeld Room, Fourth Floor, Marriott Marquis

CURRENT CONCEPTS OF THE NEUROBIOLOGY OF THE SELF

Chp.: Todd E. Feinberg, M.D.
Co-Chp.: Julian P. Keenan, Ph.D.

A What Neuropathology Can Teach Us About the Neurobiology of the Self
Todd E. Feinberg, M.D.

B Neuroimaging the Self
Julian P. Keenan, Ph.D.

C Self, Memory, and the Brain
Joseph LeDoux, Ph.D.

D Affect Regulation, the Right Hemisphere, and the Self
Allan N. Schore, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 15
Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

THE DEVELOPMENT OF ADAP: THE ADOLESCENT DEPRESSION AWARENESS PROGRAM

Chp.: Karen L. Swartz, M.D.
Co-Chp.: Todd S. Cox, M.D.

A Current Status of Depression Education in Schools
Boglarka Szabo, M.D., Todd S. Cox, M.D., Elizabeth A. Kastelic, M.D., Karen L. Swartz, M.D.

B Development of a Model Depression Education Curriculum

C Creation of Supplemental Learning Tools for Depression Education

D Evaluation of the ADAP Teenage Depression Curriculum
Todd S. Cox, M.D., Elizabeth A. Kastelic, M.D., Karen L. Swartz, M.D.

E Change in Adolescent Attitudes About Depression Treatment
Elizabeth A. Kastelic, M.D., Sally G. Hess, B.S.N., Lizza C. Gonzales, B.A., Todd S. Cox, M.D., Karen L. Swartz, M.D.

(Continued on next page)
MONDAY

F Training of ADAP Educators: Bringing the Curriculum to Schools

Discussants: J. Raymond DePaulo, Jr., M.D., Paramjit Joshi, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 16 2:00 p.m.-5:00 p.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

THE DEATH PENALTY: LAW AND MEDICAL ETHICS IN THE FACE OF NEW COURT OPINIONS
Chp.: Alfred M. Freedman, M.D.

A Capital Punishment and American Exceptionalism
Carol Steiker, J.D.

B Human Rights and Medical Ethics: The American Conflict
Alan A. Stone, M.D.

C Mental Disabilities and the Death Penalty: Evaluations and Legal Protections After Atkins Versus Virginia
James W. Ellis, J.D.

D Competency to Be Executed and Forced Medication: Singleton Versus Norris, Ethical Considerations
Howard V. Zonana, M.D.

E Diagnosis of Diminished Responsibility and the Death Penalty: Implications of Atkins Versus Virginia
Richard Bonnie, J.D.

Discussants: Paul S. Appelbaum, M.D., Ezra E.H. Griffith, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 17 2:00 p.m.-5:00 p.m.
Booth/Edison Rooms, Fifth Floor, Marriott Marquis

THE SCIENTIFIC BASIS OF EXPERT TESTIMONY: ITS APPLICATION TO MATRIMONIAL DISPUTES
Chp.: Alex Weintrob, M.D.

A Psychiatric Testimony: Science or Wizardry?
Alex Weintrob, M.D.

B The Uses and Misuses of Psychological Tests in Child-Custody Evaluations
Paul Hymowitz, Ph.D.

C The Expectation for Evidence-Based Testimony Under Daubert
Diane H. Schetky, M.D.

D An Attorney's Approach to Cross-Examination of an Expert in a Custody Dispute
Harold A. Mayers

E The Court's Role Regarding Expert Testimony in Child-Custody Proceedings
Anthony Marano, J.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 18 2:00 p.m.-5:00 p.m.
Imperial/Juliard Rooms, Fifth Floor, Marriott Marquis

EVOLUTIONARY AND ETHOLOGICAL PERSPECTIVES ON SOCIAL ANXIETY DISORDER
Chp.: Franklin R. Schneier, M.D.

A What Social Phobia Reveals About Our Evolved Human Nature and Vice Versa
Randolph M. Nesse, M.D., James L. Abelson, M.D.

B Gene-Environment Interactions and the Development of Fearfulness in Monkeys
Stephen J. Suomi, Ph.D.

C Subordinate Status, Social Anxiety Disorder, and Dopamine Function
Franklin R. Schneier, M.D., Richard G. Heimberg, Ph.D., Marc Laruelle, M.D., Michael R. Liebowitz, M.D.

D Eye Contact as a Threat in Social Anxiety Disorder
Justine M. Kent, M.D.

Discussant: Murray B. Stein, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 19 2:00 p.m.-5:00 p.m.
Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

BEYOND B12: AN UPDATE ON NUTRITION AND PSYCHIATRY
Chp.: Kathryn M. Connor, M.D.
Co-Chp.: Marian I. Butterfield, M.D.

A Nutrition and Psychiatry: A Historical Perspective
Kathryn M. Connor, M.D.

B Omega-3, Essential Fatty Acids, and Psychiatric Disorders
Jerry M. Cott, Ph.D.

C SAMe, Folate, and B12: One-Carbon Metabolism and Depression
Jonathan E. Alpert, M.D., David Mischoulon, M.D., George I. Papakostas, M.D., Timothy J. Petersen, Ph.D., John J. Worthington III, M.D., Andrew A. Nierenberg, M.D., Maurizio Fava, M.D.
D Psychiatric Applications of Chromium
Jonathan R.T. Davidson, M.D.

E Glyconutritional: Review and Relevance to Psychiatry
Marian I. Butterfield, M.D.

THIS SESSION WILL BE AU迪OTAPED.

SYMPOSIUM 20  2:00 p.m.-5:00 p.m.
Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis

TELLING STORIES: THE PSYCHIATRIST AS NOVELIST

Chp.: Dinah Miller, M.D.

A Two Views of Human Nature: Depth Perception or Diplopia?
Roderick J. Anscombe, M.D.

B Taming Demons: The Novel as a Way of Working Through Trauma
Alvin A. Rosenfeld, M.D.

C The Novel as Grist for the Mill: Whose Psychotherapy Is It Anyway?
Paul A. Buttenwieser, M.D.

D Empathy and the Mystery Novel: Getting to the Truth
Keith R. Ablow, M.D.

E Narrative Truths: Fiction and Nonfiction
Peter D. Kramer, M.D.

F From the Laptop to the Bookstore: On Getting Your Creative Writing Published
David J. Hellerstein, M.D.

THIS SESSION WILL BE AU迪OTAPED.

SYMPOSIUM 21  2:00 p.m.-5:00 p.m.
Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis

DO CHILDREN BENEFIT WHEN THEIR PARENTS WITH DEPRESSION ARE TREATED SUCCESSFULLY?

Chp.: Myrna M. Weissman, Ph.D.
Co-Chp.: Daniel J. Pilowsky, M.D.

A Children at High Risk for Depression: Current Knowledge and Future Directions
Myrna M. Weissman, Ph.D.

B STAR-D Child Study: Background and Preliminary Data
Daniel J. Pilowsky, M.D., Jonathan E. Alpert, M.D., Gabrielle M. Cerda, M.D., Judy Garber, Ph.D., Carrol Hughes, Ph.D., Cheryl King, Ph.D., Erin M. Malloy, M.D., Bella Sood, M.D., Myrna M. Weissman, Ph.D.

C Good and Bad News for Low-Income Children Whose Mothers Are Treated for Depression
Anne Riley, Ph.D., Marina Broitmand, Ph.D., Maryjo Coiro, Ph.D., Judith Robertson, B.S.

D The Effect on Children of Treating Parents for Depression
Judy Garber, Ph.D., Elizabeth McCauley, Ph.D., Guy Diamond, Ph.D., Kelly Sclorredt, Ph.D., Ginny Burks, Ph.D., Russ Hamford, Ph.D., Cynthia Flynn, M.S.

E Preventive Intervention for Families With Depression: Lessons From a Three-Year Follow-Up
William R. Beardslee, M.D.

Discussant: Patricia R. Cohen, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 22  2:00 p.m.-5:00 p.m.
Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

OBESITY: LESSONS LEARNED FROM ADDICTION Collaborative Session With the National Institute on Drug Abuse

Chp.: Joseph Frascella, Ph.D.

A Genetic, Motivational, and Metabolic Factors Modulate the Neural Drive to Maintain Body Weight
Barry Levin, M.D.

B Cortico-Striatal-Hypothalamic Networks and Motivation for Food: Integration of Cognition, Reward, and Energy
Ann E. Kelley, Ph.D.

C Food and Drug Cravings: Metaphor or Common Mechanism?
Marcia L. Pelchat, Ph.D.

D Common and Diverging Neurobiological Features of Feeding and Drug Self-Administration in Humans
Dana Small, Ph.D.

E Obesity and Addiction: Neuroimaging Studies
Gene-Jack Wang, M.D., Nora D. Volkow, M.D., Joanna S. Fowler, Ph.D.

Discussant: Nora D. Volkow, M.D.

THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SYMPOSIUM 23  2:00 p.m.-5:00 p.m.
Herald/Soho Rooms, Seventh Floor, Marriott Marquis

ALCOHOL, DRUG, AND PSYCHIATRIC DISORDERS IN THE U.S.: CURRENT STATUS AND TRENDS
Collaborative Session With the National Institute on Drug Abuse

Chp.: Deborah S. Hasin, Ph.D.
Co-Chp.: Bridget F. Grant, Ph.D.

A Prevalence, Disability, and Time Trends in Alcohol Abuse and Dependence in the U.S., 1992 to 2002
Frederick S. Sunson, Ph.D., Bridget F. Grant, Ph.D., Deborah A. Dawson, Ph.D., S. Patricia Chou, Ph.D., Mary C. Dufour, M.D., Roger P. Pickering, M.S.

B A Second Look at Binge Drinking and Alcohol Use Disorders Among College and Noncollege Youth
Deborah A. Dawson, Ph.D., Bridget F. Grant, Ph.D., Frederick S. Sunson, Ph.D., S. Patricia Chou, Ph.D.

C Major Depression and Alcohol, and Drug Use Disorders in the U.S.: Variations in Co-Occurrence
Deborah S. Hasin, Ph.D., Bridget F. Grant, Ph.D.

Wilson Compton III, M.D., James Colliver, Ph.D., Bridget F. Grant, Ph.D., Frederick S. Sunson, Ph.D.

E U.S. Prevalence of Personality Disorders and Co-Occurrence With Alcohol and Drug Use Disorders
Bridget F. Grant, Ph.D., Frederick S. Sunson, Ph.D., Deborah A. Dawson, Ph.D., S. Patricia Chou, Ph.D., Roger P. Pickering, M.S.

Discussant: Norman Sartorius, M.D.
THIS SESSION WILL BE AUDIOTAPEO.

SYMPOSIUM 24  2:00 p.m.-5:00 p.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

GENETIC AND ENVIRONMENTAL FACTORS CONTRIBUTING TO VULNERABILITY TO ADDICTION
Collaborative Session With the National Institute on Drug Abuse

Chp.: Jonathan D. Pollock, Ph.D.

A Using Twin Data to Identify Alternative Drug Abuse Phenotypes
Ming T. Tsuang, M.D., Michael Lyons, Ph.D., Stephen V. Faraone, Ph.D., William Kremen, Ph.D., Stephen Glatt, Ph.D.

B Common and Specific Genetic Factors in the Development of Substance Dependence
Laura J. Bierut, M.D., Alison Goate, D.Phil., John Rice, Ph.D., Anthony Hinrichs, Ph.D., Tatiana Foroud, Ph.D., Howard Edenberg, Ph.D., Raymond R. Crowe, M.D.

C Addiction Molecular Genetics: Remarkably Converging Results
George Uhl, M.D.

D Using the Systems Biology of Motivation for Genetic Studies in Psychiatry
Gregory P. Gasic, Ph.D., Hans C. Breiter, M.D.

E Genetic and Environmental Factors Modulate Cocaine Abuse in Monkey Models
Michael Nader, Ph.D.
THIS SESSION WILL BE AUDIOTAPEO.

SYMPOSIUM 25  2:00 p.m.-5:00 p.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

PSYCHIATRIC REHABILITATION: INTEGRATING MIND AND BODY GLOBALLY
World Psychiatric Association's Section on Rehabilitation and World Association for Psychosocial Rehabilitation

Chp.: Zebulon C. Taintor, M.D.
Co-Chp.: Ida Kosza, M.D.

A Brain Responses to the Environment: Showing Rehabilitation Works
Robert Cancro, M.D., Zebulon C. Taintor, M.D.

B Schizophrenia and Drug-Abuse Outcomes: Poverty, Culture, and Community
Gregory C. Bunt, M.D., Carole Siegel, Ph.D.

C Human Rights for Individuals With Mental Illnesses
Humberto Martinez, M.D.

D The Worldwide Family Movement
Geraldine Marshall

E Penetrating Prisons With Rehabilitation
Zebulon C. Taintor, M.D.

Discussant: Naotaka Shinifuji
THIS SESSION WILL BE AUDIOTAPEO.
SYMPOSIUM 26  2:00 p.m.-5:00 p.m.
Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis

EFFECTIVE TREATMENT OF PTSD: WHAT WORKS BEST FOR WHOM?
Chp.: Bessel A. Van Der Kolk, M.D.
Co-Chp.: Marylene Coitre, Ph.D.

A Exposure Versus Pharmacological Treatment of PTSD: Differential Response and Long-Term Outcome
Bessel A. Van Der Kolk, M.D., Joseph F. Spinazzola, Ph.D., James Hopper, Ph.D., Margaret Blaustein, Ph.D., William Simpson, Ph.D., Elise Hopper, Ph.D.

B What Works Best for Whom? Case Studies in Combination Treatment
Randall D. Marshall, M.D.

C Emotion Regulation and Interpersonal Skills Training for Chronic PTSD Related to Childhood Abuse and Multiple Traumatization
Marylene Coitre, Ph.D.

D PTSD Treatment Outcome Research: The Study of Unrepresentative Samples
Joseph F. Spinazzola, Ph.D., Margaret Blaustein, Ph.D., Bessel A. Van Der Kolk, M.D.

THIS SESSION WILL BE AUDIOTAPE.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 5
3:00 p.m.-5:00 p.m.
Galleria, Level 4, Javits Center

ANXIETY, STRESS, ADDICTIONS, AND ALCOHOL DISORDERS

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.
LECTURE 11

5:30 p.m.-6:30 p.m.
Hall 3E, Level 3, Javits Center

WILLIAM C. MENNINGER MEMORIAL LECTURE

Tom Wolfe

Body and Soul

Tom Wolfe is recognized around the world as the pre-eminent social commentator of our time. For over three decades he has chronicled and forecast American mass culture with a wit and insight that eludes most futurists. His runaway best seller The Bonfire of the Vanities stands as a brilliant evocation of both the peculiar class structure and politics of New York City, and the economic excesses of the 1980s. His most recent novel, A Man in Full has received both outstanding, critical, and popular success. Hailed by Time and The Wall Street Journal as even better than its phenomenally successful predecessor, it had an unprecedented first-run printing of 1.2 million copies and was nominated for the National Book Award four weeks prior to publication. As Newsweek states, “no writer - reporter or novelist - is getting our world on paper better than Tom Wolfe.” Called the father of “New Journalism,” Wolfe is the author of twelve books, including the national best sellers The Right Stuff, The Electric Kool-Aid Acid Test, Radical Chic and Mau-Mauing the Flak Catchers, and The Bonfire of the Vanities.

In 1979, Wolfe won the American Book Award for general nonfiction for The Right Stuff. In 1980, he was named recipient of the Harold D. Vursell Memorial Award by The American Academy and Institute of Arts and Letters and received the Columbia Journalism Award for distinguished service in the field of journalism that same year. Raised in Richmond, Virginia, Wolfe received his bachelor's degree from Washington and Lee University and his doctorate in American Studies from Yale University. Afterward, he went to work as a reporter for The Springfield Union (in Massachusetts), The Washington Post, and The New York Herald Tribune, where he first began to push the envelope of conventional journalistic license. Since then, his writing has appeared in New York Magazine, Rolling Stone, Esquire, and Harper's.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 36-42

INDUSTRY-SUPPORTED SYMPOSIUM 36
7:00 p.m.-10:00 p.m.
Grand Ballroom East, Third Floor, Hilton New York

BPD: REGULATION OF AFFECT AND IMPULSE CONTROL
Supported by Bristol-Myers Squibb Company

Chp.: John M. Oldham, M.D.
Co-Chp.: Andrew E. Skodol II, M.D.

A New Findings on the Biology of BPD
Martin Bohus, M.D., Christian G. Schmahli, M.D.

B BPD and Mood Disorder Spectrum
Pablo Goldberg, M.D., Maria A. Oquendo, M.D., Barbara H. Stanley, Ph.D.

C BPD and the Impulse-Control Spectrum
Emil F. Coccaro, M.D.

D Evidence-Based Psychotherapy for BPD
Glen O. Gabbard, M.D.

E Pharmacological Treatment of BPD: Current and Future Strategies
Jeffrey A. Lieberman, M.D.

Discussant: Mary C. Zanarini, Ed.D.

INDUSTRY-SUPPORTED SYMPOSIUM 37
7:00 p.m.-10:00 p.m.
Westside Ballroom 1-2, Fifth Floor, Marriott Marquis

INTERFERON-INDUCED DEPRESSION: CONSEQUENCES OF TREATING CHRONIC HEPATITIS C
Supported by Roche Laboratories

Chp.: Gregory M. Asnis, M.D.

A Interferon-Induced Depression: An Overview and Analysis
Gregory M. Asnis, M.D.

B Pathophysiological Mechanisms of Interferon Alpha-Induced Neuropsychiatric Symptoms
Lucile Capuron, Ph.D.

C Pegylated Interferon: Therapy of Hepatitis C With Fewer Depressive Effects
John F. Reinus, M.D.
D Diagnosis and Treatment of Interferon Alpha-Psychiatric Side Effects in Patients With Hepatitis C Virus
Charles Raison, M.D.

Discussant: Silvia Hafliger, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 38
7:00 p.m.-10:00 p.m.
Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

CONCEPTUALIZING AND TREATING ADHD ADULTS
Supported by Shire US, Inc.

Chp.: Timothy E. Wilens, M.D.

A ADHD Adult Case
Jefferson B. Prince, M.D.

B Adult ADHD: A Conceptual Model
Russell A. Barkley, Ph.D.

C Neurobiology of Adult ADHD
Francisco Castellanos, M.D.

D Adult ADHD: A Family-Genetic Perspective
Stephen V. Farone, Ph.D.

E Adult ADHD: What Does Neuropsychology Tell Us?
Larry J. Seidman, Ph.D.

F Pharmacologic Treatment of Adult ADHD
Timothy E. Wilens, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 39
7:00 p.m.-10:00 p.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

PLOTTING A COURSE TO REMISSION: NAVIGATING THE INTERSECTION OF MIND, BRAIN, AND BODY
Supported by Eli Lily and Company and Boehringer Ingelheim Pharmaceuticals, Inc.

Chp.: Alan F. Schatzberg, M.D.
Co-Chp.: Ruta M. Nonacs, M.D.

A Does Everybody Hurt? Epidemiology of Physical Symptoms and Depression
Maurice M. Ohayon, M.D.

B Comorbidity With Painful Physical Symptoms: Understanding the Intersection of Brain and Body
Bruce A. Arnow, Ph.D.

C 5HT and Norepinephrine: Navigating the Broad Range of Symptoms
Pedro L. Delgado, M.D.

D Plotting the Course to Remission: Balanced Strategies to Improve Outcomes
Vivien K. Burt, M.D.

E Looking Beyond the Symptoms of Depression: Considerations for Special Populations
Ruta M. Nonacs, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 40
7:00 p.m.-10:00 p.m.
Grand Ballroom, Mezzanine Level, Roosevelt

PHARMAOOTHERAPY OF ADDICTIONS: FROM CLINICS INTO OFFICE PRACTICE
Supported by Reckitt Benckiser Pharmaceuticals

Chp.: Thomas R. Kosten, M.D.

A A Patient's Perspective on Office-Based Opiate Treatment
Walter Ginter

B Prescription Drug Abuse and Psychiatric Comorbidity
H. Westley Clark, M.D.

C Opiate Pharmacotherapy and the Neurobiology of Opiate Abuse and Dependence
Thomas R. Kosten, M.D.

D Pain and Depression: Gateway to Addiction and Opportunity for Treatment
Walter Ling, M.D.

E Buprenorphine for Opiate Addiction Treatment: Pharmacology and Clinical Use
Laura F. McNicholas, M.D.

F Cultural Sensitivity in Addictions Treatment
Gerado Gonzalez, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 41
7:00 p.m.-10:00 p.m.
Imperial Ballroom A, Second Floor, Sheraton New York

HORMONES, MOOD, AND COGNITION: TREATMENT CONSIDERATIONS IN OLDER WOMEN
Supported by Wyeth Pharmaceuticals

Chp.: Lee S. Cohen, M.D.
Co-Chp.: Hadine Joffe, M.D.

A Gonadal Steroids and the Brain: Implications in Aging Women
Meir Steiner, M.D.

B Depression in Perimenopausal Women: Women at Risk and Response to Antidepressants
Lee S. Cohen, M.D.

(Continued on next page)
C Menopause and Mood Disturbances: From Theory to Novel Treatment Strategies
Claudio N. Soares, M.D.

D Assessment and Treatment of Hot Flashes in Menopausal Women
Hadine Joffe, M.D.

E The Women's Health Institute Memory Study: Updates on the Effect of Estrogen Plus Progestin on the Incidence of Dementia and Cognitive Impairment in Menopausal Women
Sally A. Shumaker, Ph.D., Claudine Legault, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 42
7:00 p.m.-10:00 p.m.
Imperial Ballroom B, Second Floor, Sheraton New York

REACHING BEYOND ALZHEIMER'S DISEASE WITH CHOLINERGIC THERAPY
Supported by Nourris Pharmaceuticals Corporation
Chp.: Steven G. Potkin, M.D.

A Dementia With Lewy Bodies Within Our Grasp
Ian G. McKeith, M.D.

B Parkinson's Disease Beyond Dopaminergic Therapy
Amos Korczyn, M.D.

C Exploring and Managing Vascular Features of Dementia
Martin K. Farlow, M.D.

D Extending Treatment Options and Not Letting Go
Gustavo Alva, M.D.
TUESDAY, MAY 4, 2004

157TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31-35

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART 2
7:00 a.m.-8:30 a.m.
Grand Ballroom East, Third Floor, Hilton New York

NEW ADVANCES IN THE TREATMENT OF PSYCHOSIS, PART 2
Supported by Bristol-Myers Squibb Company

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A Antipsychotic Therapies in Geriatric Patients: The Importance of Safety and Tolerability
J. Michael Ryan, M.D.

B Unique Challenges in the Pharmacotherapy of First-Episode Schizophrenia
Diana O. Perkins, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART 2
7:00 a.m.-8:30 a.m.
Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

CURRENT ALZHEIMER’S DISEASE TREATMENTS AND BEYOND: ADVANCES IMPACTING CLINICAL PRACTICE, PART 2
Supported by Forest Laboratories, Inc.

Chp.: Trey Sunderland, M.D.

A Neuroimaging in Alzheimer’s Disease: Diagnosis, Treatment and Prevention
P. Murali Doraiswamy, M.D.

B New Treatment Strategies for Alzheimer’s Disease: The Role of Early Diagnosis
Trey Sunderland, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 33, PART 2
7:00 a.m.-8:30 a.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

RECOGNIZING THE MANY FACES OF BIPOLAR DISORDER, PART 2
Supported by Eli Lilly and Company

Chp.: Bruce M. Cohen, M.D.

A Optimizing Functional Outcome in Bipolar Disorder
Deborah A. Yurgelun-Todd, Ph.D.

B Neuroimaging Findings in Bipolar Disorder
Stephan H. Heckers, M.D.

C New Directions in Medication Development for Bipolar Disorder
Bruce M. Cohen, M.D., William Carlezon, Ph.D., Perry F. Renshaw, M.D., Andrew L. Stoll, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 34, PART 2
7:00 a.m.-8:30 a.m.
Imperial Ballroom A, Second Floor, Sheraton New York

EVIDENCE-BASED MEDICINE: THE NEXT GENERATION, PART 2
Supported by Wyeth Pharmaceuticals

Chp.: K. Ranga R. Krishnan, M.D.

A Psychotherapy for Treatment of Depression: Recent Developments
Thomas Lynch, M.D.

B Pharmacological Treatment of Agitation in Dementia: Evidence-Based Recommendations
Warren D. Taylor, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 35, PART 2
7:00 a.m.-8:30 a.m.
Imperial Ballroom B, Second Floor, Sheraton New York

TRANSCENDING EFFICACY: EFFECTIVE TREATMENT OF PSYCHOSIS ACROSS DISORDERS, PART 2
Supported by AstraZeneca Pharmaceuticals

Chp.: Pierre N. Tariot, M.D.
Co-Chp.: John W. Newcomer, M.D.

A Avoiding Comorbidities in Treatment
John W. Newcomer, M.D.

B Transcending Efficacy in Psychosis: Where the Rubber Meets the Road
Jeanne Jackson-Siegel, M.D.
TUESDAY

8:00 a.m. Sessions

COURSES 53-61
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 53 8:00 a.m.-12 noon
Concourse B, Concourse Level, Hilton New York
DOING RESEARCH ON A SHOESTRING BUDGET
Director: Mantosh J. Dewan, M.D.
Faculty: Michele T. Pato, M.D., Edward K. Silberman, M.D.

COURSE 54 8:00 a.m.-12 noon
Concourse E, Concourse Level, Hilton New York
EXPANDING HEALTH CARE DELIVERY? LET TELEPSYCHIATRY HELP!
Director: Steven E. Hyler, M.D.
Faculty: Clarice J. Kestenbaum, M.D., Namita Rajouria, M.D., Gerald Segal, M.S., William M. Tucker, M.D.

COURSE 55 8:00 a.m.-12 noon
Concourse G, Concourse Level, Hilton New York
THE WAY OF YOGA AND HERBS IN THE TREATMENT OF STRESS, DEPRESSION, AND AGGRESSION
Co-Directors: Richard P. Brown, M.D., Patricia L. Gerbarg, M.D.

COURSE 56 8:00 a.m.-12 noon
Beekman Parlor, Second Floor, Hilton New York
HOW TO USE YOUR PALM OS PDA IN PSYCHIATRIC PRACTICE: BASIC
Co-Directors: John S. Luo, M.D., Richard A. Montgomery, M.D.
Faculty: Robert J. Boland, M.D., Carlyle H. Chan, M.D., Robert C. Hsiung, M.D., Christopher R. Thomas, M.D.

COURSE 57 8:00 a.m.-12 noon
Bryant Suite, Second Floor, Hilton New York
THE MISSING PIECE OF THE PUZZLE: TIC DISORDERS IN ADULTS WITH OCD OR ADD
Director: Maria A. Pugliese, M.D.
Faculty: J. Paul Hieble, Ph.D., Michael N. Rubenstein, M.D., Orrin Palmer, M.D., Paul F. Kriger, B.S., Laura J. Umbrell, L.P.N.

8:00 a.m.-12 noon
Gramercy A, Second Floor, Hilton New York
THE DETECTION OF MALINGERED MENTAL ILLNESS
Director: Phillip J. Resnick, M.D.

COURSE 59 8:00 a.m.-12 noon
Nassau Suite A, Second Floor, Hilton New York
TREATING MEDICAL STUDENTS AND PHYSICIANS
Co-Directors: Michael F. Myers, M.D., Leah J. Dickstein, M.D.

COURSE 60 8:00 a.m.-12 noon
Nassau Suite B, Second Floor, Hilton New York
DISASTER PSYCHIATRY: TERRORISM, TRAUMA, AND THINGS TO DO
APA Committee on Psychiatric Dimensions of Disaster
Director: Joseph C. Napoli, M.D.
Faculty: Michael Blumenfield, M.D., V. Alex Kehayan, Ed.D.

COURSE 61 8:00 a.m.-12 noon
Sutton North, Second Floor, Hilton New York
PAIN MANAGEMENT FOR PSYCHIATRISTS: AN OVERVIEW OF TREATMENT APPROACHES
Director: Raphael J. Leo, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 2
9:00 a.m.-10:30 a.m.
Rooms 3D06/7, Level 3, Javits Center
ASSESSING AND TREATING PSYCHIATRIC SYMPTOMS IN INDIVIDUALS WITH CARDIOVASCULAR DISEASE
Moderator: Christine E. Skotzko, M.D.
Presenters: Lynnette Krueger, M.S.N., Maria A. Rueda-Lara, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.
CONTINUOUS CLINICAL CASE CONFERENCE 1: PART 2

9:00 a.m.-12 noon
Rooms 3D01/12, Level 3, Javits Center

HELPING PATIENTS COUNTER DEMORALIZATION WHILE LIVING WITH A CHRONIC OR RECURRENT PSYCHIATRIC ILLNESS

Moderator: James L. Griffith, M.D.
Presenters: Lynne M. Gaby, M.D., Julia B. Frank, M.D., Robert W. Keisling, M.D., Jeffrey S. Akman, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 62-68
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 62 9:00 a.m.-4:00 p.m.
Concourse A, Concourse Level, Hilton New York
TREATING THE SELF AND INTERPERSONAL PROBLEMS OF PERSONALITY DISORDER
Director: John Livesley, M.D.

COURSE 63 9:00 a.m.-4:00 p.m.
Clinton Suite, Second Floor, Hilton New York
PSYCHIATRY UPDATE: IN SPANISH
American Society of Hispanic Psychiatry
Co-Directors: Gabriel Kaplan, M.D., Javier J. Escobar, M.D.
Faculty: Pedro L. Delgado, M.D., Eduardo Dunayevich, M.D., Jacobo E. Mintzer, M.D., Humberto Marin, M.D., Ana Kaplan, M.D.

COURSE 64 9:00 a.m.-4:00 p.m.
Gramercy B, Second Floor, Hilton New York
INTEGRATED DUAL DISORDER TREATMENT: EVIDENCE-BASED PRACTICE
Co-Directors: Mary F. Brunette, M.D., Robert E. Drake, M.D.
Faculty: Lindy Fox, M.A., Kim T. Mueser, Ph.D., Douglas Noordsy, M.D.

COURSE 65 9:00 a.m.-4:00 p.m.
Madison Suite, Second Floor, Hilton New York
A PSYCHODYNAMIC APPROACH TO TREATMENT-REFRACTORY MOOD DISORDERS
Director: Eric M. Plakun, M.D.
Faculty: David L. Mintz, M.D., Edward R. Shapiro, M.D.

COURSE 66 9:00 a.m.-4:00 p.m.
Murray Hill A, Second Floor, Hilton New York
UPDATES IN NEUROPSYCHIATRY: DELIRIUM, TRAUMATIC BRAIN INJURY, AND POST-STROKE DEPRESSION
Director: Jose R. Maldonado, M.D.

COURSE 67 9:00 a.m.-4:00 p.m.
Murray Hill B, Second Floor, Hilton New York
PERSONALITY AND POLITICAL BEHAVIOR
International Society for Political Psychology and APA Council on Global Psychiatry
Director: Jerrold M. Post, M.D.

COURSE 68 9:00 a.m.-4:00 p.m.
Rhinelander Gallery North/Center, Second Floor, Hilton New York
HOW TO PASS THE BOARDS: THE PART II ORAL EXAM
Co-Directors: James C.Y. Chou, M.D., Gregory C. Bunt, M.D.

DISCUSSION GROUPS 10-13
9:00 a.m.-10:30 a.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

10 Robert I. Simon, M.D., on Assessing and Managing Suicide Risk: Clinically-Based Guidelines for Risk Management (Meet the Authors)
Rooms 2D02/3, Level 2, Javits Center

11 Peter V. Rabins, M.D., on What Can Brain Diseases Teach Us About the Mind-Brain Interface?
Rooms 2D04/5, Level 2, Javits Center

12 Salman Akhtar, M.D., on Cross-Cultural Psychotherapy
Rooms 2D06/7, Level 2, Javits Center

13 Altha J. Stewart, M.D., on Public Psychiatry: Leading the Way in Transforming Service Delivery in the 21st Century Room 2D08, Level 2, Javits Center
LECTURE 12
9:00 a.m.-10:30 a.m.
Rooms 1E07/8, Level 1, Javits Center

APA'S RESEARCH IN PSYCHIATRY
AWARD LECTURE

Jack D. Barchas, M.D.

Adventures in Psychiatric Research: Neurobiology
to Public Policy

Chp.: Alan F. Schatzberg, M.D.
Co-Chp.: Darrel A. Regier, M.D.

Jack D. Barchas, M.D., is Barklie McKee Henry
Professor and Chair of the Department of Psychiatry at
Weill Medical College of Cornell University and Psychia-
trist-in-Chief at New York Hospital in New York City.
He is also Executive Director of the Pritzker Depression
Network, Chair of the Board of Trustees of the New
York Academy of Medicine and of the Board of Trustees
of the Association for Research in Nervous and Mental
Disease, and President and Chair of the Board of
Directors of the Robert J. and Claire Pasarow Founda-
tion. Dr. Barchas formerly was Editor of Archives of
General Psychiatry. His scholarly activities have centered
on the study of neurotransmitters and have included re-
search projects in the areas of molecular regulation, bio-
chemical neuroanatomy, analytical neurochemistry, be-
havioral neurochemistry, and clinical biochemistry and
pharmacology. A Distinguished Life Fellow of the
American Psychiatric Association and a member of the
Institute of Medicine of the National Academy of
Sciences, Dr. Barchas is a recipient of the A.E. Bennett
Award and the Lifetime Achievement Award from the
Society of Biological Psychiatry. Dr. Barchas received his
medical degree from Yale University School of Medicine
in New Haven, Connecticut, and completed his residency
in psychiatry at Stanford University in Stanford,
California.

MASTER EDUCATOR CLINICAL
CONSULTATION 5

9:00 a.m.-10:30 a.m.

This session is limited to 25 participants on a first-come,
first-served basis.

Francisco Fernandez, M.D., on Neuropsychiatric
Complications of HIV-1 Infection
Room 1D25, Level 1, Javits Center

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP
CARD REQUIRED FOR ADMITTANCE.
RESEARCH ADVANCES IN MEDICINE
9:00 a.m.-11:00 a.m.
Room 1E09, Level 1, Javits Center

THE EPIDEMIOLOGY AND TREATMENT OF PSYCHIATRIC COMORBIDITIES
Collaborative Session With the National Institute on Drug Abuse

Chp.: Joel J. Wallack, M.D.
Co-Chp.: Geetha Jayaram, M.D.

Participants: Kathleen Merikangas, Ph.D., on Epidemiology of Comorbid Psychiatric and Addictive Disorders
Joseph Biederman, M.D., on Comorbidity of Psychiatric and Addictive Disorders in Children
Paul Thuluvath, M.D., on Depression in Hepatitis C Patients and Interferon Treatment
Joel Gallant, M.D., on Research Advances in HIV Care

This session will be audi-taped.

REVIEW OF PSYCHIATRY: SECTION 1
9:00 a.m.-12:30 p.m.
Special Events Hall 1D, Level 1, Javits Center

NEUROPSYCHIATRIC ASSESSMENT

Chp.: Stuart C. Yudofsky, M.D.
Co-Chp.: Florence Kim, M.D.

1 Withdrawn

2 Neurological and Neuropsychological Exam of the Psychiatric Patient
Mark Lovell, Ph.D., Glen Getz, M.A.

3 Electrophysiological Testing
Nashaat N. Boutros, M.D., Struve Frederick, Ph.D.

4 Neuropsychiatric Lab Testing
Florence Kim, M.D., Stuart C. Yudofsky, M.D.

5 Selected Neuroimaging Topics in Psychiatric Disorders
Thomas E. Nordahl, M.D., Ruth E. Salo, Ph.D.

ROUND TABLE DISCUSSION
9:00 a.m.-10:30 a.m.
Room 1E10, Level 1, Javits Center

COERCION AND TREATMENT: MEDICAL, LEGAL, AND ETHICAL ISSUES

Moderator: Carol Fisler, J.D.
Participants: A. Sasha Bardey, M.D., Mary Zdanowicz, J.D., Heather Barr, J.D., Thomasetta Harper

WORKSHOPS

COMPONENTS 21-26

COMPONENT WORKSHOP 21 9:00 a.m.-10:30 a.m.
Room 1E11, Level 1, Javits Center

THE NEUROBIOLOGY OF SELF-AWARENESS:
LEARNING FROM AUTISM AND BPD ABOUT HOW WE KNOW OURSELVES
APA Committee on Psychotherapy by Psychiatrists

Chp.: Bernard D. Beitman, M.D.
Participants: George I. Viamontes, M.D., Jayotsna Nair, M.D.,
Glen O. Gabbard, M.D., Eva M. Szigethy, M.D.

COMPONENT WORKSHOP 22 9:00 a.m.-10:30 a.m.
Rooms 2D10/11, Level 2, Javits Center

BLOOD ON THE FLOOR: RESPONDING TO CATASTROPHIC EVENTS AND HIGH RISKS
APA Committee on Standards and Survey Procedures

Chp.: Steven I. Altchuler, M.D.
Participants: Marlin R.A. Mattson, M.D., Robert A. Wise, M.D.

COMPONENT WORKSHOP 23 9:00 a.m.-10:30 a.m.
Rooms 2D12/13, Level 2, Javits Center

THE TIES THAT BIND: CONSIDERATIONS OF CULTURE AND FAMILY IN MENTAL HEALTH TREATMENT
APA/SAMHSA Minority Fellowship Selection and Program Corresponding Committee

Chp.: Timothy G. Benson, M.D.
Participants: Marketa M. Wills, M.D., Shanta P. Henderson, M.D., Osvaldo Gaytan, Jr., M.D., Denise M. Richardson, M.D.

COMPONENT WORKSHOP 24 9:00 a.m.-10:30 a.m.
O’Neill Room, Fourth Floor, Marriott Marquis

UNIVERSAL HEALTH CARE AND OTHER MODELS
APA Council on Healthcare Systems and Financing

Chp.: Barry F. Chaitin, M.D.
Participants: Anita S. Everett, M.D., Bruce J. Schwartz, M.D.,
Paul H. Wick, M.D., Frederick J. Stoddard, Jr., M.D., Allison M.
Wehr, M.D., Manoj R. Shah, M.D., Carrie L. Ernst, M.D.,
Rodrigo A. Munoz, M.D., Captane P. Thomson, M.D.
COMPONENT WORKSHOP 25  9:00 a.m.-10:30 a.m.
Palace Room, Sixth Floor, Marriott Marquis

REVISION OF THE APA ETHICS ANNOTATIONS: FOSTERING DIALOGUE
APA Task Force to Update the Ethics Annotations

Chp.: Laura W. Roberts, M.D.
Participants: Michael R. Arambula, M.D., Richard D. Milone, M.D., Philip Candilis, M.D., S. Nassir Ghaemi, M.D., Scott Y. Kim, M.D., Jennifer Radden, Ph.D.

COMPONENT WORKSHOP 26  9:00 a.m.-10:30 a.m.
Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis

THE JUVENILE JUSTICE SYSTEM: ASSESSMENT, SERVICES, AND DATA USE
APA Corresponding Committee on Juvenile Justice Issues

Co-Chps.: R. Gregg Dwyer, M.D., Carl C. Bell, M.D.
Participants: Johnny L. Williamson, M.D., Richard L. Frierson, M.D.

ISSUE WORKSHOP 33  9:00 a.m.-10:30 a.m.
Rooms IE01/2, Level 1, Javits Center

MENTAL HEALTH NEEDS OF OUR SOLDIERS AND THEIR FAMILIES

Chp.: Howard J. Osofsky, M.D.
Participants: Neal Mazer, M.D., Robert J. Ursano, M.D., Marleen Wong, Ph.D.

ISSUE WORKSHOP 34  9:00 a.m.-10:30 a.m.
Rooms IE03/4/5, Level 1, Javits Center

THE IMPACT OF MIGRATION ON ADDICTIVE DISORDERS: A CHALLENGE FOR THE AMERICAS
Collaborative Session With the National Institute on Drug Abuse

Chp.: Amelia Musacchio de Zan, M.D.
Participants: Pedro Ruiz, M.D., Patricia I. Ordorica, M.D.

ISSUE WORKSHOP 35  9:00 a.m.-10:30 a.m.
Room 1E12, Level 1, Javits Center

THE CLINICAL IMPACT OF TREATING CIVIL AND CRIMINALLY-MANDATED PSYCHIATRIC PATIENTS

Co-Chps.: Merrill R. Rotter, M.D., Ali Khadivi, Ph.D.
Participants: Scott D. Rogge, M.D., Patricia Mourilhe, M.D.

ISSUE WORKSHOP 36  9:00 a.m.-10:30 a.m.
Room IE13, Level 1, Javits Center

USING COGNITIVE THERAPY FOR PSYCHOSIS IN PSYCHIATRIC PRACTICE

Chp.: David G. Kingdon, M.D.
Participants: Douglas Turkington, M.D., Shanaya Rathod, M.D.

ISSUE WORKSHOP 37  9:00 a.m.-10:30 a.m.
Room IE14, Level 1, Javits Center

THE THEATER OF EMOTIONS

Chp.: Ian E. Alger, M.D.
Participants: Ferruccio A. di Cori, M.D., Ferruccio Marotti, M.D., Stefania Papirio, Alessandro Nicolo, Lisa Colosimo, Cristiano Adiutori

ISSUE WORKSHOP 38  9:00 a.m.-10:30 a.m.
Room IE16, Level 1, Javits Center

INITIAL PSYCHIATRIC INTERVIEW: A PSYCHODYNAMIC APPROACH TO 90801
American Academy of Psychoanalysis and Dynamic Psychiatry

Chp.: Gopalakrishna K. Upadhya, M.D.
Participant: Moitri N. Datta, M.D.

ISSUE WORKSHOP 39  9:00 a.m.-10:30 a.m.
Room 3D02/11, Level 3, Javits Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE, PART 1

Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.
Participants: Jacqueline M. Melonas, J.D., Donna Vanderpool, J.D., Martin G. Tracy, J.D., Tracy R. Gordy, M.D., Chester W. Schmidt, Jr., M.D.

ISSUE WORKSHOP 40  9:00 a.m.-10:30 a.m.
Room 3D03/10, Level 3, Javits Center

MY NAME IS WALTER JAMES CROSS

Chp.: David L. Dawson, M.D.

ISSUE WORKSHOP 41  9:00 a.m.-10:30 a.m.
Rooms 3D04/9, Level 3, Javits Center

ONLINE VIDEO GAMES: PSYCHOPATHOLOGICAL OR PSYCHOTHERAPEUTIC?

Co-Chps.: Jeffrey N. Wilkins, M.D., Jack Kuo, M.D.
Participants: William Huang, M.D., Kimberly S. Young, Ph.D., Kurt Squire, Ph.D., Stephanie M. Stewart, M.D., Maressa H. Orzack, Ph.D., Constance Steinkuehler, Ph.D.
TUESDAY

ISSUE WORKSHOP 42  
9:00 a.m.-10:30 a.m.  
Odets Room, Fourth Floor, Marriott Marquis  
INFERTILITY: A CHRONIC ILLNESS WITH CHRONIC CHALLENGES  
Chp.: Roxanne C. Dryden-Edwards, M.D.

ISSUE WORKSHOP 48  
9:00 a.m.-10:30 a.m.  
Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis  
EMERGING PHARMACOTHERAPIES FOR TREATMENT OF STIMULANT DEPENDENCE  
Collaborative Session With the National Institute on Drug Abuse  
Chp.: Francis J. Voci, Ph.D.  
Participants: Steven Shoptaw, Ph.D., Kyle M. Kampman, M.D., Frances R. Levin, M.D., Stephen L. Dewey, Ph.D.

ISSUE WORKSHOP 43  
9:00 a.m.-10:30 a.m.  
Wilder Room, Fourth Floor, Marriott Marquis  
VALUES-BASED TREATMENT OF RELATIONAL DISORDERS  
Co-Chps.: Glenn N. Siegel, M.D., Mary Pittman, M.S.

ISSUE WORKSHOP 49  
9:00 a.m.-10:30 a.m.  
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis  
NEW TECHNOLOGIES FOR THE ASSESSMENT OF ADHD  
Co-Chps.: Martin H. Teicher, M.D., Gianni L. Faedda, M.D.  
Participants: Carl M. Anderson, Ph.D., F. Xavier Castellanos, M.D.

ISSUE WORKSHOP 44  
9:00 a.m.-10:30 a.m.  
Ziegfeld Room, Fourth Floor, Marriott Marquis  
ORAL BOARDS BOOT CAMP  
Co-Chps.: Elyse D. Weiner, M.D., Eric D. Peselow, M.D.

ISSUE WORKSHOP 50  
9:00 a.m.-10:30 a.m.  
Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis  
FIBROMYALGIA: CURRENT UNDERSTANDING AND FUTURE DIRECTIONS  
Chp.: Alan Z.A. Manevitz, M.D.  
Participants: James P. Halper, M.D.

ISSUE WORKSHOP 45  
9:00 a.m.-10:30 a.m.  
Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis  
ENGAGING THE HOMELESS IN TREATMENT STRATEGIES AND RESULTS  
Chp.: John S. McIntyre, M.D.  
Participants: Kevin McIntyre, M.D., Linda Morgan, Ph.D., Odysseus Adamides, Jr., M.D.

ISSUE WORKSHOP 51  
9:00 a.m.-10:30 a.m.  
Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis  
THE ART OF THE UNCONSCIOUS: SHAKESPEARE, POETRY, FILM, AND PSYCHIATRY  
Co-Chps.: Steven E. Pflanz, M.D., Charles R. Joy, M.D.

ISSUE WORKSHOP 46  
9:00 a.m.-10:30 a.m.  
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis  
THE IMPACT OF 9/11 ON PSYCHIATRIC RESIDENTS AND TRAINING PROGRAMS  
Chp.: Renato D. Alarcon, M.D.  
Participants: Nyapati R. Rao, M.D., Maria A. Oquendo, M.D., Milton Kramer, M.D., Anne O'Connell, M.D.

ISSUE WORKSHOP 52  
9:00 a.m.-10:30 a.m.  
Royale Room, Sixth Floor, Marriott Marquis  
IMPLEMENTING THE INSTITUTE OF MEDICINE REPORT: FOSTERING RESEARCH CAREERS VIA RESIDENCIES  
Chp.: Joel Yager, M.D.  
Participants: Wayne S. Fenton, M.D., Regina S. James, M.D., John F. Greden, M.D., Joel J. Silverman, M.D.
TUESDAY

ISSUE WORKSHOP 54 9:00 a.m.-10:30 a.m.
Gotham Room, Seventh Floor, Marriott Marquis

A SHARED-CARE MODEL FOR TREATING THE HOMELESS MENTALLY ILL

Chp.: Samuel Packer, M.D.
Participants: Carol Zoulalian, M.A., Sharon Gazely, M.D.

ISSUE WORKSHOP 55 9:00 a.m.-10:30 a.m.
Gramercy Room, Seventh Floor, Marriott Marquis

GROUP INTERVENTIONS WITH ADOLESCENTS IN OUTPATIENT, INPATIENT, AND SCHOOL SETTINGS

Chp.: Fady Hajal, M.D.
Participant: Saul Scheidlinger, Ph.D.

ISSUE WORKSHOP 56 9:00 a.m.-10:30 a.m.
Herald/Soho Rooms, Seventh Floor, Marriott Marquis

ADDITION RESEARCH AS A CAREER CHOICE IN PSYCHIATRY
Collaborative Session With the National Institute on Drug Abuse

Chp.: Ivan D. Montoya, M.D.
Participants: Herbert D. Kleber, M.D., Douglas M. Ziedonis, M.D., Ronald L. Cowan, M.D., Nathalie Mauzin, M.D., Kathleen T. Brady, M.D., Charles P. O'Brien, M.D.

ISSUE WORKSHOP 57 9:00 a.m.-10:30 a.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

IT DOESN'T HAPPEN TO US: EXPLORING TRAUMA AND RESILIENCY IN MINORITIES

Co-Chps.: Napoleon B. Higgins, Jr., M.D., Lacresha L. Hall, M.D.
Participants: Jean-Marie Alves-Bradford, M.D., Eric R. Williams, M.D., Aruna S. Rao, M.D.

ISSUE WORKSHOP 58 9:00 a.m.-10:30 a.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

CUTTING-EDGE MANAGEMENT OF TOURETTE'S SYNDROME AND ITS COMORBIDITIES

Co-Chps.: Cathy L. Budman, M.D., John T. Walsup, M.D.
Participants: Anthony L. Rostain, M.D., Fred Penzel, Ph.D.

MEDIA 3-4

MEDIA WORKSHOP 3 9:00 a.m.-12 noon
Room 1D06, Level 1, Javits Center

Cultural Assessment in Clinical Psychiatry: Two Training Videotapes

Co-Chps.: Francis G. Lu, M.D., Harriett Koskoff

MEDIA WORKSHOP 4 9:00 a.m.-12 noon
Room 1E06, Level 1, Javits Center

When Boys Fly: Club Drugs in the Gay Male Community

Chp.: Petros Levounis, M.D.
Participant: Steven J. Lee, M.D.

11:00 a.m. Sessions

DISCUSSION GROUPS 14-17
11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

14 Joel F. Paris, M.D., on Personality Disorders Over Time (Meet the Authors)
Rooms 2D02/3, Level 2, Javits Center

15 Barton J. Blinder, M.D., on Psychiatric Comorbidity in the Eating Disorders: Diagnosis, Treatment, and Research
Rooms 2D04/5, Level 2, Javits Center

16 Paul S. Appelbaum, M.D., on Ethics in Psychiatric Practice
Room 2D08, Level 2, Javits Center

17 Nancy C. Andreasen, M.D., on Publishing and Grant Writing (For Residents Only)
Versailles Terrace, Second Floor, Sheraton New York
LECTURE 14

11:00 a.m.-12:30 p.m.
Rooms 1E07/8, Level 1, Javits Center

APA'S OSKAR PFISTER AWARD LECTURE

Elizabeth S. Bowman, M.D.

Dialogue From the Rims of the Grand Canyon: On Bridging the Post-Freudian Chasm Between Religion and Psychiatry

Chp.: George T. Harding IV, M.D.

Freud's theories on religion advanced psychiatric understanding of religion, but his dismissive reductionism created a wide gap of eroded trust between psychiatrists and clergy. Elizabeth S. Bowman, M.D., discusses the nature of this gap and proposes a bridge for discussion between science and religion that acknowledges the differences in language and methods between these disciplines. Dr. Bowman is Clinical Professor of Neurology at Indiana University School of Medicine in Indianapolis where she formerly was Professor of Psychiatry. She is also in the private practice of psychiatry and is Attending Psychiatrist in the epilepsy clinic at Indiana University Hospitals in Indianapolis. Her religion and psychiatry curriculum taught at the Indiana University School of Medicine served as the core of the 1996 Model Curriculum for Psychiatry Residency Training Programs: Religion and Spirituality in Clinical Practice. Dr. Bowman is a Distinguished Fellow of the American Psychiatric Association and former President of the Indiana Psychiatric Society and of the International Society for the Study of Dissociation. Dr. Bowman received her medical degree from Indiana University School of Medicine where she also completed her general psychiatry residency. She holds a Master of Sacred Theology degree from Christian Theological Seminary in Indianapolis.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 15

11:00 a.m.-12:30 p.m.
Room 1E15, Level 1, Javits Center

Charles P. O'Brien, M.D.

Anticraving Medication: A New Class of Psychoactive Medication?

Collaborative Session With the National Institute on Drug Abuse

Chp.: Eric D. Collins, M.D.
Co-Chp.: David A. Baron, M.D.

Charles P. O'Brien, M.D., is Kenneth Appel Professor and Vice-Chairman of the Department of Psychiatry at the University of Pennsylvania and Director of Research at the Mental Illness Research, Education and Clinical Center at the Veterans Affairs Medical Center in Philadelphia. He established and directs a clinical research program that has elucidated the basic nature of addiction and improved the treatment of addictive disorders through investigation of new medications, behavioral interventions, and instruments for measuring the severity of addiction. The findings of Dr. O'Brien's research group have been described in more than 400 publications. A Distinguished Life Fellow of the American Psychiatric Association (APA), Dr. O'Brien is Past President of the American College of Neuropsychopharmacology and the Association for Research in Nervous and Mental Disease. He is a member of the Institute of Medicine of the National Academy of Sciences and a recipient of several awards, including the APA Award for Research and the Smithers Distinguished Scientist Award from the American Society of Addiction Medicine. Dr. O'Brien received his medical degree and doctoral degree in physiology (neurophysiology) from Tulane University in New Orleans. He completed residency training at Harvard Medical School, Tulane University, the University of London, and the University of Pennsylvania.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 6-7

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

6  Mark E. Servis, M.D., on Personality Disorders
Room 1D04, Level 1, Javits Center

(Continued on next page)
7 Ira D. Glick, M.D., on Combining and Integrating Medication and Psychotherapy for Schizophrenia and Other Axis 1 Disorders
Room 1D05, Level 1, Javits Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDICAL UPDATE 2
11:00 a.m.-12:30 p.m.
Room 1E13, Level 1, Javits Center

HEPATITIS B AND C: WHAT'S NEW?
Chp.: Silvia Hafliger, M.D.
Presenter: Robert S. Brown, Jr., M.D.
THIS SESSION WILL BE AUDIOTAPE.

RESEARCH CONSULTATION WITH
11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

2 Matcheri S. Keshavan, M.D., on Brain Imaging Studies in Schizophrenia
Room 1D03, Level 1, Javits Center

SCIENTIFIC AND CLINICAL REPORT SESSIONS 9-18
SCIENTIFIC AND CLINICAL REPORT SESSION 9
11:00 a.m.-12:30 p.m.
Rooms 1E01/2, Level 1, Javits Center

BUPRENORPHINE THERAPY
Chp.: David M. McDowell, M.D.
Co-Chp.: Daniel W. Hicks, M.D.

11:00 a.m.
26 *Challenges in Increasing Access to Buprenorphine Treatment
Joyce C. West, Ph.D., Thomas R. Kosten, M.D., Joshua E. Wilk, Ph.D., Dace Svikis, Ph.D., Elisa G. Triffleman, M.D., Donald S. Rae, M.A., William E. Narrow, M.D.

11:30 a.m.
27 *A Double-Blind, Double-Dummy, Randomized, Prospective, Efficacy Study of the Partial Mu Opiate Agonist Buprenorphine for Acute Detoxification of Heroin Addicts
Michael R. Oreskovich, M.D., Andrew J. Saxon, M.D., Meiling K. Ellis, B.S., Carol A. Malte, M.S.W., Joseph P. Reoux, M.D., Patricia C. Knox, Ph.D.

* Collaborative Session With the National Institute on Drug Abuse

12 noon
28 Buprenorphine: An Effective Treatment for Heroin Addicts
Paolo Marzorati, M.D., Livia Guglielmino, M.D., Rosella Silenzi, Pierluigi Vigezzi, M.D., Filomena Corrado, M.D., Margherita De Chiara, M.D., Edoardo Cozzolino, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 10
11:00 a.m.-12:30 p.m.
Room 1E11, Level 1, Javits Center

PANIC DISORDER
Chp.: David A. Casey, M.D.
Co-Chp.: Andrew O. Skinner, M.D.

11:00 a.m.
29 Early Detection of Relapse in Patients with Panic Disorder With Agoraphobia
Matig R. Mavissakalian, M.D., Shenyang Gou, Ph.D.

11:30 a.m.
30 Three-Year Prophylaxis in Panic Disorder: To Continue or Discontinue?
Yujuan Choy, M.D., Eric D. Peselow, M.D., Mary Paizis, M.D., Jamie A. Luff, M.D., Gonzalo Laje, M.D., Mary T. Guardino, B.A., Mary Anne Pressman, M.D.

12 noon
31 Discontinuation of Medications in Panic Patients
Eric D. Peselow, M.D., Mary Anne Pressman, M.D., Jamie A. Luff, M.D., Mary Paizis, M.D., Gonzalo Laje, M.D., Mary T. Guardino, B.A.
THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 11
11:00 a.m.-12:30 p.m.
Room 1E12, Level 1, Javits Center

ISSUES IN DEPRESSION
Chp.: Glenn J. Treisman, M.D.
Co-Chp.: Christine J. Truman, M.D.

11:00 a.m.
32 Brain Bioenergetics and Thyroid Hormone Treatment in MDD
Dan V. Iosifescu, M.D., Nicholas R. Bolo, Ph.D., John E. Jensen, Ph.D., Andrew A. Nierenberg, M.D., Julie L. Ryan, B.A., Perry F. Renshaw, M.D., Maurizio Fava, M.D.

11:30 a.m.
33 Depressed Outpatients From Primary Care Versus Speciality Care Settings
Bradley N. Gaynes, M.D., A. John Rush, M.D., Madhukar H. Trivedi, M.D., Donald Spencer, M.D., Timothy J. Petersen, Ph.D., Michael Klinkman, M.D., Robert N. Golden, M.D.
TUESDAY

12 noon
34 Limits to the Treatment of Major Depression
Gabor I. Keitner, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 12
11:00 a.m.-12:30 p.m.
Room 3D03/10, Level 3, Javits Center

ADHD
Chp.: Frances R. Levin, M.D.
Co-Chp.: Rebecca W. Brendel, M.D.

11:00 a.m.
35 ADHD Comorbidity in Preschool Children
Atilla Turgay, M.D., Rubaba Ansari, M.A., David Ng, M.D.,
Michael Schwartz, Ph.D., Aruz Mesci

11:30 a.m.
36 Atomoxetine for Comorbid ADHD and Affective
Symptoms
Jeffrey H. Newcorn, M.D.

12 noon
37 Abuse Liability Assessment of Atomoxetine in a Drug-
Abusing Population
Donald R. Jasinsky, M.D., Douglas E. Faries, Ph.D., Albert J.
Allen, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 13
11:00 a.m.-12:30 p.m.
Rooms 3D04/9, Level 3, Javits Center

UNDERSTANDING THE EFFECTS OF TERRORISM
Chp.: Randall D. Marshall, M.D.
Co-Chp.: Elspeth C. Ritchie, M.D.

11:00 a.m.
38 Effects of 9/11 and Chronic Stress on Female Drinking
and Anxiety
Judith A. Richman, Ph.D., Joseph A. Flaherty, M.D.,
Joseph S. Wislar, M.S., Michael Fendrich, Ph.D., Kathleen M.
Rospenda, Ph.D.

11:30 a.m.
39 Psychosocial Predictors of Long-Term Resilience
Following the 9/11 Attacks
David Spiegel, M.D., Lisa D. Butler, Ph.D., Cheryl
Koopman, Ph.D., Jay Azarow, Ph.D., Juliette C.
Desjardins, M.D., Xin- Hua Chen, B.A., Helena C.
Kraemer, Ph.D.

12 noon
40 The Terrorist as a Nonpatient Subject of Psychiatric
Investigation
David Rothstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 14
11:00 a.m.-12:30 p.m.
Rooms 3D05/8, Level 3, Javits Center

PSYCHOPHARMACOLOGY
Chp.: David A. Gutman, M.D.
Co-Chp.: Jeffrey M. Friend, M.D.

11:00 a.m.
41 Antipsychotic Treatment and Sexual Adverse Events:
The Role of Prolactin
Rikus Knegtering, M.D.

11:30 a.m.
42 Three-Bead Extended-Release Carbamazepine Capsule
(SPDM17) Continuation: Maintenance Therapy in Bipolar
Disorder
Terence A. Ketter, M.D., Amir H. Kalali, M.D., Richard H.
Weisler, M.D.

12 noon
43 Parkinsonism in a Nursing Home: Underrecognition
Hubert H. Fernandez, M.D., Joseph Friedman, M.D., Martha
Trieschmann, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 15
11:00 a.m.-12:30 p.m.
Rooms 3D06/7, Level 3, Javits Center

ISSUES IN PSYCHIATRIC RESEARCH AND
PSYCHOPHARMACOLOGY
Chp.: Nikhil D. Nihalani, M.D.
Co-Chp.: Robert Kelly, M.D.

11:00 a.m.
44 Concurrent Use of Multiple Antipsychotics in Psychiatric
Inpatients
Bonnie L. Szarek, R.N., John W. Goethe, M.D., Theodore F.
Mucha, M.D.

11:30 a.m.
45 How Do Psychiatric Patients Perceive Research
Participation?
Cherise Rosen, M.A., Linda S. Grossman, Ph.D.

12 noon
46 Polypharmacy and Its Ramifications in a Chronic
Psychiatric Hospital
Jambar V. Ananth, M.D., Sarath Gunatilake, M.D., Sharat
Parameswaran, B.S., Chris E. Marshall, B.S., Steven
Brown, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.
TUESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 16
11:00 a.m.-12:30 p.m.
Wilder Room, Fourth Floor, Marriott Marquis

CHILD AND ADOLESCENT PSYCHIATRY
Chp.: Cynthia R. Pfeffer, M.D.
Co-Chp.: Arun R. Kunwar, M.D.

11:00 a.m.
47 Externalizing Behaviors in Preadolescent Children: A National Panel Study
   David J. Pevalin, Ph.D., John Cairney, Ph.D., Terrance J. Wade, Ph.D.

11:30 a.m.
48 Gender and the Prediction of Drug and Alcohol Abuse in Adolescent Inpatients
   Daniel F. Becker, M.D., Carlos M. Grilo, Ph.D.

12 noon
49 Prevalence and Outcomes of Childhood Adversity in an Australian Population
   Stephen J. Rosenman, M.D., Bryan Rodgers, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 17
11:00 a.m.-12:30 p.m.
Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

SOCIAL AND COMMUNITY PSYCHIATRY
Chp.: Susan Stabinsky, M.D.
Co-Chp.: William A. James, M.D.

11:00 a.m.
50 Evaluation of an HIV Intervention for Psychiatric Care Providers in South Africa
   Pamela Y. Collins, M.D., Kezziiah Mistry, LL.B., Graham Lindegerg, Ph.D., Thobile Nzama, Francine Cournos, M.D.,
   Milton L. Wainberg, M.D.

11:30 a.m.
51 Developing Capacity Within CBOs for Health Education and Outreach
   Mary Jane Massie, M.D., David Lounsbury, Ph.D., Bruce Rapkin, Ph.D.

12 noon
52 Inter-European Countries Comparison on Treatment Use for Mental Health Disorders
   Viviane Kovess, M.D., Jordi Alonso, M.D., Mathias C. Angermeyer, Tery Brugha

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 18
11:00 a.m.-12:30 p.m.
Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

VIOLENCE, TRAUMA, AND VICTIMIZATION
Chp.: Paula G. Panzer, M.D.
Co-Chp.: Leslie L. Buckley, M.D.

11:00 a.m.
53 Evaluation of a Therapeutic Interagency Preschool for Traumatized Children
   Terrance J. Wade, Ph.D., Jane Sites, Ed.D., Frank W. Putnam, Jr., M.D.

11:30 a.m.
54 Mental Health in Postwar Afghanistan
   Barbara Lopes-Cardozo, M.D., Oleg Biluuma, M.D., Carol Gotway-Crawford, Ph.D., Maru Anderson

12 noon
55 A Three-Dimensional Model of Violence in Schizophrenia
   Menahem I. Krakowski, M.D., Pal Czobor, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 27-32

COMPONENT WORKSHOP 27    11:00 a.m.-12:30 p.m.
Rooms 2D10/11, Level 2, Javits Center

WHEREFORE NEUROSCIENCE: HOW MUCH DOES THE PSYCHIATRIST NEED TO KNOW?
APA/GlaxoSmithKline Fellows

Co-Chps.: Joshua L. Roffman, M.D., Carrie L. Ernst, M.D.
Participants: Asher B. Simon, M.D., Jason M. Morrison, M.D.,
Konstale M.R. Prasad, M.D.

COMPONENT WORKSHOP 28    11:00 a.m.-12:30 p.m.
Rooms 2D12/13, Level 2, Javits Center

WHAT DO EMPLOYERS WANT? EMPLOYEE MENTAL HEALTH BENEFITS
APA Committee on APA/Business Relationships

Co-Chps.: Norman A. Clemens, M.D., Jeffrey P. Kahn, M.D.
Participants: Michael J. Thompson, Lisa Chider, M.A.
COMPONENT WORKSHOP 29  11:00 a.m.-12:30 p.m.
Rooms 2D14/15, Level 2, Javits Center

HELPING DISTRICT BRANCHES RELATE TO APA AND TO THEIR MEMBERS
APA Corresponding Committee on District Branch/State Association Relations

Chp.: Donald G. Langsley, M.D.
Participants: Nada L. Stotland, M.D., Ann Marie T. Sullivan, M.D., Margo S. Adams

COMPONENT WORKSHOP 30  11:00 a.m.-12:30 p.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

THE TEACHING OF GAY, LESBIAN, BISEXUAL, AND TRANSGENDER ISSUES
APA New York County District Branch's Committee on Gay and Lesbian Issues

Chp.: Kenneth B. Ashley, M.D.
Participants: Stewart L. Adelson, M.D., Richard O. Hire, M.D., Elizabeth LeQuensine, M.D., Khakasa H. Wapenyi, M.D.

COMPONENT WORKSHOP 31  11:00 a.m.-12:30 p.m.
Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis

SEX, DRUGS, AND HIV: SYNERGISTIC EPIDEMICS
APA New York County District Branch's AIDS Committee

Co-Chps.: Kristina L.N. Jones, M.D., John A.R. Grimaldi, Jr., M.D.
Participants: Bryan J. McGreal, M.D., Mary Ann Cohen, M.D., Elizabeth V. Getter, M.D.

COMPONENT WORKSHOP 32  11:00 a.m.-12:30 p.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

LOOKING BACK, LOOKING FORWARD: PATHWAYS FOR BLACKS IN PSYCHIATRY
APA Committee of Black Psychiatrists

Co-Chps.: Michelle O. Clark, M.D., N. Kalaya Okereke, M.D.
Participants: Carl C. Bell, M.D., Hugh Butts, M.D., Marketa M. Wills, M.D.

ISSUE WORKSHOP 60  11:00 a.m.-12:30 p.m.
Room IE14, Level 1, Javits Center

THE PORTRAYAL OF PSYCHIATRY IN RECENT AMERICAN FILM

Chp.: Steven E. Pflanz, M.D.

ISSUE WORKSHOP 61  11:00 a.m.-12:30 p.m.
Room 3D02/11, Level 3, Javits Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE, PART 2

Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.
Participants: Tracy R. Gordy, M.D., Chester W. Schmidt, Jr., M.D.

ISSUE WORKSHOP 62  11:00 a.m.-12:30 p.m.
Odets Room, Fourth Floor, Marriott Marquis

USING ART AND POETRY: FROM MEDICATION MANAGEMENT TO COUNTERTRANSFERENCE

Chp.: Charles R. Joy, M.D.
Participant: Stuart A. Copans, M.D.

ISSUE WORKSHOP 63  11:00 a.m.-12:30 p.m.
O'Neill Room, Fourth Floor, Marriott Marquis

PSYCHIATRIC REHABILITATION AND PSYCHODYNAMICS

Co-Chps.: Anand Pandya, M.D., Grace Otto, R.N.
Participants: Veronica Popoiu, M.S.N., Eric Leventhal, C.S.W., Manuel Trujillo, M.D.

ISSUE WORKSHOP 64  11:00 a.m.-12:30 p.m.
Ziegfeld Room, Fourth Floor, Marriott Marquis

MANAGEMENT OF DIFFICULT SCHIZOPHRENIA

Chp.: Michael Y. Hwang, M.D.
Participants: Edward Kim, M.D., Faiq Hameedi, M.D., David P. Folsom, M.D., Samuel G. Siris, M.D.

ISSUE WORKSHOP 65  11:00 a.m.-12:30 p.m.
Booth/Edison Rooms, Fifth Floor, Marriott Marquis

THE APPLICATION OF BEDSIDE EXECUTIVE-FUNCTION MEASURES

Chp.: Jeffrey A. Cordes, M.D.
Participants: Jason E. Schillerstrom, M.D., Kaustubh G. Joshi, M.D.
TUESDAY

ISSUE WORKSHOP 66  11:00 a.m.-12:30 p.m.
Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis

THE PSYCHIATRY RESIDENT AS EDUCATOR: A PROPOSAL FOR CURRICULUM AND SUPERVISION

Co-Chs.: Ruth M. Lamdan, M.D., Autumn Ning, M.D.
Participants: Karriem L. Salaam, M.D., Diane B. Gottlieb, M.D.,
Edward A. Volkman, M.D., Roya Lewis, M.D.

ISSUE WORKSHOP 67  11:00 a.m.-12:30 p.m.
Lyceum Room, Fifth Floor, Marriott Marquis

INTERFACE BETWEEN PSYCHIATRY AND OBSTETRICS: COMPREHENSIVE PERINATAL CARE

Chp.: Johannes Bitzer
Participants: Maria F. Hofecker-Fallahp, M.D., Werner Tschan, M.D.

ISSUE WORKSHOP 68  11:00 a.m.-12:30 p.m.
Palace Room, Sixth Floor, Marriott Marquis

CLOSING A PSYCHIATRIC PRACTICE: CLINICAL AND RISK-MANAGEMENT ISSUES

Chp.: Robinette N. Bell, M.D.
Participants: Donna Vanderpool, J.D., Denny Rodriguez, J.D.

ISSUE WORKSHOP 69  11:00 a.m.-12:30 p.m.
Royale Room, Sixth Floor, Marriott Marquis

REHABILITATING TRAUMATIZED GIRLS IN RESIDENTIAL JUVENILE-JUSTICE SETTINGS

Chp.: Cheryl D. Wills, M.D.

ISSUE WORKSHOP 70  11:00 a.m.-12:30 p.m.
Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis

THE OUT-OF-THE-SHADOW PROJECT

Chs.: Edward F. Foulks, M.D., Susan E. Smiley
Participants: Suzanne E. Vogel-Scibilia, M.D., Stephen M. Goldfinger, M.D.

ISSUE WORKSHOP 71  11:00 a.m.-12:30 p.m.
Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

PSYCHOGENIC SEIZURES: A PROTOTYPE OF SOMATOFORM DISORDER

Chp.: Selim Benbadis, M.D.
Participant: Francisco Fernandez, M.D.

ISSUE WORKSHOP 72  11:00 a.m.-12:30 p.m.
Gotham Room, Seventh Floor, Marriott Marquis

CLINICAL EFFECTS OF SEXUAL ABUSE BY CATHOLIC PRIESTS: A FORENSIC PERSPECTIVE

Chp.: Allan S. Nineberg, M.D.

ISSUE WORKSHOP 73  11:00 a.m.-12:30 p.m.
Gramercy Room, Seventh Floor, Marriott Marquis

PROBLEMS IN THE PSYCHIATRIC EDUCATION OF INTERNATIONAL MEDICAL GRADUATES

Chp.: Milton Kramer, M.D.
Participants: Nyapati R. Rao, M.D., Brunhild Kring, M.D.,
Jeffrey Goldberg, D.O., Nalini V. Juthani, M.D.

ISSUE WORKSHOP 74  11:00 a.m.-12:30 p.m.
Herald/Soho Rooms, Seventh Floor, Marriott Marquis

DRUGS AND OTHER ADDICTIONS: DOES ONE SIZE FIT ALL?
Collaborative Session With the National Institute on Drug Abuse

Chp.: Steven J. Grant, Ph.D.
Participants: Linda Cottler, Ph.D., Nathan A. Shapira, M.D.,
Nancy M. Petry, Ph.D., Marc N. Potenza, M.D.

ISSUE WORKSHOP 75  11:00 a.m.-12:30 p.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

STRESS, TRAUMA, AND DRUG ABUSE
Collaborative Session With the National Institute on Drug Abuse

Chp.: Nancy Pilotte, Ph.D.
Participants: Paul Plotsky, Ph.D., Martin H. Teicher, M.D., Dean Kilpatrick, Ph.D., Lisa M. Najavits, Ph.D.

ISSUE WORKSHOP 76  11:00 a.m.-12:30 p.m.
Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis

CHILDREN AND FAMILIES FACING TERRORISM, DISASTERS, AND COMPLEX EMERGENCIES

Chp.: Howard J. Osofsky, M.D.
Participants: Richard F. Mollica, M.D., Sandra J. Kaplan, M.D.,
Arieh Y. Shalev, M.D., Eric Noji, M.D.
12 noon Sessions

FORUMS 6-8

FORUM 6 12 noon-1:30 p.m.
Room 1E10, Level 1, Javits Center

REVERSING THE CRIMINALIZATION OF THE SERIOUSLY MENTALLY ILL

Co-Chps.: Marcia Kraft Goin, M.D., Henry C. Weinstein, M.D.
Participants: H. Richard Lamb, M.D., Tom Hamilton, Ph.D.,
Erik J. Roskes, M.D.

FORUM 7 12 noon-1:30 p.m.
Room 1E16, Level 1, Javits Center

UNCONSCIOUS PREDICTION, CONSCIOUS MONITORING, AND THERAPEUTIC CHANGE: IS THERE A MIND-BRAIN BARRIER?

Chp.: Mirian I. Butterfield, M.D.
Participants: Regina Pally, M.D.

FORUM 8 12 noon-1:30 p.m.
Astor Ballroom, Seventh Floor, Marriott Marquis

SHOULD SEX BE PREVENTED IN PSYCHIATRIC UNITS? ARGUMENTS AND NEW DIRECTIONS

Chp.: Milton L. Wainberg, M.D.
Participants: Elizabeth B. Ford, M.D., Carol A. Bernstein, M.D.,
Marshall Forstein, M.D., Paulo E. Mattos, M.D.

NEw RESEARCH POSTER SESSION 6
12 noon - 2:00 p.m.
Galleria, Level 4, Javits Center

BIOLOGICAL PSYCHIATRY AND PSYCHOPHARMACOLOGY

For further information on New Research Sessions, please refer to the New Research Program Book included in your registration packet.

1:00 p.m. Sessions

COURSES 69-76
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 69 1:00 p.m.-5:00 p.m.
Concourse B, Concourse Level, Hilton New York

BRIEF PSYCHODYNAMIC PSYCHOTHERAPY: THE CORE CONFLICTUAL RELATIONSHIP THEME METHOD

Director: Howard E. Book, M.D.

COURSE 70 1:00 p.m.-5:00 p.m.
Concourse E, Concourse Level, Hilton New York

BASIC FAMILY SKILLS FOR AN INPATIENT PSYCHIATRIST

Director: Alison M. Heru, M.D.
Faculty: Laura Drury, M.S.W.

COURSE 71 1:00 p.m.-5:00 p.m.
Beekman Parlor, Second Floor, Hilton New York

OVERVIEW AND UPDATE OF SLEEP DISORDERS MEDICINE

Director: Karl Doghramji, M.D.
Faculty: John W. Winkelmann, M.D., Thomas D. Hurwitz, M.D.

COURSE 72 1:00 p.m.-5:00 p.m.
Bryant Suite, Second Floor, Hilton New York

MEDITATION FOR PSYCHOTHERAPISTS AND THE PARADIGM OF HEALTH

Director: James T. Sacamano, M.D.

COURSE 73 1:00 p.m.-5:00 p.m.
Gibson Suite, Second Floor, Hilton New York

WRITING ABOUT CLINICAL EXPERIENCES

Director: John S. Strauss, M.D.

COURSE 74 1:00 p.m.-5:00 p.m.
Gramercy A, Second Floor, Hilton New York

THE EVALUATION AND IDENTIFICATION OF THE MAJOR DEMENTIAS

Director: Raymond A. Faber, M.D.
Faculty: Kevin F. Gray, M.D., Randolph B. Schiffer, M.D.
TUESDAY

COURSE 75  1:00 p.m.-5:00 p.m.
Nassau Suite A, Second Floor, Hilton New York

HOW TO USE YOUR PALM OS PDA IN PSYCHIATRIC PRACTICE: ADVANCED

Director: John S. Luo, M.D.
Faculty: Richard A. Montgomery, M.D., Charles J. Rainey, M.D.,
Raymond J. Kloss, M.D., Hendry Ton, M.D.

COURSE 76  1:00 p.m.-5:00 p.m.
Sutton Center, Second Floor, Hilton New York

THE COMPLEXITIES OF CHRONIC PAIN:
PSYCHIATRIC ISSUES AND TREATMENTS

Co-Directors: Allen Lebovits, Ph.D., Matthew B. Smith, M.D.
Faculty: Andrew F. Angelino, M.D., Robert Cancro, M.D.,
Michael R. Clark, M.D., Michel Dubois, M.D.

2:00 p.m. Sessions

LECTURES 16-18

LECTURE 16
2:00 p.m.-3:30 p.m.
Rooms 1E07/8, Level 1, Javits Center

James H. Scully, Jr., M.D.

How Many Psychiatrists Do We Need?

Chp.: Linda L.M. Worley, M.D.
Co-Chp.: Catherine C. Crone, M.D.

James H. Scully, Jr., M.D., became Medical Director of
the American Psychiatric Association (APA) in January
2003. As Medical Director, Dr. Scully is responsible for
overseeing approximately 250 full-time staff in the
Association and its three corporate subsidiaries, the
American Psychiatric Institute for Research and
Education, the American Psychiatric Foundation, and
American Psychiatric Publishing, Inc. Among his areas
of responsibility are legislative advocacy and policy
development, continuing medical education and lifelong
learning, communications, member services, and health
services research. Dr. Scully formerly was the Alexander
Donald Professor and Chair of the Department of
Neuropsychiatry and Behavioral Science and President of
the Educational Trust at the University of South Carolina
School of Medicine in Columbia, South Carolina. He
served as interim director of the South Carolina
Department of Mental Health from 2000 to 2001. A
Distinguished Fellow of APA, Dr. Scully is the recipient
of numerous awards, including the American Academy
of Child and Adolescent Psychiatry Leadership Award
for Best Chairman of a Department of Psychiatry. A
graduate of Tulane University School of Medicine in
New Orleans, Dr. Scully completed his residency training
in psychiatry at the University of Colorado Medical
Center in Denver.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 17
2:00 p.m.-3:30 p.m.
Room IE15, Level 1, Javits Center

APA'S MARMOR AWARD LECTURE

David Spiegel, M.D.

Feeling and Healing: Biopsychosocial Treatments
and Their Effects on Medical Illness

Chp.: Alan F. Schatzberg, M.D.

David Spiegel, M.D., is the Jack, Lulu & Sam Willson
Professor of Medicine and Associate Chair of the
Department of Psychiatry and Behavioral Sciences at
Stanford University School of Medicine in Stanford,
California, where he is also Director of the Center on
Stress and Health. In addition, he is Medical Director of
the Stanford Center for Integrative Medicine at Stanford
Medical Center, which provides supportive care for
medically ill patients. Dr. Spiegel is Second Vice-
President of the American College of Psychiatrists (he
will assume the Presidency in 2006) and Past President of
the Society for Clinical and Experimental Hypnosis. A
Distinguished Fellow of the American Psychiatric
Association, he has received the Edward A. Strecker,
M.D., Award from the Institute of Pennsylvania Hospital
for his contributions to clinical psychiatry; and the
Hilgard Award from the International Society of
Hypnosis for his research contributions to the
development of medical hypnosis. He serves on the
editorial boards of numerous journals and was Editor of
the American Psychiatric Press' Progress in Psychiatry
series. Dr. Spiegel received his medical degree from Harvard
Medical School and completed his residency training in
psychiatry at the Massachusetts Mental Health Center
and Cambridge Hospital and a fellowship at the
Laboratory of Community Psychiatry, all at Harvard
Medical School in Boston.

THIS SESSION WILL BE AUDIOTAPED.
TUESDAY

2:00 p.m.-3:30 p.m.
Trianon Ballroom, Third Floor, Hilton New York

A. Thomas McLellan, Ph.D.

Conceptual and Methodological Flaws in the Evaluation of Addiction Treatment
Collaborative Session With the National Institute on Drug Abuse

Chp.: Renee M. Sorrentino, M.D.
Co-Chp.: Shelly F. Greenfield, M.D.

A. Thomas McLellan, Ph.D., is Professor of Psychiatry at the University of Pennsylvania School of Medicine and the Director of the Treatment Research Institute in Philadelphia. He and his colleagues developed some of the most widely used measurement instruments in addiction research, including the Addiction Severity Index (ASI) and the Treatment Services Review (TSR), which have been translated into more than 20 languages. In their research, Dr. McLellan and his colleagues have used these instruments to evaluate a variety of therapies, medications, and interventions used in the treatment of alcohol and drug dependence. They are currently investigating the active and inactive ingredients of treatment, the appropriate duration and content of treatment for various types of patients, and methods for transferring findings from treatment research into practical applications for the practitioner and provider. Dr. McLellan is the author of more than 400 articles and book chapters in addiction research and serves as the Editor-in-Chief of Journal of Substance Abuse Treatment. His many honors include the 2003 Innovators Combating Substance Abuse Award from the Robert Wood Johnson Foundation. Dr. McLellan received his doctoral degree from Bryn Mawr College in Philadelphia and received postgraduate training in psychology at Oxford University in England.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIUM 2
2:00 p.m.-5:00 p.m.
Astor Ballroom, Seventh Floor, Marriott Marquis

WITHER GO THE STATES: THE IMPACT OF BUDGET CUTS

Chp.: David A. Pollack, M.D.

A Overview of the Impact of State Budget Cuts: Problems and Solutions
Michael F. Hogan, Ph.D.

B Using Fiscal and Clinical Measures During Times of Limited Resources
Theodore C. Lutterman, Lucille Schacht, Ph.D.

C State Policy Choices for Children's Mental Health in Tough Budget Times
Chris Koyanagi

D The Impact of Budget Cuts on Rural Mental Health
Dennis Mohatt, M.A.

E Cuts Cutting Into the Possibility of Recovery
Tom Lane, Laura Lee Hall, Ph.D.

F After All This, Do You Still Want to Be a Public Psychiatrist?
Allison M. Wehr, M.D., Jennifer K. Coffman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

REVIEWS OF PSYCHIATRY: SECTION 2
2:00 p.m.-5:30 p.m.
Special Events Hall ID, Level 1, Javits Center

COGNITIVE-BEHAVIOR THERAPY

Chp.: Jesse H. Wright, M.D.

6 Cognitive Therapy for Schizophrenia
Jan L. Scott, M.D., David G. Kingdon, M.D., Douglas Turkington, M.D.

7 Cognitive Therapy for Bipolar Disorder
Monica A. Basco, Ph.D., A. John Rush, M.D., Noelle McDonald, B.S., Megan Merlock, B.A.

8 Computer-Assisted Cognitive-Behavior Therapy
Jesse H. Wright, M.D.

9 Cognitive Therapy With Medical Patients
Thomas Sensky, M.B.

10 Cognitive Therapy for Children and Adolescents
Anne Marie Albano, Ph.D., Amy L. Krain, Ph.D., Elizabeth Podniesinks, M.A., Keith Ditkowsky, M.D.

SYMPOSIA 27-58

SYMPOSIUM 27
2:00 p.m.-5:00 p.m.
Rooms 1E01/2, Level 1, Javits Center

BEHAVIORAL ACTIVATION, COGNITIVE THERAPY, AND MEDICATION FOR MAJOR DEPRESSION

Chp.: Steven D. Hollon, Ph.D.

(Continued on next page)
A Methods and Acute-Phase Outcomes
Sona A. Dimidjian, Steven D. Hollon, Ph.D., Keith S. Dobson, Ph.D., Karen B. Schmaling, Ph.D., Robert J. Kohlenberg, Ph.D., Michael Addis, Ph.D., David L. Dunner, M.D.

B Prevention of Relapse
Keith S. Dobson, Ph.D., Steven D. Hollon, Ph.D., Sona A. Dimidjian, Karen B. Schmaling, Ph.D., Robert J. Kohlenberg, Ph.D., Shireen Rizvi, David L. Dunner, M.D.

C Prediction of Treatment Response
Shireen Rizvi, Sona A. Dimidjian, Steven D. Hollon, Ph.D., Keith S. Dobson, Ph.D., Karen B. Schmaling, Ph.D., Robert J. Kohlenberg, Ph.D., David L. Dunner, M.D.

Discussants: Jan Fawcett, M.D., Marsha M. Linehan, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 28 2:00 p.m.-5:00 p.m.
Rooms 1E03/4/5, Level 1, Javits Center

NEW PERSPECTIVES IN THE TREATMENT OF COMPLEX PTSD

Chp.: James A. Chu, M.D.

A Update on the Memory Wars: Evaluating and Working With Traumatic Memory
James A. Chu, M.D.

B Betrayal Trauma Theory: Dimensions of Harm and Healing
Jennifer J. Freyd, Ph.D.

C Significance of Relationship in the Treatment of Complex Trauma
Christine Courtois, Ph.D.

D Using EMDR to Resolve Trauma-Based Distortions of the Self in Complex PTSD
Denise J. Gellinas, Ph.D.

E Treatment Outcome Research and Complex PTSD
Bessel A. Van Der Kolk, M.D., Joseph F. Spinazzola, Ph.D.

Discussant: Judith Herman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 29 2:00 p.m.-5:00 p.m.
Room 1E06, Level 1, Javits Center

BIPOLAR PATIENTS: TREATMENTS AND CULTURAL ISSUES IN LATIN AMERICA

Chp.: Carlos Leon-Andrade, M.D.
Co-Chp.: Ruby C. Castilla-Puentes, M.D.

A Interpersonal Psychotherapy in Brazil: Similarities and Differences With the U.S.
Ana CF. Andrade, M.A., Francisco Lotufo-Neto, M.D., Beny Lafer, M.D., Marcelo Feijo

B From Practice to Theory: Group Music Therapy and Medication Compliance in Patients With Bipolar Disorder
Ruby C. Castilla-Puentes, M.D., James M. Perel, Ph.D.

C What Is the Role of Psychotherapy in Patients With Bipolar Disorders? Cultural Issues
Carlos Leon-Andrade, M.D., Roxana Galeno, M.D.

D Treatment of Sleep Problems in Bipolar Patients
Franklin Escobar, M.D.

E Some Useful Interventions in the Course of Bipolar Disorders in Argentina
Jose R. Bozzo, M.D.

Discussants: Ricardo Secin, M.D., Alberto Serrano, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 30 2:00 p.m.-5:00 p.m.
Room 1E09, Level 1, Javits Center

PSYCHOTHERAPY AND PHARMACOTHERAPY: DISSOLVING THE MIND-BRAIN BARRIER

A APA Committee on Psychotherapy by Psychiatrists

Chp.: Barton J. Blinder, M.D.
Co-Chp.: Bernard D. Beitman, M.D.

A Dynamic Imaging of the Brain: Actions, Dysfunction, Therapeutic Transformation
George I. Viamontes, M.D.

B Psychotherapy and Pharmacotherapy: Theoretical Basis and Empirical Studies of Combined Treatment
Michael E. Thase, M.D.

C Split Treatment: Conflict and Collaboration
Michelle B. Riba, M.D.

D Integrating Psychotherapy and Pharmacotherapy: The Clinical Challenge
Bernard D. Beitman, M.D.

Discussants: Charles B. Nemeroff, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 31 2:00 p.m.-5:00 p.m.
Room IE 10, Level 1, Javits Center

PRACTICE GUIDELINES, QUALITY INDICATORS, AND A PRACTICE RESEARCH NETWORK: AN INTERNATIONAL VIEW
World Psychiatric Association
Chp.: John S. McIntyre, M.D.
Co-Chp.: Wolfgang Gaebel, M.D.

A Treatment Guidelines in Psychiatry: Results of an International Survey
Wolfgang Gaebel, M.D., S. Weinmann, M.D.

B Clinically-Based Quality Indicators
John M. Oldham, M.D.

C APA Practice Guideline Project: Status and Challenges
John S. McIntyre, M.D.

D Assessing Evidence-Based Practice Guidelines in Routine Psychiatric Practice
Darrel A. Regier, M.D., Joyce C. West, Ph.D., William E. Narrow, M.D., Farshid F. Duffy, Ph.D., Joshua E. Wilk, Ph.D.

Discussants: Rodrigo A. Munoz, M.D., George Christodoulou, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 32 2:00 p.m.-5:00 p.m.
Room IE 11, Level 1, Javits Center

THE SCARS OF SARS: ITS IMPACTS ON PATIENTS, HEALTH CARE WORKERS, AND THE COMMUNITY
Chp.: Rima Styra, M.D.
Co-Chp.: Francis G. Lu, M.D.

A PTSD and Depression in Patients Diagnosed With SARS
Rima Styra, M.D., Wayne L. Gold, M.D., Susan Robinson, R.N., Laura Hawryluck, M.D., Gerald Devins, M.D., Kenneth Mah, Ph.D.

B The Psychological Impact of SARS on the Uninfected Health Care Worker
Wayne L. Gold, M.D., Rima Styra, M.D., Laura Hawryluck, M.D., Susan Robinson, R.N., Allison McGeer, M.D., Sidney H. Kennedy, M.D., Calvin Fones, M.D.

C Stress in the Time of SARS: Health Care Workers’ Reactions to the Singapore SARS Outbreak
Calvin Fones, M.D., David Koh, M.D., M. K. Lim, M.D., S. E. Chia, F. Qian, N. Chew, S. M. Ko

D Impact of SARS on Health Care Professionals
Sharon Strauss, M.D., Wayne L. Gold, M.D., Kumanan Wilson, M.D., Moira Kapral, M.D., Gloria Rambaldini, M.D., Darlyne Rath, M.S.C.

E I Am So Alone: Lessons Learned From Experiences of Quarantined Individuals During the SARS Outbreak in Toronto
Laura Hawryluck, M.D., Wayne L. Gold, M.D., Susan Robinson, R.N., Sandro Gales, M.D., Rima Styra, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 33 2:00 p.m.-5:00 p.m.
Room IE 12, Level 1, Javits Center

INTERPERSONAL PSYCHOTHERAPY: RESEARCH UPDATE
Chp.: John C. Markowitz, M.D.

A Group Interpersonal Psychotherapy for Depression in Uganda
Myrna M. Weissman, Ph.D., Paul Bolton, M.B., Helena Verdeli, Ph.D., Richard Neugebauer, Ph.D., Judith Bass, M.P.H., Kathleen Clougherty, M.S.W., Priya Wickramaratne, Ph.D.

B Combination of IPT and Medication in Outpatients With Depression: Is It the Best We Can Do?
Marc B.J. Blom, M.D., Kosse Jonker, Erik Hoencamp, M.D., Philip Spinhoven, Ph.D., Judith Haftmans, Ph.D., Richard Van Dyck, M.D.

C IPT for Anxiety and Depression in Primary Care in Scotland
Rosalyn Law, Psy.D.

D Brief Interpersonal Psychotherapy for Depression in Women
Holly A. Swartz, M.D., Ellen Frank, Ph.D., M. Katherine Shear, M.D., Michael E. Thase, M.D., John Scott, M.A.

E Long-Term Prophylaxis and Other Benefits of Maintenance Interpersonal Psychotherapy
Ellen Frank, Ph.D., Jill M. Cyranowski, Ph.D., Holly A. Swartz, M.D., David J. Kupfer, M.D.

Discussant: Myrna M. Weissman, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 34 2:00 p.m.-5:00 p.m.
Room IE 13, Level 1, Javits Center

WOMEN'S SEXUALITY UPDATE: OVERCOMING OBSTACLES TO PLEASURE
Chp.: Barbara D. Bartlik, M.D.

A How Sexual Attractiveness, Pheromones, Fertility, and Hysterectomy Are Related
Winnifred B. Cutler, Ph.D.

B Changes in Sexual Functioning Across the Menstrual Cycle and During and After Pregnancy
Catherine A. Birndorf, M.D.

C New Treatment Options for Women With Sexual Dysfunction
Barbara D. Bartlik, M.D., Amy Kossoy, B.A., Marina Rozenberg, Julie Kolzet, B.S., Adriel Gerard

D The Positive Uses of Adult Movies Catering to Women
Candida Royalle

E Antidepressants and Sexual Dysfunction: A Women's Issue
James H. Kocsis, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 35 2:00 p.m.-5:00 p.m.
Room IE 14, Level 1, Javits Center

CONTEMPORARY ISSUES IN SPORT PSYCHIATRY
International Society for Sport Psychiatry
Chp.: Ronald L. Kamm, M.D.

A FIST: A Unique Program for Boxers at Career End
Ronald L. Kamm, M.D.

B The Impact of Injury on the Adolescent Athlete and the Family
Thomas S. Newmark, M.D.

C Keeping the Athlete Out of Trouble
Eric D. Morse, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 36 2:00 p.m.-5:00 p.m.
Room IE 16, Level 1, Javits Center

EATING DISORDERS 2004: FROM PETS TO PSYCHE
Chp.: Joel Yager, M.D.
Co-Chp.: David B. Herzog, M.D.

A Effects of Weight Loss on 5HT Activity and Symptoms in Anorexia Nervosa
Walter H. Kaye, M.D., Ursula Bailey, M.D., Carolyn Melitzer, M.D., Guido K. W. Frank, M.D., Chet Mathis, Ph.D., Julie Price, Ph.D.

B Osteoporosis and Anorexia Nervosa: An Update
David B. Herzog, M.D., Anne Klibanski, M.D., Karen K. Miller, Madhu Misra, M.D., Mary P. Manzo, A.B., Safia C Abidi, B.S.

C Predictors of Treatment Acceptance in Anorexia Nervosa
Katherine A. Halmi, M.D., W. Stewart Agras, M.D., Scott J. Crow, M.D., James E. Mitchell, M.D., G. Terrence Wilson, Ph.D., Susan Bryson, Ph.D., Helena C Kraemer, Ph.D.

D Eating Problems and Disorders in Bariatric Surgery Patients
James E. Mitchell, M.D., Martina deZwaan, M.D., Ross D. Crosby, Ph.D., Stephen A. Wonderlich, Ph.D.

E Body Image: Evolutionary Neurobiology Meets Psychodynamic Psychiatry in the Agora
Arnold E. Andersen, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 37 2:00 p.m.-5:00 p.m.
Rooms 3D01/12, Level 3, Javits Center

PSYCHIATRIC INTERVENTIONS WITH MEDICALLY-EVACUATED SOLDIERS
Chp.: Stephen J. Cozza, M.D.

A A Medical Center Response to Combat Casualties
Thomas M. Fitzpatrick, M.D.

B A Psychiatry Consultation Service Response to Trauma Victims: Program to Prevent Psychiatric Comorbidity
Harold J. Wain, Ph.D.

C Global War on Terror: Walter Reed Army Medical Center Inpatient Psychiatry's Perspective
Theodore S. Nam, M.D.

D A Psychiatric Continuum of Care System in Support of the Global War on Terror
Douglas A. Waldrep, M.D.

Discussants: Robert J. Ursano, M.D., Matthew J. Friedman, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 38 2:00 p.m.-5:00 p.m.
Room 3D02/11, Level 3, Javits Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE, PART 3
Chp.: William E. Callahan, Jr., M.D.
Co-Chp.: Keith W. Young, M.D.

A Personal Factors Leading to a Successful Private Practice
William E. Callahan, Jr., M.D.
B Office Location and Design for Efficiency and Success
Keith W. Young, M.D.

C Streamlining Overhead and Managing Your Business in Private Practice
Keith W. Young, M.D.

D Marketing Your Unique Private Practice
William E. Callahan, Jr., M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 39 2:00 p.m.-5:00 p.m.
Room 3D03/10, Level 3, Javits Center

USE OF MANDATES AND LEVERAGE IN COMMUNITY-BASED TREATMENT

Chp.: Paul S. Appelbaum, M.D.

A Leverage and Mandated Community Treatment
John Monahan, Ph.D.

B A Multisite Study of Mandated Community Treatment: Methods and Prevalence
Henry J. Steadman, Ph.D.

C When Are Mandates and Leverage Applied in Community Treatment?
Paul S. Appelbaum, M.D.

D Patients' Attitudes Toward the Use of Legal Leverage in Community Treatment
Jeffrey W. Swanson, Ph.D., Marvin S. Swartz, M.D., H. Ryan Wagner, Ph.D., Eric B. Elbogen, Ph.D.

E Mandated Treatment: Legal, Ethical, and Policy Implications
Marvin S. Swartz, M.D.

Discussant: Stephanie LeMelle, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 40 2:00 p.m.-5:00 p.m.
Rooms 3D04/9, Level 3, Javits Center

PERINATAL DEPRESSION: BURDEN, NEUROBIOLOGY, AND TREATMENT

Chp.: John F. Greden, M.D.
Co-Chp.: Heather A. Flynn, Ph.D.

A The Neuropsychobiology of Perinatal Mood Disorders: Are Hormonal Changes Relevant?
Meir Steiner, M.D.

B Perinatal Depression: Bridging the Gap Between Maternal Distress and Infant Well-Being
Sheila Marcus, M.D., Heather A. Flynn, Ph.D., Delia M. Vazquez, M.D., Juan F. Lopez, M.D., Susan C. McDonough, Ph.D.

C The Undertreatment and Morbidity of Perinatal Depression in Obstetrics Settings
Heather A. Flynn, Ph.D., Sheila Marcus, M.D.

D Mental Health Treatment Among Pregnant Underprivileged Women
Kimberly A. Yonkers, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 41 2:00 p.m.-5:00 p.m.
Rooms 3D05/8, Level 3, Javits Center

NEUROIMAGING SEMINAR

Chp.: Bruce M. Cohen, M.D.

A Tools and Methods of Neuroimaging Research
Perry F. Renshaw, M.D.

B Functional Neuroanatomy of Psychiatric Disorders
Deborah A. Yurgelun-Todd, Ph.D.

C Neuroimaging in Psychotic Disorders
Stephan H. Heckers, M.D.

D Brain Imaging Studies of Depressive Illness
Michael E. Henry

E Neuroimaging in Childhood Disorders
Jean A. Frazier, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 42 2:00 p.m.-5:00 p.m.
Rooms 3D06/7, Level 3, Javits Center

SMOKING AND COMORBID MENTAL DISORDERS
Collaborative Session With the National Institute on Drug Abuse

Chp.: John R. Hughes, M.D.

A Psychiatric Comorbidity of Smoking and Nicotine Dependence: An Epidemiologic Perspective
Naomi Breslau, Ph.D.

B The Neurobiology of Nicotine Dependence and Comorbid Psychiatric Disorders
George F. Koob, Ph.D., Athina Markou, Ph.D.

(Continued on next page)
C Nicotine-Dependence Treatment in Individuals With Schizophrenia
Douglas M. Ziedonis, M.D.

D Behavioral and Pharmacological Treatments for Smokers With Depression
Richard A. Brown, Ph.D.
THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 43 2:00 p.m.-5:00 p.m.
Odets Room, Fourth Floor, Marriott Marquis

TRAGIC EVENTS IN THE EMERGENCY DEPARTMENT: THE ROLE OF PSYCHIATRY AND THE INSTITUTIONAL IMPACT

Chp.: John B. Herman, M.D.

A Preparation and Organization for Tragedies in the Emergency Room
Maryfran Hughes, R.N.

B Managing Grief in the Group Setting
Jennifer M. Lafayette, M.D.

C Staff Support in Responding to Tragedies
Lawrence T. Park, M.D.

D Residency Training and Tragedy in the Emergency Department
Felicia A. Smith, M.D.
THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 44 2:00 p.m.-5:00 p.m.
O'Neill Room, Fourth Floor, Marriott Marquis

CULTURE, ETHNICITY, RACE, AND PSYCHOPHARMACOLOGY: NEW RESEARCH PERSPECTIVES

Chp.: Pedro Ruiz, M.D.

A Ethnicity, Pharmacogenetics, and Psychopharmacotherapy
Keh-Ming Lin, M.D.

B Pharmacotherapy in African Americans
William B. Lawson, M.D.

C Ethnicity, Culture, and Psychopharmacology: Asian Perspectives
Edmond H.T. Pi, M.D.

D Hispanics: Disease, Genes, and Treatment Outcome
Ricardo P. Mendoza, M.D.

E An International Perspective on Ethnicity, Culture, and Psychopharmacology
Tarek A. Okasha, M.D.

Discussants: Tarek A. Okasha, M.D., Warachal E. Faison, M.D.
THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 45 2:00 p.m.-5:00 p.m.
Wilder Room, Fourth Floor, Marriott Marquis

DELUSIONAL DISORDER: A RECONSIDERATION OF THE SCIENTIFIC AND CONCEPTUAL BASIS FOR THE DSM REFORMULATION OF PARANOIA

Chp.: Alan A. Stone, M.D.
Co-Chp.: C. Robert Cloninger, M.D.

A The Concept of Delusional Disorder in DSM-IV
Nancy C. Andreasen, M.D.

B The Importance of Narcissism in Delusional Disorders
C. Robert Cloninger, M.D.

C Delusional Disorder: The Validity of the Diagnosis
Theo C. Manschreck, M.D.

D Delusional Disorder: Does the DSM Diagnosis Make Clinical Sense?
Alan A. Stone, M.D.

E Involuntary Treatment: The Constitutional Issues
Richard G. Taranto, J.D.
THIS SESSION WILL BE AUDIOTAPEED.

SYMPOSIUM 46 2:00 p.m.-5:00 p.m.
Ziegfeld Room, Fourth Floor, Marriott Marquis

TRANSLATIONAL RESEARCH ON EATING DISORDERS

Chp.: B. Timothy Walsh, M.D.
Co-Chp.: Michael J. Devlin, M.D.

A Excitatory and Inhibitory Neurobiological Controls of Eating
Gary J. Schwartz, Ph.D., Nori Geary, Ph.D.

B Dieting and Stress Combine Synergistically to Produce an Animal Model of Binge Eating

C An Animal Model of Food Addiction That May Relate to Binge Eating or Bulimia
Bartley G. Hoebel, Ph.D., Carlo Colantuoni, A.B., Nicole N. Avena, A.B., Pedro Rada
D Symptom Profiles and 5HT Regulation in Bulimia Nervosa
David C. Jimerson, M.D., Barbara E. Wolfe, Ph.D., Eran D. Metzger, M.D.

E Inhibitory and Excitatory Controls of Eating in Patients With Eating Disorders
Michael J. Devlin, M.D., B. Timothy Walsh, M.D., Diane A. Klein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 47 2:00 p.m.-5:00 p.m.
Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

WHAT EVERY PSYCHIATRIST NEEDS TO KNOW ABOUT HIV/AIDS
Chp.: Francine Cournos, M.D.

A HIV Treatment Update
Roy M. Gulick, M.D.

B Ten Things You Need to Know About Brain Dysfunction
Stephen J. Ferrando, M.D.

C Five Things You Need to Know: Drug-Drug Interactions
Marshall Forstein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 48 2:00 p.m.-5:00 p.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

PERSONALITY DISORDERS IN THE WORKPLACE
Chp.: James H. Reich, M.D.
Co-Chp.: Per Vaglum, M.D.

A Personality, Job Stress, and Mental Health Among Physicians
Per Vaglum, M.D.

B Avoidant and Dependent Personality Traits in the Workplace
James H. Reich, M.D.

C The Relationship Between Personality Disorders and Military Service
Paul S. Links, M.D., D. Randall Boddam, M.D.

D Interventions for Personality Disorders in the Workplace
David P. Bernstein, Ph.D.

E Personality Characteristics That Support Resuming of Interrupted Careers
Elsa F. Ronningstam, Ph.D.

Discussants: Ira D. Glick, M.D., Jack Maser, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 49  2:00 p.m.-5:00 p.m.
Booth/Edison Rooms, Fifth Floor, Marriott Marquis

OBSESSIVE-COMPULSIVE SPECTRUM DISORDERS: UPDATE ON CLINICAL MANAGEMENT
Chp.: Jon E. Grant, M.D.
Co-Chp.: Katharine A. Phillips, M.D.

A Neurobiology of the OCD Spectrum
Dan J. Stein, M.D.

B Obsessive-Compulsive Personality Disorder: Its Treatment and Relationship to OCD
Jane L. Eisen, M.D.

C Update on the Clinical Features and Treatment of BDD
Katharine A. Phillips, M.D.

D Identifying and Treating Hypochondriasis
Jonathan Abramowitz, Ph.D.

E Clinical Management of Pathological Gambling and Kleptomania
Jon E. Grant, M.D.

discussant: eric hollander, m.d.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 50 2:00 p.m.-5:00 p.m.
Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis

GENETIC CORRELATES IN BIPOLAR DISORDERS
Chp.: Joseph F. Goldberg, M.D.
Co-Chp.: Anil K. Malhotra, M.D.

A Phenotype in Genetic Studies of Bipolar Disorder
Martin Alda, M.D.

B Pharmacogenetics of Bipolar Disorder
Anil K. Malhotra, M.D., Youssef Hareen, M.D., Joseph F. Goldberg, M.D.

C Bipolar Disorder and Alcohol Abuse: Are There Shared Genetic Contributions?
Joseph F. Goldberg, M.D.

D Genetics of Suicidal Behavior in Bipolar Disorder
Maria A. Oquendo, M.D., J. John Mann, M.D.

E Genetic Evidence for a Bipolar Spectrum
J. Raymond DePaulo, Jr., M.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 51 2:00 p.m.-5:00 p.m.
Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

CRITICAL PERSPECTIVES ON GENDER IDENTITY DISORDER IN CHILDREN AND ADOLESCENTS

Chp.: Richard R. Pleak, M.D.

A Diagnosing Gender-Atypical Youth: A History of Gender Identity Disorder in Childhood
Karl E. Bryant, M.A.

B Historical and Ethical Perspectives on Gender-Atypical and Transgender Youth
Richard R. Pleak, M.D.

C Transgender Teens: Gender Atypicality at Puberty and Beyond
Sarah E. Herbert, M.D.

D Gender Variance in Children and Adolescents: A Critical Reinterpretation of Case Studies
Darryl B. Hill, Ph.D.

E Childhood Gender Identity Disorder: What Should We Treat and Why?
Edgardo J. Menvielle, M.D., Catherine Tuerk, R.N.
THIS SESSION WILL BE AUDIOTAPE...
SYMPOSIUM 55 2:00 p.m.-5:00 p.m.
Herald/Soho Rooms, Seventh Floor, Marriott Marquis

ADHD SUBTYPES AND SUBGROUPS AT RISK FOR SUBSTANCE USE DISORDERS
Collaborative Session With the National Institute on Drug Abuse

Chp.: Naimah Z. Weinberg, M.D.

A Subtypes of ADHD Youth At Risk for Substance Abuse
Timothy E. Wilens, M.D.

B Childhood ADHD, Comorbidity, and Risk for Late-Adolescent Drug Abuse
Ken C. Winters, Ph.D., Gerald August, Ph.D., George M. Realmuto, M.D.

C Developmental Twin Studies of Relations Between Substance Use and ADHD
James J. Heidziak, M.D., Dorett Boomsma, M.D., Richard D. Todd, M.D.

D Variability in Risk for Substance Use and Disorder Among Children Diagnosed With ADHD
Brooke S.G. Molina, Ph.D., William E. Pelham, Jr., Ph.D., Elizabeth M. Gnagy, B.S.

E Behavioral and Cognitive Predictors of Adolescent Substance Use in Children With ADHD
Jeffrey Halperin, Ph.D., Seth Harty, M.S., Nicole Thorn, B.A., Jeffrey H. Newcorn, M.D.

F Long-Term Follow-Up of Childhood ADHD: Development of Adult Substance Abuse
F. Xavier Castellanos, M.D., Rachel G. Klein, Ph.D., Sal Mannuzza, Ph.D., John L. Moulton, Ph.D.

THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 56 2:00 p.m.-5:00 p.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

ALCOHOLICS ANONYMOUS AND SPIRITUALLY ORIENTED RECOVERY

Chp.: Marc Galanter, M.D.
Co-Chp.: Edgar Nace, M.D.

A Research on Spirituality's Role in Recovery
Marc Galanter, M.D.

B The Effectiveness of AA: Empirical Research Perspectives
Barbara S. McCrady, Ph.D.

C The Interaction Between AA and Personality Disorder
Edgar Nace, M.D.

D Integrating AA and Psychotherapy
Richard K. Hies, M.D.

Discussants: Kathleen T. Brady, M.D., Michael H. Gendel, M.D. THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 57 2:00 p.m.-5:00 p.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

AN UPDATE ON PARKINSON'S DISEASE AND ITS PSYCHIATRIC COMPLICATIONS

Chp.: Matthew A. Menza, M.D.

A Parkinson's Disease: Update on Treatment, Etiology, and Pathogenesis
Margery Mark, M.D.

B Depression in Parkinson's Disease
Jeffrey L. Cummings, M.D.

C Psychosis in Parkinson's Disease
Laura Marsh, M.D.

D Cognitive Impairment, Dementia, and Parkinson's Disease
Iracema Leroi, M.D.

E Anxiety, Fatigue, and Sleep in Patients With Parkinson's Disease
Matthew A. Menza, M.D.

Discussant: Constantine Lyketsos, M.D. THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 58 2:00 p.m.-5:00 p.m.
Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis

UNIPOLAR MDD: INTERNATIONAL UPDATE
APA Council on Global Psychiatry

Chp.: Lewis L. Judd, M.D.
Co-Chp.: Juan J. Lopez-Ibor, Jr., M.D.

A MDD: A New Paradigm of Understanding and Treatment
Lewis L. Judd, M.D.

B A Psychobiological Model of Depression: Implications for Treatment
Hagop S. Akiskal, M.D.

C Predictive Factors in Resistant Depression: New European Data
Julien Mendlewicz, M.D.

D A New Public Health Agenda for Depression
Norman Sartorius, M.D.

Discussants: Giovanni B. Cassano, M.D., Costas Stefanis, M.D. THIS SESSION WILL BE AUDIOTAPEd.
TUESDAY

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 7
3:00 p.m.-5:00 p.m.
Galleria, Level 4, Javits Center

CHILD AND ADOLESCENT PSYCHIATRY,
PSYCHOTHERAPIES, AND OUTCOME STUDIES

For further information on New Research Sessions, please refer to the New Research Program Book included in your registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 43-49

INDUSTRY-SUPPORTED SYMPOSIUM 43
7:00 p.m.-10:00 p.m.
Grand Ballroom East, Third Floor, Hilton New York

EMOTION REGULATION AND PLASICITY OF
UNDERLYING CIRCUITRY: IMPLICATIONS FOR
DEPRESSION, ANXIETY, AND LONG-TERM BRAIN
FUNCTION
Supported by Wyeth Pharmaceuticals

Chp.: Ned H. Kalin, M.D.

A Amygdala and Prefrontal Cortical Interactions in
Emotion Regulation and Psychopathology
Ned H. Kalin, M.D.

B Hippocampal Size in Depression: Cause and Effect
Alan F. Schatzberg, M.D.

C Experience-Dependent Effects on Structural-Plasticity in
Limbic and Cortical Structures Involved in Emotion
Regulation
Elizabeth Gould, Ph.D.

D The Human Amygdala: Vigilance, Threat Assessment,
and Psychopathology
Paul Whalen, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 44
7:00 p.m.-10:00 p.m.
Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

DOES THE PHARMACOLOGY OF ANTIDEPRESSANT
DRUGS MATTER?
Supported by GlaxoSmithKline

Chp.: Maurizio Fava, M.D.

A Antidepressant Treatment and the Effect of Medical and
Psychiatric Comorbidity
Dan V. losifescu, M.D.

B Response Versus Remission: Are There Meaningful
Differences Among Antidepressants?
Michael E. Thase, M.D.

C Short- and Long-Term Tolerability Issues With
Antidepressants
Anita L.H. Clayton, M.D.

D Augmentation and Combination Strategies in Depression:
What Is the Evidence?
Maurizio Fava, M.D.

E Translating Mechanisms of Action Into Clinical Outcome
Of Depression
J. Craig Nelson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 46
7:00 p.m.-10:00 p.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

PANIC ANXIETY: UNDERSTANDING ITS NATURE
AND NURTURING RECOVERY
Supported by Forest Laboratories, Inc.

Chp.: Murray B. Stein, M.D.
| A Born or Made Anxious? The Role of Temperament and Environment  
Murray B. Stein, M.D. | B Family and Genetic Studies of Binge-Eating Disorder  
James I. Hudson, M.D. |
|-----------------------------|---------------------------------|
| B Born or Made Anxious? Anxiety Disorder Gene Mapping and Identification  
Joel Gelernter, M.D. | C Treatment of Binge-Eating Disorder  
B. Timothy Walsh, M.D. |
| C Extreme Anxiety and Suicide  
David C. Purselle, M.D. | D Psychiatric Comorbidity Associated With Binge-Eating Disorder  
Justine K. Lalonde, M.D. |
| D Understanding and Treating Primary Care Panic Disorder Using a Collaborative Care Approach  
Peter P. Roy-Byrne, M.D. | E Addressing Medical Comorbidity Associated With Binge-Eating Disorder  
Louis J. Aronne, M.D. |
| E Choosing Medications for Panic Disorder  
Jonathan R.T. Davidson, M.D. | INDUSTRY-SUPPORTED SYMPOSIUM 47  
7:00 p.m.-10:00 p.m.  
Grand Ballroom, Mezzanine Level, Roosevelt |
| ADULT ADHD DIAGNOSIS AND TREATMENT  
Supported by Shire US, Inc. | Chp.: Thomas J. Spencer, M.D. |
| A Adult ADHD: Clinical Overview  
Thomas J. Spencer, M.D. | A Assessing the Complaint of Insomnia  
Mary B. O’Malley, M.D. |
| B Understanding and Utilization of Diagnostic Rating Scales  
Lenard A. Adler, M.D. | B Metabolic and Endocrine Effects of Sleep Deprivation  
Eve Van Cauter, M.D. |
| C Cognitive-Behavioral Therapies: Treatments and Outcomes  
Stephen P. McDermott, M.D. | C Psychiatric Morbidity of Insomnia  
Ruth M. Benca, M.D. |
| D Treatment With Stimulants  
Timothy E. Wilens, M.D. | D Quality of Life and Health Care Costs in Insomnia  
Daniel J. Buysse, M.D. |
| E Treatment With Nonstimulants  
James G. Waxmonsky, M.D. | E Current and Future Treatments of Insomnia  
John W. Winkelman, M.D. |
| INDUSTRY-SUPPORTED SYMPOSIUM 48  
7:00 p.m.-10:00 p.m.  
Imperial Ballroom A, Second Floor, Sheraton New York | PRESIDENTIAL FORUM 9  
7:00 p.m.-10:00 p.m.  
Astor Ballroom, Seventh Floor, Marriott Marquis |
| BINGE-EATING DISORDER: GENES, TREATMENTS, AND CONSEQUENCES  
 Supported by Ortho-McNeil Pharmaceuticals | I AM SAM  
Chp.: Marcia Kraft Goin, M.D.  
Participants: Jessie Nelson, Daniel J. Siegel, M.D. |
| A The Neurobiology of Binge-Eating and Obesity  
James F. List, M.D. |
CALL FOR PAPERS

PRESIDENT’S THEME:
Psychosomatic Medicine: Integrating Psychiatry & Medicine

Michelle Riba, M.D.
President

Marian I. Butterfield, M.D., Chairperson
Scientific Program Committee

THE SUBMISSION SCHEDULE

<table>
<thead>
<tr>
<th>Format</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry-Supported</td>
<td>June 1, 2004</td>
</tr>
<tr>
<td>Symposium</td>
<td></td>
</tr>
<tr>
<td>Course</td>
<td>September 7, 2004</td>
</tr>
<tr>
<td>Reports</td>
<td>September 7, 2004</td>
</tr>
<tr>
<td>Symposium</td>
<td>September 7, 2004</td>
</tr>
<tr>
<td>Workshops</td>
<td>Issue: September 7, 2004</td>
</tr>
<tr>
<td></td>
<td>Component: September 20, 2004</td>
</tr>
<tr>
<td>New Research</td>
<td>December 3, 2004</td>
</tr>
</tbody>
</table>

Incomplete and/or Incorrect Forms Will Not Be Considered.

For complete submission forms, you may download the forms at www.psych.org, click on the Annual Meeting logo, then click on submission forms. You may also contact the APA toll free at 1-888-357-7924, and speak directly with an Answer Center Coordinator.

If you want to volunteer to chair a session, please send a letter to the attention of Dr. Butterfield at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.
7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 50-51

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 50, PART 1
7:00 a.m.-8:30 a.m.
Imperial Ballroom A, Second Floor, Sheraton New York

PTSD: SEARCHING FOR ANSWERS IN TRAUMATIC TIMES
Supported by Capotelan, Inc.
Chp.: Jonathan R.T. Davidson, M.D.
A PTSD: Its Burden and the Toll From Terrorism
Randall D. Marshall, M.D.
B Brain Imaging in PTSD: Going Beyond 5HT
David J. Nutt, M.D.
C Sleep in PTSD and Other Anxiety Disorders
Karl Doghramji, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 51, PART 1
7:00 a.m.-8:30 a.m.
Imperial Ballroom B, Second Floor, Sheraton New York

BIPOLAR DISORDER IN WOMEN: REPRODUCTIVE IMPLICATIONS OF TREATMENT
Supported by GlaxoSmithKline
Chp.: Adele C. Viguera, M.D.
Co-Chp.: Lee S. Cohen, M.D.
A Treatment of Bipolar Illness During Pregnancy
Lee S. Cohen, M.D.
B Bipolar Illness During the Postpartum Period: Update on Treatment
Adele C. Viguera, M.D.
C Treatment of Bipolar Illness in Adolescence: Implications for Younger Women
Janet Wozniak, M.D.

8:00 a.m. Sessions

COURSE 77 8:00 a.m.-12 noon
Concourse B, Concourse Level, Hilton New York
ASSESSING POSITIVE AND NEGATIVE SYMPTOMS IN PSYCHOSIS WITH THE PANSS
Co-Directors: Lewis A. Opler, M.D., Paul M. Ramirez, Ph.D.

COURSE 78 8:00 a.m.-12 noon
Concourse E, Concourse Level, Hilton New York
BIOETHICS UPDATE 2004
Director: Edmund G. Howe, M.D.

COURSE 79 8:00 a.m.-12 noon
Bryant Suite, Second Floor, Hilton New York
PSYCHIATRIC CONSULTATION IN LONG-TERM CARE
Director: George T. Grossberg, M.D.
Faculty: Judith H. W. Crossett, M.D., Abhilash K. Desai, M.D.

COURSE 80 8:00 a.m.-12 noon
Gibson Suite, Second Floor, Hilton New York
INSANITY DEFENSE EVALUATIONS
Director: Phillip J. Resnick, M.D.

COURSE 81 8:00 a.m.-12 noon
Gramercy B, Second Floor, Hilton New York
CONTEMPORARY MALPRACTICE LIABILITY: A PRACTICAL GUIDE
Co-Directors: Eugene M. Lowenkopf, M.D., Abe M. Rychik, J.D.
Faculty: Jacqueline M. Melonas, J.D., Richard G. Hersh, M.D.
WEDNESDAY

COURSE 82 8:00 a.m.-12 noon
Murray Hill B, Second Floor, Hilton New York

PSYCHIATRY IN JAIL

Director: Ole J. Thienhaus, M.D.
Faculty: Melissa P. Piasecki, M.D., Jan Budetti, M.S.W., John N. Chappel, M.D., Richard Horton, M.D.

COURSE 83 8:00 a.m.-12 noon
Nassau Suite A, Second Floor, Hilton New York

HELPING PARENTS FROM THE INSIDE OUT: ATTACHMENT, MINDSIGHT, AND THE BRAIN

Director: Daniel J. Siegel, M.D.

COURSE 84 8:00 a.m.-12 noon
Sutton North, Second Floor, Hilton New York

INFANTICIDE: A DIALOGUE BETWEEN THE PSYCHIATRIST AND THE ATTORNEY

Co-Directors: Margaret G. Spinelli, M.D., Katherine L. Wisner, M.D.
Faculty: George Parnham, J.D.

COURSE 85 8:00 a.m.-5:00 p.m.
Gramercy A, Second Floor, Hilton New York

OFFICE-BASED BUPRENORPHINE TREATMENT OF OPIOID-DEPENDENT PATIENTS

Co-Directors: Thomas R. Kosten, M.D., Eric C. Strain, M.D.
Faculty: Walter Ling, M.D., Laura F. McNicholas, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 3
9:00 a.m.-10:30 a.m.
Rooms 3D06/7, Level 3, Javits Center

PSYCHIATRIC ISSUES IN THE MANAGEMENT OF PATIENTS WITH HIV INFECTION

Moderator: Glenn J. Treisman, M.D.
Presenters: Andrew F. Angelino, M.D., Heidi E. Hutton, Ph.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 2: PART 1
9:00 a.m.-12 noon
Rooms 3D01/12, Level 3, Javits Center

TWO HOSPITALIZED PATIENTS WITH REFRACTORY MOOD DISORDER AND COGNITIVE IMPAIRMENT

Moderator: Stuart C. Yudofsky, M.D.
Presenters: Richard L. Munich, M.D., Efrem Bleiberg, M.D., Lauren B. Marangell, M.D., Alice Rogan, M.D., Florence Kim, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 86-90
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 86 9:00 a.m.-4:00 p.m.
Concourse A, Concourse Level, Hilton New York

PSYCHOTHERAPY OF BORDERLINE PERSONALITY

Co-Directors: Otto F. Kernberg, M.D., Frank E. Yeomans, M.D.
Faculty: John F. Clarkin, Ph.D., Eve Caligor, M.D.

COURSE 87 9:00 a.m.-4:00 p.m.
Beekman Parlor, Second Floor, Hilton New York

THE NEUROENDOCRINOLOGY OF MOOD DISORDERS

Co-Directors: Mark A. Frye, M.D., Natalie L. Rasgon, M.D.
Faculty: D. Jeffrey Newport, M.D., Michael Bauer, M.D., Catherine A. Roca, M.D., Charles DeBattista, M.D.

COURSE 88 9:00 a.m.-4:00 p.m.
Clinton Suite, Second Floor, Hilton New York

MONEY MATTERS II: ADVANCED CLINICAL PRACTICE

Director: Cecilia M. Mikalac, M.D.
COURSE 89 9:00 a.m.-4:00 p.m.
Murray Hill A, Second Floor, Hilton New York

INTRODUCTION TO COGNITIVE-BEHAVIORAL THERAPY

Co-Directors: Robert M. Goisman, M.D., Philip G. Levendusky, Ph.D.

COURSE 90 9:00 a.m.-4:00 p.m.
Sutton Center, Second Floor, Hilton New York

MED-PSYCH DRUG-DRUG INTERACTIONS

Co-Directors: Scott C. Armstrong, M.D., Kelly L. Cozza, M.D.
Faculty: David M. Benedek, M.D., Jessica R. Oesterheld, M.D., Neil B. Sandson, M.D.

9:00 a.m.-10:30 a.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

18 Milton Viederman, M.D., on Psychological Engagement During the Consultation Process (Meet the Authors)
Rooms 2D02/3, Level 2, Javits Center

19 Geetha Jayaram, M.D., on Patient Safety (For Residents Only)
Versailles Terrace, Second Floor, Sheraton New York

DISCUSSION GROUPS 18-19
9:00 a.m.-10:30 a.m.

LECTURES 19-20

LECTURE 19
9:00 a.m.-10:30 a.m.
Rooms 1E07/8, Level 1, Javits Center

Joseph T. Coyle, Jr., M.D.

The Role of Glutamate in the Pathophysiology of Schizophrenia

Chp.: Yoram Barak, M.D.
Co-Chp.: Larry E. Tune, M.D.

From 1991 to 2001, Joseph T. Coyle, Jr., M.D., served as Chairman of the Consolidated Department of Psychiatry at Harvard Medical School, which included the nine hospital programs of psychiatry affiliated with the Medical School. He now holds the Eben S. Draper Chair of Psychiatry and Neuroscience at Harvard. After graduating from Holy Cross College, he received his medical degree from Johns Hopkins School of Medicine in 1969.

Following an internship in pediatrics, he spent three years at the National Institutes of Health as a research fellow in the laboratory of Nobel Prize winner Julius Axelrod, Ph.D. He returned to Hopkins in 1973 to complete his Psychiatric residency, in which he is board certified, and joined the faculty. In 1980, he was promoted to Professor of Neuroscience, Pharmacology and Psychiatry, and in 1982 he assumed the Directorship of the Division of Child and Adolescent Psychiatry, being named the Distinguished Service Professor in 1985. Dr. Coyle's research interests include developmental neurobiology, mechanisms of neuronal vulnerability, and psychopharmacology. He has published over 500 scientific articles and has edited seven books. He has received NIH funding for his research for nearly 30 years and is the Director of an NIMH Conte Center on the Neurobiology of Schizophrenia. His research contributions have been recognized by the reception of the John Jacob Abel Award from the America Society for Pharmacology and Experimental Therapeutics, the Gold Medal Award from the Society for Biological Psychiatry, the Efron Award from the American College of Neuropsychopharmacology, the Foundation Fund Research Award from the American Psychological Association (APA), the McAlpin Award from the National Mental Health Association, the Salmon Award from the New York Academy of Medicine, and the Pasarow Foundation Award for Neuroscience. Dr. Coyle is a Distinguished Fellow of the APA. He is Past-President of the American College of Neuropsychopharmacology (2001) and Past-President (1991) of the Society for Neuroscience, which has over 30,000 members. He sits on over 20 journal editorial boards including JAMA and is the Editor-in-Chief of the Archives of General Psychiatry, the most highly cited journal in the field.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 20
9:00 a.m.-10:30 a.m.
Room 1E15, Level 1, Javits Center

APA'S SIMON BOLIVAR AWARD LECTURE

Andres J. Pumariégna, M.D.

Latino Youth in the U.S.: Developmental and Mental Health Challenges

Chp.: Ana E. Campo, M.D.

Andres J. Pumariégna, M.D., is Professor and Director of Child and Adolescent Psychiatry at East Tennessee State University (ETSU) in Johnson City, Tennessee; and Director of the ETSU Center of Excellence for Children
in State Custody. Dr. Pumariega chairs the Community Psychiatry Committee and was the founding Chair of the Work Group on Community-Based Systems of Care of the American Academy of Child and Adolescent Psychiatry (AACAP); was a member of the National Advisory Council for the Center for Mental Health Services (CMHS); and chaired the Latino Panel for the CMHS Managed Care Initiative; and is a member of the Board of Directors of the American Association of Community Psychiatrists (AACP). He is the author of more than 100 scientific papers, book chapters, and monographs, mostly focusing on community child psychiatry and cross-cultural mental health. His books include *Clinical Assessment of Child and Adolescent Behavior* (co-edited with H. Vance) and *Handbook of Child and Adolescent Systems of Care: The New Community Psychiatry* (co-edited with N. Winters). A Distinguished Fellow of the American Psychiatric Association and a Fellow of AACAP, Dr. Pumariega has received numerous awards, including the Outstanding Mentor Award and the Ethics in Managed Care Award from the AACAP, and the Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill. Dr. Pumariega received his medical degree from the University of Miami and completed his residency in psychiatry and a fellowship in child and adolescent psychiatry at Duke University Medical Center in Durham, North Carolina.

**THIS SESSION WILL BE AUDIOTAPED.**

**MASTER EDUCATOR CLINICAL CONSULTATIONS 8-9**

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

8 Susan D. Block, M.D., on Psychiatric Issues and Interventions at the End of Life
   Room 1D04, Level 1, Javits Center

9 Michael D. Garrett, M.D., on Can the Ordinary Mind Empathize With Psychotic Experiences?
   Room 1D05, Level 1, Javits Center

**THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

**REVIEW OF PSYCHIATRY: SECTION 3**

9:00 a.m.-12:30 p.m.

Special Events Hall 1D, Level 1, Javits Center

**DEVELOPMENTAL PSYCHOBIOLOGY**

Chp.: B.J. Casey, Ph.D.

11 Developmental Psychobiology: An Overview
   B.J. Casey, Ph.D.

12 Withdrawn

13 The Developmental Psychobiology of Early Attachment
   Myron Hofer, M.D.

14 The Developmental Neurobiology of Face Perception
   Charleston Nelson, Ph.D., Lisa Scott, B.S.

15 Developmental Psychobiology of Tourette's Syndrome
   Kathy A. Gallardo, M.D., James E. Swain, M.D., James F. Leckman, M.D.

**WORKSHOPS**

**COMPONENTS 33-41**

**COMPONENT WORKSHOP 33**

9:00 a.m.-10:30 a.m.

Room 1D06, Level 1, Javits Center

**TERRORISM IN AMERICA: THE DISTANT VICTIMS AND THE ROLE OF IMG PSYCHIATRISTS**

*APA Committee on International Medical Graduates*

Co-Chsp.: Fructuosio R. Irigoyen-Rascon, M.D., Godheard Oopen, M.D.

Participants: Jose M. Canive, M.D., Chowallur D. Chacko, M.D.

**COMPONENT WORKSHOP 34**

9:00 a.m.-10:30 a.m.

Rooms 2D10/11, Level 2, Javits Center

**CPT CODING AND DOCUMENTATION UPDATE**

*APA Committee on RBRVS, Codes, and Reimbursements*

Chp.: Chester W. Schmidt, Jr., M.D.

Participants: Tracy R. Gordy, M.D., Edward Gordon, M.D., Napoleon B. Higgins, Jr., M.D., Melodie Morgan-Minott, M.D., Joseph M. Schwartz, M.D.

**COMPONENT WORKSHOP 35**

9:00 a.m.-10:30 a.m.

Rooms 2D12/13, Level 2, Javits Center

**THE PSYCHIATRIST IN THE SCHOOLS: MEDICATION, BOUNDARIES, AND TRANSFERENCE ISSUES**

*APA Corresponding Committee on Mental Health and Schools*

Chp.: Eugenio M. Rothe, M.D.

Participants: Hong Shen, M.D., Mary Ann Schaepper, M.D., Trina B. Allen, M.D.

**COMPONENT WORKSHOP 36**

9:00 a.m.-10:30 a.m.

Rooms 2D14/15, Level 2, Javits Center

**TAKING THE FIRST STEP: WHAT ARE MY OPTIONS IN THE TRANSITION TO PRACTICE?**

*APA Assembly Committee of Early Career Psychiatrists*

Chp.: Murali Gopal, M.D.

Participants: Jeffrey A. Naser, M.D., Matthew W. Norman, M.D., Angelique D. Goodhue, M.D., Adam R. Chester, D.O.
COMPONENT WORKSHOP 37  9:00 a.m.-10:30 a.m.
O'Neill Room, Fourth Floor, Marriott Marquis

APA ETHICS PROCEDURES
APA Ethics Appeal Board

Chp.: Wade C. Myers, M.D.
Participants: William Arroyo, M.D., Harriet C. Stern, M.D.,
Donald G. Langsley, M.D., Spencer Eth, M.D., Laura W.
Roberts, M.D., Nada L. Stotland, M.D., Richard D. Milone, M.D.

COMPONENT WORKSHOP 38  9:00 a.m.-10:30 a.m.
Ziegfeld Room, Fourth Floor, Marriott Marquis

DOLLARS: THE PHARMACEUTICAL INDUSTRY IN
PSYCHIATRIC TRAINING
APA Committee of Residents and Fellows

Co-Chps.: William C. Wood, M.D., Geoffrey M. Hopkins, M.D.
Participants: David A. Goldberg, M.D., John B. Herman, M.D.,
Michael D. Jibson, M.D., Michele T. Pato, M.D., Michael E.
Thase, M.D.

COMPONENT WORKSHOP 39  9:00 a.m.-10:30 a.m.
Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

REDUCING DISPARITIES IN ACCESS TO
PSYCHIATRIC CARE: APA PERSPECTIVES
APA Steering Committee to Reduce Disparities in Access to Psychiatric Care

Co-Chps.: Altha J. Stewart, M.D., Roger D. Walker, M.D.
Participants: Pedro Ruiz, M.D., Francis G. Lu, M.D., Edward F.
Foulks, M.D., Carl C. Bell, M.D., Patricia I. Ordonez, M.D.,
Richard K. Harding, M.D.

COMPONENT WORKSHOP 40  9:00 a.m.-10:30 a.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

NEW CLASSIFICATION OF PSYCHOPATHOLOGY OF
INFANTS AND YOUNG CHILDREN
APA Corresponding Committee on Infancy and Early Childhood

Chp.: Irene Chatoor, M.D.
Participants: Thomas F. Anders, M.D., Daniel J. Siegel, M.D.,
Jean M. Thomas, M.D.

COMPONENT WORKSHOP 41  9:00 a.m.-10:30 a.m.
Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

CONSULTATION AND LEGAL CLARIFICATION IN
SEXUAL HARASSMENT
APA New Jersey Psychiatric Association

Co-Chps.: Rita R. Newman, M.D., Annette J. Hollander, M.D.
Participants: Maria T. Lymberis, M.D., David W.
Garland, Esq., Francine Weiss, Esq.

ISSUES 77-103

ISSUE WORKSHOP 77  9:00 a.m.-10:30 a.m.
Rooms 1E01/2, Level 1, Javits Center

MIRROR, MIRROR ON THE WALL: AMBITION AND
THE TEACHING PSYCHIATRIST
Association for Academic Psychiatry

Co-Chps.: Susan J. Lieff, M.D., Philip R. Muskin, M.D.
Participants: Joseph A. Cheong, M.D.

ISSUE WORKSHOP 78  9:00 a.m.-10:30 a.m.
Rooms 1E03/4/5, Level 1, Javits Center

THE TRAUMA OF MEDICAL MISTAKES: AN
EXPERIENTIAL WORKSHOP

Co-Chps.: Michael F. Myers, M.D., Leah J. Dickstein, M.D.
Participants: Rabbi Goldie Milgram, Barry Bub, M.D.

ISSUE WORKSHOP 79  9:00 a.m.-10:30 a.m.
Room 1E09, Level 1, Javits Center

THE PORTRAYAL OF ECT ON TELEVISION, FILM,
AND THE INTERNET

Chp.: Patrick Ying, M.D.

ISSUE WORKSHOP 80  9:00 a.m.-10:30 a.m.
Room 1E10, Level 1, Javits Center

PSYCHODYNAMIC TREATMENT OF DEPRESSION

Chp.: Fredric N. Busch, M.D.
Participants: Marie G. Rudden, M.D., Theodore Shapiro, M.D.

ISSUE WORKSHOP 81  9:00 a.m.-10:30 a.m.
Room 1E11, Level 1, Javits Center

WHEN USUAL TREATMENTS FAIL: ANTIPSYCHOTIC
STRATEGIES FOR REFRACTORY SCHIZOPHRENIA

Chp.: Jean-Pierre Lindenmayer, M.D.
Participants: John W. Rosenberger, M.D., Robert R.
Conley, M.D., Richard P. Brown, M.D., Leslie L. Citrome, M.D.

ISSUE WORKSHOP 82  9:00 a.m.-10:30 a.m.
Room 1E12, Level 1, Javits Center

TREATMENT OF PATIENTS WITH DRUG
DEPENDENCE AND PSYCHIATRIC ILLNESS
Collaborative Session With the National Institute on Drug Abuse

Co-Chps.: Wilson Compton III, M.D., Roger D. Weiss, M.D.
Participants: Edward V. Nunes, M.D., Alan S. Bellack, Ph.D.
Joy M. Schmitz, Ph.D.
WEDNESDAY

ISSUE WORKSHOP 83 9:00 a.m.-10:30 a.m.
Room IE13, Level 1, Javits Center

KUNDALINI YOGA MEDITATION TECHNIQUES FOR PSYCHIATRIC DISORDERS
Chp.: David Shannahoff-Khalsa, B.A.

ISSUE WORKSHOP 84 9:00 a.m.-10:30 a.m.
Room IE14, Level 1, Javits Center

PTSD IN THE NEW YORK FIRE DEPARTMENT: BODIES AND MINDS
Chp.: Kevin V. Kelly, M.D.
Participants: Kristina L.N. Jones, M.D., Claire Cammarata, C.S.W.

ISSUE WORKSHOP 85 9:00 a.m.-10:30 a.m.
Room IE16, Level 1, Javits Center

WOMEN’S MENTAL HEALTH IN TIMES OF TURMOIL: AN INTERNATIONAL PERSPECTIVE
A ssociation of Women Psychiatrists
Chp.: Sylvia W. Olarte, M.D.
Participants: Marta B. Rondon, M.D., Unaiza Niaz, M.D., Ana E. Campo, M.D., Marian I. Butterfield, M.D.

ISSUE WORKSHOP 86 9:00 a.m.-10:30 a.m.
Room 3D02/II, Level 3, Javits Center

MIGRATION AND PROFESSIONAL IDENTITY EXPERIENCE OF ORGANIZING RUSSIAN-AMERICAN PSYCHIATRY
Chp.: Nelly Katsnelson, M.D.
Participants: Rozaliya Vernikov, M.D., Michael L. Melamed, M.D.

ISSUE WORKSHOP 87 9:00 a.m.-10:30 a.m.
Room 3D03/10, Level 3, Javits Center

VASCULAR DEMENTIA: ASSESSMENT, IMAGING, AND TREATMENT
Chp.: F. Moises Gaviria, M.D.
Participants: Neil H. Pliskin, Glenn T. Stebbins, Ph.D., Christopher C. Duros, M.D.

ISSUE WORKSHOP 88 9:00 a.m.-10:30 a.m.
Rooms 3D04/9, Level 3, Javits Center

MEDICAL TRAINING FOR PSYCHIATRISTS: WHAT DO WE NEED TO KNOW?
Chp.: Peter Manu, M.D.
Participants: Raymond E. Suarez, M.D., James L. Levenson, M.D., Bruce R. Levy, M.D., Roger G. Kathe, M.D.
WEDNESDAY

ISSUE WORKSHOP 95 9:00 a.m.-10:30 a.m.
Plymouth/Urish/Subert Rooms, Sixth Floor, Marriott Marquis

GUIDELINE DEVELOPMENT FOR THE ASSESSMENT OF COMPETENCY

Chp.: Thomas S. Zaubler, M.D.
Participants: Peter M. Bolo, M.D., Cynthia N. Hoen, J.D.

ISSUE WORKSHOP 96 9:00 a.m.-10:30 a.m.
Royale Room, Sixth Floor, Marriott Marquis

INNOVATIONS IN ACADEMIC EMERGENCY PSYCHIATRY

Co-Chps.: William R. Dubin, M.D., Henry W. Weisman, M.D.
Participants: Brook E. Zitek, D.O., Mahrulk S. Khan, M.D.,
Robert O'Brien, Harris Strokov, Margaret A. Minehart, M.D.,
Carolyn Uimer, M.S.W., Marcella Maguire, Ph.D.

ISSUE WORKSHOP 97 9:00 a.m.-10:30 a.m.
Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis

ADDITION PSYCHIATRY: SCIENCE, CRAFT, AND SPIRITUALITY

Chp.: Richard J. Frances, M.D.
Participants: Sheila B. Blume, M.D., Avram H. Mac, M.D.,
Marc Galanter, M.D., Sheldon J. Miller, M.D., Robert B.
Millman, M.D., Edgar Nace, M.D., Lionel B. Solursh, M.D.

ISSUE WORKSHOP 98 9:00 a.m.-10:30 a.m.
Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

UNDERSTANDING AND TREATING COMPELVE SEXUAL BEHAVIOR

Chp.: Eric Hollander, M.D.
Participants: Eli Coleman, Ph.D., Jon Mongarn, Ph.D.,
Frederick Muench, M.A., Jeffrey Parsons, Ph.D., Milton L.
Wainberg, M.D.

ISSUE WORKSHOP 99 9:00 a.m.-10:30 a.m.
Gotham Room, Seventh Floor, Marriott Marquis

KENDRA'S LAW BECOMES REALITY: ASSISTED OUTPATIENT TREATMENT IN MANHATTAN

Co-Chps.: Andrew M. Kleiman, M.D., Gary R. Collins, M.D.
Participant: Jennifer Correale, J.D.

ISSUE WORKSHOP 100 9:00 a.m.-10:30 a.m.
Gramercy Room, Seventh Floor, Marriott Marquis

SEXUAL SATISFACTION AND MENTAL HEALTH IN ORTHODOX JEWSHD WOMEN

Co-Chps.: Rachel Yehuda, Ph.D., Michelle E. Friedman, M.D.
Participant: Talli Rosenbaum, P.T.

ISSUE WORKSHOP 101 9:00 a.m.-10:30 a.m.
Herald/Soho Rooms, Seventh Floor, Marriott Marquis

TREATMENT OF ADULT ADHD: COMBINING COGNITIVE AND MEDICAL APPROACHES

Co-Chps.: Anthony L. Rostain, M.D., J. Russell Ramsay, Ph.D.

ISSUE WORKSHOP 102 9:00 a.m.-10:30 a.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

IMPLEMENTING PSYCHOSOCIAL TREATMENTS IN REAL-WORLD SETTINGS

Chp.: Edward Kim, M.D.
Participants: Elizabeth Vreeland, M.S.N., Anna Marie Toto, M.Ed.

ISSUE WORKSHOP 103 9:00 a.m.-10:30 a.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

CRIMINAL JUSTICE SYSTEM AND SERIOUS MENTAL ILLNESS, PROBLEMS, AND SOLUTIONS

Co-Chps.: Joseph R. Calabrese, M.D., Janet Berry, J.D.
Participants: Omar Elhaj, M.D., Sol Wachtler, J.D.

MEDIA 5-6

MEDIA WORKSHOP 5 9:00 a.m.-12 noon
Room 1E06, Level 1, Javits Center

Postgenocide Psychological Trauma in Film, The Summer of Aviya

Co-Chps.: Maurice Preter, M.D., Harold J. Bursztajn, M.D.
Participants: Leoniti H. Thompson, M.D., Yehuda Nir, M.D.,
Amira Kohn-Trattner, C.S.W., Gila Almagor

MEDIA WORKSHOP 6 9:00 a.m.-12 noon
Odets Room, Fourth Floor, Marriott Marquis

The Beginning Stages of Couples' Therapy: Video Case Studies

Chp.: Ian E. Alger, M.D.
11:00 a.m. Sessions

DISCUSSION GROUP 20

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

Larry B. Silver, M.D., on Clinical Management of ADHD With Children, Adolescents, and Adults (Meet the Author)
Rooms 2D02/3, Level 2, Javits Center

LECTURES 21-22

LECTURE 21

11:00 a.m.-12:30 p.m.
Rooms 1E07/8, Level 1, Javits Center

Kathleen T. Brady, M.D.

Stress and Relapse to Substance Use Disorders
Collaborative Session With the National Institute on Drug Abuse

Chp.: David W. Brook, M.D.
Co-Chp.: Sheila B. Blume, M.D.

Kathleen T. Brady, M.D., Ph.D., is Professor of Psychiatry at the Medical University of South Carolina in Charleston. She is also Director of Clinical Programs at the Neurosciences Institute, Associate Director of the General Clinical Research Center, and Director of the Addiction Psychiatry Fellowship Program at the Medical University of South Carolina. Dr. Brady became President of the American Academy of Addiction Psychiatry in 2003. The author of more than 150 scientific papers and book chapters, Dr. Brady is Associate Editor of *Substance Abuse* and a member of the Editorial Board of several journals, including *American Journal on Addictions*, *Drug and Alcohol Dependence*, and *American Journal of Drug and Alcohol Abuse*. She has received numerous honors for her work in addiction research, including the Betty Ford Award from the Association for Medical Education and Research in Substance Abuse. Dr. Brady received her medical degree from the Medical University of South Carolina and her doctoral degree in pharmacology from the Medical College of Virginia in Richmond. She completed her residency in psychiatry and an addiction psychiatry fellowship at the Medical University of South Carolina. Distinguished Psychiatrist Series

THIS SESSION WILL BE AUDIOTAPE D.

LECTURE 22

11:00 a.m.-12:30 p.m.
Room 1E15, Level 1, Javits Center

APA'S ADMINISTRATIVE PSYCHIATRY AWARD LECTURE

Peter F. Buckley, M.D.

Public Academic Liaison: Pursuit of Best Practices in a Time of Economic Entrenchment

Chp.: Stuart B. Silver, M.D.

Peter F. Buckley, M.D., is Professor and Chairman of the Department of Psychiatry and Health Behavior at the Medical College of Georgia in Augusta. He formerly was Professor of Psychiatry and Vice Chairman of the Department of Psychiatry at Case Western Reserve University School of Medicine and Medical Director at Northcoast Behavioral Healthcare System, the state adult psychiatric services provider for Cleveland and Toledo, Ohio. Dr. Buckley conducts research on the neurobiology and treatment of schizophrenia. He is the author of more than 200 scientific articles, abstracts, and book chapters and the author or editor of seven books, including *The Neurodevelopmental Basis of Schizophrenia and Sexuality and Serious Mental Illness*. Dr. Buckley is the Editor-in-Chief of the *Journal of Dual Disorders* and serves on the editorial board of *Academic Psychiatry, Current Psychiatry, Drug and Today*, and *Psychiatric Issues in Emergency Care Settings*. He has received numerous awards for his work, including the Mead Johnson Award from the American College of Neuropsychopharmacology and the Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill. Dr. Buckley received his medical training and completed his psychiatry residency and a fellowship in schizophrenia research at University College Dublin School of Medicine in Dublin, Ireland. THIS SESSION WILL BE AUDIOTAPE D.

MASTER EDUCATOR CLINICAL CONSULTATIONS 10-11

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

10 James L. Griffith, M.D., on Engaging Patients' Spiritual Resources in Building Resilience to Relapse of Major Psychiatric Disorders
Room 1D04, Level 1, Javits Center

THIS SESSION WILL BE AUDIOTAPE D.
11 Stephen M. Goldfinger, M.D., on Establishing Relationships, Enhancing Adherence, and Improving Outcomes
   Room 1D05, Level 1, Javits Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDICAL UPDATE 3
11:00 a.m.-12:30 p.m.
Room IE13, Level 1, Javits Center

BETTER SEX: NATURALLY
Chp.: Philip R. Muskin, M.D.
Presenter: Richard P. Brown, M.D.
THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH
11:00 a.m.-12:30 p.m.
This session is limited to 25 participants on a first-come, first-served basis.

3 Jack M. Gorman, M.D., on Designing and Implementing Studies Contrasting Psychopharmacology and Psychotherapy
   Room 1D03, Level 1, Javits Center

SCIENTIFIC AND CLINICAL REPORT SESSIONS 19-27

SCIENTIFIC AND CLINICAL REPORT SESSION 19
11:00 a.m.-12:30 p.m.
Rooms 1E01/2, Level 1, Javits Center

ALCOHOL ABUSE
Chp.: Harvey Stabinsky, M.D.
Co-Chp.: Robert Kelly, M.D.

11:00 a.m.
56 The Effects of State Income Inequality and Alcohol Tax on Alcohol Dependence
   Claire Henderson, M.D., Xinhua Liu, Ph.D., Ana Diez Roux, Ph.D., Bruce G. Link, Ph.D., Deborah S. Hasin, Ph.D.

11:30 a.m.
57 Effect of Age on Long-Term Outcomes of Inpatient Alcoholism Treatment
   Neelofar Khan, M.D., Elizabeth J. Nickel, M.A., Elizabeth C. Penick, Ph.D., Barbara J. Powell, Ph.D., Barry I. Liskow, M.D., Jan L. Campbell, M.D., Sandra B. Hall

12 noon
58 Topiramate Treatment of Alcohol Dependence: Effects on Psychosocial Functioning and Its Relationship With Heavy Drinking
   Bankole A. Johnson, M.D., Nassima Ait-Daoud, M.D., Jennie Z. Ma, Ph.D., Fatema Z. Akhtar, M.S., John D. Roache, Ph.D., Norman Rosenthal, M.D., Charles L. Bowden, M.D., Carlo C. DiClemente, Ph.D., Martin A. Javors, Ph.D.
   THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 20
11:00 a.m.-12:30 p.m.
Room IE11, Level 1, Javits Center

CROSS-CULTURAL ISSUES
Chp.: Leslie A. Horton, M.D.
Co-Chp.: Claudio O. Cabrejos, M.D.

11:00 a.m.
59 Prevalence of Maternal Depression in Honduras
   Lawson R. Wulsin, M.D., Eugene C. Somoza, M.D., Miguel Coello, M.D., Jeffrey Heck, M.D., Manuel Sierra

11:30 a.m.
60 Screening for Depression Among Chinese Americans in Primary Care Using Two Items
   Albert Yeung, M.D., Jessica L. Murakami, B.A., Maurizio Fava, M.D., Wendy M. Guyker, B.S., Melissa E. Abraham, Ph.D.

12 noon
61 Suicidal Thinking in Colombian Youth With a History of Attempted Suicide
   Ruby C. Castilla-Puentes, M.D., Wilma I. Castilla-Puentes, M.D., Sandra R. Castilla-Puentes, M.D., Leo Russo, Ph.D., Ivan S. Gomez, M.D., Gilma P. de Contreras, M.S.W., Miguel Habaych, M.D.
   THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 21
11:00 a.m.-12:30 p.m.
Room IE12, Level 1, Javits Center

SUICIDE
Chp.: Douglas G. Jacobs, M.D.
Co-Chp.: Robert M. Davis, M.D.

11:00 a.m.
62 Suicidality and Second-Generation Antipsychotics in Patients With Schizophrenia
   Yoram Barak, M.D., Dov Alzenberg, M.D., Haim Knobler, M.D., Ilona Mirecki, M.D.
WEDNESDAY

11:30 a.m.
63 Melancholia and Suicide Attempt Probability and Lethality
Michael F. Grunebaum, M.D., Hanga G. Galfalvy, Ph.D., Maria A. Oquendo, M.D., Ainsley K. Burke, Ph.D., J. John Mann, M.D.

12 noon
64 Nonviolent Suicides in Women Are Increased During and After High Exposure to Tree Pollen
Teodor T. Postolache, M.D., Mark A. Goldstein, B.A., Richard Herrell, Ph.D., Srinangam S. Sheeram, M.D., Courtney M. Thrower, M.A., John W. Stiller, M.D., Hirsh Komarow, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 22
11:00 a.m.-12:30 p.m.
Room 3D03/10, Level 3, Javits Center

BIPOLAR DISORDER

Chp.: Robert M. Post, M.D.
Co-Chp.: Candace R. Good, M.D.

11:00 a.m.
65 Characteristics of Patients Treated With Gabapentin Referred to a Bipolar Specialty Clinic
Michael J. Ostacher, M.D., Heather Schloss, B.A., Lori R. Eisner, B.A., Andrew A. Nierenberg, M.D.

11:30 a.m.
66 Olanzapine/Fluoxetine Combination: Rapid Onset With Low Risk of Mania
Sara A. Corya, M.D., Paul E. Keck, Jr., M.D., Michael E. Thase, M.D., Sanjay Dube, M.D., Susan D. Briggs, Ph.D., Michael Case, M.S., Mauricio F. Tohen, M.D.

12 noon
67 Psychotic Features in MDD Are Associated With Mania
Ekkehard Othmer, M.D., Cherilyn DeSouza, M.D., Elizabeth J. Nickel, M.A., Edward N. Hunter, Ph.D., Elizabeth C. Penick, Ph.D., Sieglinde C. Othmer, Ph.D., Barbara J. Powell, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 23
11:00 a.m.-12:30 p.m.
Rooms 3D04/9, Level 3, Javits Center

BIOLOGICAL PSYCHIATRY

Chp.: David A. Casey, M.D.
Co-Chp.: Katherine G. Ruiz-Mellott, M.D.

11:00 a.m.
68 fMRI of Spatial Working Memory in Schizotypal Personality Disorder
Harold W. Koenigsberg, M.D., Monte S. Buchsbaum, M.D., Bradley Buchsbaum, Ph.D., Jason Schneiderman, Cheuk Tang, Ph.D., Antonia S. New, M.D., Larry J. Siever, M.D.

11:30 a.m.
69 Hypofrontality in Patients With Schizophrenia and Bipolar Disorders: An fMRI Study
Mircea C. Polosan, M.D., Monica Baciu, Ph.D., Christop Segebarth, Ph.D., Thierry Bougerol, Ph.D.

12 noon
70 Low Levels of Antibodies to Cardiolipin in First-Episode and Chronic Schizophrenia
Pinkhas Sirota, M.D., Irene Bogdanov, M.D., Aviva Katzav, M.S.C., Ruth Hersko, M.D., Joab Chapman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 24
11:00 a.m.-12:30 p.m.
Rooms 3D05/8, Level 3, Javits Center

PSYCHOPHARMACOLOGY RESEARCH IN DEPRESSION

Chp.: Susan Stabinsky, M.D.
Co-Chp.: Donald W. Hicks, M.D.

11:00 a.m.
71 Prevalence of MTHFR C677T and Methionine Synthase A2756G Polymorphisms in Major Depression and Impact on Response to Fluoxetine Treatment
David Mischoulon, M.D., Laura Kean Kramer, MD., Stefania Lamon-Fava, M.D., Jacob Selhub, Ph.D., Roy H. Perlis, M.D., Jonathan E. Alpert, M.D., Maurizio Fava, M.D.

11:30 a.m.
72 Oral S-Adenosyl Methionine (SAMe) for Antidepressant Augmentation: An Open-Label Trial
Jonathan E. Alpert, M.D., George I. Papakostas, M.D., John J. Worthington III, M.D., Timothy J. Petersen, Ph.D., David Mischoulon, M.D., Alana M. Burns, B.A., Teodor Bortiglieri, Ph.D., Andrew A. Nierenberg, M.D., Maurizio Fava, M.D.

12 noon
73 Somatic Symptoms as Predictors of Time to Onset of Response to Fluoxetine in MDD
George I. Papakostas, M.D., Timothy J. Petersen, Ph.D., Dan V. Iosifescu, M.D., Katherine Sklarsky, B.A., Andrew A. Nierenberg, M.D., Jonathan E. Alpert, M.D., Maurizio Fava, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 25
11:00 a.m.-12:30 p.m.
Rooms 3D06/7, Level 3, Javits Center

OUTCOMES IN PSYCHOSIS

Chp.: Carol L. Trippitelli, M.D.
Co-Chp.: Mark N. Rudolph, M.D.

11:00 a.m.
74 IC-SOHO: Intercontinental Schizophrenia Outpatient Health Outcomes Study
Martin Dossenbach, M.D., Andrew Hodge, M.S.C., Ruth A. O'Halloran, Ph.D.

11:30 a.m.
75 Male Patients With Schizophrenia Have Impairment in the Processing of Spatial Information From Dissociated Spatial Reference Frames
Miranda H. Chakos, M.D., Yevey Gelfand, Andre Fenton, Ph.D., Peter J. Weiden, M.D., Narender Dargani, B.S.

12 noon
76 Predictors of Outcome in 52 Cases of Psychotic Nonaffective Disorders
Mauricio P. Tohen, M.D., Carlos A. Zarate, Jr., M.D., John Hennen, Ph.D., Hari M. Kaur Khalsa, A.B., Paola Salvatore, M.D., Ross J. Baldessarini, M.D.

THIS SESSION WILL BE AUDIOTAPELED.

SCIENTIFIC AND CLINICAL REPORT SESSION 26
11:00 a.m.-12:30 p.m.
Wilder Room, Fourth Floor, Marriott Marquis

SUBSTANCE ABUSE
Collaborative Session With the National Institute on Drug Abuse

Chp.: Daniel P. Chapman, M.D.
Co-Chp.: Vinal N. Shah, M.D.

11:00 a.m.
77 Risk Factors for DSM-IV Cannabis Abuse and Dependence
Jason P. Herrick, B.A., Jakob Meydan, Psy.D., Xinhua Liu, Ph.D., Deborah S. Hasin, Ph.D.

11:30 a.m.
78 Cannabis Use Reduces the Likelihood of Sustained Remission From Other Drugs
Edward V. Nunes, M.D., Efrat Aharonovich, Ph.D., Xinhua Liu, Ph.D., Rivka R. Galchen, M.D., Deborah S. Hasin, Ph.D.

12 noon
79 Substance-Induced Risk for Depression in a Substance-Dependent Population
Rivka R. Galchen, M.D., Xinhua Liu, Ph.D., Efrat Aharonovich, Ph.D., Edward V. Nunes, M.D., Deborah S. Hasin, Ph.D.

THIS SESSION WILL BE AUDIOTAPELED.

SCIENTIFIC AND CLINICAL REPORT SESSION 27
11:00 a.m.-12:30 p.m.
Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

ISSUES IN PSYCHIATRIC EPIDEMIOLOGY

Chp.: Nilhil D. Nihalani, M.D.
Co-Chp.: Mark S. Wright, M.D.

11:00 a.m.
80 Ethnicity, Diagnosis, and Health Care Utilization in Incarcerated Women
Catherine F. Lewis, M.D.

11:30 a.m.
81 Psychotropic Drug Utilization in Six European Countries
Giovanni De Girolamo, M.D., Jordi Alonso, M.D., Isabelle Gasquet, Leo Russo, Ph.D., Gemma Vilagut, Gabriella Polidori, M.D., Heather Bryson

12 noon
82 Onset of DSM-IV Alcohol Abuse and Dependence: A 10-Year Prospective Study
Deborah S. Hasin, Ph.D., Xinhua Liu, Ph.D., Jason P. Herrick, B.A.

THIS SESSION WILL BE AUDIOTAPELED.

WORKSHOPS

COMPONENTS 42-48

COMPONENT WORKSHOP 42 11:00 a.m.-12:30 p.m.
Room 1D06, Level 1, Javits Center

ONLINE INTERACTION BETWEEN APA, MEMBERS, AND THE PUBLIC
APA Ad Hoc Work Group on Information Systems

Chp.: Robert C. Hsiung, M.D.
Participants: Herbert S. Peyser, M.D., William Bruce, B.A.

COMPONENT WORKSHOP 43 11:00 a.m.-12:30 p.m.
Room 3D02/11, Level 3, Javits Center

RESPONSE TO THE SIMON BOLIVAR AWARD LECTURE ON LATINO YOUTH IN THE U.S.: DEVELOPMENTAL AND MENTAL HEALTH CHALLENGES
APA Committee of Hispanic Psychiatrists

Co-Chps.: Ana E. Campo, M.D., Andres J. Pumariega, M.D.
Participants: Ian A. Canino, M.D., Pedro Ruiz, M.D., Renato D. Alarcon, M.D.
WEDNESDAY

COMPONENT WORKSHOP 44  11:00 a.m.-12:30 p.m.
O'Neill Room, Fourth Floor, Marriott Marquis

PSYCHIATRIC ETHICS IN THE U.S. AND THROUGHOUT THE WORLD
APA Ethics Committee

Co-Chps.: Spencer Eth, M.D., Driss Moussaoui, M.D.
Participants: Wade C. Myers, M.D., Philip T. Merideth, M.D.,
Ahmed Okasha, M.D., Juan J. Lopez-Ibor, Jr., M.D.

COMPONENT WORKSHOP 45  11:00 a.m.-12:30 p.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

THE 2004 MEDICARE UPDATE AND MAKING THE MOST OF THE CARRIER ADVISORY COMMITTEE
APA Medicare Advisory Corresponding Committee

Chp.: Edward Gordon, M.D.
Participants: Gerald Rogen, M.D., Ellen Jaffe, Seth P. Stein, J.D.

COMPONENT WORKSHOP 46  11:00 a.m.-12:30 p.m.
Booth/Edison Rooms, Fifth Floor, Marriott Marquis

IS THERE A STANDARD OF CARE FOR THE TREATMENT OF DEMENTIA?
APA Committee on Access and Effectiveness of Psychiatric Services for the Elderly

Chp.: Allan A. Anderson, M.D.
Participants: Marsden H. McGuire, M.D., Julian Offsay, M.D.,
Douglas A. Kalunian, M.D.

COMPONENT WORKSHOP 47  11:00 a.m.-12:30 p.m.
Plymouth/Uriss/Shubert Rooms, Sixth Floor, Marriott Marquis

BEND IT LIKE BECKHAM: ASIAN WOMEN, ACHIEVEMENTS, AND CULTURAL CONFLICTS
APA Council on Global Psychiatry

Co-Chps.: Ramaswamy Viswanathan, M.D., Jacquelyn B. Chang, M.D.
Participants: Geetha Jayaram, M.D., Michelle B. Riba, M.D.,
Madelyn H. Hicks, M.D., Madhulika S. Khandelwal, Ph.D.,
Sudeepta Varma, M.D.

COMPONENT WORKSHOP 48  11:00 a.m.-12:30 p.m.
Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis

BUPRENORPHINE IN THE TRENCHES: WHAT THE GENERAL PSYCHIATRIST NEEDS TO KNOW
APA Corresponding Committee on Training and Education in Addiction Psychiatry and APA Corresponding Committee on Treatment Services for Patients with Addictive Disorders

Co-Chps.: Marianne T. Gschwan, M.D., John A. Renner, Jr., M.D.
Participants: George F. Kolodner, M.D., Samuel M. Silverman, M.D.

ISSUES 104-119

ISSUE WORKSHOP 104  11:00 a.m.-12:30 p.m.
Rooms 1E03/4/5, Level 1, Javits Center

INNOVATIVE METHODS OF PROMOTING USE OF EVIDENCE-BASED PSYCHOPHARMACOLOGY

Chp.: David N. Osser, M.D.
Participants: Carole C Upshur, Ed.D., Robert D. Patterson, M.D., Kenneth O. Jobson, M.D., Richard C. Hermann, M.D.

ISSUE WORKSHOP 105  11:00 a.m.-12:30 p.m.
Room 1E09, Level 1, Javits Center

WHEN PSYCHIATRISTS HAVE SUFFERED A MENTAL ILLNESS: THEIR STORIES AND INSIGHTS
National Alliance for the Mentally Ill

Co-Chps.: Michael F. Myers, M.D., Leah J. Dickstein, M.D.
Participants: Elizabeth A. Baxter, M.D., Marian Fireman, M.D.,
Raymond M. Reyes, M.D., Suzanne E. Vogel-Scibilia, M.D.,
Francine Cournos, M.D., Kay R. Jamison, Ph.D.

ISSUE WORKSHOP 106  11:00 a.m.-12:30 p.m.
Rooms 2D10/11, Level 2, Javits Center

WILL OUTCOMES EVALUATION AND RESEARCH INITIATIVES SAVE THE THERAPEUTIC COMMUNITY?

Chp.: Gregory C Bunt, M.D.
Participants: Charles Devlin, George DeLeon, Ph.D., Britta Muehlbach, M.A., Marc Galanter, M.D.

ISSUE WORKSHOP 107  11:00 a.m.-12:30 p.m.
Rooms 2D12/13, Level 2, Javits Center

NEGATIVE-SYMPTOM SPECTRUM DISORDERS: RESPONSE TO PHARMACOTHERAPY OF ASPERGER’S DISORDER

Chp.: Elizabeth Sirota, M.D.
Participants: Donna L. Londino, M.D., Jeffrey L. Rausch, M.D.

ISSUE WORKSHOP 108  11:00 a.m.-12:30 p.m.
Rooms 2D14/15, Level 2, Javits Center

SOMETIMES IT IS ABOUT YOU: THE USE OF SELF IN ENGAGING AND TREATING HOMELESS INDIVIDUALS

Chp.: Marvin A. Nierenberg, M.D.
Participants: Amy Cohen, N.P., Dillon C. Euler, M.D.,
Van Yu, M.D.
WEDNESDAY

ISSUE WORKSHOP 109 11:00 a.m.-12:30 p.m.
Ziegfeld Room, Fourth Floor, Marriott Marquis

MULTIPLE PERSPECTIVES ON THE PATHOLOGICAL FEAR RESPONSE: INTEGRATION OF PSYCHOTHERAPEUTIC AND PSYCHOPHARMACOLOGIC THERAPIES

Co-Chps.: David Steinman, M.D., Jennifer M. Bonovitz, Ph.D.

ISSUE WORKSHOP 110 11:00 a.m.-12:30 p.m.
Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis

THE DAY I DIED: A NEAR-DEATH DOCUMENTARY AND THE MIND-BRAIN BARRIER

Chp.: B. Jason MacLurg, M.D.

ISSUE WORKSHOP 111 11:00 a.m.-12:30 p.m.
Lyceum Room, Fifth Floor, Marriott Marquis

WHAT LOVE HAS TO DO WITH IT: EXPLORING THE ROLE OF LOVE IN MENTAL ILLNESS

Co-Chps.: Robert W. Hierholzer, M.D., Bita Ghafoori, Ph.D.

ISSUE WORKSHOP 112 11:00 a.m.-12:30 p.m.
Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

PSYCHIATRY AND HOMELAND SECURITY: AN EXERCISE IN WEAPONS OF MASS DESTRUCTION RESPONSE PLANNING

Co-Chps.: Larry H. Pastor, M.D., Dickson S. Diamond, M.D.
Participant: Richard T. Keller, R.N.

ISSUE WORKSHOP 113 11:00 a.m.-12:30 p.m.
Royale Room, Sixth Floor, Marriott Marquis

FITNESS-FOR-DUTY EVALUATIONS FOR LAW-ENFORCEMENT OFFICERS

Chp.: Marilyn Price, M.D.
Participants: Debra A. Pinals, M.D., Bernice Kelly, Psy.

ISSUE WORKSHOP 114 11:00 a.m.-12:30 p.m.
Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis

EVALUATING TREATMENT WITH FUNCTIONAL BRAIN IMAGING

Co-Chps.: Daniel G. Amen, M.D., Joseph C. Wu, M.D.
Participant: Barton J. Blinder, M.D.

ISSUE WORKSHOP 115 11:00 a.m.-12:30 p.m.
Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

SUICIDE AND SCHIZOPHRENIA: A FAMILY INTERVIEW

Chp.: Paul A. Kettl, M.D.

ISSUE WORKSHOP 116 11:00 a.m.-12:30 p.m.
Gotham Room, Seventh Floor, Marriott Marquis

ETHICAL AND PRACTICAL CHALLENGES IN EMERGENCY PSYCHIATRIC RESEARCH

Co-Chps.: Rebecca W. Brendel, M.D., Melissa E. Abraham, Ph.D.
Participant: Lawrence T. Park, M.D.

ISSUE WORKSHOP 117 11:00 a.m.-12:30 p.m.
Herald/Soho Rooms, Seventh Floor, Marriott Marquis

DEVELOPING A COMMUNITY MENTAL HEALTH RESPONSE TO DISASTERS AND TERRORISM

Co-Chps.: John W. Burruss, M.D., Jennifer E. Pate, M.D.
Participant: Meg Crady

ISSUE WORKSHOP 118 11:00 a.m.-12:30 p.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

JUVENILE-JUSTICE SUCCESS SERIES, CHAPTER 1: MUSICIANSHIP, JAZZ, AND BLUES

Chp.: Cheryl D. Wills, M.D.

ISSUE WORKSHOP 119 11:00 a.m.-12:30 p.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

POLITICS AND PREGNANCY: THE REGINA MCKNIGHT CASE

Chp.: Andrea G. Stolar, M.D.
Participants: David J. McDowell, Ph.D., Lynn M. Paltrow, J.D.

12 noon Sessions

FORUMS 10-11

FORUM 10 12 noon-1:30 p.m.
Room 1E10, Level 1, Javits Center

BUPRENORPHINE: WHAT THE CLINICIAN SHOULD KNOW

Chp.: Herbert D. Kleber, M.D.
Participants: David M. McDowell, M.D., Roberta Sales, R.N., Erik W. Gunderson, M.D., Patricia I. Ordone, M.D.
WEDNESDAY

FORUM 11 12 noon-1:30 p.m.
Astor Ballroom, Seventh Floor, Marriott Marquis

9/11 RESEARCH: A REVIEW AND REVIEWS

Chp.: Anand Pandya, M.D.
Participants: Carol S. North, M.D., Craig L. Katz, M.D., Sandro Galea, M.D., Ezra S. Susser, M.D.

NEW RESEARCH POSTER SESSION 8
12 noon-2:00 p.m.
Galleria, Level 4, Javits Center

SCHIZOPHRENIA AND PSYCHOTIC DISORDERS, AND BRAIN IMAGING

For further information on New Research Sessions, please refer to the New Research Program Book included in your registration packet.

1:00 p.m. Sessions

COURSES 91-97
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 91 1:00 p.m.-5:00 p.m.
Concourse B, Concourse Level, Hilton New York

PSYCHIATRY AND THE INTERNET
American Association for Technology and Psychiatry

Co-Directors: Robert S. Kennedy, M.A., Thomas A.M. Kramer, M.D.

COURSE 92 1:00 p.m.-5:00 p.m.
Concourse E, Concourse Level, Hilton New York

THE CLINICAL APPLICATION OF CULTURAL PSYCHIATRY

Director: Wen-Shing Tseng, M.D.
Faculty: J. David Kinzie, M.D., Keh-Ming Lin, M.D., Jon M. Streltzer, M.D., Joseph J. Westermeyer, M.D.

COURSE 93 1:00 p.m.-5:00 p.m.
Bryant Suite, Second Floor, Hilton New York

MEN SEXUALLY ABUSED AS BOYS: MEANINGS, CONSEQUENCES, AND TREATMENT

Director: Murray D. Schane, M.D.
Faculty: Howard Fradkin, Ph.D., Bill Bunester, M.A., William Holmes, M.D., Kenneth Singer, M.S.W.

LECTURES 23-24

LECTURE 23
2:00 p.m.-3:30 p.m.
Rooms 1E07/8, Level 1, Javits Center

Helen E. Fisher, Ph.D.
The Brain In Love

Chp.: Philip R. Muskin, M.D.

Helen E. Fisher, Ph.D., is Research Professor and Member of the Center for Human Evolutionary Studies in the Department of Anthropology at Rutgers University in New Brunswick, New Jersey. Dr. Fisher
has lectured widely on the evolution of human sexuality, romance and family life, and gender differences in the brain and behavior. Her most recent book *Why We Love: The Nature and Chemistry of Romantic Love* is based in part on research on brain physiology conducted with colleagues at the Albert Einstein College of Medicine and the State University of New York at Stony Brook. Her other books include *The First Sex: The Natural Talents of Women and How They Are Changing the World*, *Anatomy of Love: The Natural History of Monogamy, Adultery, and Divorce*, and *The Sex Contract: The Evolution of Human Behavior*. Dr. Fisher has served as an anthropological commentator and consultant for businesses and the media, including the BBC, NBC's "Today Show," WNET-TV (New York), the Canadian Broadcasting Corporation, Reader's Digest, and Time-Life Books. She has been honored with the Distinguished Service Award of the American Anthropological Association for her work in communicating anthropology to the broad public audience. Dr. Fisher received her doctorate in physical anthropology at the University of Colorado in Boulder.

THIS SESSION WILL BE AUDIOTAPED.

LEC T URE 2 4

2:00 p.m.-3:30 p.m.
Room IE15, Level 1, Javits Center

AP A/ NIMH VESTERMARK PSYCHIATRY EDUCATOR AWARD LECTURE

Eugene V. Beresin, M.D.

Striking Accord: Tales of Teaching and the Heart

Chp.: Richard Balon, M.D.

Eugene V. Beresin, M.D., is Associate Professor of Psychiatry at Harvard Medical School and Director of the Consolidated Massachusetts General Hospital and McLean Hospital Child and Adolescent Psychiatry Residency Training Program in the Boston area. He is also Medical Director of the Massachusetts General Hospital Child and Adolescent Psychiatry Outpatient Clinic, Co-Director of the Harvard Medical School Center for Mental Health and Media, and Director of the Elizabeth Thatcher Acampora Endowment, an outreach program for underserved youth and families. Dr. Beresin is Media Editor for *Academic Psychiatry* and Editor of the Child Psychiatry Residents In-Training Examination (Child PRITE), and has been appointed as the next Editor-in-Chief of PRITE. A former President of the American Association of Directors of Psychiatry Residency Training, Dr. Beresin has won a number of local and national teaching awards, including the Parker J. Palmer "Courage to Teach" Award of the Accreditation Council of Graduate Medical Education. He received his medical degree from the University of Pennsylvania and completed his residency in psychiatry at Massachusetts General Hospital, and his residency in child psychiatry at Children's Hospital Medical Center and Judge Baker Guidance Center in Boston.

THIS SESSION WILL BE AUDIOTAPED.

PRE Si TO Na Li AY SY M Po Si Um 3

2:00 p.m.-5:00 p.m.
Room IE 11, Level 1, Javits Center

RE CONSTRUCTING POSTWAR MENTAL HEALTH SERVICES

American Psychiatric Association and the World Psychiatric Association

Chp.: Marcia Kraft Goin, M.D.
Co-Chp.: Rodrigo A. Munoz, M.D.

A Wars and Mental Health in Iraq
Abdul M. Al-Jadiry, M.D.

B Mental Health in Iraq and the U.S. Military
Elspeth C. Ritchie, M.D.

C Strategies for Post-War Rehabilitation of Mental Health Services: Focusing on Iraq
Ahmed Okasha, M.D.

Discussants: Norman Sartorius, M.D., Norwood Knight-Richardson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

RE VIEW OF PSY CHIATRY: SECO ND 4

2:00 p.m.-5:30 p.m.
Special Events Hall 1D, Level 1, Javits Center

DEEP BRAIN STIMULATION IN PSYCHIATRIC TREATMENT

Chp.: Sarah H. Lisanby, M.D.

16 Transcranial Magnetic Stimulation in Depression
Thomas E. Schlaepfer, M.D., Markus Kosel, M.D.

17 Transcranial Magnetic Stimulation Studies of Schizophrenia and Other Disorders
Ralph E. Hoffman, M.D.

18 Deep Brain Stimulation in Psychiatry
Benjamin D. Greenberg, M.D.

19 Vagus Nerve Stimulation in Psychiatry
Harold A. Sackeim, Ph.D.

20 Magnetic Seizure Therapy: Development of a Novel Convulsive Technique
Sarah H. Lisanby, M.D.
SYMPOSIA 59-89

SYMPOSIUM 59 2:00 p.m.-5:00 p.m.
Rooms 1E01/2, Level 1, Javits Center

WHAT YOU NEED TO KNOW ABOUT TREATMENT OF HIV-RELATED DISORDERS

Chp.: Marshall Forstein, M.D.

A Treating Mood Disorders
Warren M. Liang, M.D.

B Treating Anxiety
Antoine B. Douaihy, M.D.

C Treating Psychosis
Shahrad Rod Amiri, M.D.

D Treating Sleep
Marshall Forstein, M.D.

E Treating Pain
Philip Bialer, M.D.

THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 60 2:00 p.m.-5:00 p.m.
Rooms 1E03/4/5, Level 1, Javits Center

CHOOSING THE BEST TREATMENT FOR SUBSTANCE ABUSE
Collaborative Session With the National Institute on Drug Abuse

Chp.: Herbert D. Kleber, M.D.
Co-Chp.: David M. McDowell, M.D.

A Choosing the Right Treatment for Opioid Dependence
Herbert D. Kleber, M.D.

B Choosing the Best Treatment for Cocaine Dependence
Adam M. Bisaga, M.D.

C Choosing the Best Treatment: Marijuana and Club Drugs
David M. McDowell, M.D.

D Treatment of Comorbid Conditions
Frances R. Levin, M.D., Suzette M. Evans, Ph.D., Herbert D. Kleber, M.D.

E Choosing the Best Treatment for Psychosocial Interventions
Jami Rothenberg, Ph.D.

Discussant: Edward V. Nunes, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 61 2:00 p.m.-5:00 p.m.
Room 1E09, Level 1, Javits Center

PRACTICAL TECHNIQUES IN THE ASSESSMENT AND TREATMENT OF TOBACCO DEPENDENCE
Collaborative Session With the National Institute on Drug Abuse

Chp.: Jill Williams, M.D.

A Assessment of Tobacco Dependence
Jonathan Foulds, Ph.D.

B Motivational Assessment and Enhancement Strategies in Tobacco Treatment
Jonathan Krejci, Ph.D.

C Pharmacotherapy Treatments for Tobacco Dependence
Jill Williams, M.D.

D Psychosocial Treatment of Tobacco Dependence in Mental Health Settings
Marc L. Steinberg, Ph.D.

E Addressing Tobacco Through Program and System Changes
Douglas M. Ziedonis, M.D.

THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 62 2:00 p.m.-5:00 p.m.
Room 1E10, Level 1, Javits Center

TREATMENT-RESISTANT DEPRESSION

Chp.: Charles B. Nemeroff, M.D.

A Introduction to Treatment-Resistant Depression
Charles B. Nemeroff, M.D.

B Long-Term Outcomes in Treatment-Resistant Depression
A. John Rush, M.D.

C Introduction to a Treatment-Resistant Depression Patient Registry
Martin B. Keller, M.D.

D Long-Term Treatment and Outcomes in Treatment-Resistant Depression With Pharmacotherapy, ECT, Repetitive Transcranial Magnetic Stimulation, MST, and VNS Therapy
Thomas E. Schlaepfer, M.D.

THIS SESSION WILL BE AUDIOTAPEd.
SYMPOSIUM 63 2:00 p.m.-5:00 p.m.
Room IE 12, Level 1, Javits Center

PSYCHOTIC DEPRESSION IN 2004: THE NIMH COLLABORATIVE SEVERE DEPRESSION STUDY

Chp.: Barnett S. Meyers, M.D.

A Challenges in the Diagnosis of Psychotic Depression: Assessment, Epidemiology, and Biology
Anthony J. Rothschild, M.D., Michael A. Bell, M.D., Jayendra K. Patel, M.D., David P. Morin, M.D., Dorothy Sit, M.D., Colby Calkins, B.S., Denette Guerin, M.S.

B Pharmacotherapy of Unipolar Major Depression: What Is the Evidence?
Benoit H. Mulsant, M.D., Robert H. Howland, M.D., Michael E. Thase, M.D., Mary C. McShea, M.S., Taafoi S. Kamara, B.A.

C NIMH Severe Depression Trial: Background and Design Choices
Barnett S. Meyers, M.D., Sibel Klimstra, M.D., Catherine Peasley-Mikus, Ph.D., Michelle Gabriele, M.S.W., Judith English, B.S.C., MoonSeong Heo, Ph.D., Melissa Carroll, Ph.D.

D Challenges in Conducting a Pharmacotherapy Study in Psychotic Depression
Alastair J. Flint, M.B.

E Real-Life Outcomes in Real-Life Patients: Discussion
Barry D. Lebowitz, Ph.D.

Discussant: Barry D. Lebowitz, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 64 2:00 p.m.-5:00 p.m.
Room IE 13, Level 1, Javits Center

SEPTEMBER 11TH: AFTER TWO-AND-A-HALF YEARS
Chp.: Zebulon C. Taintor, M.D.

A The First Two Weeks Onsite
Antonio Abad, M.D.

B New York State Office of Mental Health Response
William M. Tucker, M.D.

C New York City Health and Mental Health: First Responders
Neal L. Cohen, M.D.

D Disaster Psychiatry Outreach: Service and Training
Craig L. Katz, M.D.

E Medical and Psychiatric Organizations and Findings
Zebulon C. Taintor, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 65 2:00 p.m.-5:00 p.m.
Room IE 14, Level 1, Javits Center

NEUROIMAGING AND EMOTIONAL DYSREGULATION IN BPD

Chp.: Kenneth R. Silk, M.D.
Co-Chp.: Martin Bohus, M.D.

A Brain Imaging of Impulsivity and Affective Instability in BPD
Larry J. Siever, M.D., Antonia S. New, M.D., Monte S. Buchsbaum, M.D., W. Gordon Frankle, M.D., Harold W. Koenigsberg, M.D., Isak Prohovnik, Ph.D., Marc Laruelle, M.D.

B Affect Regulation and BPD: fMRI and Daily Experience of Mood
Katherine M. Putnam, Ph.D.

C Emotional Processing of Psychosocial Stimuli in BPD
Jill M. Hooley, D.Phl., Deborah A. Yurgelun-Todd, Ph.D., Staci A. Gruber, Ph.D.

D Investigation of Pain Processing in BPD
Christian G. Schmahl, M.D., Martin Bohus, M.D.

E A PET Study of u-Opioid Neurotransmission and Affective Lability in BPD
Kenneth R. Silk, M.D., Jon-Kar Zubieta, M.D., Robert Koepp, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 66 2:00 p.m.-5:00 p.m.
Room IE 16, Level 1, Javits Center

DIAGNOSING AND MANAGING AGGRESSIVE MOOD-DYSREGULATED YOUTH

Chp.: Joseph Biederman, M.D.

A Parsing the Association Between Bipolar, Conduct, and Substance Use Disorders
Joseph Biederman, M.D., Stephen V. Faraone, Ph.D., Janet Wozniak, M.D., Michael Monuteaux, Sc.D.

B A Family Genetic Perspective on Childhood Mania
Stephen V. Faraone, Ph.D.

C Risperidone Treatment of Affective Symptoms in Mentally Retarded Youth With Conduct Disorder
Eric Mick, Sc.D., Joseph Biederman, M.D., Georges Gharabawi, M.D., Stephen V. Faraone, Ph.D., Gahan J. Pandina, Ph.D.

D Clinical Trials of a Mood Stabilizer for Aggressive, Mood-Dysregulated Youth
Janet Wozniak, M.D.

(Continued on next page)
E Collaborative Problem-Solving Therapy for Aggressive Youth
  Ross W. Greene, Ph.D.

F Anticonvulsants in the Management of Aggression in Youth
  Joseph M. Gonzalez-Heydrich, M.D.

SYMPOSIUM 69  2:00 p.m.-5:00 p.m.
Room 3D03/10, Level 3, Javits Center
SUPPORTIVE PSYCHOTHERAPY: AN UPDATE
Chp.: Roger Peele, M.D.
Co-Chp.: Maryam Razavi, M.D.

A History of Supportive Psychotherapy
  Stephen Rojcewicz, Jr., M.D.

B Role of Psychotherapy in the Management of Depression
  Michael E. Thase, M.D.

C Use of Supportive Psychotherapy With Bipolar Disorder
  Karen L. Swartz, M.D.

D Adapting Supportive Therapy for Treatment of BPD
  David J. Hellerstein, M.D., Ron B. Aviram, Ph.D., Jessica Gerson, Ph.D., Kimberly Kotov, Ph.D., Barbara H. Stanley, Ph.D.

E Development of Competencies in Supportive Therapy: Process and Problems
  Lisa A. Mellman, M.D.

Discussants: Henry Pinsker, M.D., Julia B. Frank, M.D.

SYMPOSIUM 70  2:00 p.m.-5:00 p.m.
Rooms 3D04/9, Level 3, Javits Center
ANXIETY DISORDERS IN YOUTH: CLINICAL AND RESEARCH UPDATES
Chp.: Marcia J. Slattery, M.D.

A Evidence-Based Assessment Instruments With Children and Adolescents
  Thomas H. Ollendick, Ph.D.

B Pharmacological Treatment of Anxiety Disorder in Youth
  Marcia J. Slattery, M.D.

C Anxiety Disorders in Children and Adolescents: Are We Ready To Move Beyond The Study of Treatment Efficacy?
  Anne Marie Albano, Ph.D.

D A Cognitive Neuroscience Perspective on Childhood Anxiety Disorders
  Amy L. Krain, Ph.D.

Discussants: Donna E. Stewart, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 71 2:00 p.m.-5:00 p.m.
Rooms 3D05/8, Level 3, Javits Center

DSM-V CLASSIFICATION OF PERSONALITY DISORDERS: THE WHITE PAPER AND BEYOND
Chp.: Michael B. First, M.D.

A Dimensional Models of Personality Disorder
Thomas A. Widiger, Ph.D.

B Relationship of Personality Traits and Disorders to Axis I Disorders
M. Tracie Shea, Ph.D.

C Axis I/Axis II Boundary: Spectrum Diseases and Molecular Neuroscience
John H. Krystal, M.D., Robert T. Malison, M.D., Jaakko A. Lappalainen, M.D., Joel Gelernter, M.D.

D Temperament, Personality, and Personality Disorder: The Externalizing Spectrum Model
Robert F. Krueger, Ph.D.

E The Neurobiology of Personality Traits: Focus on Aggression
Emil F. Coccaro, M.D.

THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 73 2:00 p.m.-5:00 p.m.
Odets Room, Fourth Floor, Marriott Marquis

DISSOCIATIVE DISORDERS: ISSUES OF CULTURE AND ISSUES OF TRUST
Association for the Advancement of Philosophy and Psychiatry
Chp.: Deborah Spitz, M.D.

A Diversity in Presentation of Dissociative Disorders in Turkey
Vedat Sar, M.D.

B Differences Between Western and South African Models of Dissociation
Christa Kruger, M.D.

C Dissociation, Trances, and Transcendence: Cultural Values and Their Effects on Trust
Nancy L. Potter, Ph.D.

THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 72 2:00 p.m.-5:00 p.m.
Rooms 3D06/7, Level 3, Javits Center

GROUP THERAPY IN MEDICAL/PSYCHIATRIC CARE
Chp.: David Spiegel, M.D.

A Group Therapy for Breast Cancer: Feeling and Healing
David Spiegel, M.D., Janine Giese-Davis, Ph.D., Lisa D. Butler, Ph.D., Catherine Classen, Ph.D., Cheryl Koopman, Ph.D.

B Impact of Group Therapy on Anticancer Treatment Adherence
David W. Kissane, M.D., David M. Clarke, Ph.D., Graeme C. Smith, M.D., Brenda Grabsch, B.S.W.

C Mindfulness-Based Stress-Reduction Groups
Susan E. Abbey, M.D.

D Psychiatrist-Led Group Psychotherapy for the Chronically Mentally Ill
Leslie H. Gise, M.D., Annette Crisanti, Ph.D., Robert Randall, Ph.D., Dana Kiyabu, R.N., Travis Ho, B.A.

E Group Therapy for Substance Abuse
David W. Brook, M.D.

F Group Interventions for Psychological Trauma and Terrorism
Henry I. Spitz, M.D.

Discussant: Henry Grunebaum, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 74 2:00 p.m.-5:00 p.m.
O'Neill Room, Fourth Floor, Marriott Marquis

NEUROPSYCHIATRY OF TRAUMATIC BRAIN INJURY: CURRENT RESEARCH
American Neuropsychiatric Association
Chp.: Jonathan M. Silver, M.D.

A The Cholinergic Hypothesis of Cognitive Impairment Due to Traumatic Brain Injury
David B. Arciniegas, M.D.

B Catecholaminergic Dysfunction After Traumatic Brain Injury: Impact on Cognition
Thomas McAllister, M.D., Laura Flashman, Ph.D., Brenna McDonald, Psy.D., Heather Washart, Ph.D., Richard B. Ferrell, M.D., Andrew Saykin, Psy.D.

C Traumatic Brain Injury, Gene Expression, and Risk for Schizophrenia
Dolores Malaspina, M.D., Cheryl M. Corcoran, M.D., Jill Hartlavy-Friedman, Ph.D., Raymond Goetz, Ph.D., David J. Prinz, M.D., Roberto Gil, M.D.

(Continued on next page)
D Blast Injuries to the Brain: Armed Forces Injured During Operation Iraqi Freedom
Deborah Lee Warden, M.D., Louis M. French, Psy.D., Elisabeth Moyer-Martin, R.N.C, Robert J. Labutta, M.D., James M. Ecklund, M.D.

E Multicenter, Placebo-Controlled Trials in Traumatic Brain Injury: A Work in Progress
Jonathan M. Silver, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 75 2:00 p.m.-5:00 p.m.
Wilder Room, Fourth Floor, Marriott Marquis

PSYCHIATRY, ETHNICITY, AND CULTURE: AN UPDATE ON ETHNOPSYCHOPHARMACOLOGY, MOOD, AND ANXIETY DISORDERS IN MINORITY POPULATIONS

Chp.: Shamsah B. Sonawalla, M.D.
Co-Chp.: Rajesh M. Parikh, M.D.

A Ethnopsychopharmacology Update
David C. Henderson, M.D.

B Treatment of Anxiety and Depression Among Chinese Americans
Albert Yeung, M.D.

C Psychiatric Management of Hispanic Patients: Cross-Cultural Issues and Ethnopsychopharmacology
David Mischoulon, M.D.

D Depression and Anxiety in Women: An Update on Cross-Cultural Aspects and Pharmacologic Strategies
Claudio N. Soares, M.D.

E Cultural Differences in the Diagnosis and Treatment of Mood and Anxiety Disorders: Considerations in the Asian Indian Population
Rajesh M. Parikh, M.D., Shamsah B. Sonawalla, M.D.

Discussant: Jerrold F. Rosenbaum, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 76 2:00 p.m.-5:00 p.m.
Ziegfeld Room, Fourth Floor, Marriott Marquis

ADOPTING EVIDENCE-BASED PRACTICE IN THE TREATMENT OF MOOD DISORDERS: THE CANADIAN EXPERIENCE

Chp.: Sidney H. Kennedy, M.D.
Co-Chp.: Roumen V. Milev, M.D.

A Treating Depression Effectively: Applying Clinical Guidelines
Sidney H. Kennedy, M.D.

B Strategies to Enhance Mental Health Care in the Primary Care Sector: Working With Family Physicians
Sagar V. Parikh, M.D.

C Evidence-Based Practice Leads to Improved Efficiency in the Work of a Specialized Mood-Disorders Service
Roumen V. Milev, M.D., Gaby Abraham, M.D., Fia Voutsilakos, M.D.

D Translating Research Into Practice: The Application of Clinical Guidelines in Mood Disorders
Valerie Taylor, M.D., Glenda M. MacQueen, M.D.

E Developing a Community-Based Strategy for Depression: The British Columbia Experience
Raymond W. Lam, M.D., Elliot M. Goldner, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 77 2:00 p.m.-5:00 p.m.
Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

IMPACT OF TRAUMA AND LIFE STRESS IN BIPOLAR DISORDER

Chp.: Joseph F. Goldberg, M.D.
Co-Chp.: David Miklowitz, Ph.D.

A Psychosocial Stress and Vulnerability to Affective Relapse
Michael J. Gitlin, M.D.

B Childhood Trauma and Outcome in Bipolar Patients
Joseph F. Goldberg, M.D., Jessica L. Garno, Ph.D.

C Bipolar Disorder and the Family Environment
David Miklowitz, Ph.D.

D Neurofunctional Correlates of Affective Stressors in Bipolar Patients
Caleb M. Adler, M.D., Stephen M. Strakowski, M.D., Scott Holland, Ph.D., Melissa P. DelBello, M.D.

E Implications of the Kindling Model for Affective Relapse
Robert M. Post, M.D., Gabriele S. Leverich, L.C.S.W., Andrew M. Speer, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 78 2:00 p.m.-5:00 p.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

GAY AND LESBIAN ORTHODOX JEWS: A PRIMER FOR CLINICIANS

Chp.: Jack Drescher, M.D.

A Orthodox Jewish Gays and Lesbians: The Filmmaker's Perspective
Sandi Dubowski
B Failed Reparative Therapy of Orthodox Jewish Homosexual Men and Women
Abba E. Borowich, M.D.

C Identities in Conflict: Treating Gay and Lesbian Orthodox Jews
Naomi Mark, M.S.W.

D Gayness and God: The Gay Orthodox Rabbi’s Perspective
Steven Greenberg

Discussant: Paul S. Appelbaum, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 79 2:00 p.m.-5:00 p.m.
Booth/Edison Rooms, Fifth Floor, Marriott Marquis

PERSONALITY, THERAPEUTIC ALLIANCE, AND OUTCOME IN BRIEF PSYCHOTHERAPY

Chp.: Arnold Winston, M.D.
Co-Chp.: J. Christopher Muran, Ph.D.

A Personality, Therapeutic Alliance, and Outcome in Short-Term Dynamic and Cognitive-Behavioral Psychotherapies
Sarah L. Aderholt, M.D., Elena Bruck, M.D., J. Christopher Muran, Ph.D., Arnold Winston, M.D.

B Personality, Therapeutic Alliance, and Overall Outcome in Brief Relational Therapy
Regina Biscoglio, M.A., J. Christopher Muran, Ph.D., Paul Watchel, Ph.D., Bernard S. Gorman, Ph.D.

C Patient-Rated Alliance and Overall Outcome in Brief Psychotherapies
Christopher Stevens, Ph.D., J. Christopher Muran, Ph.D., Jeremy D. Safran, Ph.D., Bernard S. Gorman, Ph.D.

D Therapist-Rated Alliance and Overall Outcome in Brief Psychotherapies
Kevin Gillett, J. Christopher Muran, Ph.D., Bernard S. Gorman, Ph.D., Karen Riggs-Skean, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 80 2:00 p.m.-5:00 p.m.
Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis

CONSEQUENCES AND TREATMENT OF MARIJUANA ABUSE
Collaborative Session With the National Institute on Drug Abuse

Chp.: Susan R.B. Weiss, Ph.D.
Co-Chp.: Jag Khalsa, Ph.D.

A Cognitive Toxicity of Cannabis: The Devil Is in the Confounding Variables
Harrison G. Pope, Jr., M.D., Deborah A. Yurgelun-Todd, Ph.D.

B Cognitive Effects in Adolescents Exposed Prenatally to Marijuana or Cigarettes
Peter A. Fried, Ph.D.

C Effects of Chronic Marijuana Use and THC on Brain Function in Humans: A fmRI Study
Alan S. Bloom, Ph.D.

D Behavioral and Treatment Research on Marijuana Withdrawal and Dependence
Alan J. Budney, Ph.D.

E The Endogenous Cannabinoids and the Control of Drug Craving
Billy R. Martin, Ph.D.

Discussant: Billy R. Martin, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 81 2:00 p.m.-5:00 p.m.
Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

PERSONALITY DISORDERS: MULTIPLE PERSPECTIVES IN THE UNDERSTANDING AND TREATMENT OF RESISTANCE

Chp.: Joseph DiGiacomo, M.D.

A Resistance in Personality Disorders From a Psychodynamic Perspective
R. Rao Gogineni, M.D.

B Resistance in BPD: Cognitive-Behavioral Strategies That Facilitate Change
Donna M. Sudak, M.D.

C Family Therapy With Personality Disorders
G. Pirooz Sholevar, M.D.

D Clinical Practices That Lead to Treatment Resistance
William R. Dubin, M.D.

Discussant: Thomas S. Newmark, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 82 2:00 p.m.-5:00 p.m.
Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis

CLINICAL CONTROVERSIES IN ECT

Chp.: Conrad M. Swartz, M.D.

A Controversies in ECT: Electrode Placement
Conrad M. Swartz, M.D.

B Controversies in ECT: Stimulus Dosing
W. Vaughn McCall, M.D.

(Continued on next page)
WEDNESDAY

SYMPOSIUM 85 2:00 p.m.-5:00 p.m.
Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

DRUG ABUSE TREATMENT ISSUES IN WOMEN
Collaborative Session With the National Institute on Drug Abuse

Chp.: Cora Lee Wetherington, Ph.D.

A Gender Differences in Treatment Needs, Services, Utilization, and Outcomes
Karol A. Kaltenbach, Ph.D.

B Treatment Issues in Drug-Dependent Women With Comorbid Depression
Rajita Sinha, Ph.D.

C Trauma and PTSD: Issues in the Treatment of Drug-Dependent Women
Denise Hien, Ph.D.

D Drug-Dependent Women With Partner Violence: Treatment Issues
Brenda A. Miller, Ph.D., Linda P. King, Ph.D., Eugene Maguin, Ph.D., Nancy J. Smyth, Ph.D.

E Drug-Treatment Issues in Drug-Dependent, Pregnant Women
Hendree Jones, Ph.D.

Discussant: Kathleen T. Brady, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 86 2:00 p.m.-5:00 p.m.
Herald/Soho Rooms, Seventh Floor, Marriott Marquis

MANAGING HIPAA-RELATED TENSIONS IN CLINICAL PRACTICE

Chp.: John O. Bearrs, M.D.

A Intended and Actual Effects of HIPAA on Clinical Practice
Claudette H. Bearrs, M.S.W.

B The Impact of HIPAA on Psychiatric Hospital Care: The Good, the Bad, and the Ugly
Steven S. Sharfeinstein, M.D., Robert P. Roca, M.D., Angela Niparko, Erin Scally

C Regulation, HIPAA, and the Quest for Optimum Constraint
John O. Bearrs, M.D.

D Complying With HIPAA Made Less Difficult
Jeffrey L. Metzner, M.D.

Discussant: Harold I. Eist, M.D.
THIS SESSION WILL BE AUDIOTAPE D.
SYMPOSIUM 87  2:00 p.m.-5:00 p.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

MEMORY IN THE U.S. AND FRANCE: VIVE LA DIFFERENCE

Chp.: John A. Talbott, M.D.
Co-Chp.: Francois C. Petitjean, M.D.

A  What Can We Learn From the False-Memory Wars?
Paul R. McHugh, M.D.

B  PTSD: Too Much or Too Little Memory?
Anne-Marie F. Pezous, M.D., Barbara Cochet, Eric Guillem, M.D., Saena Bouchez, M.D., Jean-Pierre Lepine, Ph.D.

C  The Nature of Traumatic Memory: Implications for Treatment
Bessel A. Van Der Kolk, M.D.

D  Depression and Dementia: Looking for Specific Memory Impairments
Eric Fakra, M.D., Bernard Michel, M.D., Jean-Michel Azorin, M.D.

E  Cognitive Impairment in Late-Life Depression
Charles F. Reynolds III, M.D., Meryl A. Butters, Ph.D.

F  Depression: Remembering the Bad Things
Natacha Fouilhoux, M.D., Francois C. Petitjean, M.D.

Discussant: Alexandra Malean, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 88  2:00 p.m.-5:00 p.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

QUALITY OF CARE FOR CHILDREN: MULTIPLE PERSPECTIVES

Chp.: Bonnie T. Zima, M.D.

A  Quality of Care From the Agency's Perspective: Are Medicaid Claims Data Valid?
Penelope Knapp, M.D., Bonnie T. Zima, M.D., Michael Hulburt, Ph.D., Lingqi Tang, Ph.D., Heather Ladd, M.S., Naihua Duan, Ph.D., Kenneth B. Wells, M.D.

B  Quality of Care for Children in Outpatient Mental Health Programs
Bonnie T. Zima, M.D., Michael Hulburt, Ph.D., Penelope Knapp, M.D., Lingqi Tang, Ph.D., Heather Ladd, M.S., Naihua Duan, Ph.D., Kenneth B. Wells, M.D.

C  Unraveling Variations in Access to ADHD Care: Deductive Analysis Findings
Regina Bussing, M.D., Mirka K. Ljungberg, Ph.D., Cynthia Garvan, Ph.D., Dana Mason, B.S., Christine Leon, M.A.

D  Quality Improvement of Mental Health Services for Children in Special Education
Sheryl H. Kataoka, M.D., Jeanne Miranda, Ph.D.

Discussant: John M. Oldham, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 89  2:00 p.m.-5:00 p.m.
Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis

MEETING THE MENTAL HEALTH NEEDS OF LATINOS IN COMMUNITY AND PRIMARY CARE

Chp.: Myrna M. Weissman, Ph.D.
Co-Chp.: Amarendra Das, M.D.

A  PTSD in Latinos: Reactions in Primary Care to the World Trade Center Attacks
Yuval Y. Neria, Ph.D., Amarendra Das, M.D., Rafael Lantigua, M.D., Marc J. Gameroff, Ph.D., Mark Olfson, M.D., Adriana Feder, M.D., Myrna M. Weissman, Ph.D.

B  Depression and Diabetes in an Urban General Medicine Clinic
Raz Gross, M.D., Mark Olfson, M.D., Marc J. Gameroff, Ph.D., Olveen Carrasquillo, M.D., Steven Shea, M.A, Rafael Lantigua, M.D., Myrna M. Weissman, Ph.D.

C  Bipolar Spectrum Disorder in Hispanic Primary Care Patients
Amarendra Das, M.D., Marc J. Gameroff, Ph.D., Rafael Lantigua, M.D., Steven Shea, M.A., Mark Olfson, M.D., Myrna M. Weissman, Ph.D.

D  Disparities in Mental Health Treatment for Latinos in Community Care
William Vega, Shula Minsky, Ed.D., Michael Gara, Ph.D., Theresa M. Miskimen, M.D.

Discussant: Roberto Lewis-Fernandez, M.D.
THIS SESSION WILL BE AUDIOTAPED.
3:00 p.m. Sessions

NEW RESEARCH POSTER SESSION 9
3:00 p.m.-5:00 p.m.
Galleria, Level 4, Javits Center

MOOD DISORDERS

For further information on New Research Sessions, please refer to the New Research Program Book included in your registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 52-54

INDUSTRY-SUPPORTED SYMPOSIUM 52
7:00 p.m.-10:00 p.m.
Grand Ballroom East, Third Floor, Hilton New York

OPTIMIZING ANTIPSYCHOTIC TREATMENT IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER
Supported by Bristol-Myers Squibb Company

Chp.: Rajiv Tandon, M.D.

A Optimizing Pharmacotherapy for Maximized Outcomes
   Alan J. Mendelowitz, M.D.

B Keeping Tolerability in Mind: Ensuring Adherence to Maintain Recovery
   Henry A. Nasrallah, M.D.

C Finding Effectiveness Across Patient Age Groups
   Rajiv Tandon, M.D.

D Balancing the Efficacy and Tolerability for Pediatric Bipolar Disorder
   Melissa P. DelBello, M.D.

E Treatment Considerations in Special Populations: Sex Differences
   Diana O. Perkins, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 53
7:00 p.m.-10:00 p.m.
Imperial Ballroom A, Second Floor, Sheraton New York

CORE SYMPTOM DOMAINS IN THE ANXIETY DISORDERS
Supported by Wyeth Pharmaceuticals

Chp.: Michael R. Liebowitz, M.D.
Co-Chp.: Eric Hollander, M.D.

A Differential Diagnosis and Biology of Panic and GAD
   Jack M. Gorman, M.D.

B Symptoms and Biologic Correlates of PTSD: From Early Adulthood to Old Age
   Rachel Yehuda, Ph.D.

C The Social Anxiety Spectrum
   Michael R. Liebowitz, M.D., Franklin R. Schneier, M.D.,
   Jonathan E. Shaywitz, M.D.

D The Repetitive Behavior Domain in Obsessive-Compulsive and Developmental Disorders
   Eric Hollander, M.D., Stacey Wasserman, M.D.

E Mixed Anxiety and Depression: A Gordian Knot
   Joseph Zohar, M.D., Yehuda Sasson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 54
7:00 p.m.-10:00 p.m.
Imperial Ballroom B, Second Floor, Sheraton New York

BACK TO THE FUTURE: THE ROLE OF GAMMA-AMINOBUTYRIC ACID IN PSYCHIATRIC DISORDERS AND TREATMENT
Supported by Cephalon, Inc.

Chp.: Mark H. Pollack, M.D.

A Gamma-Aminobutyric Acid in the CNS
   Philip T. Ninan, M.D.

B Neuroimaging and Anxiety
   Justine M. Kent, M.D.

C Gamma-Aminobutyric Acidergic Agents in Anxiety Treatment: A Look Back and Ahead
   Mark H. Pollack, M.D.

D Emerging Gamma-Aminobutyric Acidergic Targets for Insomnia
   John W. Winkelman, M.D.

E Beyond Anxiety Disorders: The Role of Gamma-Aminobutyric Acid in Mood Disorders
   Naomi M. Simon, M.D.
THURSDAY, MAY 6, 2004
157TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 50-51

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 50, PART 2
7:00 a.m.-8:30 a.m.
Imperial Ballroom A, Second Floor, Sheraton New York

PTSD: SEARCHING FOR ANSWERS IN TRAUMATIC TIMES
Supported by Cephalon, Inc.

Chp.: Jonathan R.T. Davidson, M.D.

A Treatment and Prevention of Chronic PTSD: Psychosocial Approaches
Edna B. Foa, Ph.D.

B Novel Drug Treatments for PTSD Beyond SSRIs
Wei Zhang, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 51, PART 2
7:00 a.m.-8:30 a.m.
Imperial Ballroom B, Second Floor, Sheraton New York

BIPOLAR DISORDER IN WOMEN: REPRODUCTIVE IMPLICATIONS OF TREATMENT
Supported by GlaxoSmithKline

Chp.: Adele C. Viguera, M.D.
Co-Chp.: Lee S. Cohen, M.D.

A Use of Antiepileptic Medications in Women
Martha J. Morrell, M.D.

B Reproductive Endocrine Consequences of Treatment
Hadine Joffe, M.D.

8:00 a.m. Sessions

COURSES 98-100
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 98 8:00 a.m.-12 noon
Concourse A, Concourse Level, Hilton New York

INTRODUCTION TO TRANSCRANIAL MAGNETIC STIMULATION (TMS)

Co-Directors: Ziad H. Nahas, M.D., Leon J. Grunhaus, M.D.
Faculty: Sarah H. Lisanby, M.D., Ehud M. Klein, M.D.

COURSE 99 8:00 a.m.-12 noon
Bryant Suite, Second Floor, Hilton New York

ONLINE COMMUNICATION IN MENTAL HEALTH: DIFFERENT CONTEXTS, DIFFERENT ISSUES

Director: Robert C. Hsiung, M.D.
Faculty: Ivan K. Goldberg, M.D., Alfred Herzog, M.D.,
Ronald W. Pies, M.D., Joel Yager, M.D.,
Elizabeth Zelvin, A.C.S.W.

COURSE 100 8:00 a.m.-12 noon
Sutton North, Second Floor, Hilton New York

NEUROPSYCHIATRY OF TRAUMATIC BRAIN INJURY
American Neuropsychiatric Association

Director: David B. Arciniega, M.D.
Faculty: Thomas McAllister, M.D., Jonathan M. Silver, M.D.

9:00 a.m. Sessions

CONTINUOUS CLINICAL CASE CONFERENCE 2: PART 2
9:00 a.m.-12 noon
Rooms 3D01/12, Level 3, Javits Center

TWO HOSPITALIZED PATIENTS WITH REFRACTORY MOOD DISORDER AND COGNITIVE IMPAIRMENT

Moderator: Stuart C. Yudofsky, M.D.
Presenters: Richard L. Munich, M.D., Efram Bleiberg, M.D.,
Lauren B. Marangell, M.D., Alice Rogan, M.D., Florence Kim, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.
THURSDAY

LECTURE 25
9:00 a.m.-10:30 a.m.
Rooms 1E07/8, Level 1, Javits Center
Godfrey D. Pearlson, M.D.

Through the Looking Glass: Uses of Simulation and Virtual Reality in Clinical Practice and Brain Imaging Research

Chp.: Mahmoud A. Mohamed, M.D.
Co-Chp.: Maria A. Oquendo, M.D.

The concept of virtual reality goes back almost 40 years, but only recently have advances in computing and associated hardware allowed for clinical applicability. Godfrey D. Pearlson, M.D., reviews current achievements, caveats, and future prospects of virtual reality applications in psychiatry, including uses in the treatment of phobias and eating disorders, assessment and rehabilitation, and as stimuli in brain imaging studies of complex behaviors such as driving, substance abuse, and pathological gambling. Dr. Pearlson is Professor of Psychiatry at Yale University School of Medicine in New Haven, Connecticut, and Director of the Olin Neuropsychiatry Research Center at the Institute of Living in Hartford, Connecticut. His work in psychiatric neuroimaging has spanned the investigation of Alzheimer's Disease, Huntington's Disease, schizophrenia, bipolar disorder, neurodevelopmental disorders, and normal aging. He is the author of over 200 scientific papers and book chapters. Dr. Pearlson founded and formerly directed the Psychiatry Neuroimaging Laboratory at Johns Hopkins University School of Medicine in Baltimore, Maryland. A Distinguished Fellow of the American Psychiatric Association, Dr. Pearlson has received the Ziskind-Somerfeld Research Award of the Society of Biological Psychiatry and the Distinguished Investigator Award of the National Alliance for Research on Schizophrenia and Depression. He received his medical degree from the Newcastle Upon Tyne University Medical School in Newcastle Upon Tyne, England.

MASTER EDUCATOR CLINICAL CONSULTATION 12
9:00 a.m.-10:30 a.m.

This session is limited to 25 participants on a first-come, first-served basis.

Iqbal Ahmed, M.D., on Psychiatric Disorders in the Elderly
Room ID04, Level 1, Javits Center

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

WORKSHOPS

COMPONENT WORKSHOP 49
9:00 a.m.-10:30 a.m.
Rooms 1E01/2, Level 1, Javits Center

THE BLAME AND SHAME GAME IN MEDICAL ERRORS: DO YOU WANT TO PLAY IT?
APA Committee on Patient Safety

Co-Chps.: Geetha Jayaram, M.D., Benjamin C. Grasso, M.D.
Participants: David M. McDowell, M.D., Robert Michels, M.D.

ISSUES 120-137

ISSUE WORKSHOP 120
9:00 a.m.-10:30 a.m.
Rooms 1E03/4/5, Level 1, Javits Center

THE HORNS OF A DILEMMA: MYTHS AND REALITIES OF DRUG-INDUSTRY INTERACTION

Chp.: John W. Burruss, M.D.
Participants: Woodie M. Zachry, Ph.D., Ali A. Asghar-Ali, M.D.

ISSUE WORKSHOP 121
9:00 a.m.-10:30 a.m.
Room 1E09, Level 1, Javits Center

GROUP PSYCHOTHERAPY WITH SUBSTANCE ABUSERS
American Group Psychotherapy Association

Co-Chps.: David W. Brook, M.D., Henry I. Spitz, M.D.
THURSDAY

ISSUE WORKSHOP 122  9:00 a.m.-10:30 a.m.
Room IE 11, Level 1, Javits Center

MILIEU THERAPIES IN THE AGE OF MANAGED CARE, REVISITED

Chp.: C. Deborah Cross, M.D.
Participants: Howard D. Kibel, M.D., Saul Scheidlinger, Ph.D., Janet A. Bezmen, R.N.

ISSUE WORKSHOP 123  9:00 a.m.-10:30 a.m.
Room IE 12, Level 1, Javits Center

PSYCHIATRIC CONSULTATION REPORTS IN MINUTES: EXPLORING NEW TECHNOLOGIES

Chp.: Henry H. Leung, M.D.
Participant: Anna E. Rogers, M.D.

ISSUE WORKSHOP 124  9:00 a.m.-10:30 a.m.
Room IE 14, Level 1, Javits Center

A COMPREHENSIVE APPROACH TO THE TREATMENT OF PAIN IN HIV ILLNESS

Chp.: David G. Krefetz, D.O.

ISSUE WORKSHOP 125  9:00 a.m.-10:30 a.m.
Room IE 16, Level 1, Javits Center

DETECTION OF MALINGERING

Chp.: Alan R. Hirsch, M.D.
Participants: David E. Hartman, Ph.D., Paul Ekman, Ph.D., Carl M. Wahlstrom, Jr., M.D.

ISSUE WORKSHOP 126  9:00 a.m.-10:30 a.m.
Rooms 2D10/11, Level 2, Javits Center

CAN SOCIAL THEORY BE INTEGRATED INTO THE LIBERATORY GOALS OF PSYCHIATRY?

Co-Chps.: Carl I. Cohen, M.D., Kenneth S. Thompson, M.D.
Participants: Astrid N. Rusquellas, M.D., Bradley E. Lewis, M.D., Sami Timimi

ISSUE WORKSHOP 127  9:00 a.m.-10:30 a.m.
Rooms 2D14/15, Level 2, Javits Center

TREATMENT-RESISTANT PATIENTS WITH BULIMIA NERVOSA

Co-Chps.: Edi Cooke, Psy.D., Frampton Gwynette, M.D.
Participants: Nettie Levine, R.D., Waguih W. Ishak, M.D., Antonia Noble-Ludwig, M.F.T.

ISSUE WORKSHOP 128  9:00 a.m.-10:30 a.m.
O'Neill Room, Fourth Floor, Marriott Marquis

LEASH ON LIFE: HUMAN ATTACHMENT TO ANIMALS

Chp.: Debra A. Katz, M.D.
Participants: Jon Katz, Dehra A. Glueck, M.D., Tagalie Heister, M.S.L.S.

ISSUE WORKSHOP 129  9:00 a.m.-10:30 a.m.
Wildier Room, Fourth Floor, Marriott Marquis

AVOIDING DUAL-AGENCY PITFALLS OF WORK-RELATED NEUROPSYCHIATRIC IMPAIRMENTS

Chp.: Harold J. Bursztajn, M.D.
Participants: Robindra K. Paul, M.D., David M. Reiss, M.D., Christine A. Martone, M.D.

ISSUE WORKSHOP 130  9:00 a.m.-10:30 a.m.
Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

TEACHING CORE COMPETENCIES: THE CHALLENGE FOR ACADEMIC PSYCHIATRY

Co-Chps.: Mary S. Sciutto, M.D., Mary E. Bongovi-Garcia, M.D.
Participants: Kareem D. Ghalib, M.D., David A. Lowenthal, M.D.

ISSUE WORKSHOP 131  9:00 a.m.-10:30 a.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

KEEP IT REAL: PSYCHOLOGICAL PREPAREDNESS AND ACTIVE-COPING GROUP

Chp.: Paula G. Panzer, M.D.
Participants: Robert H. Abramovitz, M.D., Susan E. Paula, Ph.D.

ISSUE WORKSHOP 132  9:00 a.m.-10:30 a.m.
Booth/Edison Rooms, Fifth Floor, Marriott Marquis

PSYCHIATRIC ASPECTS OF TREATING PRIMARY CAREGIVERS OF HOSPICE PATIENTS

Co-Chps.: Jay L. Wung, M.D., Robert Taub, M.D.
Participant: Linda Gorman, R.N.
THURSDAY

ISSUE WORKSHOP 133 9:00 a.m.-10:30 a.m.
Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis

PSYCHIATRY TRAINING FOR PRIMARY-CARE PHYSICIANS: WHAT, HOW, AND WHEN?

Chp.: Hoyle Leigh, M.D.
Participants: Tana A. Grady-Weliky, M.D., Don R. Lipsitt, M.D., Seth M. Powsner, M.D., Deborah C. Stewart, M.D.

ISSUE WORKSHOP 134 9:00 a.m.-10:30 a.m.
Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

WHOSE RESPONSIBILITY IS IT ANYWAY? THE TREATING PSYCHIATRIST'S?

Chp.: Bernard J. Arseneau, D.O.

ISSUE WORKSHOP 135 9:00 a.m.-10:30 a.m.
Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis

SAD DAYS: A VIDEO OF PSYCHIATRIC PROBLEMS IN AFGHANISTAN AND ITS REFUGEES

Chp.: Nigel M. Bark, M.D.
Participants: Khalid A. Mufti, M.D., Haroon R. Chaudhry, M.D.

ISSUE WORKSHOP 136 9:00 a.m.-10:30 a.m.
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

PROGRAM EVALUATION MADE SIMPLE

Co-Chps.: Barbara A. Johnson, M.D., James A. Schuster, M.D.
Participants: John G. Lovelace, M.S., Frank A. Ghinassi, Ph.D., Mario Cruz, M.D.

ISSUE WORKSHOP 137 9:00 a.m.-10:30 a.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

THE STALKING VICTIM: CAUSES, CONSEQUENCES, AND THERAPEUTIC CONSIDERATIONS

Chp.: Gail E. Robinson, M.D.
Participant: Karen M. Abrams, M.D.

MEDIA 7-8

MEDIA SESSION 7 9:00 a.m.-12 noon
Room IE06, Level 1, Javits Center

Robot Stories: Emotional and Ethical Challenges of a Technological Age

Co-Chps.: Ravi Chandra, M.D., John E. Beebe III, M.D.
Participants: Paul S. Appelbaum, M.D., Arthur Caplan, Ph.D., Raj Reddy, Ph.D., Greg Pak, B.A.

MEDIA SESSION 8 9:00 a.m.-12 noon
Ziegfeld Room, Fourth Floor, Marriott Marquis

Personality Disorders and the Film, Noir Femme Fatale

Chp.: Scott Snyder, M.D.

11:00 a.m. Sessions

MEDICAL UPDATE 4
11:00 a.m.-12:30 p.m.
Room IE13, Level 1, Javits Center

HOW TO SHRINK OBESITY

Chp.: Evelyn Attia, M.D.
Presenter: Judith Korner, M.D.
THIS SESSION WILL BE AUDIOTAPE-D.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 28-35

SCIENTIFIC AND CLINICAL REPORT SESSION 28
11:00 a.m.-12:30 p.m.
Rooms IE01/2, Level 1, Javits Center

EATING DISORDERS

Chp.: Theodore E. Weltzin, M.D.
Co-Chp.: Andrew O. Skinner, M.D.

11:00 a.m.
83 *Weight and Relapse to Cocaine and Alcohol Use in Patients With Eating Disorders
Olivera J. Bogunovic, M.D., David R. Gastfriend, M.D.

11:30 a.m.
84 DSM-IV Comorbidity in Binge-Eating Disorder
Carlos M. Grilo, Ph.D., Robin M. Masheb, Ph.D.

12 noon
85 Males at Risk: Hawaiian and Filipino Adolescents
Alayne Yates, M.D., Jeanne Edman, Ph.D.
THIS SESSION WILL BE AUDIOTAPE-D.

*Collaborative Session With the National Institute on Drug Abuse
THURSDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 29
11:00 a.m.-12:30 p.m.
Room 1E12, Level 1, Javits Center

ADDITION PSYCHIATRY
Collaborative Session With the National Institute on Drug Abuse

Chp.: Lisa M. Goldfarb, M.D.
Co-Chp.: Marketa M. Wills, M.D.

11:00 a.m.
86 PRISM-IV: Reliable Diagnosis in Alcohol and Drug Abusers
Sharon Samet, M.S.W., Edward V. Nunes, M.D., Jakob Meydan, Psy.D, Karen Matsecone, B.A., Deborah S. Hasin, Ph.D.

11:30 a.m.
87 Cognitive Functioning: Predictors of Outcome in Cocaine-Dependent Patients
Efrat Aharonovich, Ph.D., Edward V. Nunes, M.D., Xinhua Liu, Ph.D., Adam M. Bisaga, M.D., David M. McDowell, M.D., Deborah S. Hasin, Ph.D.

12 noon
88 Cocaine Expectancy Questionnaire: Psychometric and Underlying Model
Marie C. Martin, Ph.D., Bruce J. Rounsaville, M.D., Adam J. Jaffe, Ph.D., Charles H. Wilber, M.Ed.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 30
11:00 a.m.-12:30 p.m.
Room 3D03/10, Level 3, Javits Center

ISSUES IN ADDICTIONS

Chp.: David A. Casey, M.D.
Co-Chp.: Jesse H. Wright, M.D.

11:00 a.m.
89 *Psychosocial Therapies for Cocaine Dependence: A Controlled Study
Adam J. Jaffe, Ph.D., Charles H. Wilber, M.Ed., Bruce J. Rounsaville, M.D.

11:30 a.m.
90 Patient Treatment Matching With Ambulatory Cocaine Abusers
Charles H. Wilber, M.Ed., Adam J. Jaffe, Ph.D., Joshua J. Brant, Psy.D., Marie C. Martin, Ph.D., Richard A. Rodriguez, B.S., Bruce J. Rounsaville, M.D.

12 noon
91 Virtual Reality Cue-Reactivity-Controlled Trial for Nicotine Dependence
Patrick S. Bordnick, Ph.D., Ken Graap, M.Ed., Hilary Copp, M.S.W., Jeremy Brooks, Bobby Logue, B.S., Mirtha Ferrer, M.S.

THIS SESSION WILL BE AUDIOTAPED.

*Collaborative Session With the National Institute on Drug Abuse

SCIENTIFIC AND CLINICAL REPORT SESSION 31
11:00 a.m.-12:30 p.m.
Rooms 3D04/9, Level 3, Javits Center

SLEEP AND SEASONALITY

Chp.: Karl Doghramji, M.D.
Co-Chp.: Gerald F. Donovan, M.D.

11:00 a.m.
92 Modafinil Improves Patient Functioning in Shift Work Sleep Disorder
Milton K. Erman, M.D., Charles A. Czeisler, Ph.D., David F. Dinges, Ph.D., James K. Walsh, Ph.D., Thomas Roth, Ph.D.

11:30 a.m.
93 Modafinil Treatment of Chronic Shift Work Sleep Disorder
James K. Walsh, Ph.D., Charles A. Czeisler, Ph.D., David F. Dinges, Ph.D., Thomas Roth, Ph.D.

12 noon
94 A Comparison of Seasonality of Mood and Behavior in African and African-American Students
Samina M. Yousufi, M.D., Kelly J. Rohan, Ph.D., Courtney M. Thrower, M.A., Michael A. Jackson, B.S., John J. Bartko, Ph.D., Charles O. Agumadu, M.D., Teodor T. Postolache, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 32
11:00 a.m.-12:30 p.m.
Rooms 3D06/7, Level 3, Javits Center

ISSUES IN BPD

Chp.: Anthony J. Rothschild, M.D.
Co-Chp.: John J. Schwab , M.D.

11:00 a.m.
95 The Frequency of DSM-IV Personality Disorders in Psychiatric Outpatients
Mark Zimmerman, M.D., Louis Rothschild, Ph.D.

11:30 a.m.
96 Inhibitory Functioning in BPD: A fMRI Study
Sabine Herpertz, Knut Schnell, M.D., Britta Winter, Ph.D., Martina Ahrens, M.D., Armin Thron, M.D.

12 noon
97 Life Changes, Social Adjustment, and Attempted Suicide in BPD and MDD
Thomas M. Kelly, Ph.D., Paul H. Soloff, M.D., J. John Mann, M.D.

THIS SESSION WILL BE AUDIOTAPED.
THURSDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 33
11:00 a.m.-12:30 p.m.
Wilder Room, Fourth Floor, Marriott Marquis

CONSULTATION LIAISON PSYCHIATRY

Chp.: Anton C. Trinidad, M.D.
Co-Chp.: Sermsak Lolak, M.D.

11:00 a.m.
98 Depression and Nonlinear Heart Rate Dynamics in Older Coronary Patients

11:30 a.m.
99 The Role of Dexmedetomidine in Reducing Delirium in Cardiotomy Patients
Jose R. Maldonado, M.D., Ashley Wysong, M.S., Thaddeus S. Block, M.D.

12 noon
100 Psychiatry Training in Primary Care: Factors for a Satisfactory Program
Hoyle Leigh, M.D., Deborah C. Stewart, M.D., Ronna Mallios, M.P.H

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 34
11:00 a.m.-12:30 p.m.
Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

OCD

Chp.: Carl I. Cohen, M.D.
Co-Chp.: Geoffrey M. Hopkins, M.D.

11:00 a.m.
101 Self-Administered Versus Therapist-Administered Cognitive-Behavior Therapy for Medication Nonresponders With OCD
David Tolin, Ph.D., Scott Hannan, Ph.D., Gretchen Diefenbach, Ph.D., Nicholas Malby, Ph.D., Patrick Worhunsky, B.S.

11:30 a.m.
102 Effectiveness of Intensive Residential Treatment of Severe Refractory OCD
S. Evelyn Stewart, M.D., Colleen Farrell, B.A., Denise Egan-Stack, M.A., Michael A. Jenike, M.D.

12 noon
103 Hyperactive Error Processing in OCD
Nicholas Malby, Ph.D., Patrick Worhunsky, B.S., Kent A. Kiehl, Ph.D., David Tolin, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 35
11:00 a.m.-12:30 p.m.
Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis

ADULT ADHD

Chp.: Catherine C. Grone, M.D.
Co-Chp.: Robert Kelly, M.D.

11:00 a.m.
104 Cognitive-Behavioral Therapy for Residual ADHD in Adults
Steven A. Safren, Ph.D., Michael W. Otto, Ph.D., Timothy E. Wilens, M.D., Susan Sprich, Ph.D., Joseph Biederman, M.D., Carol Winette, Ph.D.

11:30 a.m.
105 A Controlled Study of Functional Impairments in 500 ADHD Adults
Stephen V. Faraone, Ph.D., Joseph Biederman, M.D.

12 noon
106 Long-Term Safety and Efficacy of Mixed Amphetamine Salts Extended-Release for Adult ADHD
Joseph Biederman, M.D., Thomas J. Spencer, M.D., Allan K. Chrisman, M.D., Timothy E. Wilens, M.D., Simon J. Tulloch, M.D., Richard H. Weisler, M.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

ISSUES 138-146

ISSUE WORKSHOP 138 11:00 a.m.-12:30 p.m.
Rooms 1E03/4/5, Level 1, Javits Center

DIVERSE CULTURAL EXPRESSIONS AND INTERVENTIONS FOR ANXIETY AND DEPRESSIVE DISORDERS

Chp.: Nalini V. Juthani, M.D.
Participants: Virginia Contreras, M.D., Kingsley Nwokeji, M.D., Akhtar Hossain, M.D.

ISSUE WORKSHOP 139 11:00 a.m.-12:30 p.m.
Room 1E09, Level 1, Javits Center

SPIRITUAL AND RELIGIOUS ASSESSMENT IN CLINICAL PRACTICE

Co-Chps.: Francis G. Lu, M.D., Christina M. Puchalski, M.D.
Participants: James L. Griffith, M.D.
ISSUE WORKSHOP 140 11:00 a.m.-12:30 p.m.  
Room IE 11, Level 1, Javits Center  
LONG-TERM CARE INSURANCE DENIALS TO ONE-TIME PSYCHIATRIC PATIENTS  
Co-Chps.: Rita R. Newman, M.D., Ruth B. Kantor, M.D.  
Participants: Lynn Lavendar, Esq., Brenda McElnea, Esq., Mark Wilensky, MBA  

ISSUE WORKSHOP 141 11:00 a.m.-12:30 p.m.  
Room IE 14, Level 1, Javits Center  
AN EXTENSION OF THE ANALYSIS OF RESTORATIVE JUSTICE AND THERAPEUTIC JURISPRUDENCE  
Co-Chps.: Lawrence K. Richards, M.D., Abraham L. Halpern, M.D.  
Participants: Michael L. Perlin, Bruce J. Winick, Marjorie A. Silver  

ISSUE WORKSHOP 142 11:00 a.m.-12:30 p.m.  
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis  
CHALLENGING SLEEP PROBLEMS: LOOKING AT SLOW-WAVE SLEEP  
Chp.: Lois E. Krahn, M.D.  
Participants: Peter C. Gleason, M.D., Martin B. Scharf, Ph.D.  

ISSUE WORKSHOP 143 11:00 a.m.-12:30 p.m.  
Booth/Edison Rooms, Fifth Floor, Marriott Marquis  
WORKPLACE BURNOUT IN PSYCHIATRISTS: EVIDENCE FROM THE UNITED KINGDOM  
Co-Chps.: Alex P. Mears, Ph.D., John Sharkey, M.D.  

ISSUE WORKSHOP 144 11:00 a.m.-12:30 p.m.  
Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis  
REACTIONS AFTER 9/11 IN A PRETRAUMATIZED COMMUNITY IN THE SOUTH BRONX  
Co-Chps.: Jeffrey M. Levine, M.D., Andreas Evdokas, Ph.D.  
Participants: Ibet Hernandez, C.S.W., Patrick J. Moynihan  

ISSUE WORKSHOP 145 11:00 a.m.-12:30 p.m.  
Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis  
TREATMENT OF RECENT-ONSET SCHIZOPHRENIA IN COMMUNITY AND RESEARCH SETTINGS  
Chp.: Raman C. Patel, M.D.  
Participants: Gilbert Robinson, M.D., Rachel Miller, M.S.W., Jose M. Soto, M.D., Beth Lorell, C.S.W.  

ISSUE WORKSHOP 146 11:00 a.m.-12:30 p.m.  
Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis  
EVIDENCE-BASED TREATMENT FOR SCHIZOPHRENIA IN A CORRECTIONAL SETTING  
Chp.: Larry H. Dizmang, M.D.  
Participants: John A. Chiles, M.D., Karen Alexander, Ph.D., David Silbaugh, Ph.D., Ira D. Glick, M.D.  

12 noon Sessions  
FORUM 12  
12 noon-1:30 p.m.  
Room IE 16, Level 1, Javits Center  
APA AND THE PHARMACEUTICAL INDUSTRY: AN OPEN FORUM  
Chp.: Stephen M. Goldfinger, M.D.  
Participants: Charles R. Goldman, M.D., Geetha Jayaram, M.D., David M. McDowell, M.D., Trevor R.P. Price, M.D., Nyapati R. Rao, M.D., Anand Pandya, M.D., David B. Mallott, M.D.  

NEW RESEARCH POSTER SESSION 10  
12 noon-2:00 p.m.  
Galleria, Level 4, Javits Center  
MEDICAL PSYCHIATRY AND GERIATRIC PSYCHIATRY  
For further information on New Research Sessions, please refer to the New Research Program Book included in your registration packet.  

2:00 p.m. Sessions  
SYMPOSIA 90-116  
SYMPOSIUM 90 2:00 p.m.-5:00 p.m.  
Rooms 1E01/2, Level 1, Javits Center  
NEW CLINICAL INDICATIONS FOR LIGHT TREATMENT: STATUS REPORT  
Chp.: Raymond W. Lam, M.D.  
A Treatment of Winter Depression: Light or Drugs?  
Raymond W. Lam, M.D., Anthony J. Levitt, M.D., Robert D. Levitan, M.D., Murray W. Enns, M.D., Rachel L. Morehouse, M.D.  

(Continued on next page)
THURSDAY

B Light Treatment for Antepartum Depression
Katherine L. Wisner, M.D.

C Bright Light and Negative Ion Treatment for Chronic Depression
Namni Goel, Ph.D., Juan Su Terman, Ph.D.,
Michael Terman, Ph.D., Mela M. Macchi, Ph.D.,
Jonathan W. Stewart, M.D.

D A Meta-Analysis of Light Treatment for Nonseasonal Depression
Arja L. Tuunainen, M.D., Daniel F. Kripke, M.D.,
Takuro Endo, M.D.

Discussant: Michael Terman, Ph.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 91 2:00 p.m.-5:00 p.m.
Rooms 1E03/4/5, Level 1, Javits Center

MOOD DISORDERS IN WOMEN THROUGHOUT THE LIFE CYCLE
Chp.: Nina E. Cerfolio, M.D.

A Pregnant Addicts Do Not Use Drugs
Leslie H. Gise, M.D.

B Postpartum Psychosis: Phenomenology, Treatment, and Prevention
Margaret G. Spinelli, M.D.

C Cyclic Moods and Acyclic Moods
Kimberly A. Yonkers, M.D.

D The Greatest Experiment Ever Performed on Women
Barbara Seaman, Ph.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 92 2:00 p.m.-5:00 p.m.
Room 1E06, Level 1, Javits Center

OVERCOMING BARRIERS TO LONG-TERM CARE AND TREATMENT OF THE ELDERLY
APA Corresponding Committee on Long-Term Care and Treatment for the Elderly
Chp.: Helen H. Kyomen, M.D.

A An Inspirational Model of Care in Rural Long-Term-Care Facilities
David W. Hodo, M.D.

B The PACE Model of Community-Based Care
Robert K. Dolgoff, M.D.

C An Ethno-Cultural Model of Care in Long-Term-Care Facilities
Ronald Brenner, M.D.

D Can You Ever Get Paid for Treating Patients in Long-Term Care Settings?
Istvan J.E. Bolsay, M.D.

E Barriers to Psychiatric Care in Assisted-Living Facilities
Helen H. Kyomen, M.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 93 2:00 p.m.-5:00 p.m.
Room 1E09, Level 1, Javits Center

DEVELOPMENTAL DISABILITIES FROM CHILDHOOD TO ADULTHOOD
Chp.: Roxanne C. Dryden-Edwards, M.D.
Co-Chp.: Paula J. Lockhart, M.D.

A Fetal Alcohol Spectrum Disorders for Mental Health Professionals: A Brief Review
Paula J. Lockhart, M.D.

B Behavioral Interventions for Autism and Developmental Disorders in Adults
Joel D. Bregman, M.D., John Gertz, M.D.

C Substance Use Disorders in Young Adults With and Without Learning Disabilities
Joseph H. Beitchman, M.D., Lori Wilson, Arlene Young,
Edward Adlaf

D Psychopharmacology in Mental Retardation and Pervasive Developmental Disorders
Bryan H. King, M.D.

Discussants: Joseph H. Beitchman, M.D., Bryan H.
King, M.D., Joel D. Bregman, M.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 94 2:00 p.m.-5:00 p.m.
Room 1E10, Level 1, Javits Center

UPDATE ON TREATMENT OF STIMULANT ABUSE
Collaborative Session With the National Institute on Drug Abuse
Chp.: David A. Gorelick, M.D.

A Recovery-Oriented Psychosocial Treatment
Douglas M. Ziedonis, M.D.

B Therapy and Placement Approaches for Cocaine Abuse Treatments
David R. Gastfriend, M.D., Gurmit Shimi Kang, M.D.,
Sandrine Pirard, M.D., Estee Sharon, Psy.D.

C Pharmacological Treatment of Stimulant Abuse
David A. Gorelick, M.D.
THURSDAY

D Psychiatric Comorbidity in Stimulant Abusers
   Richard N. Rosenthal, M.D.

E Methamphetamine Abuse: 2004 Update
   Steven L. Batki, M.D.
   THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 95  2:00 p.m.-5:00 p.m.
   Room IE11, Level 1, Javits Center

DEPRESSIVE PERSONALITY DISORDER VERSUS
DYSTHYMIC DISORDER

Chp.: John C. Markowitz, M.D.
   Co-Chp.: Andrew E. Skodol II, M.D.

A Conceptual Issues in the Overlap of Depressive
Personality and Dysthymia
   Steven Huprich, Ph.D.

B Longitudinal Comparison of Depressive Personality
Disorder and Dysthymic Disorder
   John C. Markowitz, M.D., Andrew E. Skodol II, M.D.,
   Eva Petkova, Ph.D., Hui Xie, Ph.D., David J.
   Hellerstein, M.D.

C Depressive Personality: Ten-Year Follow-Up
   Daniel N. Klein, Ph.D.

D Impact of Comorbid Dysthymic Disorder on Outcome
   in Personality Disorders
   David J. Hellerstein, M.D., Andrew E. Skodol II, M.D.,
   John C. Markowitz, M.D., Eva Petkova, Ph.D.,
   Hui Xie, Ph.D.

E Clinical Correlates of Chronicity in Depression: Results
   From the Rhode Island MIDAS Project
   Mark Zimmerman, M.D., Iwona Chelminski, Ph.D.
   THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 96  2:00 p.m.-5:00 p.m.
   Room IE13, Level 1, Javits Center

BEHAVIORAL TREATMENTS FOR DRUG
DEPENDENCE
   Collaborative Session With the National Institute on Drug Abuse

Chp.: Lisa S. Onken, Ph.D.
   Co-Chp.: Bruce J. Rounsaville, M.D.

A Durability of Cognitive-Behavioral Therapy Efficacy for
   Substance Abusers
   Bruce J. Rounsaville, M.D.

B HIV Risk Reduction and Substance Abuse Treatment
   George E. Woody, M.D.

C Low-Cost Contingency Management in Community
   Settings
   Nancy M. Petry, Ph.D.

D Cognitive-Behavioral Therapy and Naltrexone for
   Cocaine Dependence
   Joy M. Schmitz, Ph.D., Angela L. Stotts, Ph.D.,
   John Grabowski, Ph.D.

E Behavioral Family Counseling and Naltrexone for Male,
   Opioid-Dependent Patients
   William S. Fals-Stewart, Ph.D., Timothy J. O'Farrell, Ph.D.
   THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 97  2:00 p.m.-5:00 p.m.
   Room IE14, Level 1, Javits Center

ITALIAN PSYCHIATRY: 25 YEARS OF CHANGES

Chp.: Mariano Bassi, M.D.
   Co-Chp.: Allan Tasman, M.D.

A Italian Psychiatrists and Italian Psychiatry: 25 Years of
   Changes
   Mariano Bassi, M.D.

B Intensive Community Care: Is It the Same in Italy and
   the Rest of the World?
   Angelo Fioritti, M.D.

C Variations in Mental Health Service Provision in Italy
   and Their Links With Socioeconomic Predictors
   Giuseppe Tibaldi

D Residential Care in Italy: A National Survey
   Giovanni De Girolamo, M.D., Angelo Picardi, M.D.,
   Giovanni Santone, M.D.

E Community Treatment of Schizophrenia in Italy
   Mirella Ruggeri, M.D., Antonio Lasalua, M.D.,
   Michele Tansella, M.D.
   THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 98 - WITHDRAWN

101
THURSDAY

SYMPOSIUM 99 2:00 p.m.-5:00 p.m.
Rooms 3D01/12, Level 3, Javits Center

MIND, BRAIN, AND INTERPERSONAL EXPERIENCE IN PSYCHOTHERAPY

Chp.: Daniel J. Siegel, M.D.
Co-Chp.: Marcia Kraft Goin, M.D.

A The Present Moment in Psychotherapy
Daniel N. Stern, M.D.

B The Central Role of Emotion in Psychotherapy
Diana Fosha, Ph.D.

C Intersubjectivity, Narrative, and the Brain in Psychotherapy
Daniel J. Siegel, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 100 2:00 p.m.-5:00 p.m.
Room 3D02/11, Level 3, Javits Center

FROM RESEARCH TO CLINICAL PRACTICES IN TREATING PATIENTS WITH BPD

Chp.: John G. Gunderson, M.D.

A Levels of Care: A Scientific and Clinical Overview
John G. Gunderson, M.D.

B Intensive Outpatient and Partial Hospital Care for BPD
Anthony Bateman, M.D.

C Comparing Psychotherapies for Patients With BPD: A Progress Report
Otto F. Kernberg, M.D.

D Effects of Psychotherapy on MDD in Patients With BPD
Janine L. Stevenson, M.D., Russell Meares, M.D.

E A Randomized Trial of Psychoeducation for Patients With BPD
Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 101 2:00 p.m.-5:00 p.m.
Room 3D03/10, Level 3, Javits Center

MEANING IN SUICIDE: OVERCOMING BARRIERS AND CONNECTING DIVERSE PERSPECTIVES

Chp.: Michael F. Myers, M.D.

A Existential Meaning: Unifying Diverse Perspectives to Understanding Suicide
James R. Rogers, Ph.D., Karen M. Soyka, M.S.

B Meaning in Suicide From the Survivor's Perspective
Carla Fine, M.S.

C Approaches to Engaging People of Color in Program Initiatives for Suicide Prevention and Intervention
Donna H. Barnes, Ph.D.

D Suicide: What Survivors Want From Mental Health Care Professionals
Frank R. Campbell, Ph.D.

E The Clinician's Perspective: Why Is This Subject So Tough for Us?
Michael F. Myers, M.D.

Discussant: Morton Silverman, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 102 2:00 p.m.-5:00 p.m.
Rooms 3D04/9, Level 3, Javits Center

INDIVIDUALIZING INTERPERSONAL PSYCHOTHERAPY FOR MOOD DISORDERS

Chp.: Ellen Frank, Ph.D.
Co-Chp.: Nancy K. Grote, Ph.D.

A Interpersonal and Social Rhythm Therapy for Bipolar I Disorder
Ellen Frank, Ph.D.

B Individualizing Treatment for Depressed Patients With Co-Occurring Panic or Anxiety
Jill M. Cryanowski, Ph.D., Ellen Frank, Ph.D., M. Katherine Shear, M.D.

C Motivational Interviewing and IPT: An Approach to Treatment Engagement
Holly A. Swartz, M.D., Nancy K. Grote, Ph.D., Allan Zuckoff, M.D., Ellen Frank, Ph.D., M. Katherine Shear, M.D.

D Group Psychotherapy for Infertile Women With Depression
Ellen F. Olshansky, D.Sc., Ellen Frank, Ph.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 103 2:00 p.m.-5:00 p.m.
Rooms 3D05/8, Level 3, Javits Center

BDD: IS IT A MIND, BODY, OR SOCIOCULTURAL PROBLEM AND HOW DO YOU TREAT IT?

Chp.: Fugen Neziroglu, Ph.D.

A BDD: Phenomenology, Etiology, and Sociocultural Influences
Sony Khemlani-Patel, Ph.D.
THURSDAY

B How to Apply Cognitive and Behavior Therapy for BDD
Fugen Neziroglu, Ph.D.

C Update on Pharmacotherapy for BDD
Katharine A. Phillips, M.D.

D Cosmetic Surgery in BDD
David Veale

E SNRI Treatment and Functional Imaging of BDD
Eric Hollander, M.D., Andrea Allen, Ph.D., Lauren Priday, B.A.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 104 2:00 p.m.-5:00 p.m.
Rooms 3D06/7, Level 3, Javits Center

MODEL PSYCHIATRY RESIDENCY PROGRAMS ON RELIGION AND SPIRITUALITY

Chp.: Francis G. Lu, M.D.
Co-Chp.: Christina M. Puchalski, M.D.

A Religion, Spirituality, and Culture in Psychiatric Practice at the University of Louisville
James Hyde, Ph.D.

B Enhancing Spirituality Teaching at the Medical University of South Carolina
David W. Hiott, M.D., Dana King, M.D.

C University of Saskatchewan Curriculum on Spirituality and Mental Health
Marilyn D. Baetz, M.D.

Discussants: John R. Peteet, M.D., Allan M. Josephson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 105 2:00 p.m.-5:00 p.m.
O'Neill Room, Fourth Floor, Marriott Marquis

HEALTH AND LIFESTYLE OF PEOPLE WITH SCHIZOPHRENIA: THE VIEW FROM SCOTLAND

Chp.: Robin G. McCreddie, D.Sc.
Co-Chp.: Ciara Kelly, M.D.

A Smoking Habits of Scottish People With Schizophrenia
Ciara Kelly, M.D., Robin G. McCreddie, D.Sc., Roch Cantwell, M.D., John Eagles, M.D., Paul Sclare, M.D., Simon Naji, M.D.

B Diet and Cardiovascular Risk: Descriptive Study and Randomized, Controlled Trial
Robin G. McCreddie, D.Sc.
C Countertransference and Ethical Issues in End-of-Life Care
Brian J. Kelly, M.B., Frances T. Varghese, M.B., Dan Pelusi, B.A., Paul Burnett, Ph.D., Marguerite Robertson, M.B., Shirlene Badger, B.A.

D Competing Paradigms of Responding to Assisted-Suicide Requests in Oregon: Case Report
N. Gregory Hamilton, M.D., Catherine Hamilton, M.A.

Discussant: Herbert Hendin, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 108 2:00 p.m.-5:00 p.m.
Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

AN INTEGRATION OF THE PATHOPHYSIOLOGY AND PHARMACOTHERAPY FOR PTSD
Chp.: Lori L. Davis, M.D.

A Noradrenergic Function in the Pathophysiology and Treatment of PTSD
Steven M. Southwick, M.D.

B Hypothalamic Pituitary Adrenal Axis and Serotonergic Function in PTSD
J. Douglas Bremner, M.D.

C Amino Acid Neurotransmitter Modulation in PTSD
Lori L. Davis, M.D., Frederick Petty, M.D.

Discussant: Charles R. Marmar, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 109 2:00 p.m.-5:00 p.m.
Booth/Edison Rooms, Fifth Floor, Marriott Marquis

FEELING UNREAL: A CONTEMPORARY OVERVIEW OF DEPERSONALIZATION DISORDER
Chp.: Daphne Simeon, M.D.

A The Phenomenology of Depersonalization Disorder
Daphne Simeon, M.D., Margaret Knutelska, M.P.H., Dorothy Nelson, B.S.C., Orna Guralnik, Psy.D.

B The Neurophysiological Basis of Depersonalization Disorder
Anthony S. David, M.D., Mary L. Phillips, M.D., Nicholas Medford, M.D., Mauricio Sierra, M.D.

C Neurobiology of the Dissociative States Produced by Ketamine
John H. Krystal, M.D., J. Douglas Bremner, M.D., Amit Anand, M.D., Dennis S. Charney, M.D., Cyril Dsouza, M.D.

D Cognitive Processes in Depersonalization Disorder
Orna Guralnik, Psy.D., Margaret Knutelska, M.P.H., Daphne Simeon, M.D.

E Neurochemistry and Pharmacological Treatment of Depersonalization Disorder
Daphne Simeon, M.D., Margaret Knutelska, M.P.H., Orna Guralnik, Psy.D., Dorothy Nelson, B.S.C.

F A Cognitive-Behavioral Approach to Depersonalization Disorder
Anthony S. David, M.D., Dawn Baker, Ph.D., Elaine Hunter, Ph.D., Mauricio Sierra, M.D., Mary L. Phillips, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 110 2:00 p.m.-5:00 p.m.
Majestic/Music Box/Winter Garden, Sixth Floor, Marriot Marquis

PSYCHOSOCIAL IMPACT OF SARS ON PATIENTS, HOSPITALS, AND HEALTH CARE PROVIDERS
Chp.: Donna E. Stewart, M.D.

A The Traumatic Impact of SARS on Nurses and Health Care Workers With Children
Robert G. Maunder, M.D., William J. Lancee, Ph.D., Jonathan J. Hunter, M.D., Kenneth E. Balderson, M.D., Sean B. Rourke, Ph.D., Patricia M. Petryshen, Ph.D., David S. Goldbloom, M.D., Donald A. Waylenki, M.D., Calvin Fones, M.D.

B Academic Physicians Coping During SARS
Donna E. Stewart, M.D., Sherry Grace, Ph.D., Karen Hershenfield, B.S.C., Emma K. Robertson, Ph.D.

C Consultation-Liaison Psychiatry During the SARS Outbreak: Response to Patients and Administration
Jonathan J. Hunter, M.D.

D Psychosocial Effects of Quarantine Due to SARS in Health Care Workers
Emma K. Robertson, Ph.D., Karen Hershenfield, B.S.C., Sherry Grace, Ph.D., Donna E. Stewart, M.D.

E Group Psychological Perspectives on the SARS Epidemic in Toronto
Molyn Leszcz, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 111 2:00 p.m.-5:00 p.m.
Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriot Marquis

TRAUMATIC STRESS: THE BRIDGE BETWEEN NEUROSCIENCE AND PSYCHODYNAMIC PSYCHIATRY
Chp.: Andrei Novae, M.D.
A Disorganized Attachment Alters the Cortisol Stress Response in Human Infants
Robert D. Levitan, M.D., Eman Leung, M.A., Susan Goldberg, Ph.D., Stephen Matthews, Ph.D., Leslie Atkinson, Ph.D.

B Biological Aspects of Intergenerational Responses to Traumatic Stress
Rachel Yehuda, Ph.D.

C The Neurobiology of Cognitive Bias
Andrei Novac, M.D.

D Psychodynamic Neurobiology
Barton J. Blinder, M.D.

Discussant: Roger K. Pitman, M.D.
THIS SESSION WILL BE AUDIOTAPE.
THURSDAY

SYMPOSIUM 115  2:00 p.m.-5:00 p.m.
Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis

MEETING THE CHALLENGE OF ADOLESCENT ADHD

Chp.: Timothy E. Wilens, M.D.

A  Functional Outcomes in Adolescents With ADHD
   Eric Mick, Sc.D.

B  Diagnostic Issues: The Challenge of Adolescent ADHD
   Laurence L. Greenhill, M.D.

C  Comorbidities in Adolescents With ADHD
   Joseph Biederman, M.D.

D  Safety and Efficacy of OROS Methylphenidate in Adolescents With ADHD
   Timothy E. Wilens, M.D.

E  Improvements in Adolescents' Driving Performance With OROS Methylphenidate
   Daniel J. Cox, Ph.D.

THIS SESSION WILL BE AUDIOTAPE.D.

SYMPOSIUM 116  2:00 p.m.-5:00 p.m.
Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis

HOW TO PRACTICE EVIDENCE-BASED MEDICINE

Chp.: Donna M. Sudak, M.D.

A  Introduction to Evidence-Based Medicine
   Bryce Templeton, M.D.

B  Review of Basic Statistical Concepts
   Maju Mathews, M.D.

C  Critical Appraisal of Randomized Controlled Trials
   Adedapo B. Williams, M.D.

D  Critical Appraisal of Systematic Reviews and Meta-Analysis
   Babatunde A. Adetunji, M.D.

THIS SESSION WILL BE AUDIOTAPE.D.
2004 ANNUAL MEETING
TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

DISORDERS
1. AIDS and HIV-Related Disorders
2. Alcohol and Drug-Related Disorders
3. Anxiety Disorders
4. Attention Spectrum Disorders
5. Cognitive Disorders (Delirium, Dementia, Amnestic, etc.)
6. Dissociative Disorders
7. Eating Disorders
8. Mental Retardation (Child/Adolescent/Adult)
9. Mood Disorders
10. Personality Disorders
11. Schizophrenia and Other Psychotic Disorders
12. Sexual and Gender Identity Disorders
13. Sleep Disorders
14. Somatoform Disorders

PRACTICE AREAS/SETTINGS
15. Psychiatric Administration and Services: Public, Private, and University

SUBSPECIALTY AREAS OR SPECIAL INTERESTS
16. Addiction Psychiatry
17. Biological Psychiatry and Neuroscience
18. Brain Imaging
19. Child and Adolescent Psychiatry and Disorders
20. Consultation-Liaison and Emergency Psychiatry
21. Cross-Cultural and Minority Issues
22. Diagnostic Issues
23. Epidemiology
24. Ethics and Human Right
25. Forensic Psychiatry
26. Genetics
27. Geriatric Psychiatry
28. Neuropsychiatry
29. Psychiatric Education
30. Psychiatric Rehabilitation
31. Psychoanalysis
32. Psychoimmunology
33. Research Issues
34. Social and Community Psychiatry
35. Stress
36. Suicide
37. Violence, Trauma, and Victimization

TREATMENTS
38. Behavior and Cognitive Therapies
39. Combined Pharmacotherapy and Psychotherapy
40. Couple and Family Therapies
41. Group Therapy
42. Individual Psychotherapies
43. Psychopharmacology
44. Other Somatic Therapies
45. Treatment Techniques and Outcome Studies

OTHER ISSUES
46. Computers
47. Creativity and the Arts
48. Gender Issues
49. Health Services Research
50. Historical Questions
51. Information Technology
52. Internet
53. Lesbian/Gay/Bisexual/Transgender Issues
54. Managed Care and Health Care Funding
55. Men's Health Issues
56. National Institute on Drug Abuse
57. Personal Digital Assistants (PDAs)
58. Political Questions
59. Presidential Theme: Psychotherapy and Psychopharmacology: Dissolving the Mind-Brain Barrier
60. Professional and Personal Issues
61. Religion, Spirituality, and Psychiatry
62. Resident and Medical Student Concerns
63. Stigma/Advocacy
64. Telepsychiatry
65. Virtual Reality
66. Women's Health Issues

GUIDE TO USING THE TOPIC INDEX

Use this index to find sessions of interest to you. There are five overall topics: Disorders, Practice Areas/Settings, Subspecialty Areas or Special Interests, Treatments, and Other Issues. Under each overall topic, you will find subtopics listed in alphabetical order with the formats (type of session) listed alphabetically underneath. Within each format, you will find the title of the individual session listed by number. The listing will also show the page number the session appears on. You should refer to the page number in this Program Book to obtain further details about the session.
<table>
<thead>
<tr>
<th>DISORDERS</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TOPIC 1: AIDS AND HIV-RELATED DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>CLINICAL CASE CONFERENCE</strong></td>
<td></td>
</tr>
<tr>
<td>3 Psychiatric Issues in the Management of Patients With HIV Infection</td>
<td>70</td>
</tr>
<tr>
<td><strong>DISCUSSION GROUP</strong></td>
<td></td>
</tr>
<tr>
<td>9 HIV (For Residents Only)</td>
<td>20</td>
</tr>
<tr>
<td><strong>MASTER EDUCATOR CLINICAL CONSULTATION</strong></td>
<td></td>
</tr>
<tr>
<td>5 Neuropsychiatric Complications of HIV-1 Infection</td>
<td>44</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORT</strong></td>
<td></td>
</tr>
<tr>
<td>50 Evaluation of an HIV Intervention for Psychiatric Care Providers in South Africa</td>
<td>52</td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
<td></td>
</tr>
<tr>
<td>47 What Every Psychiatrist Needs to Know About HIV/AIDS</td>
<td>63</td>
</tr>
<tr>
<td>59 What You Need to Know About Treatment of HIV-Related Disorders</td>
<td>84</td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOP</strong></td>
<td></td>
</tr>
<tr>
<td>31 Sex, Drugs, and HIV: Synergistic Epidemics</td>
<td>53</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
<td></td>
</tr>
<tr>
<td>14 Early Trauma, PTSD, and HIV: Association With Transmission and Nonadherence</td>
<td>19</td>
</tr>
<tr>
<td>124 A Comprehensive Approach to the Treatment of Pain in HIV Illness</td>
<td>95</td>
</tr>
<tr>
<td><strong>TOPIC 2: ALCOHOL AND DRUG-RELATED DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>COURSE</strong></td>
<td></td>
</tr>
<tr>
<td>12 Systemic Therapies for Substance Abuse Disorders</td>
<td>3</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
</tr>
<tr>
<td>56 The Effects of State Income Inequality and Alcohol Tax on Alcohol Dependence</td>
<td>77</td>
</tr>
<tr>
<td>57 Effect of Age on Long-Term Outcomes of Inpatient Alcoholism Treatment</td>
<td>77</td>
</tr>
<tr>
<td>58 Topiramate Treatment of Alcohol Dependence: Effects on Psychosocial Functioning and Its Relationship With Heavy Drinking</td>
<td>77</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
</tr>
<tr>
<td>54 Anticonvulsants for Treating Multiple Components of Alcohol-Dependence Syndrome</td>
<td>64</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOP</strong></td>
<td></td>
</tr>
<tr>
<td>25 Drug Abuse and Mental Health Treatment in Lieu of Imprisonment</td>
<td>26</td>
</tr>
<tr>
<td><strong>TOPIC 3: ANXIETY DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>FOCUS LIVE SESSION</strong></td>
<td></td>
</tr>
<tr>
<td>2 PTSD and Anxiety Disorders: Test Your Knowledge</td>
<td>21</td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIA</strong></td>
<td></td>
</tr>
<tr>
<td>7 Impulsivity: Emerging Clinical Perspectives</td>
<td>3</td>
</tr>
<tr>
<td>9 GAD: Evidence-Based Considerations From Pathophysiology to Long-Term Management</td>
<td>4</td>
</tr>
<tr>
<td>14 The Many Faces of Anxiety: Origins, Pathogenesis, and Management</td>
<td>6</td>
</tr>
<tr>
<td><strong>TOPIC 4: ATTENTION SPECTRUM DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
<td></td>
</tr>
<tr>
<td>2 ADD in Children and Adolescents</td>
<td>1</td>
</tr>
<tr>
<td>14 ADD in Adults</td>
<td>5</td>
</tr>
<tr>
<td>38 Advanced Assessment and Treatment of ADD</td>
<td>14</td>
</tr>
<tr>
<td><strong>DISCUSSION GROUP</strong></td>
<td></td>
</tr>
<tr>
<td>20 Clinical Management of ADHD With Children, Adolescents, and Adults (Meet the Authors)</td>
<td>76</td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIA</strong></td>
<td></td>
</tr>
<tr>
<td>4 Adult ADHD: Clinical Utility and Validity</td>
<td>2</td>
</tr>
<tr>
<td>18 Targeting Executive Dysfunctions for Treatment</td>
<td>7</td>
</tr>
<tr>
<td>38 Conceptualizing and Treating ADHD Adults</td>
<td>39</td>
</tr>
<tr>
<td>47 Adult ADHD Diagnosis and Treatment</td>
<td>67</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
</tr>
<tr>
<td>35 ADHD Comorbidity in Preschool Children</td>
<td>51</td>
</tr>
<tr>
<td>36 Atomoxetine for Comorbid ADHD and Affective Symptoms</td>
<td>51</td>
</tr>
<tr>
<td>37 Abuse Liability Assessment of Atomoxetine in a Drug-Abusing Population</td>
<td>51</td>
</tr>
<tr>
<td>104 Cognitive-Behavioral Therapy for Residual ADHD in Adults</td>
<td>98</td>
</tr>
<tr>
<td>105 A Controlled Study of Functional Impairments in 500 ADHD Adults</td>
<td>98</td>
</tr>
<tr>
<td>106 Long-Term Safety and Efficacy of Mixed Amphetamine Salts Extended-Release for Adult ADHD</td>
<td>98</td>
</tr>
<tr>
<td>TOPIC INDEX</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td><strong>Page #</strong></td>
</tr>
<tr>
<td>115</td>
<td>Meeting The Challenge of Adolescent ADHD</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOP</strong></td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>New Technologies for the Assessment of ADHD</td>
</tr>
<tr>
<td><strong>TOPIC 5: COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
<td></td>
</tr>
<tr>
<td>74</td>
<td>The Evaluation and Identification of the Major Dementias</td>
</tr>
<tr>
<td>94</td>
<td>Delirium in the General Hospital</td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIAS</strong></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>From Pathology to Practice: Evolving Therapeutic Strategies for Alzheimer’s Disease</td>
</tr>
<tr>
<td>25</td>
<td>Novel Intervention Strategies Across the Spectrum of Dementia: Real Patients and Real Outcomes</td>
</tr>
<tr>
<td>32</td>
<td>Current Alzheimer’s Disease Treatments and Beyond: Advances Impacting Clinical Practice, Part 1</td>
</tr>
<tr>
<td>32</td>
<td>Current Alzheimer’s Disease Treatments and Beyond: Advances Impacting Clinical Practice, Part 2</td>
</tr>
<tr>
<td>42</td>
<td>Reaching Beyond Alzheimer’s Disease With Cholinergic Therapy</td>
</tr>
<tr>
<td><strong>REVIEW OF PSYCHIATRY: SECTION 2</strong></td>
<td></td>
</tr>
<tr>
<td>Cognitive-Behavior Therapy</td>
<td>57</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORT</strong></td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>The Role of Desmopressin in Reducing Delirium in Cardiomyopathy Patients</td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOP</strong></td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>Is There a Standard of Care for the Treatment of Dementia?</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOP</strong></td>
<td></td>
</tr>
<tr>
<td>87</td>
<td>Vascular Dementia: Assessment, Imaging, and Treatment</td>
</tr>
<tr>
<td><strong>TOPIC 6: DISSOCIATIVE DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>SYMPOSIAS</strong></td>
<td></td>
</tr>
<tr>
<td>73</td>
<td>Dissociative Disorders: Issues of Culture and Issues of Trust</td>
</tr>
<tr>
<td>109</td>
<td>Feeling Unreal: A Contemporary Overview of Depersonalization Disorder</td>
</tr>
<tr>
<td><strong>TOPIC 7: EATING DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Therapeutic Interventions in Eating Disorders: Basic Principles</td>
</tr>
<tr>
<td>28</td>
<td>Current Concepts in Child and Adolescent Eating Disorders</td>
</tr>
<tr>
<td><strong>DISCUSSION GROUP</strong></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Psychiatric Comorbidity in the Eating Disorders: Diagnosis, Treatment, and Research</td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIUM</strong></td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>Binge-Eating Disorder: Genes, Treatments, and Consequences</td>
</tr>
<tr>
<td><strong>MASTER EDUCATOR CLINICAL CONSULTATION</strong></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Evaluation and Treatment of Eating Disorders</td>
</tr>
<tr>
<td><strong>MEDICAL UPDATE</strong></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>How to Shrink Obesity</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
</tr>
<tr>
<td>84</td>
<td>DSM-IV Comorbidity in Binge-Eating Disorder</td>
</tr>
<tr>
<td>85</td>
<td>Males at Risk: Hawaiian and Filipino Adolescents</td>
</tr>
</tbody>
</table>

**SYMPOSIAS**

15 Eating Disorders 2004: From PETs to Psyche 60
46 Translational Research on Eating Disorders 62

**ISSUE WORKSHOP**

127 Treatment-Resistant Patients With Bulimia Nervosa 95

**TOPIC 8: MENTAL RETARDATION (CHILD/ADOLESCENT/ADULT)**

**FORUM**

I Am Sam 67

**SYMPOSIUM**

93 Developmental Disabilities From Childhood to Adulthood 100

**COMPONENT WORKSHOP**

9 Mission Possible: The Science of Psychiatry and the Art of Advocacy 18

**TOPIC 9: MOOD DISORDERS**

**CONTINUOUS CLINICAL CASE CONFERENCE**

2 Two Hospitalized Patients With Refractory Mood Disorder and Cognitive Impairment, Part 1 70
2 Two Hospitalized Patients With Refractory Mood Disorder and Cognitive Impairment, Part 2 93

**COURSE**

87 The Neuroendocrinology of Mood Disorders 70

**DISCUSSION GROUPS**

1 Dementia and Delirium 15
8 Depression in Alzheimer’s and Other Neurologic Conditions: Evaluation and Treatment 20

**INDUSTRY-SUPPORTED SYMPOSIAS**

2 Preventive Psychiatry in Mood Disorders: A New Frontier 1
3 Bipolar Disorder and Alcoholism Diagnostic Challenges and Therapeutic Interventions 2
5 Towards DSM-V: Phenomenology, Neurobiology, and Treatment Response in Depression 2
8 Bipolar Disorder: Improving Outcomes When Theory, Science, and Clinical Practice Converge 4
11 Interface Between Depression and Medical Illness 4
12 Antidepressant Treatments You May Not Know About, But Should… 5
19 The Treacherous Triad for Depression 8
20 Beyond 5HT: New Treatments for Depression 9
23 Unmasking Bipolar Disorder: Overcoming the Barriers to Treatment Success 9
27 Moderators and Mediators of Antidepressant Response 11
33 Recognizing the Many Faces of Bipolar Disorder, Part 1 13
33 Recognizing the Many Faces of Bipolar Disorder, Part 2 41
39 Placing a Course to Remission: Navigating the Intersection of Mind, Brain, and Body 39
44 Challenges in Treating Bipolar Illness and Comorbid Disorders 66
45 Does the Pharmacology of Antidepressant Drugs Matter? 66

**LECTURE**

6 The Search for Genes of Bipolar Disorder: From Classical Genetics to Novel Molecular Targets 21

**SCIENTIFIC AND CLINICAL REPORTS**

20 Duloxetine Versus Placebo in the Prevention of Relapse of MDD 24
21 Response to Antidepressant Is Independent of Gender 24
22 Depression and BPD During the Immediate Prepartum Period 24

(Continued on next page) 109
<table>
<thead>
<tr>
<th>TOPIC INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
</tr>
<tr>
<td>11  Do Patients With Schizophrenia Show Periods of Complete Recovery? A 20-Year Follow-Up 23</td>
</tr>
<tr>
<td>12  Twenty-Year Outcome in Schizophrenia: What's Sex Got to Do With It? 23</td>
</tr>
<tr>
<td>13  Recovery From Schizophrenic Psychoses Until Age 35 23</td>
</tr>
<tr>
<td>74  ICSOHQ Intercontinental Schizophrenia Outpatient Health Outcomes Study 79</td>
</tr>
<tr>
<td>75  Male Patients With Schizophrenia Have Impairment in the Processing of Spatial Information From Dissociated Spatial Reference 79</td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
</tr>
<tr>
<td>13  Neurodevelopment and Schizophrenia: Clinical and Basic Science Perspectives 33</td>
</tr>
<tr>
<td>45  Delusional Disorder: A Reconsideration of the Scientific and Conceptual Basis for the DSM Reformulation of Paranoia 62</td>
</tr>
<tr>
<td>105 Health and Lifestyle of People With Schizophrenia: The View From Scotland 103</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
</tr>
<tr>
<td>10  Can Early Intervention Prevent Psychosis? Management of the Prodromal Phase 19</td>
</tr>
<tr>
<td>40  My Name is Walter James Cross 46</td>
</tr>
<tr>
<td>64  Management of Difficult Schizophrenia 53</td>
</tr>
<tr>
<td>70  The Out-of-the-Shadow Project 54</td>
</tr>
<tr>
<td>145 Treatment of Recent-Onset Schizophrenia in Community and Research Settings 99</td>
</tr>
<tr>
<td><strong>MEDIA WORKSHOP</strong></td>
</tr>
<tr>
<td>1  Dr. merBoy 20</td>
</tr>
<tr>
<td><strong>TOPIC 12: SEXUAL AND GENDER IDENTITY DISORDERS</strong></td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIUM</strong></td>
</tr>
<tr>
<td>10  Sex, Sexuality, and 5HT 4</td>
</tr>
<tr>
<td><strong>MEDICAL UPDATE</strong></td>
</tr>
<tr>
<td>3  Better Sex: Naturally 77</td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
</tr>
<tr>
<td>34  Women's Sexuality Update: Overcoming Obstacles to Pleasure 60</td>
</tr>
<tr>
<td>51  Critical Perspectives on Gender Identity Disorder in Children and Adolescents 64</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
</tr>
<tr>
<td>89  The Sissy Duckling: The Perils of Childhood Gender Variance 74</td>
</tr>
<tr>
<td>98  Understanding and Treating Compulsive Sexual Behavior 75</td>
</tr>
<tr>
<td>100 Sexual Satisfaction and Mental Health in Orthodox Jewish Women 75</td>
</tr>
<tr>
<td><strong>TOPIC 13: SLEEP DISORDERS</strong></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
</tr>
<tr>
<td>24  Melatonin and Light Treatment of SAD, Sleep, and Other Body Clock Disorders 8</td>
</tr>
<tr>
<td>32  Irresistible Sleep: Narcolepsy Update 14</td>
</tr>
<tr>
<td>71  Overview and Update of Sleep Disorders Medicine 55</td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIUM</strong></td>
</tr>
<tr>
<td>28  Beyond Sleep Onset: New Perspectives on the Treatment of Insomnia 11</td>
</tr>
<tr>
<td>49  Exploring the True Morbidity of Insomnia 67</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
</tr>
<tr>
<td>92  Modafinil Improves Patient Functioning in Shift Work Sleep Disorder 97</td>
</tr>
<tr>
<td>93  Modafinil Treatment of Chronic Shift Work Sleep Disorder 97</td>
</tr>
<tr>
<td><strong>TOPIC 14: SOMATOFORM DISORDERS</strong></td>
</tr>
<tr>
<td><strong>CLINICAL CASE CONFERENCE</strong></td>
</tr>
<tr>
<td>1  Boundary Issues and the Challenge of the Somatizing Patient 15</td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
</tr>
<tr>
<td>61  Pain Management for Psychiatrists: An Overview of Treatment Approaches 42</td>
</tr>
<tr>
<td>76  The Complexities of Chronic Pain: Psychiatric Issues and Treatments 56</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
</tr>
<tr>
<td>103  BDD: Is It a Mind, Body, or Sociocultural Problem and How Do You Treat It? 102</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
</tr>
<tr>
<td>21  Chronic Fatigue Syndrome: Disease or Abnormal Illness Behavior? 25</td>
</tr>
<tr>
<td>50  Fibromyalgia: Current Understanding and Future Directions 47</td>
</tr>
<tr>
<td>71  Psychogenic Seizures: A Prototype of Somatoform Disorder 54</td>
</tr>
<tr>
<td><strong>PRACTICE AREAS/SETTINGS</strong></td>
</tr>
<tr>
<td><strong>TOPIC 15: PSYCHIATRIC ADMINISTRATION AND SERVICES: PUBLIC, PRIVATE, AND UNIVERSITY</strong></td>
</tr>
<tr>
<td><strong>LECTURES</strong></td>
</tr>
<tr>
<td>3  The Changing Face of Mental Health Services 16</td>
</tr>
<tr>
<td>16  How Many Psychiatrists Do We Need? 56</td>
</tr>
<tr>
<td>22  Public Academic Liaison: Pursuit of Best Practices in a Time of Economic Entrenchment 76</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORT</strong></td>
</tr>
<tr>
<td>52  Inter-European Countries Comparison on Treatment Use for Mental Health Disorders 52</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
</tr>
<tr>
<td>38  How to Launch a Successful Private Practice, Part 3 60</td>
</tr>
<tr>
<td>86  Managing HIPAA-Related Tensions in Clinical Practice 90</td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOPS</strong></td>
</tr>
<tr>
<td>7  State Hospital Psychiatry: Been Down to Long It Looks Like up to Me 18</td>
</tr>
<tr>
<td>29  Helping District Branches Relate to APA and to Their Members 53</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
</tr>
<tr>
<td>19  Psychiatry in the Primary Care Setting: Making It Work for the Psychiatrist 25</td>
</tr>
<tr>
<td>39  How to Launch a Successful Private Practice, Part 1 46</td>
</tr>
<tr>
<td>61  How to Launch a Successful Private Practice, Part 2 53</td>
</tr>
<tr>
<td>102 Implementing Psychosocial Treatments in Real-World Settings 75</td>
</tr>
<tr>
<td><strong>TOPIC 16: ADDICTION PSYCHIATRY</strong></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
</tr>
<tr>
<td>85  Office-Based Buprenorphine Treatment of Opioid-Dependent Patients 70</td>
</tr>
<tr>
<td>96  Street Drugs and Mental Disorders: Overview and Treatment 82</td>
</tr>
<tr>
<td>98  Introduction to Transcranial Magnetic Stimulation (TMS) 93</td>
</tr>
<tr>
<td>111</td>
</tr>
<tr>
<td>TOPIC INDEX</td>
</tr>
<tr>
<td>-------------</td>
</tr>
<tr>
<td>FORUM</td>
</tr>
<tr>
<td>10 Buprenorphine: What the Clinician Should Know</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIUM</td>
</tr>
<tr>
<td>LECTURE</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
</tr>
<tr>
<td>COMPONENT WORKSHOP</td>
</tr>
<tr>
<td>ISSUE WORKSHOP</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
</tr>
<tr>
<td>103 Hyperactive Error Processing in OCD</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
</tr>
<tr>
<td>REVIEW OF PSYCHIATRY: SECTION 3 Developmental Psychobiology</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
</tr>
<tr>
<td>98 Depression and Nonlinear Heart Rate Dynamics in Older Coronary Patients</td>
</tr>
<tr>
<td>SYMPOSA</td>
</tr>
<tr>
<td>MODULE WORKSHOP</td>
</tr>
<tr>
<td>REVIEW OF PSYCHIATRY: SECTION 4 Brain Stimulation in Psychiatric Treatment</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
</tr>
<tr>
<td>114 Evaluating Treatment With Functional Brain Imaging</td>
</tr>
<tr>
<td>TOPIC 17: BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE</td>
</tr>
<tr>
<td>REVIEW OF PSYCHIATRY: SECTION 3 Developmental Psychobiology</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
</tr>
<tr>
<td>103 Hyperactive Error Processing in OCD</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
</tr>
<tr>
<td>LECTURE</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
</tr>
<tr>
<td>98 Depression and Nonlinear Heart Rate Dynamics in Older Coronary Patients</td>
</tr>
<tr>
<td>SYMPOSA</td>
</tr>
<tr>
<td>MODULE WORKSHOP</td>
</tr>
<tr>
<td>REVIEW OF PSYCHIATRY: SECTION 4 Brain Stimulation in Psychiatric Treatment</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
</tr>
<tr>
<td>114 Evaluating Treatment With Functional Brain Imaging</td>
</tr>
<tr>
<td>TOPIC 18: BRAIN IMAGING</td>
</tr>
<tr>
<td>LECTURE</td>
</tr>
<tr>
<td>REVIEW OF PSYCHIATRY: SECTION 4 Brain Stimulation in Psychiatric Treatment</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
</tr>
<tr>
<td>98 Depression and Nonlinear Heart Rate Dynamics in Older Coronary Patients</td>
</tr>
<tr>
<td>SYMPOSA</td>
</tr>
<tr>
<td>MODULE WORKSHOP</td>
</tr>
<tr>
<td>REVIEW OF PSYCHIATRY: SECTION 4 Brain Stimulation in Psychiatric Treatment</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
</tr>
<tr>
<td>114 Evaluating Treatment With Functional Brain Imaging</td>
</tr>
<tr>
<td>TOPIC 19: CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS</td>
</tr>
<tr>
<td>ADVANCES IN RESEARCH</td>
</tr>
<tr>
<td>RESEARCH ADVANCES IN MEDICINE</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
</tr>
<tr>
<td>47 Externalizing Behaviors in Preadolescent Children: A National Panel Study</td>
</tr>
<tr>
<td>48 Gender and the Prediction of Drug and Alcohol Abuse in Adolescent Inpatients</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
</tr>
<tr>
<td>COMPONENT WORKSHOPS</td>
</tr>
<tr>
<td>35 The Psychiatrist in the Schools: Medication, Boundaries, and Transference Issues</td>
</tr>
<tr>
<td>40 New Classification of Psychopathology of Infants and Young Children</td>
</tr>
<tr>
<td>ISSUE WORKSHOP</td>
</tr>
<tr>
<td>TOPIC 20: CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY</td>
</tr>
<tr>
<td>DISCUSSION GROUPS</td>
</tr>
<tr>
<td>18 Psychological Engagement During the Consultation Process (Max the Author)</td>
</tr>
<tr>
<td>LECTURE</td>
</tr>
<tr>
<td>MEDICAL UPDATES</td>
</tr>
<tr>
<td>2 Hepatitis B and C: What's New</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
</tr>
<tr>
<td>98 Depression and Nonlinear Heart Rate Dynamics in Older Coronary Patients</td>
</tr>
<tr>
<td>SYMPOSA</td>
</tr>
<tr>
<td>MODULE WORKSHOP</td>
</tr>
<tr>
<td>REVIEW OF PSYCHIATRY: SECTION 4 Brain Stimulation in Psychiatric Treatment</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
</tr>
<tr>
<td>114 Evaluating Treatment With Functional Brain Imaging</td>
</tr>
<tr>
<td>TOPIC 21: CROSS-CULTURAL AND MINORITY ISSUES</td>
</tr>
<tr>
<td>CLINICAL CASE CONFERENCE</td>
</tr>
<tr>
<td>2 Assessing and Treating Psychiatric Symptoms in Individuals With Cardiovascular Disease</td>
</tr>
</tbody>
</table>
# TOPIC INDEX

## COURSES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>DSM-IV-TR Cultural Formulations: Diagnosis and Therapy</td>
</tr>
<tr>
<td>82</td>
<td>The Clinical Application of Cultural Psychiatry</td>
</tr>
</tbody>
</table>

## LECTURE

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>71</td>
<td>Latino Youth in the U.S.: Developmental and Mental Health Challenges</td>
</tr>
</tbody>
</table>

## SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>Ethnic-Matched, Culturally-Competent, Model-Based ACT Team: Early Outcome Report</td>
</tr>
<tr>
<td>77</td>
<td>Screening for Depression Among Chinese Americans in Primary Care Using Two Items</td>
</tr>
<tr>
<td>77</td>
<td>Suicidal Thinking in Colombian Youth: A History of Attempted Suicide</td>
</tr>
<tr>
<td>79</td>
<td>Ethnicity, Diagnosis, and Health Care Utilization in Incarcerated Women</td>
</tr>
</tbody>
</table>

## SYMPOSIA

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>88</td>
<td>Psychiatry, Ethnicity, and Culture: An Update on Ethno-Pharmacology, Mood, and Anxiety Disorders in Minority</td>
</tr>
<tr>
<td>91</td>
<td>Memory in the U.S. and France: Vive La Difference</td>
</tr>
<tr>
<td>91</td>
<td>Meeting the Mental Health Needs of Latinos in Community and Primary Care</td>
</tr>
</tbody>
</table>

## COMPONENT WORKSHOPS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>How to Teach and Learn Cultural Competence in Geriatric Psychiatry</td>
</tr>
<tr>
<td>18</td>
<td>Facilitating Research on Minority Populations by Minority Researchers</td>
</tr>
<tr>
<td>18</td>
<td>Bridging Across Culture and Generations: An Asian-American Perspective</td>
</tr>
<tr>
<td>45</td>
<td>The Ties That Bind: Considerations of Culture and Family in Mental Health Treatment</td>
</tr>
<tr>
<td>73</td>
<td>Reducing Disparities in Access to Psychiatric Care: APA Perspectives</td>
</tr>
<tr>
<td>79</td>
<td>Response to the Simon Bolivar Award Lecture on Latino Youth in the U.S.: Developmental and Mental Health Challenges</td>
</tr>
</tbody>
</table>

## ISSUE WORKSHOPS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>Treating African-American Patients With Psychotherapy: A Training Dilemma</td>
</tr>
<tr>
<td>48</td>
<td>It Doesn't Happen to Us: Exploring Trauma and Resilience in Minorities</td>
</tr>
<tr>
<td>74</td>
<td>Migration and Professional Identity Experience of Organizing Russian-American Psychiatry</td>
</tr>
<tr>
<td>74</td>
<td>Perinatal Counseling: The Facts of Life and More</td>
</tr>
<tr>
<td>74</td>
<td>Psychotherapy Issues Throughout the Life Cycle in Asian Women</td>
</tr>
</tbody>
</table>

## MEDIA WORKSHOP

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>48</td>
<td>Cultural Assessment in Clinical Psychiatry: Two Training Videotapes</td>
</tr>
</tbody>
</table>

## SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>51</td>
<td>Effects of 9/11 and Chronic Stress on Female Drinking and Anxiety</td>
</tr>
<tr>
<td>52</td>
<td>Prevalence and Outcomes of Childhood Adversity in an Australian Population</td>
</tr>
<tr>
<td>79</td>
<td>Psychotropic Drug Utilization in Six European Countries</td>
</tr>
<tr>
<td>79</td>
<td>Onset of DSM-IV Alcohol Abuse and Dependence: A 10-Year Prospective Study</td>
</tr>
<tr>
<td>97</td>
<td>A Comparison of Seasonality of Mood and Behavior in African and Asian-American Students</td>
</tr>
</tbody>
</table>

## TOPIC 24: ETHICS AND HUMAN RIGHTS

### COURSE

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>69</td>
<td>Bioethics Update 2004</td>
</tr>
</tbody>
</table>

### DISCUSSION GROUP

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>Ethics in Psychiatric Practice</td>
</tr>
</tbody>
</table>

### FORUMS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td>Ethical Dilemmas in Practice and Research</td>
</tr>
<tr>
<td>55</td>
<td>Should Sex Be Prevented in Psychiatric Units? Arguments and New Directions</td>
</tr>
<tr>
<td>99</td>
<td>APA and the Pharmaceutical Industry: An Open Forum</td>
</tr>
</tbody>
</table>

### MASTER EDUCATOR CLINICAL CONSULTATION

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>72</td>
<td>Psychiatric Issues and Interventions at the End of Life</td>
</tr>
</tbody>
</table>

### ROUND TABLE DISCUSSION

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>45</td>
<td>Coercion and Treatment: Medical, Legal, and Ethical Issues</td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORT

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>51</td>
<td>How Do Psychiatric Patients Perceive Research Participation?</td>
</tr>
</tbody>
</table>

### SYMPOSIA

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td>The Death Penalty: Law and Medical Ethics in the Face of New Court Opinions</td>
</tr>
<tr>
<td>105</td>
<td>Institutional Ethics in Psychiatry: A Multidisciplinary Perspective</td>
</tr>
</tbody>
</table>

### COMPONENT WORKSHOPS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>46</td>
<td>Revision of the APA Ethics Annotations: Fostering Dialogue</td>
</tr>
<tr>
<td>73</td>
<td>APA Ethics Procedures</td>
</tr>
<tr>
<td>80</td>
<td>Psychiatric Ethics in the U.S. and Throughout the World</td>
</tr>
</tbody>
</table>

### ISSUE WORKSHOPS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>Are There Limits to Boundary Limits?</td>
</tr>
<tr>
<td>26</td>
<td>Boundary Violations: History, Typology, and Prevention</td>
</tr>
<tr>
<td>53</td>
<td>Approaching Moral Issues in Mental Health Treatment</td>
</tr>
<tr>
<td>75</td>
<td>Guideline Development for the Assessment of Competency</td>
</tr>
</tbody>
</table>

## TOPIC 25: FORENSIC PSYCHIATRY

### COURSES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>The Psychiatrist as Expert Witness</td>
</tr>
<tr>
<td>42</td>
<td>The Detection of Malingered Mental Illness</td>
</tr>
<tr>
<td>69</td>
<td>Insanity Defense Evaluations</td>
</tr>
<tr>
<td>69</td>
<td>Contemporary Malpractice Liability: A Practical Guide</td>
</tr>
<tr>
<td>70</td>
<td>Infanticide: A Dialogue Between the Psychiatrist and the Attorney</td>
</tr>
</tbody>
</table>

### FORUMS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td>Jails or Treatment? Alternatives to Incarceration</td>
</tr>
<tr>
<td>55</td>
<td>Reversing the Criminalization of the Seriously Mentally Ill</td>
</tr>
</tbody>
</table>

### LECTURE

<table>
<thead>
<tr>
<th>Page #</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Infanticide: The Hope of Prevention and the Promise of Saved Lives</td>
</tr>
</tbody>
</table>
### TOPIC INDEX

**SYMPOSIUM**

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
<th>Page</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>The Scientific Basis of Expert Testimony: Its Application to Matrimonial Disputes</td>
<td>34</td>
<td></td>
</tr>
</tbody>
</table>

**COMPONENT WORKSHOPS**

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
<th>Page</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>What's New in Psychiatry and the Law at APA?</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Fitness to Practice Medicine: The Roles of the Evaluating Psychiatrist</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>The Juvenile Justice System: Assessment, Services, and Data Use</td>
<td>46</td>
<td></td>
</tr>
</tbody>
</table>

**ISSUE WORKSHOPS**

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
<th>Page</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Brooklyn Mental Health Court: Felony Offenders With Mental Illness</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>The Clinical Impact of Treating Civil and Criminally-Mandated Psychiatric Patients</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>69</td>
<td>Rehabilitating Traumatized Girls in Residential Juvenile-Justice Settings</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>Kendra's Law Becomes Reality: Assisted Outpatient Treatment in Manhattan</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>113</td>
<td>Fitness-for-Duty Evaluations for Law-Enforcement Officers</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>118</td>
<td>Juvenile Justice Success Series, Chapter 1: Musicianship, Jazz, and Blues</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>119</td>
<td>Politics and Pregnancy: The Regina McKnight Case</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>125</td>
<td>Detection of Malingering</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>129</td>
<td>Avoiding Dual-Agency Pitfalls of Work-Related Neuropsychiatric Impairment</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>134</td>
<td>Whose Responsibility Is It Anyway? The Treating Psychiatrist?</td>
<td>96</td>
<td></td>
</tr>
<tr>
<td>141</td>
<td>An Extension of the Analysis of Restorative Justice and Therapeutic Jurisprudence</td>
<td>99</td>
<td></td>
</tr>
</tbody>
</table>

### TOPIC 26: GENETICS

**COURSE**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychiatric Genomics: Applications for Clinical Practice</td>
<td>3</td>
</tr>
</tbody>
</table>

**SCIENTIFIC AND CLINICAL REPORT**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence of MTHFR C677T and Methionine Synthase A2756G Polymorphisms in Major Depression and Impact on Response to Fluoxetine Treatment</td>
<td>78</td>
</tr>
</tbody>
</table>

### TOPIC 27: GERIATRIC PSYCHIATRY

**COURSES**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression in Later Life: An Interdisciplinary Approach</td>
<td>27</td>
</tr>
<tr>
<td>Psychiatric Consultation in Long-Term Care</td>
<td>69</td>
</tr>
</tbody>
</table>

**MASTER EDUCATOR CLINICAL CONSULTATION**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychiatric Disorders in the Elderly</td>
<td>94</td>
</tr>
</tbody>
</table>

**SCIENTIFIC AND CLINICAL REPORT**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interpersonal Psychotherapy for Depressed Elders With Cognitive Dysfunction</td>
<td>24</td>
</tr>
</tbody>
</table>

**SYMPOSIUM**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overcoming Barriers to Long-Term Care and Treatment of the Elderly</td>
<td>100</td>
</tr>
</tbody>
</table>

**COMPONENT WORKSHOP**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helping Older Persons With Schizophrenia: Treatment, Research, and Policy</td>
<td>25</td>
</tr>
</tbody>
</table>

**ISSUE WORKSHOPS**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>The After-Death Telephone Call to Family Members: Clinical Perspectives</td>
<td>19</td>
</tr>
<tr>
<td>The Transitional Object in Dementia</td>
<td>26</td>
</tr>
<tr>
<td>Geriatric Psychiatry Around the Globe: Present and Future</td>
<td>74</td>
</tr>
</tbody>
</table>

### TOPIC 28: NEUROPSYCHIATRY

**COURSES**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advances in Neuropsychiatry</td>
<td>7</td>
</tr>
<tr>
<td>Determining Medical Fitness to Drive: Relevant Issues for Psychiatrists</td>
<td>8</td>
</tr>
<tr>
<td>Traumatic Brain Injury: Neuropsychiatric Assessment</td>
<td>15</td>
</tr>
<tr>
<td>Temporal Lobe and Limbic System Anatomy and the Relation to Psychiatric Illness</td>
<td>28</td>
</tr>
<tr>
<td>The Missing Piece of the Puzzle: Tic Disorders in Adults With OCD or ADD</td>
<td>42</td>
</tr>
<tr>
<td>Updates in Neuropsychiatry Delirium, Traumatic Brain Injury, and Post-Stroke Depression</td>
<td>43</td>
</tr>
<tr>
<td>Neuropsychiatry of Traumatic Brain Injury</td>
<td>93</td>
</tr>
</tbody>
</table>

**INDUSTRY-SUPPORTED SYMPOSIUM**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interferon-Induced Depression: Consequences of Treating Chronic Hepatitis C</td>
<td>38</td>
</tr>
</tbody>
</table>

**LECTURE**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Social Neuroscience: A New Basic Science for Psychiatry</td>
<td>28</td>
</tr>
</tbody>
</table>

**MASTER EDUCATOR CLINICAL CONSULTATION**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuropsychiatry of Stroke: Recent Advances</td>
<td>22</td>
</tr>
</tbody>
</table>

**REVIEW OF PSYCHIATRY: SECTION 1**

Neuropsychiatric Assessment | 45 |

**SYMPOSIA**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>An Update on Parkinson's Disease and Its Psychiatric Complications</td>
<td>65</td>
</tr>
<tr>
<td>Neuropsychiatry of Traumatic Brain Injury Current Research</td>
<td>87</td>
</tr>
<tr>
<td>Traumatic Stress: The Bridge Between Neuroscience and Psychodynamic Psychiatry</td>
<td>104</td>
</tr>
</tbody>
</table>

**COMPONENT WORKSHOPS**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Neurobiology of Self-Awareness: Learning From Autism and BPD About How We Know Ourselves</td>
<td>45</td>
</tr>
</tbody>
</table>

**ISSUE WORKSHOP**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Application of Bedside Executive-Function Measures</td>
<td>53</td>
</tr>
</tbody>
</table>

### TOPIC 29: PSYCHIATRIC EDUCATION

**COURSES**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Biopsychosocial Formulation: An Approach to Oral Board Presentations</td>
<td>1</td>
</tr>
<tr>
<td>Teaching Psychiatry: Let Hollywood Help!</td>
<td>5</td>
</tr>
<tr>
<td>Evidence-Based Medicine: An Introduction for Psychiatrists</td>
<td>7</td>
</tr>
<tr>
<td>Dimensions of Psychotherapy Supervision: A Case-Based Approach</td>
<td>27</td>
</tr>
<tr>
<td>How to Pass the Boards! The Part II Oral Exam</td>
<td>43</td>
</tr>
<tr>
<td>I Found It at the Movies: Using Film Clips to Understand and Teach Psychiatry</td>
<td>82</td>
</tr>
</tbody>
</table>

**DISCUSSION GROUP**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Future Structure of Psychiatric Classification and Its Role in Enhancing Therapy, Teaching, and Research</td>
<td>20</td>
</tr>
</tbody>
</table>

**FORUM**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABPN Update: Requirements for ABPN Examination</td>
<td>27</td>
</tr>
</tbody>
</table>

**LECTURE**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Striking Accord: Tales of Teaching and the Heart</td>
<td>83</td>
</tr>
</tbody>
</table>

**SCIENTIFIC AND CLINICAL REPORT**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychiatry Training in Primary Care: Factors for a Satisfactory Program</td>
<td>98</td>
</tr>
</tbody>
</table>
### SYMPOSIUM

- **116 How to Practice Evidence-Based Medicine**

### COMPONENT WORKSHOPS

- **27 Where Fore Neuroscience: How Much Does the Psychiatrist Need to Know?**
- **49 The Blame and Shame Game in Medical Errors: Do You Want to Play It?**

### ISSUE WORKSHOPS

- **66 The Psychiatry Resident as Educator: A Proposal for Curriculum and Supervision**
- **73 Problems in the Psychiatric Education of International Medical Graduates**
- **77 Mirror, Mirror on the Wall: Ambition and the Teaching Psychiatrist**
- **88 Medical Training for Psychiatrists: What Do We Need to Know?**
- **130 Teaching Core Competencies: The Challenge for Academic Psychiatry**
- **133 Psychiatry Training for Primary-Care Physicians: What, How, and When?**

### TOPIC 35: PSYCHIATRIC REHABILITATION

#### COURSE

- **33 Recovery From Mental Illness and Stigma: Integrating Medicine and Rehabilitation**

#### ISSUE WORKSHOP

- **63 Psychiatric Rehabilitation and Psychodynamics**

### TOPIC 31: PSYCHOANALYSIS

#### DISCUSSION GROUP

- **2 Who Should Be Psychoanalyzed?**

### ISSUE WORKSHOP

- **38 Initial Psychiatric Interview: A Psychodynamic Approach to 90801**

### TOPIC 32: PSYCHOIMMUNOLOGY

#### SCIENTIFIC AND CLINICAL REPORT

- **70 Low Levels of Antibodies to Cardiolipin in First-Episode and Chronic Schizophrenia**

### TOPIC 33: RESEARCH ISSUES

#### COURSES

- **1 Assessment and Treatment of Drug-Induced Movement Disorders**
- **53 Doing Research on a Shoestring Budget**

#### LECTURE

- **12 Adventures in Psychiatric Research: Neurobiology to Public Policy**

#### NEW RESEARCH SESSIONS

- **1 Young Investigator's Poster Session**
- **2 Young Investigators' Oral/Slide Session**
- **3 Young Investigators' Oral/Slide Session**
- **4 Young Investigator's Oral/Slide Session**
- **5 Poster Session**
- **6 Poster Session**
- **7 Poster Session**
- **8 Poster Session**
- **9 Poster Session**
- **10 Poster Session**

#### RESEARCH CONSULTATION

- **1 Evaluating Evidence in Clinical Trials and Research Papers**

### ISSUE WORKSHOP

- **18 Psychiatric Research Perspectives in Latin America**

### TOPIC 34: SOCIAL AND COMMUNITY PSYCHIATRY

#### CONTINUOUS CLINICAL CASE CONFERENCE

- **1 Helping Patients Counter Demoralization While Living With a Chronic or Recurrent Psychiatric Illness, Part 1**
- **2 Helping Patients Counter Demoralization While Living With a Chronic or Recurrent Psychiatric Illness, Part 2**

#### COURSES

- **60 Disaster Psychiatry: Terrorism, Trauma, and Things to Do**
- **82 Psychiatry in Jail**

#### DISCUSSION GROUPS

- **12 Cross-Cultural Psychotherapy**
- **13 Public Psychiatry: Leading the Way in Transforming Service Delivery in the 21st Century**

#### FORUM

- **11 9/11 Research: A Review and Reviews**

#### LECTURE

- **10 Language, Psychosis, and the Speciation Event**

#### PRESIDENTIAL SYMPOSIUM

- **3 Reconstructing Postwar Mental Health Services**

#### SCIENTIFIC AND CLINICAL REPORTS

- **14 A Program for Treating Weight Gain Induced by Atypical Antipsychotics**
- **51 Developing Capacity Within CBOs for Health Education and Outreach**

#### SYMPOSIA

- **15 The Development of ADAP: The Adolescent Depression Awareness Program**
- **39 Use of Mandates and Leverage in Community-Based Treatment**
- **114 Providing Psychiatric Services Around the World With a Shortage of Psychiatrists**

#### COMPONENT WORKSHOP

- **16 Public Psychiatry: Leading the Way in Transforming Service Delivery in the 21st Century**

#### ISSUE WORKSHOPS

- **46 Engaging the Homeless in Treatment Strategies and Results**
- **54 A Shared-Care Model for Treating the Homeless Mentally Ill**
- **103 Criminal Justice System and Serious Mental Illness, Problems, and Solutions**
- **108 Sometimes It Is About You: The Use of Self in Engaging and Treating Homeless Individuals**
- **126 Can Social Theory Be Integrated Into the Liberatory Goals of Psychiatry?**

#### TOPIC 35: STRESS

#### COURSE

- **52 Child Murder by Parents**

#### SYMPOSIA

- **10 Mental Health Teams: Health Promotion and Preservation in War and Peace**
- **64 September 11th: After Two-and-a-Half Years**
TOPIC INDEX

COMPONENT WORKSHOP
33 Terrorism in America: The Distant Victims and the Role of IMG Psychiatrists 72

ISSUE WORKSHOPS
42 Infertility: A Chronic Illness With Chronic Challenges 47
131 Keep It Real: Psychological Preparedness and Active-Coping Group 95

TOPIC 36: SUICIDE

DISCUSSION GROUP
10 Assessing and Managing Suicide Risk: Clinically-Based Guidelines for Risk Management (Meet the Authors) 43

SCIENTIFIC AND CLINICAL REPORTS
10 High-Lethality Suicide Attempts in BPD 23
62 Suicidality and Second-Generation Antipsychotics in Patients With Schizophrenia 77
63 Melancholia and Suicide Attempts Probability and Lethality 78
64 Nonviolent Suicides in Women Are Increased During and After High Exposure to Tree Pollen 78
97 Life Changes, Social Adjustment, and Attempted Suicide in BPD and MDD 97

SYMPOSIA
97 Italian Psychiatry: 25 Years of Changes 101
101 Meaning in Suicide: Overcoming Barriers and Connecting Diverse Perspectives 102

ISSUE WORKSHOPS
12 Death by Suicide: The Words of Those Left Behind 19
15 Responding to the Impact of Suicide on Clinicians 19
20 No-Suicide Decisions, Contracts, and Assessment of Risk: Values and Cautions 25
115 Suicide and Schizophrenia: A Family Interview 81

TOPIC 37: VIOLENCE, TRAUMA, AND VICTIMIZATION

COURSES
11 Assessing the Risk of Violence in Both Forensic and Sex Offender Settings 3
13 Risk Assessment for Violence 5
30 Psychiatric Interventions in Disasters: Lessons From Experience 8
93 Men Sexually Abused as Boys: Meanings, Consequences, and Treatment 82

SCIENTIFIC AND CLINICAL REPORTS
39 Psychosocial Predictors of Long-Term Resilience Following the 9/11 Attacks 51
40 The Terrorist as a Nonpatient Subject of Psychiatric Investigation 51
53 Evaluation of a Therapeutic Interagency Preschool for Traumatized Children 52
54 Mental Health in Postwar Afghanistan 52
55 A Three-Dimensional Model of Violence in Schizophrenia 52

SYMPOSIA
5 Child Soldiers, Child and Adolescent Victims of War and Terrorism: Biopsychosocial Treatment for Reintegration Into Family and Society 31
6 New Directions in Terrorism and Political Violence: Causes and Responses 31
11 PTSD in Persons With Serious Mental Illness 32
28 New Perspectives in the Treatment of Complex PTSD 58
35 Contemporary Issues in Sport Psychiatry 60
37 Psychiatric Interventions With Medically-Evacuated Soldiers 62
113 The Effects of Sexual and Physical Abuse on Women's Health 105

COMPONENT WORKSHOPS
3 Public Health and Mental Health Partnership in Terrorism and Disasters 17
4 Child Soldiers: Child Victims of War and Terrorism: Psychosocial and Spiritual Needs 17
11 VA Mental Health's Response to Terrorism 18
18 Terror at Home: Addressing Domestic Violence in Your Practice 25
41 Consultation and Legal Clarification in Sexual Harassment 73

ISSUE WORKSHOPS
1 Disruptive Employees: Feedback-Assisted Counseling and Treatment 18
33 Mental Health Needs of Our Soldiers and Their Families 46
72 Clinical Effects of Sexual Abuse by Catholic Priests: A Forensic Perspective 54
76 Children and Families Facing Terrorism, Disasters, and Complex Emergencies 54
84 PTSD in the New York Fire Department: Bodies and Minds 74
117 Developing a Community Mental Health Response to Disasters and Terrorism 81
135 The Stalking Victim: Causes, Consequences, and Therapeutic Considerations 96
144 Reactions After 9/11 in a Pretraumatized Community in the South Bronx 99

MEDIA WORKSHOP
5 Postgenocide Psychological Trauma in Film, The Swimmer of Aries 75

TOPIC 38: BEHAVIOR AND COGNITIVE THERAPIES

ADVANCES IN RESEARCH
Hippocampal Volume in Major Depression: Effect of Antidepressant Treatment 20

COURSES
8 Behavioral Neuroanatomy: An Introduction 3
10 Cognitive Therapy for Severe Mental Disorders 3
15 Engaging Resistant and Hostile Patients Into Participatory Treatment 5
23 Basic Hypnosis: Principles and Applications 7
25 Cognitive Therapy for Schizophrenia 8
40 Cognitive-Behavior Therapy for Adult and Pediatric OCD: The Basics 14
44 Advanced Hypnosis: Applications in Psychiatry 15
89 Introduction to Cognitive-Behavioral Therapy 71

SCIENTIFIC AND CLINICAL REPORT
101 Self-Administrated Versus Therapist-Administered Cognitive-Behavior Therapy for Medication Nonresponders With OCD 98

ISSUE WORKSHOP
36 Using Cognitive Therapy for Psychosis in Psychiatric Practice 46

TOPIC 39: COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY

COURSES
65 A Psychodynamic Approach to Treatment-Refractory Mood Disorders 43
95 Integrating Psychotherapy and Pharmacotherapy 82
TOPIC INDEX

SCIENTIFIC AND CLINICAL REPORT
18 Integrating Psychotherapy With Medication to Improve Outcome 24

SYMPOSA
9 Recent Advances in the Treatment of Psychiatric Disorders in Primary Care: A U.S./U.K. Perspective 32
29 Bipolar Patients: Treatments and Cultural Issues in Latin America 58
30 Psychotherapy and Pharmacotherapy: Dissolving the Mind-Brain Barrier 58
49 Obsessive-Compulsive Spectrum Disorders: Update on Clinical Management 63

ISSUE WORKSHOPS
30 Cognitive Therapy and Pharmacotherapy: Teaching Residents Integrated Treatment Methods 26
101 Treatment of Adult ADHD: Combining Cognitive and Medical Approaches 75

MEDIA WORKSHOP
6 The Beginning Stages of Couples’ Therapy: Video Case Studies 75

TOPIC 40: COUPLE AND FAMILY THERAPIES

COURSES
37 Families Coping With Medical Illness: An Integrative Treatment Approach 14
70 Basic Family Skills for an Inpatient Psychiatrist 55

TOPIC 41: GROUP THERAPY

SYMPOSIUM
72 Group Therapy in Medical/Psychiatric Care 87

ISSUE WORKSHOPS
55 Group Interventions With Adolescents in Outpatient, Inpatient, and School Settings 48
121 Group Psychotherapy With Substance Abusers 94
122 Milieu Therapies in the Age of Managed Care, Revisited 95

TOPIC 42: INDIVIDUAL PSYCHOTHERAPIES

COURSES
4 Interpersonal Psychotherapy 1
17 Interpersonal Psychotherapy 5
29 Using Boundary Crossings as Creative Therapy Instead of Slippery Slopes 8
43 Davanloo’s Intensive Short-Term Dynamic Psychotherapy in Clinical Practice 15
46 Dream Translation: One Empirically-Based Approach 27
49 The Advanced Practice of Psychotherapy 27
69 Brief Psychodynamic Psychotherapy: The Core Confictual Relationship Theme Method 55

FORUM
1 Evidence-Based Psychotherapy 27

MASTER EDUCATOR CLINICAL CONSULTATION
4 Finding the Hidden Self: Engaging Difficult Patients in Exploratory Psychotherapy 22

SCIENTIFIC AND CLINICAL REPORT
19 Review of Psychotherapy Research Involving a Pill-Placebo Control 24

SYMPOSA
33 Interpersonal Psychotherapy: Research Update 59
52 The Art and Science of Brief Therapies 64
69 Supportive Psychotherapy: An Update 86

79 Personality, Therapeutic Alliance, and Outcome in Brief Psychotherapy 89
102 Individualizing Interpersonal Psychotherapy for Mood Disorders 102

COMPONENT WORKSHOP
2 Can’t Work, Shouldn’t Work, Mustn’t Work: Assessing Function and Mental Impairment in Psychiatric Illness 17

ISSUE WORKSHOPS
80 Psychodynamic Treatment of Depression 73
128 Leash on Life: Human Attachment to Animals 95

TOPIC 43: PSYCHOPHARMACOLOGY

ADVANCES IN PSYCHOPHARMACOLOGY
An Update for Clinicians 28

COURSES
34 Drug Treatment of Schizophrenia 14
63 Psychiatry Update: In Spanish 43
90 Med-Psych Drug-Drug Interactions 71

INDUSTRY-SUPPORTED SYMPOSA
22 Combination Therapy: New Strategies in the Management of Severe Mental Disorders 9
29 Psychopharmacology and Reproductive Transitions: Impact of Psychotropic Medications and Sex Hormones on Brain Functioning, Weight, and Reproductive Safety 12
30 Choosing the Right Dose of Atypical Antipsychotics: Art or Science? 12

RESEARCH CONSULTATION
3 Designing and Implementing Studies Contrasting Psychopharmacology and Psychotherapy 77

SCIENTIFIC AND CLINICAL REPORTS
2 Rivastigmine and Glantamine Treatment of Schizophrenic Cognitive Impairment 22
3 Dosing of Second-Generation Antipsychotics in a Large State Hospital System 22
7 Tiagabine Treatment of Social Anxiety Disorder 23
15 Increased Lipid Levels and Antipsychotic Medication 23
16 QTc Prolongation Associated With Ziprasidone 23
28 Buprenorphine: An Effective Treatment for Heroin Addicts 50
41 Antipsychotic Treatment and Sexual Adverse Events: The Role of Prolactin 51
42 Three-Bead Extended-Release Carbamazepine Capsule (SPD417) Continuation: Maintenance Therapy in Bipolar Disorder 51
43 Parkinsonism in a Nursing Home: Underrecognition 51
44 Concurrent Use of Multiple Antipsychotics in Psychiatric Inpatients 51
46 Polypharmacy and Its Ramifications in a Chronic Psychiatric Hospital 51
72 Oral S-Adenosyl Methionine (SAMe) for Antidepressant Augmentation: An Open-Label Trial 78
73 Somatic Symptoms as Predictors of Time to Onset of Response to Fluoxetine in MDD 78

SYMPOSA
19 Beyond B12: An Update on Nutrition and Psychiatry 34
44 Culture, Ethnicity, Race, and Psychopharmacology: New Research Perspectives 62
63 Psychotic Depression in 2004: The NIMH Collaborative Severe Depression Study 85

117
### TOPIC INDEX

#### TOPIC 57: PERSONAL DIGITAL ASSISTANTS (PDA)

**COURSES**
- 56 How to Use Your Palm OS PDA in Psychiatric Practice: Basic
- 75 How to Use Your Palm OS PDA in Psychiatric Practice: Advanced

#### TOPIC 58: POLITICAL QUESTIONS

**COURSE**
- 67 Personality and Political Behavior

#### TOPIC 59: PRESIDENTIAL THEME: PSYCHOTHERAPY AND PSYCHOPHARMACOLOGY: DISSOLVING THE MIND-BRAIN BARRIER

**COURSE**
- 83 Helping Parents From the Inside Out: Attachment, Mindset, and the Brain

**DISCUSSION GROUP**
- 11 What Can Brain Diseases Teach Us About the Mind-Brain Interface?

**FORUM**
- 7 Unconscious Prediction, Conscious Monitoring, and Therapeutic Change: Is There a Mind-Brain Barrier?

**PRESIDENTIAL SYMPOSIUM**
- 1 The Biopsychosocial Model: Myth or Reality?

#### TOPIC 60: PROFESSIONAL AND PERSONAL ISSUES

**COURSES**
- 6 The Conceptual Basis of Psychiatry
- 31 Improving Your Presentation Skills: A Coaching Approach
- 41 Money Matters I: Using Theory in Clinical Practice
- 59 Treating Medical Students and Physicians
- 88 Money Matters II: Advanced Clinical Practice

**SYMPOSIA**
- 78 Meditation for Psychotherapists and the Paradigm of Health
- 4 Psychiatry and Spirituality: A Holistic Perspective
- 14 Dialogue From the Rims of the Grand Canyon: On Bridging the Post-Freudian Chasm Between Religion and Psychiatry
- 72 Helping Parents From the Inside Out: Attachment, Mindset, and the Brain

**ISSUE WORKSHOPS**
- 17 Controversies at the Interface Between Religion and Psychiatric Practice
- 94 Dissolving Therapeutic Barriers: Spirituality Group Work With Psychiatric Staff
- 110 The Day I Died: A Near-Death Documentary and the Mind-Brain Barrier
- 139 Spiritual and Religious Assessment in Clinical Practice

#### TOPIC 61: RELIGION, SPIRITUALITY, AND PSYCHIATRY

**COURSE**
- 72 Meditation for Psychotherapists and the Paradigm of Health

**LECTURES**
- 4 Psychiatry and Spirituality: A Holistic Perspective
- 14 Dialogue From the Rims of the Grand Canyon: On Bridging the Post-Freudian Chasm Between Religion and Psychiatry

**MASTER EDUCATOR CLINICAL CONSULTATION**
- 10 Engaging Patients' Spiritual Resources in Building Resilience to Relapse of Major Psychiatric Disorders

**SYMPOSIA**
- 78 Gay and Lesbian Orthodox Jews: A Primer for Clinicians
- 104 Model Psychiatry Residency Programs on Religion and Spirituality

**ISSUE WORKSHOPS**
- 17 Controversies at the Interface Between Religion and Psychiatric Practice
- 94 Dissolving Therapeutic Barriers: Spirituality Group Work With Psychiatric Staff
- 110 The Day I Died: A Near-Death Documentary and the Mind-Brain Barrier
- 139 Spiritual and Religious Assessment in Clinical Practice

#### TOPIC 62: RESIDENT AND MEDICAL STUDENT CONCERNS

**DEBATE**
- Resolved: The RRC Should Continue to Require That Psychiatric Residency Programs Must Demonstrate That the Residents Have Achieved Competency in Psychodynamic Psychotherapy

**DISCUSSION GROUPS**
- 17 Publishing and Grant Writing (For Residents Only)
- 19 Patient Safety (For Residents Only)

**RESIDENT'S SESSION**
- Meet the Experts: Sunny-Side Up

**SYMPOSIUM**
- 106 Do Not Wait Until You Practice, Know It Now: What Residents and Early Psychiatrists Need to Know

**COMPONENT WORKSHOPS**
- 5 Career Choices in Psychiatry: Exploring Fellowship Training
- 36 Taking the First Step: What Are My Options in the Transition to Practice?
- 38 Dollars: The Pharmaceutical Industry in Psychiatric Training

**ISSUE WORKSHOPS**
- 23 What Psychiatry Residents Can Expect From NIMH-Sponsored Research Training
- 44 Oral Boards Boot Camp
- 52 The Impact of 9/11 on Psychiatric Residents and Training Programs
- 53 Implementing the Institute of Medicine Report: Fostering Research Careers via Residencies
### TOPIC 63: STIGMA/ADVOCACY

**SYMPOSIUM**
- 7  I Rest My Case 31

**COMPONENT WORKSHOP**
- 8  Leadership Skills for Public Advocacy 18

**ISSUE WORKSHOP**
- 105 When Psychiatrists Have Suffered a Mental Illness: Their Stories and Insights 80

### TOPIC 64: TELEPSYCHIATRY

**COURSE**
- 54  Expanding Health Care Delivery? Let Telepsychiatry Help! 42

### TOPIC 65: VIRTUAL REALITY

**SCIENTIFIC AND CLINICAL REPORT**
- 91  Virtual Reality Cue-Reactivity-Controlled Trial for Nicotine Dependence 97

**ISSUE WORKSHOP**
- 140 Long-Term Care Insurance Denials to One-Time Psychiatric Patients 99
### A

Adersen, Thomas F ........................................... 73  
Ahrendsen, Arnold E ........................................ 60  
Ahrendsen, Allan A .......................................... 80  
Ahrendsen, Berry ........................................... 97  
Ahrendsen, Carl M ........................................... 47  
Ahrendsen, Maru ............................................. 52  
Ahrendsen, Mary Beth ........................................ 19  
Ahrendsen, Tanya R ........................................... 26  
Andrade, Ana C ................................................ 58  
Andreasen, Nanci C .......................................... 48, 62  
Andreasen, Maryann ......................................... 95  
Anfang, Stuart A ............................................. 25  
Angelino, Andrew F .......................................... 47, 56, 70  
Angermeyer, Mathias C ...................................... 52  
Angur, Rube  .................................................. 51  
Ancombe, Rodenick J ........................................ 35  
Anton, Jr., Raymond F ........................................ 64  
Appelbaum, Paul S ........................................... 16, 34, 48, 61, 89, 96  
Argha, Ali A ................................................... 94  
Ashkenazy, Yaakov ........................................... 23  
Ashley, Kenneth B ............................................ 53  
Asnis, Gregory M ............................................. 38  
Atallah, Sherif F ............................................. 105  
Atkinson, Leslie ............................................. 105  
Atkinson, Jr., J. H ........................................... 82  
Aria, Evelyn ................................................... 96  
Aubin, Elizabeth ............................................. 22  
August, Gerald .............................................. 65  
Avena, Nicole N ............................................... 62  
Aviram, Ron B ................................................ 86  
Azarow, Jay ................................................... 51  
Azorin, Jean-Michel ......................................... 91  
Azoriniknam, M ............................................... 33  
Azarow, Jay ................................................... 51  
Beach, John O ................................................ 90  
Beaver, Alan R .............................................. 15  
Bege, Melissa D .............................................. 33  
Beitman, Joseph H ............................................ 100  
Beitzman, Bernard D ......................................... 45, 58, 82  
Belger, Aysenil ............................................... 10  
Bell, Carl C .................................................. 46, 53, 73  
Bell, Michael A ............................................. 85  
Bell, Robinette N ............................................ 54  
Bell, Alan S ................................................... 73  
Bennett, Selim ............................................... 54  
Bergen, Ruth M .............................................. 67  
Benedek, David M ........................................... 25, 71  
Benedek, Elispa S ............................................ 19  
Bennon, Timothy G .......................................... 45  
Berresin, Eugene V ......................................... 37, 83  
Bernstein, Carol A .......................................... 5, 7, 55  
Bernstein, David P .......................................... 30, 63  
Berry, Janet .................................................. 75  
Benzon, Janet A ............................................. 95  
Bhan, Shyam K ............................................... 14  
Baker, Philip A ............................................... 84  
Biederman, Joseph .......................................... 2, 45, 85, 98, 106  
Bierut, Laura J ............................................... 36  
Bijou, Outeg ................................................ 52  
Binder, Rene L ............................................... 14  
Birndorf, Catherine A ....................................... 60  
Biagita, Adam M ............................................ 84, 97  
Bisogno, Regina ............................................. 89  
Bishop, Leigh C ............................................. 53  
Bizer, Johannes ............................................. 54  
Black, Donald W ............................................ 64  
Black, Jed E ................................................ 11  
Blank, John L ............................................... 17  
Blaauw, Margaret .......................................... 37
PARTICIPANT INDEX

Coffman, Jennifer K ........................................... 57
Cohen, Amy ......................................................... 80
Cohen, Bruce M .................................................... 13, 41, 61
Cohen, Carl ......................................................... 25, 98, 99
Cohen, Lee S ....................................................... 39, 69, 93
Cohen, Mary ........................................................ 19, 53
Cohen, Michael ................................................... 1
Cohen, Neal I ....................................................... 85
Cohen, Patricia .......................... ................................ 35
Cairo, MaryJo .................................................... 35
Colantuoni, Carlo ................................................ 62
Coiro, Maryjo ...................................................... 35
Cohen, Patricia R .................................................. 35
Cohen, MaryAnn .................................................. 19, 53
Cohen, Carl ......................................................... 25, 95, 98
Coffman, Jennifer K ............................................. 57
Correak, Jennifer .................................................. 75
Corral, Maria R ................................................... 3
Corrado, Filomena .............................................. 50
Cornelius, Tehran ................................................ 18
Cordes, Jeffrey A .................................................. 53
Corcoran, Cheryl M .............................................. 87
Coplan, Jeremy D ................................................ 6
Copans, Stuart A .................................................. 53
Cooke, Edith ....................................................... 95
Connor, Kathryn M ................................................ 34
Connolly, Moira A ............................................... 103
Compton, Wilson .................................................. 36, 73
Combrinck-Hertz, Mark ........................................ 18
Colosimo, Lisa .................................................... 46
Colliver, James .................................................... 36
Cozza, Kelly L ..................................................... 71
Coyle, Jr., Joseph T ................................................ 71
Cowan, Ronald L .................................................. 85
Crisanti, Annette .................................................. 87
Crow, Deborah A .................................................. 42
Crow, Deborah ..................................................... 42
Crow, Scott ......................................................... 58
Crow, Todd S ........................................................ 33, 34
Coye, Joseph T .................................................... 71
Copp, Hilary ........................................................ 97
Correll, Jennifer ................................................... 75
Cornall, Maria R .................................................... 3
Corseille, Jennifer ................................................ 75
Cory, Sara A ........................................................ 34
Cott, Jerry M ....................................................... 34
Cowley, Deborah .................................................. 54
Courtois, Christine .............................................. 58
Cowen, Ronald L ................................................... 48
Cowley, Deborah .................................................. 29
Cox, Daniel J ........................................................ 106
Cox, Todd S .......................................................... 33
Coyne, Joseph T .................................................... 71
Cozza, Kelly L ..................................................... 71
Cozza, Stephen J ................................................... 60
Cox, Daniel J ........................................................ 106
Cox, Dee瑕疵 ..................................................... 60
Cox, Jolynn A ........................................................ 69
Crow, Scott ........................................................... 58
Crow, Timothy J ..................................................... 29
Crowe, Raymond R .............................................. 36
Cruz, Maria ........................................................ 96
Cryanowski, Jill M ................................................ 102
Czotler, Charles A .................................................. 97
Czekalski, Jeffrey L .................................................. 7
Czotler, Paul .......................................................... 52
Czotler, Paul .......................................................... 52
Dargani, Narender ............................................... 79
Das, Anandata ..................................................... 91
Datta, Mosti M ..................................................... 46
David, Anthony S .................................................. 77
David, Panakkal ................................................... 32
Davidoff, Donald A ............................................... 27
Davidson, Jonathan R T ....................................... 21, 35, 67, 69, 93
Davis, Jack ........................................................ 28
Davis, Lori L ....................................................... 66, 104
Davis, Mary H ..................................................... 18
Davis, Robert M .................................................... 77
Dawson, Michael .................................................. 20, 46
Dawson, Deborah A .............................................. 36
DeBattista, Charles .............................................. 2
De Chiara, Margherita .......................................... 50
de Contreras, Alfredo ........................................... 31
De Decker, Matthias .............................................. 24
De Girolamo, Giovanni .......................................... 79, 101
De Chiara, Margherita .......................................... 50
de Contreras, Alfredo ........................................... 31
PARTICIPANT INDEX
PARTICIPANT INDEX

Krystal, John H. .......................... 87, 104
Kudler, Harold S. ......................... 18
Kunwar, Arun R. .......................... 52
Kuo, Jack .................................. 46
Kupfer, David J. .......................... 11, 59
Kupper, Lawrence L ....................... 105
Kutshir, Marina L ......................... 34, 85
Kweder, Sandra L ........................ 12
Kwyten, Helen H. ......................... 100

Lamon-Fava, Stefania ..................... 78
Lamdan, Ruth M. .......................... 54
Lam, Raymond W. ......................... 88, 99
Lalonde, Justine K ......................... 67
Laje, Gonzalo .............................. 50
Ladd, Heather ............................. 91
Labutta, Robert J ........................ 88
Lauriello, John ............................ 28
Laurence, Jessica ......................... 33
Laor, Yoav ................................ 30
Laorondeguevara, M. Soledad .......... 98
Langsley, Donald G ...................... 53, 73
LaFer Bony ................................. 58
Lafayette, Jennifer M .................... 62
Lawson, J. Stuart ........................ 90
Lawson, William B ...................... 62, 105
Lebovis, Allen ............................ 56
Lewey, Barry J. .......................... 48
Lebowski, Michael R ..................... 34, 92
Leff, Susan J ................................ 73
Lefley, Harriet P .......................... 25
Leo, Raphael J ............................ 42
LeNestour, Annick ......................... 24
Leon, Raphael J. .......................... 42
Leoni, Christine .......................... 91
Leondra, Carlos .......................... 58
Lepe, Jean-Pierre ......................... 91
Lequesne, Elizabeth ...................... 53
Levi, Jerome .............................. 99
Levi, Nettie ................................ 95
Levy, Bruce R. ............................ 74
Li, Eric C. .................................. 18
Li, Xingbo ................................. 30
Liang, Warren M. ......................... 84
Lieberman, Jeffrey A ..................... 10, 28, 38
Lieberman, Ted ......................... 10, 34
Liddick, Graham ......................... 52
Lin, Kenneth .............................. 27
Lin, Russell F ............................. 5
Lindegger, Graham ........................ 52
Lirebent, Frank A ......................... 34
List, James F ................................ 77
List, John .................................. 30
List, Paul S. ............................... 30, 63
Law, Samuel F ............................. 24
Low, Joseph ............................... 11
Low, Kenneth ............................. 103
Lowenkopf, Eugene M ................... 69
Lowenthal, David A ...................... 27, 95
Loza, Nasser F ............................ 105
Lu, Francis G. ............................ 5, 42, 59, 73, 98, 103
Luby, Joan L. ............................. 25
Lucas, Suzie ............................... 22
Ludeman, Evelette ......................... 32
Luff, Jamie A .............................. 50
Lukas, Scott E ............................. 105
Luo, John S. ............................... 18, 42, 56
Lunzerman, Theodore G .................. 37
Lynam, Maria T ............................ 73
Lynch, Thomas ............................ 41
Lyons, Michael ........................... 36
Ma, Jie ................................. 77
Macchi, Mela M. .......................... 110
Macdonald, Shona M .................... 103
Macewan, Thomas ......................... 103
Mack, Avram H ............................ 16, 24, 75
MacKenzie, K. Roy ....................... 21
MacLurg, B. Jason ......................... 104
MacQueen, Glenda M .................... 38
Maguin, Eugene ........................... 90
Maguire, Marcella ....................... 75
Mah, Kenneth ............................. 59
Malaspina, Dolores ......................... 33, 87
Malcoun, John Robert .................... 64
Maldonado, Jose R ......................... 7, 15, 43, 98
Malean, Alexandra ....................... 91
Malhotra, Anil K ......................... 63
Malison, Robert T. ....................... 87
Malios, Ronna ............................. 98
Mallott, David B .......................... 99
Malloy, Erin M. ........................... 35
Maltman, Carl P ........................... 19
Malone, Kevin M .......................... 23
Malvy, Nicholas ........................... 98
Maree, Carol A. ........................... 50
Mancini, Catherine L ..................... 23
Manevitz, Alan Z.A ....................... 47
Manji, Hassan K .......................... 28
Man, Henry B. ............................ 1
Man, Joseph ............................... 23, 63, 76
Manuzza, Sal .............................. 65
Manos, Peter J ............................ 82
Manschreck, Theo C ....................... 62
Manu, Peter ................................ 25, 74
Maragou, Mary F .......................... 60
Marangell, Lauren B ....................... 30, 79, 93
Marano, Anthony ......................... 34
March, John S. ............................ 20
Marcus, Eric R. ............................ 19, 20
Marcus, Sheila ............................. 61
Marder, Stephen R ......................... 14
Martin, Flamberto ......................... 43, 86
Mark, Margery ............................ 65
Mark, Naomi ............................... 89
Marlot, Anaïs .............................. 61
Marlowitz, John C ........................ 5, 59, 101
Marzano, Charles R ....................... 104
Marotti, Ferruccio ......................... 46
Marrocco, Mary K ........................ 7
Marsh, Laura .............................. 65
<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prochownik, Isak</td>
<td>104</td>
</tr>
<tr>
<td>Puchalski, Christina M</td>
<td>99, 103</td>
</tr>
<tr>
<td>Puddles, Derek</td>
<td>65</td>
</tr>
<tr>
<td>Pugliese, Maria A</td>
<td>42</td>
</tr>
<tr>
<td>Pullen, Ian M</td>
<td>25</td>
</tr>
<tr>
<td>Pumaruga, Andres J</td>
<td>71, 79</td>
</tr>
<tr>
<td>Purcell, David C</td>
<td>67</td>
</tr>
<tr>
<td>Putsnam, Katherine M</td>
<td>85</td>
</tr>
<tr>
<td>Putnam, Jr., Frank W.</td>
<td>52</td>
</tr>
<tr>
<td>Pyles, Robert L</td>
<td>31</td>
</tr>
<tr>
<td>Qiu, F.</td>
<td>59</td>
</tr>
<tr>
<td>Quanbeck, Cameron D.</td>
<td>2</td>
</tr>
<tr>
<td>Qasida, Gonzalo F.</td>
<td>18</td>
</tr>
<tr>
<td>Rabins, Peter V.</td>
<td>131</td>
</tr>
<tr>
<td>Racy, John C</td>
<td>17</td>
</tr>
<tr>
<td>Raden, Jennifer</td>
<td>105</td>
</tr>
<tr>
<td>Rae, Donald S</td>
<td>50</td>
</tr>
<tr>
<td>Rainey, Charles J</td>
<td>56</td>
</tr>
<tr>
<td>Raison, Charles</td>
<td>39</td>
</tr>
<tr>
<td>Rajouria, Namita</td>
<td>42</td>
</tr>
<tr>
<td>Rakic, Pasko</td>
<td>33</td>
</tr>
<tr>
<td>Rambadiani, Gloria</td>
<td>59</td>
</tr>
<tr>
<td>Ramirez, C.</td>
<td>31</td>
</tr>
<tr>
<td>Ramirez, Luis F</td>
<td>8, 27</td>
</tr>
<tr>
<td>Ramirez, Paul M</td>
<td>69</td>
</tr>
<tr>
<td>Ramsay, J. Russell</td>
<td>75</td>
</tr>
<tr>
<td>Randall, Robert</td>
<td>87</td>
</tr>
<tr>
<td>Rao, Aruna S</td>
<td>48</td>
</tr>
<tr>
<td>Rao, Najati F</td>
<td>47, 54, 64</td>
</tr>
<tr>
<td>Rapaport, Mark H</td>
<td>1, 16, 21, 28</td>
</tr>
<tr>
<td>Rapin, Bruce</td>
<td>52</td>
</tr>
<tr>
<td>Rapp, Stephen R</td>
<td>12</td>
</tr>
<tr>
<td>Ranson, Natalie I</td>
<td>66, 70</td>
</tr>
<tr>
<td>Rath, Darlyne</td>
<td>85</td>
</tr>
<tr>
<td>Rathod, Shanaya</td>
<td>49</td>
</tr>
<tr>
<td>Rausch, Jeffrey L</td>
<td>80</td>
</tr>
<tr>
<td>Ravitz, Paula</td>
<td>40</td>
</tr>
<tr>
<td>Ray, Neepa</td>
<td>105</td>
</tr>
<tr>
<td>Razavi, Maryam</td>
<td>86</td>
</tr>
<tr>
<td>Realmuto, George M</td>
<td>65</td>
</tr>
<tr>
<td>Reddy, Raj</td>
<td>96</td>
</tr>
<tr>
<td>Regier, Darrel A</td>
<td>24, 27, 44, 59</td>
</tr>
<tr>
<td>Reich, D. Bradford</td>
<td>82</td>
</tr>
<tr>
<td>Reich, James H</td>
<td>30, 63</td>
</tr>
<tr>
<td>Reid, William H</td>
<td>16</td>
</tr>
<tr>
<td>Reifler, Burton V</td>
<td>27</td>
</tr>
<tr>
<td>Reinelt, Shaula P</td>
<td>18, 25</td>
</tr>
<tr>
<td>Reiman, John F</td>
<td>38</td>
</tr>
<tr>
<td>Riss, David M</td>
<td>95</td>
</tr>
<tr>
<td>Reisman, Dori B</td>
<td>17</td>
</tr>
<tr>
<td>Renner, Jr., John A</td>
<td>80</td>
</tr>
<tr>
<td>Renshaw, Perry F</td>
<td>41, 50, 61</td>
</tr>
<tr>
<td>Reoux, Joseph P</td>
<td>50</td>
</tr>
<tr>
<td>Resnick, Patricia</td>
<td>32</td>
</tr>
<tr>
<td>Resnick, Phillip J</td>
<td>5, 14, 28, 42, 69</td>
</tr>
<tr>
<td>Restakowski, Ray O</td>
<td>5</td>
</tr>
<tr>
<td>Ressler, Kerry J</td>
<td>2</td>
</tr>
<tr>
<td>Reus, Victor I</td>
<td>27</td>
</tr>
<tr>
<td>Reyes, Raymond M</td>
<td>80</td>
</tr>
<tr>
<td>Ryniakos III, Charles F</td>
<td>91</td>
</tr>
<tr>
<td>Riba, Michelle B</td>
<td>10, 14, 37, 58, 80</td>
</tr>
<tr>
<td>Rice, John</td>
<td>36</td>
</tr>
<tr>
<td>Richards, Lawrence K</td>
<td>99</td>
</tr>
<tr>
<td>Richardson, Denise M</td>
<td>45</td>
</tr>
<tr>
<td>Richardson, Jarrett W</td>
<td>14</td>
</tr>
<tr>
<td>Richman, Judith A</td>
<td>51</td>
</tr>
<tr>
<td>Rie, Richard R</td>
<td>19, 65</td>
</tr>
<tr>
<td>Rilf, Arthur</td>
<td>24</td>
</tr>
<tr>
<td>Riggs, Karen</td>
<td>89</td>
</tr>
<tr>
<td>Riley, Anne</td>
<td>35</td>
</tr>
<tr>
<td>Rinaldi, Paul J</td>
<td>26</td>
</tr>
<tr>
<td>Rinne, Thomas</td>
<td>30</td>
</tr>
<tr>
<td>Ritchie, Elspeth C</td>
<td>51, 83</td>
</tr>
<tr>
<td>Ritvo, Eva C</td>
<td>18</td>
</tr>
<tr>
<td>Rivin, Shureen</td>
<td>58</td>
</tr>
<tr>
<td>Roache, John D</td>
<td>77</td>
</tr>
<tr>
<td>Roberts, Laura W</td>
<td>16, 46, 73</td>
</tr>
<tr>
<td>Robertson, Emma K</td>
<td>104</td>
</tr>
<tr>
<td>Robertson, Judith</td>
<td>35</td>
</tr>
<tr>
<td>Robertson, Margarette</td>
<td>104</td>
</tr>
<tr>
<td>Robinson, Carolyn B</td>
<td>19</td>
</tr>
<tr>
<td>Robinson, Gail E</td>
<td>8, 96</td>
</tr>
<tr>
<td>Robinson, Gilbert</td>
<td>99</td>
</tr>
<tr>
<td>Robinson, Robert G</td>
<td>22</td>
</tr>
<tr>
<td>Robinson, Susan</td>
<td>59</td>
</tr>
<tr>
<td>Robinson, Terry E</td>
<td>90</td>
</tr>
<tr>
<td>Roca, Cathleen A</td>
<td>70</td>
</tr>
<tr>
<td>Roca, Robert F</td>
<td>90</td>
</tr>
<tr>
<td>Rodenhausler, Paul</td>
<td>27</td>
</tr>
<tr>
<td>Rodgers, Bryan</td>
<td>52</td>
</tr>
<tr>
<td>Rodiguez, Denry</td>
<td>54</td>
</tr>
<tr>
<td>Rodrigues, Richard A</td>
<td>97</td>
</tr>
<tr>
<td>Roffman, Joshua I</td>
<td>52</td>
</tr>
<tr>
<td>Rogan, Alice</td>
<td>70, 93</td>
</tr>
<tr>
<td>Rogan, Gerald</td>
<td>80</td>
</tr>
<tr>
<td>Rogers, Anna E</td>
<td>95</td>
</tr>
<tr>
<td>Rogers, James R</td>
<td>102</td>
</tr>
<tr>
<td>Rogge, Scott D</td>
<td>46</td>
</tr>
<tr>
<td>Rohan, Kelly J</td>
<td>97</td>
</tr>
<tr>
<td>Rohrbough, Robert M</td>
<td>1</td>
</tr>
<tr>
<td>Roczewicz, Jr., Stephen</td>
<td>86</td>
</tr>
<tr>
<td>Rolland, John S</td>
<td>14</td>
</tr>
<tr>
<td>Rondon, Marta B</td>
<td>74</td>
</tr>
<tr>
<td>Ronningstam, Elsa F</td>
<td>63</td>
</tr>
<tr>
<td>Roose, Steven P</td>
<td>5, 11</td>
</tr>
<tr>
<td>Rosen, Cherise</td>
<td>23, 51</td>
</tr>
<tr>
<td>Rosenbaum, Jerold F</td>
<td>5, 30, 88</td>
</tr>
<tr>
<td>Rosenbaum, Talli</td>
<td>75</td>
</tr>
<tr>
<td>Rosenberg, Stanley</td>
<td>32</td>
</tr>
<tr>
<td>Rosenberger, John W</td>
<td>73</td>
</tr>
<tr>
<td>Rosenfeld, Arvon A</td>
<td>35</td>
</tr>
<tr>
<td>Rosenman, Stephen J</td>
<td>52</td>
</tr>
<tr>
<td>Rosenthal, Norman</td>
<td>77</td>
</tr>
<tr>
<td>Rosenthal, Richard N</td>
<td>18, 101</td>
</tr>
<tr>
<td>Rossel, Erik J</td>
<td>55</td>
</tr>
<tr>
<td>Rospenda, Kathleen M</td>
<td>51</td>
</tr>
<tr>
<td>Rossian, Anthony L</td>
<td>48, 75</td>
</tr>
<tr>
<td>Rod, Thomas</td>
<td>11, 97</td>
</tr>
<tr>
<td>Rohe, Eugenio M</td>
<td>72</td>
</tr>
<tr>
<td>Rothenberg, Jami</td>
<td>84</td>
</tr>
<tr>
<td>Rothschild, Anthony J</td>
<td>85, 97</td>
</tr>
<tr>
<td>Rothschild, Louis</td>
<td>97</td>
</tr>
<tr>
<td>Rothenstein, David</td>
<td>31, 51</td>
</tr>
<tr>
<td>Rossetti, Alvin A</td>
<td>35</td>
</tr>
<tr>
<td>Rosen, Stephen J</td>
<td>52</td>
</tr>
<tr>
<td>Rosenthal, Norman</td>
<td>77</td>
</tr>
<tr>
<td>Rosenthal, Richard N</td>
<td>18, 101</td>
</tr>
<tr>
<td>Roy-Moore, Peter P</td>
<td>104</td>
</tr>
<tr>
<td>Roye, Candenika</td>
<td>60</td>
</tr>
<tr>
<td>Roy, Byrne</td>
<td>32, 67</td>
</tr>
<tr>
<td>Rozenberg, Marina</td>
<td>60</td>
</tr>
<tr>
<td>Rubenstein, Michael N</td>
<td>42</td>
</tr>
<tr>
<td>Rubin, Eugene H</td>
<td>15</td>
</tr>
<tr>
<td>Ruddin, Marie G</td>
<td>73</td>
</tr>
<tr>
<td>Rudil, John R</td>
<td>27</td>
</tr>
<tr>
<td>Rudin, F.</td>
<td>24</td>
</tr>
<tr>
<td>Rudolph, Mark N</td>
<td>79</td>
</tr>
<tr>
<td>Rudolph, Steven E</td>
<td>19</td>
</tr>
<tr>
<td>Rueda-Lara, Maria A</td>
<td>42</td>
</tr>
<tr>
<td>Ruggieri, Mirella</td>
<td>101</td>
</tr>
<tr>
<td>Ruiz, Pedro</td>
<td>20, 26, 46, 62, 73, 79</td>
</tr>
<tr>
<td>Ruiz, Robert T</td>
<td>32</td>
</tr>
<tr>
<td>Ruiz-Mellot, Katherine G</td>
<td>78</td>
</tr>
<tr>
<td>Rush, A. John</td>
<td>78, 11, 30, 50, 57, 84</td>
</tr>
<tr>
<td>Rusquelet, Astrid N</td>
<td>95</td>
</tr>
<tr>
<td>Russo, Leo</td>
<td>77, 79</td>
</tr>
<tr>
<td>Ryan, Deirdre M</td>
<td>3</td>
</tr>
<tr>
<td>Ryan, J. Michael</td>
<td>13, 41</td>
</tr>
<tr>
<td>Ryan, Julie L</td>
<td>50</td>
</tr>
<tr>
<td>Ryan, Abe M</td>
<td>69</td>
</tr>
<tr>
<td>Ryck, Joel H</td>
<td>30</td>
</tr>
<tr>
<td>Saeidi, Martha</td>
<td>27</td>
</tr>
<tr>
<td>Salaye, Kenneth M</td>
<td>17</td>
</tr>
<tr>
<td>Sallam, Karreni L</td>
<td>34</td>
</tr>
<tr>
<td>Salo, Roberta</td>
<td>81</td>
</tr>
<tr>
<td>Salliyeh, Stephen F</td>
<td>1</td>
</tr>
<tr>
<td>Salo, Ruth E</td>
<td>45</td>
</tr>
<tr>
<td>Salvatore, Paola</td>
<td>79</td>
</tr>
<tr>
<td>Saltman, Carl</td>
<td>4</td>
</tr>
<tr>
<td>Same, Sharon</td>
<td>97</td>
</tr>
<tr>
<td>Sampo, Eduardo</td>
<td>98</td>
</tr>
<tr>
<td>Sandison, Neil B</td>
<td>71</td>
</tr>
<tr>
<td>San, Mary</td>
<td>6</td>
</tr>
<tr>
<td>Santone, Giovanni</td>
<td>101</td>
</tr>
<tr>
<td>Sar, Vedat</td>
<td>87</td>
</tr>
<tr>
<td>Sartoris, Norman</td>
<td>36, 65, 83</td>
</tr>
<tr>
<td>Sasson, Yehuda</td>
<td>92</td>
</tr>
<tr>
<td>Savage, Seddon R</td>
<td>30</td>
</tr>
<tr>
<td>Savallhein, Maritza J</td>
<td>23</td>
</tr>
<tr>
<td>Sax Amendment, Andrew J</td>
<td>10</td>
</tr>
<tr>
<td>Saykin, Andrew</td>
<td>87</td>
</tr>
<tr>
<td>Scally, Erin</td>
<td>90</td>
</tr>
<tr>
<td>Scandall, Donna</td>
<td>105</td>
</tr>
<tr>
<td>Schacht, Lucille</td>
<td>57</td>
</tr>
<tr>
<td>Schofer, Catherine A</td>
<td>33</td>
</tr>
<tr>
<td>Schaeffer, Mary Anne</td>
<td>72</td>
</tr>
<tr>
<td>Schane, Murray D</td>
<td>82</td>
</tr>
<tr>
<td>Schart, Martin B</td>
<td>99</td>
</tr>
<tr>
<td>Schatzberg, Alan F</td>
<td>28, 39, 44, 56, 66</td>
</tr>
<tr>
<td>Scheiber, Stephen C</td>
<td>27</td>
</tr>
<tr>
<td>Schendler, Saul</td>
<td>48, 95</td>
</tr>
<tr>
<td>Schmidt, Diane H</td>
<td>34</td>
</tr>
<tr>
<td>Schiffer, Randolph B</td>
<td>55</td>
</tr>
<tr>
<td>Schillerstrom, Jason E</td>
<td>53</td>
</tr>
<tr>
<td>Schlaepfer, Thomas E</td>
<td>83, 84</td>
</tr>
<tr>
<td>Schlodros, Kelly</td>
<td>35</td>
</tr>
<tr>
<td>Schloos, Heather</td>
<td>78</td>
</tr>
<tr>
<td>Schmit, Christian G</td>
<td>38, 85</td>
</tr>
<tr>
<td>Name</td>
<td>Pages</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Toth, Anna M.</td>
<td>75</td>
</tr>
<tr>
<td>Tracy, Martin G.</td>
<td>26, 46, 103</td>
</tr>
<tr>
<td>Tran, Pierre V.</td>
<td>24</td>
</tr>
<tr>
<td>Treisman, Glenn J.</td>
<td>19, 20, 47, 50, 70</td>
</tr>
<tr>
<td>Trieschmann, Martha</td>
<td>51</td>
</tr>
<tr>
<td>Tripod, Elisa G.</td>
<td>50</td>
</tr>
<tr>
<td>Triplin, Michael R.</td>
<td>7</td>
</tr>
<tr>
<td>Trinidad, Anton C.</td>
<td>23, 90, 98</td>
</tr>
<tr>
<td>Tripittelli, Carol L.</td>
<td>79</td>
</tr>
<tr>
<td>Trivedi, Madhukar H.</td>
<td>50</td>
</tr>
<tr>
<td>Troch, Richard N.</td>
<td>13</td>
</tr>
<tr>
<td>Trujillo, Manuel</td>
<td>53</td>
</tr>
<tr>
<td>Truman, Christine J.</td>
<td>50</td>
</tr>
<tr>
<td>Tisch, Werner</td>
<td>59</td>
</tr>
<tr>
<td>Tseng, Wen-Shing</td>
<td>82</td>
</tr>
<tr>
<td>Tsu, Alice C.</td>
<td>74</td>
</tr>
<tr>
<td>Tsosidlov, Faina</td>
<td>23</td>
</tr>
<tr>
<td>Tsu, John W.</td>
<td>19, 82</td>
</tr>
<tr>
<td>Tsu, Ming T.</td>
<td>36</td>
</tr>
<tr>
<td>Tucker, Pheebe M.</td>
<td>8</td>
</tr>
<tr>
<td>Tucker, William M.</td>
<td>42, 85</td>
</tr>
<tr>
<td>Turck, Catherine</td>
<td>64, 74</td>
</tr>
<tr>
<td>Tulloch, Simon J.</td>
<td>98</td>
</tr>
<tr>
<td>Tune, Larry E</td>
<td>15, 71</td>
</tr>
<tr>
<td>Turgay, Atilla</td>
<td>51</td>
</tr>
<tr>
<td>Turkelston, Douglas</td>
<td>8, 46, 57</td>
</tr>
<tr>
<td>Tu, Ania L.</td>
<td>100</td>
</tr>
<tr>
<td>Uhl, George</td>
<td>36</td>
</tr>
<tr>
<td>Ulmer, Carolyn</td>
<td>75</td>
</tr>
<tr>
<td>Unlrett, Laura J.</td>
<td>42</td>
</tr>
<tr>
<td>Upadhyaya, Gopalakrishna K.</td>
<td>46</td>
</tr>
<tr>
<td>Upshur, Carole C.</td>
<td>46, 80</td>
</tr>
<tr>
<td>Urban, John C.</td>
<td>25</td>
</tr>
<tr>
<td>Usano, Robert J.</td>
<td>17, 25, 31, 46, 60</td>
</tr>
<tr>
<td>Utun, T. Bedirhan</td>
<td>2</td>
</tr>
<tr>
<td>Vagahn, Per</td>
<td>30, 63</td>
</tr>
<tr>
<td>Vadnaj, Nutan A.</td>
<td>26</td>
</tr>
<tr>
<td>Valenta, Alexandre M.</td>
<td>23</td>
</tr>
<tr>
<td>Van Ameringen, Michael A.</td>
<td>23</td>
</tr>
<tr>
<td>Van Gauter, Eve</td>
<td>67</td>
</tr>
<tr>
<td>Van Der Brink, Wim</td>
<td>24, 30</td>
</tr>
<tr>
<td>Van Der Kolk, Bessel A.</td>
<td>37, 58, 91</td>
</tr>
<tr>
<td>Vaale, D.</td>
<td>25</td>
</tr>
<tr>
<td>Van Deck, Richard</td>
<td>59</td>
</tr>
<tr>
<td>Van Prag, Herman M.</td>
<td>1</td>
</tr>
<tr>
<td>van Zwieten, Barbara J.</td>
<td>24</td>
</tr>
<tr>
<td>Varghese, Frances T.</td>
<td>104</td>
</tr>
<tr>
<td>Varma, Sahid C.</td>
<td>16</td>
</tr>
<tr>
<td>Varma, Sudeepa</td>
<td>80</td>
</tr>
<tr>
<td>Viequez, Delia M.</td>
<td>61</td>
</tr>
<tr>
<td>Vieal, David</td>
<td>103</td>
</tr>
<tr>
<td>Veenstra-VanderWeele, Jerry</td>
<td>18</td>
</tr>
<tr>
<td>Vega, William</td>
<td>91</td>
</tr>
<tr>
<td>Vejle, Juha M.</td>
<td>23</td>
</tr>
<tr>
<td>Verdes, Helena</td>
<td>59</td>
</tr>
<tr>
<td>Verver, Sander</td>
<td>47</td>
</tr>
<tr>
<td>Verne, Sumer</td>
<td>32</td>
</tr>
<tr>
<td>Vernou, Rozalia</td>
<td>74</td>
</tr>
<tr>
<td>Viamontes, George I.</td>
<td>45, 58</td>
</tr>
<tr>
<td>Viana, Jason B.</td>
<td>62</td>
</tr>
<tr>
<td>Viederman, Milton</td>
<td>71</td>
</tr>
<tr>
<td>Vigezzi, Pietro</td>
<td>50</td>
</tr>
<tr>
<td>Vigo, Daniel E</td>
<td>98</td>
</tr>
<tr>
<td>Vigaeva, Adile C</td>
<td>4, 69, 93</td>
</tr>
<tr>
<td>Vlagut, Gemma</td>
<td>79</td>
</tr>
<tr>
<td>Viswanathan, Ramaswamy</td>
<td>80</td>
</tr>
<tr>
<td>Voci, Frances J.</td>
<td>47</td>
</tr>
<tr>
<td>Vogel-Scibilia, Suzanne E.</td>
<td>25, 54, 80</td>
</tr>
<tr>
<td>Volk, Edward A.</td>
<td>54</td>
</tr>
<tr>
<td>Volkov, Marina</td>
<td>26</td>
</tr>
<tr>
<td>Volkow, Nora D.</td>
<td>3, 20, 35, 44</td>
</tr>
<tr>
<td>Volpp, Selma Y.</td>
<td>4</td>
</tr>
<tr>
<td>Von Kon, Michael</td>
<td>32</td>
</tr>
<tr>
<td>Voutsilakos, Fu</td>
<td>88</td>
</tr>
<tr>
<td>Vreeland, Elizabeth</td>
<td>75</td>
</tr>
<tr>
<td>Wachtler, Sol</td>
<td>75</td>
</tr>
<tr>
<td>Wade, Terrance J.</td>
<td>22</td>
</tr>
<tr>
<td>Waddler, Gary I.</td>
<td>47</td>
</tr>
<tr>
<td>Wagner, H. Ryan</td>
<td>61</td>
</tr>
<tr>
<td>Wign, Karen D.</td>
<td>9</td>
</tr>
<tr>
<td>Widd友情, J.</td>
<td>95</td>
</tr>
<tr>
<td>Wain, Harroid J.</td>
<td>60</td>
</tr>
<tr>
<td>Wainberg, Milton L.</td>
<td>52, 55, 75</td>
</tr>
<tr>
<td>Wakschlag, Lauren S.</td>
<td>20</td>
</tr>
<tr>
<td>Wadrep, Douglas A</td>
<td>60</td>
</tr>
<tr>
<td>Walker, Edward A</td>
<td>32</td>
</tr>
<tr>
<td>Walker, Roger D.</td>
<td>18, 73</td>
</tr>
<tr>
<td>Wallap, John T.</td>
<td>18, 78</td>
</tr>
<tr>
<td>Wall, Susan</td>
<td>153</td>
</tr>
<tr>
<td>Wallack, Joel J.</td>
<td>45</td>
</tr>
<tr>
<td>Walsh, B. Timothy</td>
<td>62, 63, 67</td>
</tr>
<tr>
<td>Walsh, James K.</td>
<td>97</td>
</tr>
<tr>
<td>Wang, Fujia</td>
<td>24</td>
</tr>
<tr>
<td>Wang, Gene-Jack</td>
<td>35</td>
</tr>
<tr>
<td>Wang, Lee</td>
<td>33</td>
</tr>
<tr>
<td>Wapeny, Khakara H.</td>
<td>53</td>
</tr>
<tr>
<td>Ward, Deborah Lee</td>
<td>88</td>
</tr>
<tr>
<td>Warshaw, Carole L.</td>
<td>25</td>
</tr>
<tr>
<td>Wasterman, Stacy</td>
<td>92</td>
</tr>
<tr>
<td>Wavylenar, Donald A.</td>
<td>104</td>
</tr>
<tr>
<td>Watchel, Paul</td>
<td>89</td>
</tr>
<tr>
<td>Wauford, Pamela K.</td>
<td>62</td>
</tr>
<tr>
<td>Waxedowsky, James G.</td>
<td>47</td>
</tr>
<tr>
<td>Wayken, Andrea</td>
<td>23</td>
</tr>
<tr>
<td>Wehr, Allison M.</td>
<td>45, 57</td>
</tr>
<tr>
<td>Weiden, Peter J.</td>
<td>3, 11, 79</td>
</tr>
<tr>
<td>Weimann, Gabriel</td>
<td>31</td>
</tr>
<tr>
<td>Wein, Simon</td>
<td>103</td>
</tr>
<tr>
<td>Weinberg, Nannah Z.</td>
<td>65</td>
</tr>
<tr>
<td>Weine, Stevan M.</td>
<td>55</td>
</tr>
<tr>
<td>Wein, Elde Y.</td>
<td>47</td>
</tr>
<tr>
<td>Weiner, Richard D.</td>
<td>31</td>
</tr>
<tr>
<td>Weinmann, S.</td>
<td>59</td>
</tr>
<tr>
<td>Weinstein, Henry C.</td>
<td>55</td>
</tr>
<tr>
<td>Weaver, Alex</td>
<td>34</td>
</tr>
<tr>
<td>Wernberg, Rita B.</td>
<td>98</td>
</tr>
<tr>
<td>Weink, Richard H.</td>
<td>51, 98</td>
</tr>
<tr>
<td>Weisman, Henry W.</td>
<td>75</td>
</tr>
<tr>
<td>Weiss, Francine</td>
<td>73</td>
</tr>
<tr>
<td>Weiss, Jeffrey</td>
<td>19</td>
</tr>
<tr>
<td>Weiss, Margaret D.</td>
<td>2</td>
</tr>
<tr>
<td>Weiss, Roger D.</td>
<td>73</td>
</tr>
<tr>
<td>Weiss, Susan B.</td>
<td>89</td>
</tr>
<tr>
<td>Weissman, Myrna M.</td>
<td>27, 35, 59, 91</td>
</tr>
<tr>
<td>Weller, Elizabeth B.</td>
<td>27</td>
</tr>
<tr>
<td>Wells, Kenneth B.</td>
<td>91</td>
</tr>
<tr>
<td>Weiznin, Theodore E.</td>
<td>96</td>
</tr>
</tbody>
</table>
PARTICIPANT INDEX

Wenk, Gary L .......................... 6
Wessels, Michael ........................ 31
West, Joyce C .......................... 24, 50, 59
Westermeyer, Joseph J .................. 82
Weatherington, Cora Lee ................. 90
Whalen, Paul .......................... 66
Whiteside, Stephen .................... 14
Whitman, Anne ........................ 31
Wick, Paul H .......................... 45
Wickramaratne, Priya .................... 59
Widiger, Thomas A ........................ 87
Wien, Irving S .......................... 20
Wilber, Charles K ........................ 97
Wilen, Timothy E ........................ 39, 65, 67, 98, 106
Wiensky, Mark .......................... 99
Wilk, Joshua E .......................... 27, 50, 59
Wilkins, Jeffrey N ....................... 46
Williams, Adedapo B .................... 106
Williams, Eric R ........................ 48
Williams, Jill ........................... 84
Williamson, Johnny L .................... 46
Wills, Cheryl D .......................... 54, 81
Wills, Marketa M ......................... 24, 45, 53, 97
Wilson, G. Terrence ..................... 60
Wilson, Kumanan ......................... 59
Wilson, Lori ............................ 100
Winette, Carol ........................... 98
Wink, Bruce J ........................... 99
Winkelmann, John W ...................... 55, 67, 92
Winiarski, Daniel K ...................... 27
Winston, Arnold ........................ 89
Winter, Breita ........................... 97
Winters, Ken C ........................... 65
Wise, Brian R ............................ 23
Wise, Robert A ........................... 45
Wishart, Heather ........................ 87
Witsar, Joseph S ......................... 51
Wixter, Katherine L ...................... 70, 100
Wohlfarth, Tamar D ...................... 24
Wohlfrech, Madeleine M .................. 25
Wolf, Marina E ........................... 90
Wolfe, Barbara E ........................ 7, 63
Wolfe, Tom ............................... 38
Wolke, Dieter ............................ 23
Wollin, Adam ............................ 28
Wolff, Stephen A ......................... 60
Wong, Marleen ........................... 46
Wood, William C ........................ 25, 73
Woody, George E ........................ 101
Worhunsky, Patrick ...................... 98
Worley, Linda L.M ........................ 56
Worthington III, John J .................. 34, 78
Wozniak, Janet ........................... 69, 85
Wright, Harry H .......................... 25
Wright, Jesse H ........................... 3, 8, 26, 57, 97
Wright, Mark S ........................... 79
Wu, Joseph C ............................. 19, 81
Wulsin, Lawson R ......................... 77
Wung, Jay L ............................. 95
Wyatt, Richard J ........................ 33
Wyatt, John D ............................ 29
Wyoming, Ashley ......................... 98

X

Xie, Hui .................................. 101

Y

Yager, Joel ............................... 7, 15, 47, 60, 93
Yang, C. Paul ............................ 74
Yang, Brian ............................... 24
Yates, Alayne .............................. 96
Yehuda, Rachel ........................... 75, 92, 105
Yeomans, Frank E ......................... 70
Yeung, Albert ............................. 77, 88
Ying, Patrick .............................. 73
Yonkers, Kimberly A ..................... 6, 61, 100
Young, Arlene ............................ 100
Young, Judy ............................... 74
Young, Keith W ............................ 46, 53, 60, 61
Young, Kimberly S ....................... 46
Yousufi, Zainab ........................... 97
Yu, Van ..................................... 80
Yudofsky, Stuart C ....................... 13, 41, 45, 70, 93
Yurgelun-Todd, Deborah A ............. 4, 41, 61, 85, 89

Z

Zachry, Woodie M ........................ 94
Zanarini, Mary C ......................... 23, 38, 64, 102
Zarate, Jr, Carlos A ....................... 79
Zatzick, Douglas F ........................ 25
Zaubler, Thomas S ......................... 75
Zdanowicz, Mary .......................... 45
Zelnick, Elizabeth ......................... 93
Zhang, Wei ................................. 4, 93
Ziedonis, Douglas M ...................... 48, 62, 84, 100
Zima, Bonnie T ............................ 91
Zimmerman, Mark ........................ 97, 101
Zin, Walter A ............................. 23
Zietek, Brook E ............................ 75
Zoltar, Joseph ............................. 92
Zonana, Howard V ........................ 24, 34
Zoulalian, Carol .......................... 48
Zubieta, Jon-Kar .......................... 8, 30, 85
Zuckoff, Allan ............................ 102
CALL FOR PAPERS

PRESIDENT'S THEME:
Psychosomatic Medicine: Integrating Psychiatry & Medicine

Michelle Riba, M.D.
President

Marian I. Butterfield, M.D., Chairperson
Scientific Program Committee

THE SUBMISSION SCHEDULE

<table>
<thead>
<tr>
<th>Format</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry-Supported</td>
<td>June 1, 2004</td>
</tr>
<tr>
<td>Symposium</td>
<td></td>
</tr>
<tr>
<td>Course</td>
<td>September 7, 2004</td>
</tr>
<tr>
<td>Reports</td>
<td>September 7, 2004</td>
</tr>
<tr>
<td>Symposium</td>
<td>September 7, 2004</td>
</tr>
<tr>
<td>Workshops</td>
<td>Issue: September 7, 2004</td>
</tr>
<tr>
<td></td>
<td>Component: September 20, 2004</td>
</tr>
<tr>
<td>New Research</td>
<td>December 3, 2004</td>
</tr>
</tbody>
</table>

Incomplete and/or Incorrect Forms Will Not Be Considered.

For complete submission forms, you may download the forms at www.psych.org, click on the Annual Meeting logo, then click on submission forms. You may also contact the APA toll free at 1-888-357-7924, and speak directly with an Answer Center Coordinator.

If you want to volunteer to chair a session, please send a letter to the attention of Dr. Butterfield at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.
American Psychiatric Association

Audiotapes
Recorded Live!

High Quality Continues for
the 2004 Annual Meeting ...

Live recordings will be available
for most of the following:

- Lectures • Advances in Research
- Advances in Psychopharmacology
- Presidential Symposia • Medical Updates
- Scientific and Clinical Reports • Symposia
- Debate • Roundtable Discussion
- Research Advances in Medicine

Tapes may be purchased on site at Mobiltape's booth at the Javits Convention Center.

Mobiltape Company, Incorporated
24730 Avenue Tibbitts, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504 ◆ (800) 369-5718
Fax: (661) 295-8474
Website: www.mobiltape.com
Who Should Attend?
- Psychiatrists in community practice or public sector including state, community, and Veterans Affairs hospitals, community clinics, and jails
- Psychiatric administrators
- Persons interested in social issues that have an impact on patients
- Minority psychiatrists and International Medical Graduates
- Psychiatric Residents
- Medical Students

Why Should You Attend?
- Earn up to 48 hours of category 1 credit
- Receive a 40% discount on APA member registration fees
- Industry-Supported Lunch and Dinner Symposia are presented each day

How Will You Benefit?
- Learn the latest knowledge and skills in clinical psychiatry, which can be utilized to improve patient care
- Acquire a deeper understanding of how the current health care system affects patient care
- Gain new knowledge and skills useful in clinical and public psychiatry settings
- Recognize and improve mental health disparities in the community

IPS is your comprehensive educational and networking event with a clinical focus on topics including:
- Cross-cultural and minority issues
- Social and community psychiatry
- Psychopharmacology
- Resident and medical student concerns
- Substance abuse
- Child and adolescent issues
- AIDS
- Psychiatric administration and services
- Treatment techniques and outcome studies
- And much more

Registration starts June 1, 2004.
Visit www.psych.org for detailed program information and to register.

Questions?
Call: 1-888-357-7924 (Toll Free) or 703-907-7300
Fax: 703-907-1090
Email: apa@psych.org
Visit: www.psych.org

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 48 credits toward the AMA Physician's Recognition Award and for the CMS requirement of the AOA. Each physician should claim only those credits that he/she actually spent in the activity.
The First and Last Word

At Your Annual Meeting Bookstore

APPI Bookstore at the 2004 APA Annual Meeting

Psychiatry's premiere publisher brings the cutting-edge titles you've been waiting for directly to you! Come check out APPI's latest groundbreaking selection, from the newest textbooks, review series, and journals, to electronic products for your handheld or online. The APPI Bookstore is the one place you can go to gather all the resources you'll need in the next year. Update subscriptions, complete your series collections, browse through hard to find titles, and even develop your course adoptions—all in one stop. Don't miss the Author Book Signings or the Sunrise Special, with discounts of 25% for APA Members-in-Training—see you there!

APPI Bookstore Hours

Saturday, May 1: 10:00am - 5:00pm
Sunday, May 2: 10:00am - 4:30pm
Monday, May 3: 10:00am - 5:30pm
Tuesday, May 4: 10:00am - 6:00pm
Wednesday, May 5: 10:00am - 3:00pm

Sunrise Special

Deep Discounts for APA Members-in-Training!
APPI is committed to helping APA MTs gain the knowledge needed to excel in the psychiatric profession. Between the hours of 8:00am and 9:30am, on Sunday, May 2, the APPI Bookstore will be open to members-in-training only for our annual Sunrise Special, and will offer a 25% discount. Don't miss out on this enormous opportunity to stock up!

1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209-3901
Phone: 703-907-7322 or 1-800-368-5777
Fax: 703-907-1091
Email: appi@psych.org
Web: www.appi.org

The First and Last Word in Psychiatry
Please reference priority code AH421 when ordering

Treatment Companion to the DSM-IV-TR Casebook
Edited by Robert L. Spitzer, M.D., Michael B. First, M.D., Mirtiin Gibbon, M.S.W., and Janet B. W. Williams, D.S.W.
2004 • 360 pages • ISBN 1-58562-139-0
paperback • $39.00 • Item #62139
2004 • 360 pages • ISBN 1-58562-194-3
hardcover • $54.00 • Item #62194

Edited by Jerry M. Wisner, M.D., and Mina K. Dulcan, M.D.
2004 • 1,140 pages • ISBN 1-58562-057-2
hardcover • $165.00 • Item #62057

Edited by Alan F. Schatzberg, M.D., and Charles B. Nemeroff, M.D., Ph.D.
2004 • 1296 pages • ISBN 1-58562-060-2
hardcover • $178.00 • Item #62060

Edited by Dan G. Blazer, M.D., Ph.D., David C. Steffens, M.D., M.H.S., and Ewald W. Busse, M.D.
2004 • 608 pages • ISBN 1-58562-065-3
hardcover • $110.00 • Item #62065

The American Psychiatric Publishing Textbook of Forensic Psychiatry
Edited by Robert I. Simon, M.D., and Liza H. Gold, M.D.
2004 • 656 pages • ISBN 1-58562-087-4
hardcover • $75.00 • Item #62087

The American Psychiatric Publishing Textbook of Substance Abuse Treatment, Third Edition
Edited by Marc Galanter, M.D., and Herbert D. Kleber, M.D.
2004 • 704 pages • ISBN 1-58562-099-8
hardcover • $125.00 • Item #62099

1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209-3901
Phone: 703-907-7322 or 1-800-368-5777
Fax: 703-907-1091
Email: appi@psych.org
Web: www.appi.org

The First and Last Word in Psychiatry
Please reference priority code AH421 when ordering
in Psychiatry

Review of Psychiatry, Volume 23
Series Editors: John M. Oldham, M.D., M.S., and Michelle B. Riba, M.D., M.S.

Brain Stimulation in Psychiatric Treatment
Edited by Sarah H. Lisanby, M.D.
2004 • 160 pages • ISBN 1-58562-175-7
paperback • $34.95 • Item #62175

Cognitive-Behavior Therapy
Edited by Jesse H. Wright, M.D., Ph.D.
2004 • 160 pages • ISBN 1-58562-178-1
paperback • $34.95 • Item #62178

Neuropsychiatric Assessment
Edited by Stuart C. Yudofsky, M.D., and H. Florence Kim, M.D.
2004 • 176 pages • ISBN 1-58562-177-3
paperback • $34.95 • Item #62177

Developmental Psychobiology
Edited by B.J. Casey, Ph.D.
2004 • 176 pages • ISBN 1-58562-176-5
paperback • $34.95 • Item #62176

SET of Review of Psychiatry, Volume 23
2004 • $109.00 • Item #5082

Cognitive Guide to Ethics in Mental Health Care
Laura Weiss Roberts, M.D., and Allen R. Dyer, M.D., Ph.D.
2004 • 384 pages • ISBN 0-89048-944-8
paperback • $29.95 • Item #9944

APRIL

2005 Appointment Book
American Psychiatric Association
2004 • 172 pages • ISBN 0-89042-331-8
spiralbound • $32.50 • Item #62130

The Art and Science of Brief Psychotherapies
A Practitioner’s Guide
(Core Competencies in Psychotherapy)
Edited by Marston J. Dewan, M.D., Brett N. Steinbarger, Ph.D., and Roger F. Greenberg, Ph.D.
2004 • 336 pages • ISBN 1-58562-067-X
paperback • $38.50 • Item #62067

New Core Competencies!
Core Competencies for Psychiatric Education
Defining, Teaching, and Assessing Resident Competence
Linda Bechter Andrews, M.D., and John William Burress, M.D.
2004 • 176 pages • ISBN 1-58562-130-7
paperback • $32.50 • Item #62130

FEBRUARY

Clinical Manual of Anxiety Disorders
Edited by Dan J. Stein, M.D., Ph.D.
2004 • 200 pages • ISBN 1-58562-076-9
paperback • $32.00 • Item #62076

MARCH

Essentials of Clinical Psychiatry, Second Edition
Edited by Robert E. Hales, M.D., M.B.A., and Stuart C. Yudofsky, M.D.
2004 • 1032 pages • ISBN 1-58562-033-5
paperback • $72.00 • Item #62033

Doing the Right Thing
An Approach to Moral Issues in Mental Health Treatment
John P. Peter, M.D.
2004 • 144 pages • ISBN 1-58562-083-1
paperback • $24.95 • Item #62083

Clinical Manual of Anxiety Disorders
Edited by Dan J. Stein, M.D., Ph.D.
2004 • 200 pages • ISBN 1-58562-076-9
paperback • $32.00 • Item #62076

PSYCHOLOGY TO NEUROBIOLOGY
Edited by Sunil H. Mitt, M.D., Andrew P. Nissen, M.D., and Harry Passler, M.D.
2004 • 256 pages • ISBN 1-58562-085-8
paperback • $32.95 • Item #62085

Gestalt Therapy
From Psychopathology to Neurobiology
Edited by Stanley N. Farber, M.D., Stephen C. Mann, M.D., Andrew Francis, M.D., Ph.D., and Gregory L. Frischman, M.D.
2004 • 320 pages • ISBN 1-58562-084-X
paperback • $32.95 • Item #62084

CPT Handbook for Psychiatrists, Third Edition
Firster W. Schmitt, Jr., M.D., Rebecca Vowell, and Ellen Jaffe
2004 • 160 pages • ISBN 1-58562-157-9
spiralbound • $39.00 • Item #62157

Trance and Treatment
Clinical Uses of Hypnosis, Second Edition
Herbert Spiegel, M.D., and David Spiegel, M.D.
2004 • 448 pages • ISBN 1-58562-190-0
paperback • $52.00 • Item #62190

Prices subject to change without notice.
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or at 703-907-7300.

Supported by an unrestricted educational grant from JANSSEN RS-U52

Sponsored by the American Psychiatric Association

Preventive Psychiatry in Mood Disorders: The New Frontier

Symposium to be held at the American Psychiatric Association 157th Annual Meeting

SATURDAY, MAY 1, 2004
12:30 PM – 3:30 PM
Grand Hyatt New York
Park Avenue at Grand Central
Empire State Ballroom B/C/D
New York, New York

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from GlaxoSmithKline

PROGRAM OBJECTIVES

After attending this continuing medical education symposium, the psychiatrist should be able to:
- Understand the effects of early-life trauma on neurobiology and the subsequent development of psychiatric illness
- Provide psychiatrists and psychologists with available information on medication use during pregnancy and lactation
- Discuss the emerging role of neuroimaging as it affects psychiatry
- Become familiar with data suggesting various genetic changes may be associated with psychiatric disease.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or at 703-907-7300.

Supported by an unrestricted educational grant from GlaxoSmithKline

Sponsored by the American Psychiatric Association

INDUSTRY-SUPPORTED SYMPOSIUM 2

Saturday, May 1, 12:30 p.m. - 3:30 p.m.
Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

PROGRAM OBJECTIVES

After attending this continuing medical education symposium, the psychiatrist should be able to:
- Understand the effects of early-life trauma on neurobiology and the subsequent development of psychiatric illness
- Provide psychiatrists and psychologists with available information on medication use during pregnancy and lactation
- Discuss the emerging role of neuroimaging as it affects psychiatry
- Become familiar with data suggesting various genetic changes may be associated with psychiatric disease.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or at 703-907-7300.

Supported by an unrestricted educational grant from GlaxoSmithKline

Sponsored by the American Psychiatric Association

AGENDA

12:00 PM Lunch
12:30 PM Welcome and Introduction
CHARLES B. NEMEROFF, MD, PhD
SYMPOSIUM CHAIR
Emory University School of Medicine
1:05 PM Achieving the Optimal Balance Between Treatment of Maternal Depression and Infant Medication Exposure
ZACHARY N. STOWE, MD
Emory University School of Medicine
2:05 PM Genetic Research in Psychiatry: Diagnostic and Therapeutic Implications
STEPHAN CLAES, MD, PhD
University of Antwerp (UA)
3:00 PM Closing Remarks, Adjournment
CHARLES B. NEMEROFF, MD, PhD
INDUSTRY-SUPPORTED SYMPOSIUM 3
Saturday, May 1, 12:30 p.m. - 3:30 p.m.
Grand Ballroom East, Third Floor, Hilton New York

Bipolar Disorder and Alcoholism:
Diagnostic Challenges and Therapeutic Interventions

An educational symposium to be presented at the 2004 Annual Meeting of the American Psychiatric Association

Program Agenda
12:00-12:30 p.m. Lunch
12:30-1:00 p.m. Welcome and Introduction
  Program Chair: Mark A. Freud, MD
  Department of Psychiatry, University of California, San Francisco
1:00-1:30 p.m. Maintenance of Alcoholic Intoxication
  Hugh R. N. M.
  Medical University of South Carolina
1:30-2:00 p.m. The Impact of Alcoholism on the Presentation and Course of Bipolar Disorder
  Joseph J. McHugh, MD
  University of St. Louis, Missouri
2:00-2:30 p.m. Bipolar Disorder: Treatment Options and Response Patterns in Adult ADHD
  Joseph F. Biederman, MD
  Children's Hospital, Boston, Massachusetts
3:00-3:30 p.m. Program Adjournment

Accreditation Statement:
The American Psychiatric Association, APA, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity is approved for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

INDUSTRY-SUPPORTED SYMPOSIUM 4
Saturday, May 1, 12:30 p.m. - 3:30 p.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

Adult ADHD: Clinical Utility and Validity

Don't Miss This Important Educational Event!

Learning Objectives:
1. Define the symptoms and consequences of ADHD in adults based on original data from the US and in different countries around the world.
2. Identify the diagnostic criteria for symptoms and comorbidities in adults with ADHD.
3. Evaluate the impact of ADHD on comorbidities and treatment outcomes.
4. Identify the role of treatment options and response patterns in adults with ADHD.
5. Discuss the prevalence of ADHD in the general population and in different subgroups of the population.
6. Describe the benefits and limitations of various treatments for ADHD.
7. Identify the role of school and community-based interventions in the treatment of ADHD.

Accreditation Statement:
The American Psychiatric Association, APA, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity is approved for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit Designation Statement:
The APA designates this educational activity for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Supported by: Ely Lilly and Company

Attendants must be registered to attend the APA Annual Meeting to attend the symposium. Seating is limited and will be based on registration. For more information about the meeting, please visit the APA Annual Meeting website.
INDUSTRY-SUPPORTED SYMPOSIUM 5
Saturday, May 1, 12:30 p.m. - 3:30 p.m.
Imperial Ballroom A, Second Floor, Sheraton New York

TOWARDS DSM-V:
PHENOMENOLOGY, NEUROBIOLOGY, AND TREATMENT RESPONSE IN
DEPRESSION

PROGRAM AGENDA
12:00 pm - 1:00 pm
Lunch
1:30 pm - 2:45 pm
MINI-Lessons from the Brain
2:45 pm - 3:30 pm
Panel Discussion/S & A
3:30 pm
Meeting Adjourns

INDUSTRY-SUPPORTED SYMPOSIUM 6
Saturday, May 1, 6:00 p.m. - 9:00 p.m.
Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

THE ROLE of DOPAMINE in HEALTH and ILLNESS: FROM SCIENCE to PRACTICE

AGENDA:

5:30-6:00 pm Dinner
6:00-6:15 pm Welcome & Introductions
Peter J. Widen, MD
Chairperson
NPV7 Health Science Center
6:15-6:31 pm The Role of Dopamine as a Mediator of Normal Reward
P. V. Volkow, MD
National Institute on Drug Abuse
6:31-7:00 pm From Dopamine to Salience in Psychosis
Why Antipsychotics Are Called “Psychotics”
Shyam Kapur, MD
University of Wisconsin
7:00-7:25 pm Dopamine and Neuropathic
Dysfuncion in Practice
Peter J. Widen, MD
NPV7 Health Science Center
7:25-7:50 pm The Role of Dopaminergic/Cholinergic
Interactions in Cognition
and Psychosis
Kathy Towey, MD
University of Michigan
7:50-8:15 pm The Role of Dopamine in the Neuropsychology of
Sexual Dysfunction
Albert Elmqvist, MD
SUNY Downstate Medical Center
8:15-9:00 pm Question & Answer
Session
All Faculty
9:00 PM Adjourn

LEARNING OBJECTIVES:

- Describe the neurophysiologic mechanisms of dopamine in reinforcement, motivation, drive, and self-control as it relates to normal human reward
- Review different theories regarding dopamine and how the theories relate to psychosis and antipsychotics
- Describe neurologic dysfunctions and its possible impact on poor compliance in patients treated with neuroleptics, discuss dopamine’s role in this response, as it occurs in approximately one-third of patients treated with neuroleptics, and discuss how differences in activity of D2 receptors may be responsible for differences in occurrence of neuroleptic dyskinesia
- Review dopamine’s critical role in the working memory functions of the prefrontal cortex
- Define the role of dopamine in the neurobiology of actual dysfunction in schizophrenia and ways to manage this problem in clinical practice

CME STATEMENT:

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 10 Category 1 credits toward the AMA Physician Recognition Award and for the CME requirements of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees may apply for the APA Annual Meeting as an accredited symposium. Sponsoring OAS is limited and will be based on availability. For more information, contact the meeting planner with the APA at www.psych.org or contact the APA at 1-800-357-7344 (within the US or Canada) or 703-907-7300.

If any participant in this educational activity is in need of accommodations, please call 800-485-4680.

142
INDUSTRY-SUPPORTED SYMPOSIUM 7
Saturday, May 1, 6:00 p.m. - 9:00 p.m.
Grand Ballroom East, Third Floor, Hilton New York

Impulsivity:
Emerging Clinical Perspectives

An educational symposium to be presented at the 2004 Annual Meeting of the American Psychiatric Association

Program Agenda
5:30 pm - 6:00 pm  Dinner
6:00 pm - 6:10 pm  Welcome and Introduction
6:10 pm - 6:30 pm  Program Chair, Erc Hollander, MD
Mount Sinai School of Medicine
6:30 pm - 6:35 pm  Neurobiology of Impulsive Behavior
Alm E. Crome, MD
The University of Texas Health Science Center at Houston
6:35 pm - 7:00 pm  When Does Impulsive Behavior Become Pathologic?
Eric S. Hollander, PhD
The University of Texas Medical Branch at Galveston
7:00 pm - 7:25 pm  Clinical Issues of Impulsivity in Psychiatry
Dan J. Stein, MD
University of Stellenbosch
7:25 pm - 7:50 pm  Addressing Impulsive Behavior in Eating Disorders
Renu Akhtar, MD
University of Cincinnati College of Medicine
7:50 pm - 8:15 pm  Identifying the Spectrum of Impulse Control Disorders
Eric Hollander, MD
8:15 pm - 9:10 pm  Summary and Conclusions/Questions and Answers
Eric Hollander, MD
8:30 pm - 9:00 pm  Panel Discussion/Questions and Answers
9:00 pm  Adjournment

INDUSTRY-SUPPORTED SYMPOSIUM 8
Saturday, May 1, 6:00 p.m. - 9:00 p.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

BIPOLAR DISORDER:
IMPROVING OUTCOMES WHEN THEORY, SCIENCE, AND CLINICAL PRACTICE CONVERGE

Saturday, May 1, 2004
5:30pm-6:00pm Dinner  •  6:00pm-9:00pm Educational Program
Marriott Marquis  •  Sixth Floor, Broadway Ballroom  •  New York, New York

5:30pm-6:00pm Dinner

6:00pm Welcome and Introduction
Joseph E. Blumenthal, MD
Montefiore Medical Center,
Bronx, NY
North Shore-Long Island Jewish Health System

6:10pm The Convergence of Pharmacology and Psychosurgery in Maintenance Treatment of Bipolar Disorder
Paul J. Kohn, MD
University of California, San Diego

6:20pm Considerations in the Female Patient During Childbearing Years
Mark J. Fava, MD
Massachusetts General Hospital
Harvard Medical School

7:00pm Choosing Treatments in Bipolar Depression: What, When, and Why?
Ray A. Perlis, MD
Hospital of the University of Pennsylvania

7:15pm Cognitive Functioning Outcomes: From First Episode to Functional Recovery
Dowling A. Van Pelt, PhD
McLean Hospital
Harvard School of Medicine

7:30pm Translating Research Into Clinical Practice: From the Bench to the Trenches
Joseph F. Hollander, MD
Program Chair

8:15pm Question and Answer Session

9:00pm Program Adjournment

Learning Objectives
1. To describe new pharmacological and psychosurgical treatments and their potential use in the treatment of bipolar disorder.
2. To provide information on new pharmacological and psychosurgical treatments and their potential use in the treatment of bipolar disorder.
3. To discuss the role of psychosurgery in the treatment of bipolar disorder.
4. To identify the role of new pharmacological and psychosurgical treatments in the treatment of bipolar disorder.
5. To provide information on new pharmacological and psychosurgical treatments and their potential use in the treatment of bipolar disorder.

Accreditation Statement
The American Psychiatric Association Office on Continuing Medical Education awards AMA PRA Category 1 Credits™ and the APA's designated provider number for this educational activity.
INDUSTRY-SUPPORTED SYMPOSIUM 9
Saturday, May 1, 6:00 p.m. - 9:00 p.m.
Grand Ballroom, Mezzanine Level, Roosevelt

INDUSTRY-SUPPORTED SYMPOSIUM 10
Saturday, May 1, 6:00 p.m. - 9:00 p.m.
Imperial Ballroom A, Second Floor, Sheraton New York

INDUSTRY-SUPPORTED SYMPOSIUM 10
Saturday, May 1, 6:00 p.m. - 9:00 p.m.
Imperial Ballroom A, Second Floor, Sheraton New York

Sex, Sexuality,
& SEROTONIN

SUNDAY, MAY 1
5:30–6 PM DINNER + 6–9 PM CLINICAL PROGRAM
SHERATON NEW YORK HOTEL & TOWERS
IMPERIAL BALLROOM A + 2ND FLOOR

Opening Remarks
Phil R. Mulsant, MD
Symposium Chair & Speaker
Anika H. Clayton, MD, Symposium Co-Chair & Speaker

6:30 PM – Do Sexual Side Effects of Most Antidepressants Jeopardize Romantic Love & Marriage?
Helen E. Fisher, PhD
Rutgers University

6:45 PM – Love & Sex
Ethel S. Person, MD
Columbia University College of Physicians & Surgeons

7:00 PM – Nothing to Gray Patients About Sex: What Do You Need to Know?
Serene Yuan Voelp, MD, MPH
New York University School of Medicine

8:45 PM – Effects of Psychotropic Medication on Sexual Function
Phil R. Mulsant, MD
University of Virginia Health System

9:00 PM – Talking About Sexual Dysfunction to Enhance Affective Awareness with Medication
Phil R. Mulsant, MD
Columbia University College of Physicians & Surgeons

9:15 PM – Sexual Orientation & Gender Identification
Anika H. Clayton, MD

9:30 PM – Program Concludes
INDUSTRY-SUPPORTED SYMPOSIUM 11
Saturday, May 1, 6:00 p.m. - 9:00 p.m.
Imperial Ballroom B, Second Floor, Sheraton New York

Presented at the APA 157th Annual Meeting
INTERFACE BETWEEN DEPRESSION
AND MEDICAL ILLNESS
Dwight L. Evans, MD, Co-Chair
Dennis Charme, MD, Co-Chair

Target Audience
This activity is designed specifically for psychiatrists.

Learning Objective
Upon completion of this symposium, the participants should be able to:
- Discuss the relationship between depression and comorbid medical conditions.

Accreditation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 4 category 1 credits toward the APA Physician Recognition Award and for the CMS requirement of the APA. Each physician should claim only those credits that reflect actual participation in the activity.

Registration Policy
Members must be registered for the APA Annual Meeting or Institute on Psychiatric Services to attend this symposium. Seating is limited and will be based on first come, first served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-557-7924 within the U.S. or Canada at 703/907-7928.

Sponsored by Eli Lilly and Co. and Wyeth.

INDUSTRY-SUPPORTED SYMPOSIUM 12
Sunday, May 2, 8:00 a.m. - 11:00 a.m.
Special Events Hall 1D, Level 1, Javits Center

Antidepressant Treatments You May Not Know About... But Should
Program Chair: Jerrold F. Rosenbaum, MD
Massachusetts General Hospital
Boston, Massachusetts

Held at The American Psychiatric Association's 157th Annual Meeting
Sunday, May 2, 2004
7:30 - 8:00 a.m. Breakfast - 8:00 - 11:00 a.m. Symposium
Special Events Hall 1D, Level 1, Javits Center

Overall Educational Objectives: The audience will become familiar with a broad array of technologies for the treatment of depression, with a concentration on those in development, soon to be available, or less well known to the practitioner.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first come, first served. For information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-557-7924.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 1 category 1 credit toward the APA Physician Recognition Award and for the CMS requirement of the APA. Each physician should claim only those credits that reflect actual participation in the activity.

Sponsored by the American Psychiatric Association.

8:00 - 8:10 a.m. Introduction
Jerrold F. Rosenbaum, MD
Massachusetts General Hospital
Boston, Massachusetts

8:10 - 8:35 a.m. The Next Generation of Antidepressants: What's in the Pipeline?
Raymond J. Judge, MD
New York, New York

8:35 - 9:00 a.m. Alternative Medications for Depression
Andrew A. Nierenberg, MD
Massachusetts General Hospital
Boston, Massachusetts

9:00 - 9:25 a.m. Evidence-Based Psychotherapy for Depression: Principles and Practice
Timothy J. Petersen, MD
Massachusetts General Hospital
Boston, Massachusetts

9:25 - 9:50 a.m. Device-Based Treatments for Depression
A. Jair Byun, MD
University of Texas-Southwestern Medical Center
Dallas, Texas

9:50 - 10:15 a.m. The Future of Treatment-Matching in Depression
Steven R. Roose, MD
Columbia University
New York, New York

10:15 - 11:00 a.m. Question and Answer Session/Adjourn

Sponsored by an unrestricted educational grant from Organon Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 13
Sunday, May 2, 8:00 a.m. - 11:00 a.m.
Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

AGENDA:
7:00-8:00 AM Registration
8:00-8:10 AM Welcome & Introduction
S. Charles Schatz, MD
Chairman
University of Mississippi Medical School
8:10-8:25 AM Apoptosis in the Treatment of Pediatric Psychotic Disorders and Common Comorbidities
Melissa P. DeRitte, MD
University of Mississippi College of Medicine
8:25-8:40 AM Apoptosis in the Treatment of Autism spectrum
Walter H. Kier, MD
President of St. Jude's Children's Research Hospital
8:40-8:55 AM Apoptosis in Bipolar: Genetics and Treatment
S. Charles Schatz, MD
University of Mississippi Medical School
8:55-9:10 AM Question & Answer Session
All Faculty
9:10 AM Breakfast

LEARNING OBJECTIVES:
• Examine possible indications for apoptosis, especially for anxiety disorders and for anxiety disorders with comorbid psychotic symptoms
• Assess the role of apoptotic neuroprotection in the treatment of patients with substance-related disorders
• Demonstrate the role of apoptosis in the treatment of pediatric psychotic disorders and the common associated comorbidities
• Understand the use of apoptosis in the treatment of anxiety disorders, and how symptoms can be affected
• Evaluate the data regarding the use of apoptotic neuroprotection and the strength and weaknesses of the results

CME STATEMENT:
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The APA designates this educational activity for a maximum of 1.5 Category I credits toward the APA's Psychopharmacology: Treatment of the Adult Patient requirement. Physicians should claim only those credits commensurate with the extent of their participation in the activity.
To participate in this activity, physicians must complete the self-assessment examination before April 20, 2006. To receive credit, physicians must submit their completed examination with their registration fee to the APA by April 14, 2006. After the examination is mailed, contact the APA at 800-APA-0001, ext. 1400. For more information, please call 800-APA-0001 ext. 1400.

INDUSTRY-SUPPORTED SYMPOSIUM 14
Sunday, May 2, 8:00 a.m. - 11:00 a.m.
Grand Ballroom East, Third Floor, Hilton New York

AGENDA:
2:00 AM Registration
2:00 AM Welcome and Introduction
Maria E. Vranic, MD
Chief, Psychiatry and Behavioral Sciences
Cleveland Clinic
2:15 PM Pharmaceutics: Apoptosis in the Treatment of Psychotic Disorders
David B. Sacks, MD, MBA
Professor of Psychiatry and Behavioral Sciences
Cleveland Clinic
2:30 PM Generalized Anxiety, Social Anxiety, and Panic Disorder: New Vistas in Anxiety and Depression
Rebecca F. Alpert, MD
Assistant Professor
Department of Psychiatry
Columbia University Medical Center
2:45 PM Psychopharmacology: Apoptosis in Bipolar: Genetics and Treatment
S. Charles Schatz, MD
Chairman
University of Mississippi Medical School
3:00 PM Question & Answer Session
3:15 PM Adjournment

OBJECTIVES:
All physicians who participate in this activity will be able to:
• Recognize the differences and similarities of generalized anxiety disorder, panic anxiety disorder, and posttraumatic stress disorder
• Treat anxiety disorders appropriately by integrating the pharmacologic and psychosocial aspects of treatment
• Select and appropriately use medications for treating panic disorder
• Understand the recent pharmacologic and neurobiologic advances in the treatment of anxiety disorders

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The APA designates this educational activity for a maximum of 1.5 Category I credits toward the APA's Psychopharmacology: Treatment of the Adult Patient requirement. Physicians should claim only those credits commensurate with the extent of their participation in the activity.
To participate in this activity, physicians must complete the self-assessment examination before April 20, 2006. To receive credit, physicians must submit their completed examination with their registration fee to the APA by April 14, 2006. After the examination is mailed, contact the APA at 800-APA-0001, ext. 1400. For more information, please call 800-APA-0001 ext. 1400.
INDUSTRY-SUPPORTED SYMPOSIUM 17
Sunday, May 2, 8:00 a.m. - 11:00 a.m.
Imperial Ballroom A, Second Floor, Sheraton New York

**PROGRAM OBJECTIVES**
After attending this continuing medical education symposium, the psychiatrist should be able to:

• Become familiar with the physical comorbidities associated with anxiety disorders and their bidirectional relationship
• Identify gender differences associated with anxiety disorders with respect to presentation, progression of disease, and response to treatment
• Appreciate the wide variation in presentation, prevalence, and treatment response of anxiety disorders in different cultures and ethnic groups
• Increase awareness of the difficulties in recognizing and treating anxiety in the elderly.

**AGENDA**

7:30 AM Breakfast
8:00 AM Welcome and Program Introduction
   PRAKASH S. MASAND, MD
   SYMPOSIUM CHAIR
   Duke University Medical Center
8:05 AM The Somatic Face of Anxiety
   PRAKASH S. MASAND, MD
8:35 AM Anxiety in Men and Women:
   Two Faces of the Same Coin
   KIMBERLY A. YONKERS, MD
   Yale University School of Medicine
9:05 AM The Many Faces of Anxiety:
   Understanding Cultural and Ethnic Variation in Psychiatric Illness
   GEETHA JAYARAM, MD
   The Johns Hopkins Hospital
9:35 AM Facets of Anxiety in the Elderly
   WARREN D. TAYLOR, MD
   Duke University Medical Center
10:05 AM Panel Discussion With Questions and Answers
11:00 AM Closing Remarks, Adjournment
   PRAKASH S. MASAND, MD

**INDUSTRY-SUPPORTED SYMPOSIUM 18**
Sunday, May 2, 8:00 a.m. - 11:00 a.m.
Imperial Ballroom B, Second Floor, Sheraton New York

**TARGETING EXECUTIVE DYSFUNCTIONS FOR TREATMENT**

**PROGRAM AGENDA**

7:00 AM - 8:00 AM Breakfast
9:00 AM - 10:10 AM

8:10 AM - 9:20 AM
8:20 AM - 9:45 AM
8:45 AM - 3:10 AM
9:10 AM - 9:35 AM
9:35 AM - 10:00 AM
10:06 AM - 10:15 AM
10:15 AM - 11:00 AM
11:00 AM - 12:00 PM

**EDUCATIONAL OBJECTIVES**
Upon completion of the symposium, participants should be able to:

• Identify neurochemical mechanisms of executive dysfunction in psychiatric disorders
• Evaluate the ability of treatment strategies in addressing executive dysfunctions
• Pragmatically apply acquired knowledge regarding treatment strategies for executive dysfunctions in late-life and adult depression and in ADHD

**ACCREDITATION STATEMENT**
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 703-907-7300.
INDUSTRY-SUPPORTED SYMPOSIUM 19
Sunday, May 2, 1:30 p.m. - 4:30 p.m.
Special Events Hall ID, Level 1, Javits Center

PRESENTED AT THE APA 157TH ANNUAL MEETING
The Treacherous Triad for Depression:
Physical Symptoms, Absence of Remission, and Systemic Consequences

John F. Greden, MD, Chairperson

Target Audience
This activity is designed specifically for psychiatrists.

Learning Objectives
Upon completion of this symposium, the participants should be able to:
- Discuss the role of physically unexplained symptoms in depression
- Describe recent neuroimaging studies linking the underlying mechanisms of affective disorders and pain
- Discuss changes observed in the hippocampus in response to stress
- Describe why major depression is often overlooked in multimodal treatment plans

Accreditation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician Recognition Award and for the CME requirement of the APA. Each participant should claim only those credits that he/she actually spent in the activity.

Registration Policy
Attendees must be registered for the APA Annual Meeting or Institute on Psychiatric Services to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA staff free at:
1-888-377-7224 (within the U.S., or Canada), or 703/967-7160

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Wyeth

INDUSTRY-SUPPORTED SYMPOSIUM 20
Sunday, May 2, 1:30 p.m. - 4:30 p.m.
Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

BEYOND SEROTONIN
NEW TREATMENTS FOR DEPRESSION

At the conclusion of this symposium, the participant should be able to:
- Have a working knowledge of emerging strategies, both based on research and on anecdotal evidence, for enhancing the response of depressed patients to standard pharmacotherapy, the SSRIs. In addition, they will be informed about new medications that may be available soon for the treatment of depression
- Understand what evidence exists for combining an SSRI with another treatment in order to improve outcome for patients with depression
- Discuss how the relative merits of combining or switching antideprssants when an initial SSRI trial has failed
- Review and summarize biological data describing relationships between substance P (NK1 receptor) and other neurotransmitter systems implicated in mood and anxiety disorders
- Learn about the clinical utility of substance P antagonists in psychiatry

SUNDAY, MAY 2, 2004
1:30 PM - 4:30 PM

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician Recognition Award and the CME requirement of the APA. Each participant should claim only those credits he/she actually spent in the activity.

Attendees must be registered for the APA 2004 Annual Meeting to attend this ISS. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA staff free at 1-888-377-7224 (within the U.S., or Canada) or 703/967-7160.
INDUSTRY-SUPPORTED SYMPOSIUM 21
Sunday, May 2, 1:30 p.m. - 4:30 p.m.
Grand Ballroom East, Third Floor, Hilton New York

Are All Atypical Antipsychotics Equal for the Treatment of Cognition and Affect in Schizophrenia?

AGENDA
1:30 p.m.
Lunch

1:45 p.m.
Welcoming and Introduction
Geoffrey G. and Carol S. Herrick Professor, Neuropsychopharmacology, Psychiatry, and Behavioral Sciences, Stanford University School of Medicine

2:00 p.m.
Objective 1: Are all atypical antipsychotics equal for the treatment of cognition and affect in schizophrenia?

2:30 p.m.
Objective 2: Are some atypical antipsychotics better than others for the treatment of cognition and affect in schizophrenia?

3:00 p.m.
Objective 3: What are the implications for clinical practice and research?

3:30 p.m.
Panel Discussion

INDUSTRY-SUPPORTED SYMPOSIUM 22
Sunday, May 2, 1:30 p.m. - 4:30 p.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

Combination Therapy: New Strategies in the Management of Severe Mental Disorders

LEARNING OBJECTIVE
- Review clinical trials of combination therapy and implement treatment strategies in the management of severe mental disorders.

ACCREDITATION
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates these educational activities for a maximum of 1.5 CME category credits towards the APA Psychopharmacology Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attention: The APA is not responsible for training in new or unusual techniques and assumes no liability for the use and adverse reactions to the drugs and medications used in this meeting. Prescribing or administering a medication, even for a PA with a license to prescribe, must be done only in accordance with the state laws of the state in which the PA is licensed.

Sponsored by the American Psychiatric Association.

This activity is supported by an unrestricted educational grant from Abbott Laboratories.
INDUSTRY-SUPPORTED SYMPOSIUM 23
Sunday, May 2, 1:30 p.m. - 4:30 p.m.
Imperial Ballroom A, Second Floor, Sheraton New York

A symposium to be held during the APA 2004 Annual Meeting

Unmasking Bipolar Disorder: Overcoming Barriers to Treatment Success

Agenda
1:00 PM - 1:30 PM
Lunch
1:30 PM - 1:35 PM
Welcome and Introduction
S. Nassir Ghaemi, MD, Chair
Cambridge Hospital
1:35 PM - 2:10 PM
Bipolar Disorder: A National Health Concerns
Roger S. McIntyre, MD
University of Toronto
2:10 PM - 2:20 PM
Redefining Mood Stabilizing Agents: Improved Treatment Options for Bipolar Disorder
S. Nassir Ghaemi, MD
2:45 PM - 3:15 PM
Safety Considerations in Treating the Bipolar Patient
Prakash Nanandi, MD
Duke University Medical Center
3:15 PM - 3:45 PM
Managing Bipolar Disorder: From the Acute to the Long-Term: What Are the Treatment Goals?
Michael Otto, PhD
Massachusetts General Hospital
3:45 PM - 4:30 PM
Questions and Answers
4:30 PM
Symposium Adjourned

At the conclusion of this symposium, the participant should be able to:
- Describe the safety profiles of commonly used psychotropic treatments.
- Discuss treatments for the acute bipolar episode and the long-term management of the condition.
- Identify the goals for different phases of treatment.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity. Seating is limited and will be based on first-come, first-served.

For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 within the U.S. or Canada or at 703-907-7300.

Supported by an unrestricted educational grant from JANSSEN

RS-1451

INDUSTRY-SUPPORTED SYMPOSIUM 24
Sunday, May 2, 7:00 p.m. - 10:00 p.m.
Special Events Hall 1D, Level 1, Javits Center

Recovering from SCHIZOPHRENIA How to Treat It, How to Cope, How to Live Happily Ever After

Learning Objectives
- Understand the causes of schizophrenia.
- Learn the latest treatment options.
- Improve coping skills for patients and caregivers.
- Recognize the importance of early intervention.

Accreditation Statement
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been planned and implemented in accordance with the ACCME’s Essential Areas and Policies, including the policies on commercial interests.

On-Hold CME Attestation
At the conclusion of this activity, the participant should be able to:
- Underline at least 80% of the key points.
- Complete the post-test with a score of 70% or higher.
- Select the correct treatment plan for each patient.

Sponsored by the American Psychiatric Association

RS-1451

151
INDUSTRY-SUPPORTED SYMPOSIUM 25
Sunday, May 2, 7:00 p.m. - 10:00 p.m.
Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

Novel Intervention Strategies Across the Spectrum of Dementia:
REAL PATIENTS, REAL OUTCOMES

AGENDA

0:20 p.m.  
Dean

0:25 p.m.  
Welcome and Introduction

0:35 p.m.  
Rapidfire Early Treatment Case Studies and Treatment Update

0:45 p.m.  
Improving Functionality in Dementia: Vitality and Economy

0:50 p.m.  
Exploring Differences Between Medication Treatment and Brain Metabolism: Effects of Cognitive Functioning

0:55 p.m.  
Defining and Addressing Positive and Negative Symptoms in Dementia: Pharmacotherapy

1:00 p.m.  
Addressing Cognitive and Behavioral Challenges in Dementia: Clinical Management Strategies

1:05 p.m.  
Introduction to the American Psychiatric Association

1:10 p.m.  
Discussion of the American Psychiatric Association

1:15 p.m.  
Introduction to the American Psychiatric Association

1:20 p.m.  
Discussion of the American Psychiatric Association

1:25 p.m.  
Closing Remarks

OBJECTIVES

At this conclusion of this program, participants should be able to:

- Understand the complexities of dementia and its impact on family members
- Discuss the evidence supporting the use of cognitive-behavioral therapy for treating dementia
- Identify the role of pharmacotherapy in managing the symptoms of dementia
- Evaluate the potential benefits and limitations of non-pharmacological interventions
- Discuss the importance of early identification and intervention in managing dementia

INDUSTRY-SUPPORTED SYMPOSIUM 26
Sunday, May 2, 7:00 p.m. - 10:00 p.m.
Grand Ballroom East, Third Floor, Hilton New York

APA 2004 ANNUAL MEETING

Effective Long-Term Management of Schizophrenia: Real-World Considerations

Agenda

SUNDAY, MAY 2, 2004
Hilton New York • 1313 Avenue of the Americas
Grand Ballroom East
Dinner 6:00 – 7:00 p.m.; Cocktails 7:00 – 10:00 p.m.

Registration
JOHN L. EATON, M.D.
Albert Einstein College of Medicine

Learning Objectives
At the conclusion of this educational activity, the participant should be able to:

- Discuss the evidence supporting the use of cognitive-behavioral therapy for treating dementia
- Identify the role of pharmacotherapy in managing the symptoms of dementia
- Evaluate the potential benefits and limitations of non-pharmacological interventions
- Discuss the importance of early identification and intervention in managing dementia
INDUSTRY-SUPPORTED SYMPOSIUM 27
Sunday, May 2, 7:00 p.m. - 10:00 p.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

Beyond Sleep Onset
New Perspectives on the Treatment of Insomnia

Sunday, May 2, 2004
7:00 PM - 10:00 PM
Grand Ballroom, Mezzanine Level, Roosevelt

Faculty
Andrew Krystal, MD (Program Chair)
Director, Sleep Research Laboratory and Insomnia Program
Associate Professor of Psychiatry and Behavioral Sciences
Duke University Medical Center
Durham, North Carolina
Mugdha Thakur, MD
Clinical Associate, Psychiatry and Behavioral Sciences
Duke University Medical Center
Duke, North Carolina
Jed Black, MD
Director, Stanford Sleep Disorders Clinic
Stanford University
Stanford, California
Thomas Roth, PhD
Chief, Division Head, Sleep Disorders and Research Center
Henry Ford Hospital
Detroit, Michigan

Scientific Program Agenda
6:30 PM - 7:00 PM
Dinner
7:00 PM - 7:10 PM
Introduction and Welcome
Chair: Andrew Krystal, MD
7:10 PM - 7:40 PM
Prevalence and Impact of Insomnia: Treating the Entire Insomnia Syndrome
Mugdha Thakur, MD
7:40 PM - 8:10 PM
Differential Diagnosis of Insomnia and Co-Medical Conditions: Importance of Sleep History
Jed Black, MD
8:10 PM - 8:40 PM
Measures of Treatment Efficacy
Thomas Roth, PhD
8:40 PM - 9:10 PM
Overview of the Treatment of Insomnia
Andrew Krystal, MD
9:10 PM - 10:00 PM
Question-and-Answer Session
Chair: Andrew Krystal, MD
10:00 PM Adjournment

Accreditation Statement
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Registration
Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first come, first served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-800-357-7524 (within the U.S. or Canada) or 703/907-7300.

This program is supported by the American Psychiatric Association and supported by an unrestricted educational grant from Forest Pharmaceuticals, Inc.

At the conclusion of this symposium participants should be able to:
- recognize that demographic and clinical characteristics can affect treatment outcomes, as can variables such as age, sex, weight, and sleep patterns.
- select treatment strategies based on the severity of insomnia, the presence of co-morbid conditions, and the patient's history.
- understand the importance of sleep hygiene and lifestyle modifications in the treatment of insomnia.
- evaluate the role of nonpharmacological treatments in the management of insomnia.
- understand the role of pharmacological treatments in the management of insomnia.
- appreciate the importance of follow-up and monitoring of treatment outcomes.
PROGRAM OBJECTIVES
After attending this continuing medical education symposium, the psychiatrist should be able to:
• Understand some of the complex interactions between gender-based characteristics, psychopharmacologic interventions, and reproductive biology.
• Recognize the challenges of labeling products for use in pregnancy and lactation, and to better understand different sources available to assist physicians in assessing toxicities from drug exposures.
• Identify gender-related characteristics associated with weight gain while using psychotropic medications, and to learn about novel strategies to manage this problem.
• Understand the concept of a male menopause or andropause and its clinical implications, with particular emphasis on the role of testosterone as a potential hormonal intervention for depression.
• Examine the association between menopausal transition and the occurrence of mood disturbances, and to understand the extent to which symptomatic women may benefit from hormonal and nonhormonal interventions.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada), or 703-907-7300.
INDUSTRY-SUPPORTED SYMPOSIUM 31
Monday, May 3, and Tuesday, May 4, 7:00 a.m. - 8:30 a.m.
Grand Ballroom East, Third Floor, Hilton New York

INDUSTRY-SUPPORTED SYMPOSIUM 32
Monday, May 3, and Tuesday, May 4, 7:00 a.m. - 8:30 a.m.
Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

Current Alzheimer's Disease Treatments and Beyond: Advances Impacting Clinical Practice

HELD AT THE APA 2004 ANNUAL MEETING | Monday and Tuesday, May 3 and 4, 2004
7:00-8:30 a.m.; Breakfast 6:30-7:00 a.m.; Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

SYMPOSIUM AGENDA

DAY 1 | MONDAY, MAY 3
6:30-7:00
Breakfast
7:00-7:30
Welcome and Introduction
Tony Sunderland, MD, Symposium Chair
National Institute on Mental Health
7:30-7:50
The Molecular Genetics of Alzheimer's Disease
Rudolph E. Tanzi, PhD
Massachusetts General Hospital
Genetics and Aging Research Unit
7:50-8:10
Interactive Panel Discussion
With Q&A
8:10-8:30
Diversity of Neuropsychiatric Impairment: Cognitive and Behavioral Implications
Jeffrey L. Cummings, MD
University of California, Los Angeles
8:30-8:50
Interactive Panel Discussion
With Q&A
8:50 Adjournment

DAY 2 | TUESDAY, MAY 4
8:00-9:00
Breakfast
9:00-9:30
Brief Overview of Day One Discussion
Tony Sunderland, MD, Symposium Chair
National Institute on Mental Health
9:30-10:30
Neuropathology in Alzheimer's Disease: Diagnosis, Treatment, and Prevention
F. Murat Demirci, MD
Duke University Medical Center
10:30-11:30
Interactive Panel Discussion
With Q&A
11:30-11:50
New Treatment Strategies for Alzheimer's Disease: The Role of Early Diagnosis
Tony Sunderland, MD
National Institute of Mental Health
11:50-12:10
Interactive Panel Discussion
With Summary Statement
12:10 Adjournment

In the conclusion of the symposium participants should be able to:
• integrate new findings in Alzheimer's disease (AD) genetics into clinical practice
• discuss the assessment and treatment of AD-associated neuropsychiatric symptoms
• understand the impact of emerging neuroimaging techniques better
• evaluate alternative therapeutic options for possible treatment and prevention of AD

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 8.5 Category 1 credits toward the APA Physician Recognition Award and for the CMS recredentialing of the APA. Each physician should claim only those credits that are actually spent in the activity.

Participants must be present to receive credit for the APA Annual Meeting to attend this symposium. Sessions are limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.apa.org or call the APA Office at 1-888-352-7944 (within the U.S. or Canada) or 703-573-3000.

This program is sponsored by the American Psychiatric Association and supported by an unrestricted educational grant from Forest Pharmaceuticals, Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 33
Monday, May 3, and Tuesday, May 4, 7:00 a.m. - 8:30 a.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

INDUSTRY-SUPPORTED SYMPOSIUM 34
Monday, May 3, and Tuesday, May 4, 7:00 a.m. - 8:30 a.m.
Imperial Ballroom A, Second Floor, Sheraton New York

Presented at the APA 157th Annual Meeting
EVIDENCE-BASED MEDICINE:
THE NEXT GENERATION, PARTS 1 & 2
K. Ranga R. Krishnan, MD, Chairperson

Faculty and Agenda
Monday, May 3, 2004 - Part 1
5:30 am - 9:00 am
Breakfast
7:00 am - 7:30 am
Psychopharmacology of Treatment of Depression: New Developments
Thomas R. Lynch, PhD
Ohio University, Athens, North Carolina

7:30 am - 8:05 am
Pharmacological Treatment of Agitation in Dementia: Evidence-Based Recommendations
Vassos C. Taylor, MD
Ohio University, Athens, North Carolina

8:05 am - 8:15 am
Question-and-Answer Session

Tuesday, May 4, 2004 - Part 2
7:00 am - 8:30 am
Breakfast
7:00 am - 8:30 am
Physiotherapy for the Treatment of Depression: Recent Developments
Theresa R. Lynch, PhD
Ohio University, Athens, North Carolina

7:30 am - 8:30 am
Pharmacological Treatment of Agitation in Dementia: Evidence-Based Recommendations
Vassos C. Taylor, MD
Ohio University, Athens, North Carolina

8:30 am - 9:00 am
Question-and-Answer Session
INDUSTRY-SUPPORTED SYMPOSIUM 35

Monday, May 3, and Tuesday, May 4, 7:00 a.m. - 8:30 a.m.
Imperial Ballroom B, Second Floor, Sheraton New York

TRANSCENDING EFFICACY: EFFECTIVE TREATMENT OF PSYCHOSIS ACROSS DISORDERS

Monday, May 3 & Tuesday, May 4, 2004 • Breakfast: 6:30-7:00 a.m. • Symposium: 7:00-8:30 a.m.
Imperial Ballroom B, Second Floor • Sheraton New York Hotel & Towers, New York, New York

AGENDA:

MONDAY, MAY 3

6:30-7:00 AM Breakfast
Welcome & Introductions
Pierre V. Pizzi, MD
Chairperson
Center for Addiction and Mental Health, Toronto
John W. Newsome, MD
Co-Chairperson
Washington University School of Medicine

7:00-7:30 AM Tranquilizing Efficacy in Psychosis Where the Rubber Meets the Road
Richard M. Trochler, MD
Professor Emeritus, University of Southern California School of Medicine

7:30-8:00 AM Lavish Body Dysmorphic What for Promising Needs in Therapy
John W. Newsome, MD
Chairperson
Washington University School of Medicine

8:00-8:30 AM Quarter & Round Sessions
All Faculty
9:00 AM Adjourn

TUESDAY, MAY 4

6:30-7:00 AM Breakfast
Welcome & Introductions
Pierre V. Pizzi, MD
Chairperson
Center for Addiction and Mental Health, Toronto
John W. Newsome, MD
Co-Chairperson
Washington University School of Medicine

7:00-7:30 AM Tranquilizing Efficacy in Psychosis Where the Rubber Meets the Road
Richard M. Trochler, MD
Professor Emeritus, University of Southern California School of Medicine

7:30-8:00 AM Lavish Body Dysmorphic What for Promising Needs in Therapy
John W. Newsome, MD
Chairperson
Washington University School of Medicine

8:00-8:30 AM Quarter & Round Sessions
All Faculty
9:00 AM Adjourn

LEARNING OBJECTIVES:

• Review the prevalence of psychosis disorders in the elderly, with special emphasis on dementia, develop a practical evaluation and management strategy, and discuss the potential and pitfalls of available forms of symptomatic and other pharmacologic treatments.

• Define the spectrum of antipsychotic-induced weight gain, including the potential for development of metabolic disturbances in the elderly patient and the clinical factors which distinguish these conditions.

• Review and test pharmacologic therapies for Lewy body dementia.

• Describe the neurocognitive and behavioral problems in Parkinson's disease, and discuss the current practice of care in these patients.

• Discuss the role of antidepressants in the management of major depression in the elderly.

CME STATEMENT:

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3.0 Category 1 credits toward the AMA Physician Recognition Award and for the ASCME requirement of the APA. Each physician should claim only those credits that he or she actually spent in the activity.

Accreditation may be requested for the APA Annual Meeting to meet the accreditation criteria set by the APA. For more information about the meeting, please visit the APA Web site at www.psych.org or call the APA at 1-866-286-APA (2729), within the United States on 703-907-2001.

Many participants in the educational activities is the record of attendance and evaluation; please call 1-866-286-APA (2729) by April 15, 2004, in order to receive service.

INDUSTRY-SUPPORTED SYMPOSIUM 36

Monday, May 3, 7:00 p.m. - 10:00 p.m.
Grand Ballroom East, Third Floor, Hilton New York

APA 2004

ANNUAL MEETING

MIDAY, MAY 3, 2004

Borderline Personality Disorder: Regulation of Affect and Impulse Control

Agenda

7:00 PM - 7:10 PM Welcome and Opening Remarks
Jane M. Odorico, MD
8:29 PM - 8:30 PM Evidence-Based Psychotherapy for BPD
John Levenson, MD
8:31 PM - 8:30 PM Broiler College of Medicine
8:32 PM - 8:30 PM Pharmacological Treatment of BPD: Current and Future Strategies
Jeffrey Liebman, MD
8:31 PM - 8:30 PM University of North Carolina School of Medicine
8:32 PM - 8:30 PM GPA Panel Discussion
Chair: Mary Zavala, MD
8:31 PM - 8:30 PM Harvard Medical School
8:32 PM - 8:30 PM Adjourned

Supported by an unrestricted educational grant from Bristol-Myers Squibb Company and Shionogi America, Pharmaceutical Co., Ltd.
INDUSTRY-SUPPORTED SYMPOSIUM 37
Monday, May 3, 7:00 p.m. - 10:00 p.m.
Westside Ballroom 1-2, Fifth Floor, Marriott Marquis

American Psychiatric Association’s 157th Annual Meeting
INTERFERON INDUCED DEPRESSION: CONSEQUENCES FOR TREATING CHRONIC HEPATITIS C
Marriott Marquis—New York City | Westside Ballrooms 1 & 2 | Monday, May 3, 2004 | 7:00—10:00PM

LEARNING OBJECTIVES
Upon completion of this activity, participants will be able to:
• Discuss the pathophysiology of the neuropsychiatric symptoms produced by interferon.
• Understand the effect of peglated interferon on decreasing depression in Hepatitis C patients.
• Appreciate the efficacy of peglated interferon in the treatment of Hepatitis C patients.
• Develop a plan of care for the diagnosis and treatment of interferon-induced psychiatric side effects in Hepatitis C patients.

AGENDA
6:30—7:00 PM Dinner
7:00—7:25 PM Interferon Induced Depression: An Overview and Analysis—G. Aires, MD
7:25—7:50 PM Pathophysiological Mechanisms of Interferon Induced Neuropsychiatric Symptoms—L. Capuron, MD
7:55—8:25 PM Audience Q&A Faculty
8:25—8:55 PM Pegylation Interferon: Therapy of Hepatitis C with Less Depressive Effects—J. Reins, MD
8:55—9:30 PM Diagnosis and Treatment of Interferon Induced Psychiatric Side Effects in Patients with Hepatitis C—C. Raison, MD
9:30—10:00 PM Audience Q&A Faculty

FACULTY
Gregory M. Aires, MD
Montefiore Medical Center
Charles Raison, MD
Emory University, School of Medicine
Lucile Capuron, MD
Emory University, School of Medicine
John Reins, MD
Montefiore Medical Center

ACCREDITATION
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits towards the AMA Physician Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting please visit the APA website at www.psych.org or contact the APA toll-free number at 1-888-307-7224 (within the U.S. or Canada) or 703/907-7300.

Supported by an unrestricted educational grant from Shire/Lannett

INDUSTRY-SUPPORTED SYMPOSIUM 38
Monday, May 3, 7:00 p.m. - 10:00 p.m.
Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

APA 2004 Annual Meeting Conceptualizing and Treating ADHD Adults
5:30 PM Dinner
7:00 PM Welcome/Introduction—Timothy E. Wilems, MD, Chair
Massachusetts General Hospital
7:35 PM ADHD Adult Care—Jefferson Prince, MD
Massachusetts General Hospital
8:29 PM Adult ADHD: What Does Neuropsychology Tell Us?—Larry Selkem, PhD
Massachusetts Mental Health Center
8:52 PM Pharmacologic Treatment of Adult ADHD—Timothy E. Wilems, MD
Massachusetts General Hospital
9:15—10:00 PM Question and Answer Session—Faculty
10:00 PM Adjournment

Learning objectives: At the conclusion of this symposium, the participant should be able to:
1. Understand the executive function deficit model of adult ADHD impairment and recognize the neurobiological/functional model of adult ADHD impairment as well as describe the neuro/psychological state of the disorder.
2. Discuss the effects of pharmacological treatment options.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours of category 1 credit(s) towards the Physician Recognition Award of the American Medical Association and for the CME requirements of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Supported by an unrestricted educational grant from Shire/Lannett
INDUSTRY-SUPPORTED SYMPOSIUM 39
Monday, May 3, 7:00 p.m. - 10:00 p.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

INDUSTRY-SUPPORTED SYMPOSIUM 40
Monday, May 3, 7:00 p.m. - 10:00 p.m.
Grand Ballroom, Mezzanine Level, Roosevelt
Presented at the APA 157th Annual Meeting

Hormones, Mood, and Cognition: Treatment Considerations in Older Women

Lee S. Cohen, MD, Chairperson • Hadine Joffe, MD, MSc, Co-Chairperson

Faculty and Agenda

8:00 Am - 7:00 Pm: Dinner

7:00 Am - 7:25 Am: Gonadal Steroids and the Brain: Implications for Aging Women: The Server, MC, MD, PhD, KCI, McMaster University, Ontario, Canada

7:25 Am - 7:50 Am: Depression in Postmenopausal Women: Women at Risk and Response to Antidepressant Treatment: Lee S. Cohen, MD, Chairperson, Massachusetts General Hospital, Boston, Massachusetts

7:50 Am - 8:00 Am: Discussion/Q&A

8:00 Am - 8:30 Am: Menopause and Mood Disturbances: From Theory to Novel Treatment Strategies: Claude V. Sorensen, MC, PhD, Massachusetts General Hospital, Boston, Massachusetts

8:30 Am - 9:30 Am: Discussion/Q&A

9:30 Am - 9:55 Am: The effects of Estrogen on the incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: Gayla Skir anticipated, PhD, Pacific Western University School of Medicine, Los Angeles, California

9:55 Am - 10:00 Am: Wrap-up Discussion/Q&A

10:00 Am: Adjournment

Target Audience

This activity is designed specifically for psychiatrists.

Learning Objective

Upon completion of this symposium, the participants should be able to:

- Recognize the impact of reproductive hormones on mood and cognitive function and potential treatment-emergent side effects on subpopulations of patients.

Accreditation

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Registration Policy

Attendance must be verified for the APA Annual Meeting or International Psychiatric Congress attended by the Symposium Speaker. Seating is limited and will be based on first come, first served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA at 555 555-5555 (within the U.S. or Canada) or 555-555-5555 (international). Sponsored by the American Psychiatric Association.

Sponsored by an unrestricted educational grant from Novartis.
INDUSTRY-SUPPORTED SYMPOSIUM 43
Tuesday, May 4, 7:00 p.m. - 10:00 p.m.
Grand Ballroom East, Third Floor, Hilton New York

Presented at the APA 157th Annual Meeting
Emotion Regulation and Plasticity of Underlying Circuitry:
Implications for Depression, Anxiety, and Long-Term Brain Function
Ned H. Kalin, MD, PhD, Chairperson

Faculty and Agenda
6:00 p.m. - 7:00 p.m. Dinner
7:00 p.m. - 7:10 p.m. Welcome and Introduction
Ned H. Kalin, MD, PhD, Chairperson
University of Wisconsin, Madison, Wisconsin
7:10 p.m. - 7:30 p.m. Affective and Prophylactic Cortical Interactions Involved in
Emotion Regulation and Psychopathology
Ned H. Kalin, MD, PhD, Chairperson
University of Wisconsin, Madison, Wisconsin
7:30 p.m. - 8:10 p.m. The Human Amygdala: Vigilance, Threat Assessment,
and Psychopathology
Pat Wexler, PhD
University of Wisconsin, Madison, Wisconsin
8:10 p.m. - 8:30 p.m. Experience-Dependent Effects on Structural Plasticity in Limbic
and Cortical Structures Involved in Emotion Regulation
Elizabeth Gold, PhD
Princeton University, Princeton, New Jersey
8:30 p.m. - 9:10 p.m. Vagal Nerve Stimulation in Depression: Cause or Effect?
Alan J. Schatzberg, MD
Stanford University, Stanford, California
9:10 p.m. - 10:00 p.m. Wrap-up Discussion/Questions and Answers
10:00 p.m. Adjourn

Target Audience
This activity is designed specifically for psychiatrists.

Learning Objectives
Upon completion of this symposium, the participants should be able to:
- Identify the relationship between negative affect and anxiety and depression
- Address interactions between cortical nodes and limbic regions as a substrate for
  emotion regulation
- Describe environmental influences that promote and impair structural plasticity in brain
  regions associated with emotion regulation
- Discuss the influence of stress and depression on hippocampal structure

Accreditation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing
Medical Education to provide continuing medical education for physicians.
The APA designates these educational activities for a maximum of 3 category 1 credits toward the APA's
Physician's Recognition Awards and for the ACEME requirement of the APA. Each physician should
claim only those credits that he/she actually spent in the activity.

Registration Policy
Attendees must be registered for the APA Annual Meeting or Institute on Psychiatric Services to
attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more
information about the meeting, please visit the APA website at www.psych.org or contact the APA
registration office at 1-888-355-7924 (within the U.S. of Canada) or 703-907-7900.
Sponsored by the American Psychiatric Association.
Supported by an unrestricted educational grant from Wyeth.

INDUSTRY-SUPPORTED SYMPOSIUM 44
Tuesday, May 4, 7:00 p.m. - 10:00 p.m.
Westside Ballroom 1-2, Fifth Floor, Marriott Marquis

CHALLENGES IN TREATING
Bipolar Illness 
& COMORBID DISORDERS

Learning Objectives
- Discuss the impact of differential diagnosis and comorbid disorders on the clinical course of bipolar disorders.
- Implement pharmacologic treatment strategies for bipolar disorder and comorbid disorders.

Accreditation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates these educational activities for a maximum of 3 category 1 credits toward the APA's Physician's Recognition Awards and for the ACEME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA registration office at 1-888-355-7924 (within the U.S. or Canada) or 703-907-7900.
Sponsored by the American Psychiatric Association.

The activity is supported by an unrestricted educational grant from Abbott Laboratories.

Held at the APA 2004 Annual Meeting

Lori Davis, MD - Program Chair
Tuesday, May 4, 2004
Marriott Marquis - Westside Ballroom 1-2, 5th Floor
6:30 - 7:00 p.m. Dinner
7:00 - 7:05 p.m. Welcome and Introductions
Lori Davis, MD - Program Chair
Touche Ross Medical Center
7:05 - 7:30 p.m. Evidence-Based Utilization of AEDs
S. Hassan Choudry, MD
Harvard Medical School
7:30 - 7:55 p.m. Treatment of Bipolar Disorder
in Children and Adolescents
Kati D. Greer, MD
Stamford University School of Medicine
7:55 - 8:20 p.m. Bipolar Disorders in Women:
Clinical and Metabolic Correlates
Natalie Rangan, MD, PhD
Stanford University School of Medicine
8:20 - 8:45 p.m. Recognizing and Treating Comorbid Depression and Anxiety in Bipolar Disorder
Lori Davis, MD - Program Chair
8:45 - 9:10 p.m. The Challenge of Treating Bipolar Disorder and Substance Abuse
HI. A. Faiz, MD
UCLA Medical Center
9:10 - 10:00 p.m. Panel Discussion / Q&A
All Faculty
10:00 p.m. Adjourn

161
INDUSTRY-SUPPORTED SYMPOSIUM 45
Tuesday, May 4, 7:00 p.m. - 10:00 p.m.
Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

DOES THE PHARMACOLOGY OF ANTIDEPRESSANT DRUGS MATTER?

Tuesday, May 4
6:30 p.m.
Marriott Marquis, Westside Ballroom 3-4, Fifth Floor

7:00 PM - Introduction
Maurizio Pavo, MD
Symposium Chair & Speaker

7:10 PM - Antidepressant Treatment & the Impact of Medical & Psychiatric Comorbidity
Dan V. Ruscuccu, MD
Harvard Medical School

7:35 PM - Response vs. Resistant: Are There Meaningful Differences Among Antidepressants?
Michael E. Thureson, MD
University of Pittsburgh Medical Center

8:00 PM - Short & Long-Term Tolerability Issues with Antidepressants
Anita H. Clayton, MD
University of Virginia Health System

8:25 PM - Augmentation & Combination Strategies in Depression: What's the Evidence?
Maurizio Pavo, MD
Harvard Medical School

6:50 PM - Translating Mechanisms of Action into Clinical Outcomes in Depression
J. Craig Nelson, MD
University of California - San Francisco

8:15 PM - Question & Answer Session
10:00 PM - Program Concludes

Supported by an unrestricted educational grant from AstraZeneca

INDUSTRY-SUPPORTED SYMPOSIUM 46
Tuesday, May 4, 7:00 p.m. - 10:00 p.m.
Broadway Ballroom, Sixth Floor, Marriott Marquis

Panic Anxiety: Understanding Its Nature and Nurturing Recovery

Tuesday, May 4, 2004
Dinner 6:30 PM - 7:00 PM
Scientific Program 7:00 PM - 10:00 PM

Marriott Marquis
Broadway Ballroom • Sixth Floor
New York, NY

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served basis. For more information about the meeting, please contact the APA at 1-800-357-7164 (within the U.S. or Canada) at 703-907-7300.

Educational Objectives
- Review the possible basis for panic disorder
- Discuss and evaluate data regarding the genetic substrates of panic disorder and other anxiety traits and disorders
- Examine the incidence of suicide in patients with panic disorder
- Discuss the identification of panic disorder in primary care and a collaborative approach for treatment
- Review strategies for the pharmacological treatment of panic disorder, recognize advantages and disadvantages of antidepressants and benzodiazepines, and learn about the comparative and combined effects of drug and cognitive behavioral therapy
INDUSTRY-SUPPORTED SYMPOSIUM 47
Tuesday, May 4, 7:00 p.m. - 10:00 p.m.
Grand Ballroom, Mezzanine Level, Roosevelt

APA 2004 Annual Meeting
Adult ADHD: Diagnosis and Treatment

6:30 PM Dinner
7:00 PM Welcome/Introduction
Thomas Spencer, MD, Chair
Massachusetts General Hospital

7:10 PM Adult ADHD: Clinical Overview
Thomas Spencer, MD
Massachusetts General Hospital

7:35 PM Understanding & Utilization of Diagnostic Rating Scales
Lori Adler, MD
New York University School of Medicine

8:00 PM Cognitive-Behavioral Therapies: Treatments and Outcomes
Stephen McDermott, MD
Massachusetts General Hospital

8:25 PM Treatment with Stimulants
Timothy E. Wetter, MD
Massachusetts General Hospital

9:00 PM Treatment with Non-Stimulants
James Wincovich, MD
State University of New York/Buffalo

9:15 – 10:00 PM Question and Answer Session

10:00 PM Adjournment

Learning objectives: At the conclusion of this symposium, the participant should be able to:
1. Discuss the diagnostic subdivision and diagnostic criteria of adult ADHD
2. Evaluate the efficacy and use of cognitive therapy and treatments supporting the use of stimulants and non-stimulant treatments.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours of Category 1 credit towards the Physician Recognition Award of the American Medical Association and for the MOC requirements of the APA. Each physician should earn only those hours of credit that relate actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 48
Tuesday, May 4, 7:00 p.m. - 10:00 p.m.
Imperial Ballroom A, Second Floor, Sheraton New York

Binge Eating Disorder: Genes, Treatments, and Consequences

An educational symposium to be presented at the 2004 Annual Meeting of the American Psychiatric Association

Tuesday, May 4, 2004
7:00 PM - 9:00 PM
Sheraton New York
Imperial Ballroom A
Second Floor
New York, New York

Educational Objectives

Upon completion of the program, participants should be able to understand the etiology of binge eating and obesity, and identify treatment options for these disorders.

Accreditation Statement

The American Psychiatric Association has accredited this educational activity for the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours of Category 1 credit towards the Physician Recognition Award of the American Medical Association and for the MOC requirements of the APA. Each physician should earn only those hours of credit that relate actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 48
Tuesday, May 4, 7:00 p.m. - 10:00 p.m.
Imperial Ballroom A, Second Floor, Sheraton New York
PTSD: Searching for Answers in Traumatic Times

Wednesday and Thursday, May 5 & 6, 2004
Sheraton New York Hotel & Towers
Imperial Ballroom A, Second Floor

Educational Objectives
In the conclusion of this symposium, the participants should be able to:

1. Understand the overall consequences of PTSD.
2. Describe the impact of terrorist actions on mental health.
3. Understand the neurobiology of PTSD, including the roles of GABA and glutamate.
4. Recognize the nature of sleep disturbance and its treatment.
5. Discuss effective and ineffective forms of psychotherapy and pharmacotherapy.

Agenda
Wednesday, May 5, 2004
6:30am-7:00am Breakfast
7:00am-7:05am Introduction • Jonathan Davidson, MD
7:05am-7:30am PTSD: Its Burden and the Toll From Terrorism • Randall Marshall, MD
7:30am-7:55am Treatment and Prevention of Chronic PTSD: Psychosocial Approaches • Edna Foa, PhD
7:55am-8:30am Discussion Q&A

Thursday, May 6, 2004
6:30am-7:00am Breakfast
7:00am-7:05am Introduction • Jonathan Davidson, MD
7:05am-7:30am Brain Imaging in PTSD: Going Beyond Serotonin • David Nutt, MD, PhD
7:30am-7:55am Sleep in PTSD and Other Anxiety Disorders • Karl Doghramji, MD
7:55am-8:20am Novel Drug Treatments for PTSD Beyond SSRIs • Wei Zhang, MD, PhD
8:20am-8:30am Q&A Panel Discussion
8:30am Program Adjourns

This symposium is supported by an unrestricted educational grant from Cephalon, Inc.

Sponsored by the American Psychiatric Association

An educational symposium to be presented at the 2004 APA Annual Meeting

Support for this educational symposium is from Cephalon, Inc.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category I credits toward the AMA Physician Recognition Award and for the APA Continuing Education Credits. Each physician should claim only those credits that he/she actually spent in the activity. Participation in this symposium is an option. The American Psychiatric Association is not responsible for the content of symposiums presented by organizations other than the APA.

The APA maintains a list of organizations known to AMA Board certified, licensed physicians that are accredited to provide continuing medical education. The APA also makes these organizations available to the public. The list is available at www.psych.org or call 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300.
INDUSTRY-SUPPORTED SYMPOSIUM 51
Wednesday, May 5, and Thursday, May 6, 7:00 a.m. - 8:30 a.m.
Imperial Ballroom B, Second Floor, Sheraton New York

BIPOLAR DISORDER IN WOMEN
REPRODUCTIVE IMPLICATIONS OF TREATMENT
TWO-PART SYMPOSIUM - WEDNESDAY & THURSDAY * MAY 5-6

6:30–7 AM BREAKFAST + 7–8:30 AM CLINICAL PROGRAM
SHERATON NEW YORK HOTEL & TOWERS
IMPERIAL BALLROOM B, 2ND FLOOR

SYMPOSIUMS

INDUSTRY-SUPPORTED SYMPOSIUM 52
Wednesday, May 5, 7:00 p.m. - 10:00 p.m.
Grand Ballroom East, Third Floor, Hilton New York

Optimizing Antipsychotic Treatment in Patients With Schizophrenia and Bipolar Disorder

Agenda
7:00 PM - 7:10 PM: Welcome and Opening Remarks
Rajiv Randen, MD

7:10 PM - 7:30 PM: Optimizing Pharmacotherapy for Maintained Outcomes
Alan Mendelson, MD
Albert Einstein College of Medicine

7:30 PM - 8:00 PM: Keeping Tolerability in Mind: Ensuring Adherence to Maintain Recovery
Henry Husain, MD
University of Cincinnati Medical Center

8:00 PM - 8:25 PM: Finding Effectiveness Across Typical Age Groups
Rajiv Randen, MD

8:25 PM - 8:50 PM: Balancing Efficacy and Tolerability in Pediatric Bipolar Disorder
Michael DeBellis, MD
University of Cincinnati/Children's Hospital Medical Center

8:50 PM - 9:15 PM: Treatment Considerations in Special Populations: Sex Differences
Diana Parsons, MD
University of North Carolina at Chapel Hill

9:15 PM - 10:00 PM: Q&A/Panel Discussion

10:00 PM: Adjournment

TO BE HELD AT THE APA 2004 ANNUAL MEETING
NEW YORK
APRIL 23-27, 2004
WEDNESDAY, MAY 5, 2004

Learning Objectives

Supported by an unrestricted educational grant from Bristol-Myers Squibb Company
and Otsuka America Pharmaceutical, Inc.

Bristol-Myers Squibb Company Otsuka America Pharmaceutical, Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 53
Wednesday, May 5, 7:00 p.m. - 10:00 p.m.
Imperial Ballroom A, Second Floor, Sheraton New York

INDUSTRY-SUPPORTED SYMPOSIUM 54
Wednesday, May 5, 7:00 p.m. - 10:00 p.m.
Imperial Ballroom B, Second Floor, Sheraton New York
Look for us right next door to the APPI Bookstore in the Exhibit Hall.

Presenting...

...all the benefits of membership in the nation’s oldest medical specialty society. APA’s mission is to promote the highest quality care for individuals with mental disorders and their families, promote psychiatric education and research advances, represent the profession of psychiatry, and serve the professional needs of its members.

Whether you’re a prospective, new, long-time, or international member, visit the APA exhibit and find out how APA can help you in your professional life.

At the exhibit you can:
• Pick up your APA membership information and resource handbook
• Learn about new APA programs and initiatives
• Participate in APA advocacy efforts
• Search the Job Bank for the latest employment opportunities
• Activate your online subscriptions to APA journals
• Submit your new member application and enter to win an APPI gift certificate
• And more!

While at the exhibit, take a moment to learn about the key roles of these APA subsidiary organizations

AMERICAN PSYCHIATRIC INSTITUTE
for RESEARCH and EDUCATION

Our mission is to contribute to psychiatry’s science base and to improve the quality of psychiatric care through research, education, health policy analysis and dissemination.

American Psychiatric Foundation
Advancing public understanding of mental illnesses

The charitable and educational subsidiary, our mission is to advance public understanding that mental illnesses are real and can be effectively treated.